The impact of HIV infection on the burden and severity of influenza illness in Malawian adults by Ho, A et al.
 The Impact of HIV Infection on the 
Burden and Severity of Influenza Illness 
in Malawian Adults 
 
 
Thesis submitted in accordance with the requirements of the 
University of Liverpool for the degree of 
Doctor of Philosophy 
by 
 
 
 
Antonia Ying Wai Ho 
BSc, MBChB, MRCP (Infectious Diseases), DTMH, MSc, MRes  
 
 
April 2016 
 
 
Introduction 
 
 
 
ii 
Declaration 
I declare that this thesis was composed by me, and that the work contained therein is my own, except 
where explicitly stated otherwise. I was not involved in the design of the adult influenza surveillance 
study, or in the first two years of data collection. 
The work within this thesis has not been submitted for any other degree or professional qualification.  
 
Funding  
This study was funded by a Wellcome Trust Clinical PhD fellowship (097464). 
 
Acknowledgements 
This work would not have been possible without the enthusiastic input from a great number of 
people. First of all, I am extremely grateful to the patients and their guardians who took part in this 
study, and willingly returning for repeated reviews and nasopharyngeal specimens. 
I wish to thank Dr Jane Mallewa, Dr Joep van Oosterhout, Dr Mulinda Nyirenda, Sister Rose Malamba, 
Sister Molly Lungu. and Christine Hamuza at the Department of Medicine, Adult Emergency Trauma 
Centre, and HIV services at the Queen Elizabeth  Central Hospital (QECH) for their helpful advice and 
input when I was planning and setting up the project and for their support throughout the study.  
Special thanks to my study team: Nyasha Gutukunuhwa, Sitithana Muyaso, Mike Magola, Chimwemwe 
Mtawali, Blessings Mkwaila, Dan Chunda, Collins Chiliwawa, Hannah Masangwi, Emily Lifa, and 
Rosaleen N’goma, for their hard work, dedication and for maintaining their enthusiasm throughout 
this project. 
I would also like to thank Naor Bar-Zeev and Ingrid Peterson for their epidemiological input. Thanks 
also to Marc-Allain Widdowson and Meredith McMorrow, from the Influenza Division of the Centers 
for Disease Control and Prevention, for their expert advice on influenza surveillance and epidemiology. 
I am particularly indebted to the molecular laboratory team for generating all the PCR results for my 
study, with special thanks extended to Dean Everett, Brigitte Denis, Maaike Alaerts, and Mavis 
Menyere. Thanks also go to Mavuto Mukaka and Nico Nagelkerke for their statistical advice.  
Introduction 
 
 
 
iii 
I am grateful to Kate Jones, John Spafford, Carolyn O’Leary and Matt Hanlon from the Wellcome Trust 
Liverpool Glasgow Centre for Global Health Research for helping me relocate to and from Malawi, and 
their logistical assistance in all aspects of my study. 
The Malawi-Liverpool-Wellcome Trust (MLW) Clinical Research Programme was a stimulating and 
supporting research environment to study in. I received excellent support from the operational 
departments at MLW. This study also benefited enormously from the input of fellow students and 
senior researchers, who challenged and encouraged me in equal measures. I am also grateful to the 
Wellcome Trust for funding my Clinical PhD Fellowship. 
Patients in the case control study were recruited with my co-investigators, Stephen Aston and Hannah 
Jary (since July 2014). Heartfelt thanks go to them for their invaluable support through the ups and 
downs of this study, for being my ‘work family’, and most of all for the great fun we have had in the 
last three years.  
I would like to express my sincere gratitude to my supervisors Professor Neil French and Professor Rob 
Heyderman. I really appreciate the time they have generously given me, as well as their continuous 
support, sage advice, motivation, and encouragement to develop as an independent researcher. Their 
expert guidance has helped me throughout the study and writing of this thesis.  
Most of all, I would like to thank my family for their unrelenting support and belief in everything I do. 
Lastly, I would like to express my deepest love and gratitude to my boyfriend Jamie for his emotional 
support, encouragement, and patience during the most difficult times of thesis writing. 
 
  
Introduction 
 
 
 
iv 
Abstract 
 
 
Background.  Influenza infection and its complications cause substantial morbidity and mortality 
worldwide. However, the epidemiology of influenza in sub-Saharan Africa (SSA) is not well known. 
Furthermore, the effects of HIV infection on influenza burden and severity in adults in a region with 
high HIV prevalence are also poorly characterised. Although seasonal influenza vaccination is 
recommended for HIV-infected persons in developed settings, it is not part of routine HIV care in 
Africa. The primary aim of this thesis was to examine the impact of HIV on the incidence and severity 
of influenza infection among adults in urban Malawi, to determine whether HIV-infected adults should 
be prioritised for influenza preventative measures. 
Methods.  At the Queen Elizabeth Central Hospital in Blantyre, Malawi, we characterised the 
epidemiology, seasonality and risk factors for influenza infection in Malawian adults enrolled in a 
sentinel surveillance study. Secondly, we established a prospective cohort to compare the incidence of 
laboratory-confirmed influenza illness between HIV-infected and HIV-uninfected adults over two 
years. Thirdly, we conducted a case control study of adults with mild (influenza-like illness (ILI)) and 
severe (hospitalised lower respiratory tract infection (LRTI)) influenza illness to explore risk factors for 
severe influenza presentation, with HIV as the primary exposure of interest. Lastly, as a potential 
mechanism through which influenza and other respiratory viral infections predispose to secondary 
bacterial pneumonia, we investigated the association between respiratory viral infections and 
nasopharyngeal carriage density of Streptococcus pneumoniae in a cross-sectional and case control 
analysis nested within the prospective cohort. 
Results. Influenza was a common cause of mild and severe acute respiratory infections in Malawian 
adults in the hospital-based sentinel surveillance. Pregnant women were found to have nearly double 
the risk of hospital-attended influenza infection compared to non-gravid women of childbearing age. 
In the prospective cohort of 608 adults (59% HIV-reactive), 24/229 (10.5%) ILI episodes in HIV-infected 
and 5/119 (4.2%) in HIV-uninfected adults were influenza PCR-positive (incidence rates 46.0 vs. 14.5 
per 1000 person years). After accounting for potential confounders, HIV-infected adults had an 
approximately three times higher incidence of influenza infection compared to HIV-uninfected adults. 
In the case control study, HIV was the single most important risk factor for severe influenza-related 
presentation; HIV-infected adults experienced a five-fold greater risk of severe influenza disease 
compared to HIV-uninfected adults, and over 50% of influenza-related hospitalised LRTI were 
attributable to HIV. Influenza infection was associated with pneumococcal carriage, but respiratory 
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viral infection was not associated with pneumococcal acquisition or an increase in pneumococcal 
colonisation density. 
Conclusion. We have clearly demonstrated a high burden of influenza disease among Malawian 
adults. Moreover, HIV-infected adults have increased susceptibility and severity of influenza 
presentations, thus should be considered a priority group for targeted vaccination in the region. 
Influenza vaccine policies that maximise health benefit through efficient use of limited resources are 
urgently needed.  
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CHAPTER 1.   INTRODUCTION 
            
    
1.1  Overview of Influenza 
1.1.1  Characteristics of influenza viruses  
Human influenza viruses are enveloped single-stranded RNA viruses of the Orthomyxoviridae family. It 
was first isolated from ferrets that had been infected by throat swabs from patients with clinical 
influenza in 1933 (Smith et al., 1933). There are three types of influenza viruses – A, B and C, classified 
on the basis of their nucleoprotein (NP) (Figure 1.1). Influenza A and B account for most cases of the 
disease, and thus will be the focus of this thesis. In contrast, influenza C viruses cause a mild 
respiratory illness and are not thought to cause epidemics. Influenza A viruses are divided into 
subtypes based on the antigenic properties of the haemagglutinin (HA) and neuraminidase (NA) 
surface glycoproteins (figure 1.1) (Lamb and Krug, 2001). To date 18 haemagglutinin and 11 
neuraminidase subtypes have been identified (H1-H18 and N1-N11 respectively) (Centers for Disease 
Control and Prevention, 2014), with H1-H3 and N1-N2 causing the majority of human disease. The 
predominant circulating strains are currently H1N1 and H3N2.  
Influenza A viruses circulate in many animal hosts, such as birds, pigs, horses, and sea mammals. 
Phylogenetic studies have suggested that aquatic birds are the source of all influenza A viruses in 
other animals (Webster et al., 1992). All influenza A virus subtypes except H17N10 and H18N11 are 
found in the digestive and respiratory tracts of aquatic bird populations, but the majority do not 
produce disease (Centers for Disease Control and Prevention, 2015b). However, a number of avian 
influenza strains are highly virulent (highly pathogenic avian influenza (HPAI)). Direct avian-to-human 
transmission of A(H5N1) in Southeast Asia, Africa, and the Middle East, and A(H7N9) in Asia, have 
been reported (Qin et al., 2015). Although human-to-human transmission is rare (Nguyen et al., 2008), 
avian influenza is of public health concern as the reported sporadic infections have been associated 
with severe morbidity and mortality (World Health Organization, 2015a; Qin et al., 2015). 
In contrast, influenza B viruses only circulate among humans. They are divided into lineages and 
strains, rather than subtypes. Two distinct influenza B lineages have co-circulated since the mid-1980s: 
B/Yamagata and B/Victoria. 
The nomenclature for influenza virus isolates follows a World Health Organization (WHO)-accepted 
convention (1980), and comprises: 
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i) the influenza virus type (e.g. A,B or C) 
ii) the host of origin (for non-human-origin viruses) 
iii) Geographical origin 
iv) Strain number 
v) Year of isolation 
vi) For influenza A viruses, the haemagglutinin and neuraminidase variants in brackets 
For example: A/Wisconsin/15/2009 (H3N2)  
                      B/Brisbane/9/2014 
The unique ability of influenza viruses to cause recurrent epidemics and pandemics is largely due to 
two types of antigenic variations: minor changes (antigenic drift) due to frequent point mutations in 
the RNA gene segments coding for HA or NA in both influenza A and B viruses, result in new strains 
that can evade host immune response, thus causing seasonal outbreaks or epidemics. Major changes 
(antigenic shift) occur only in influenza A viruses, either from the genetic reassortment between a 
human and a non-human virus or from direct transmission of an animal strain to humans, resulting in 
a novel strain in human population that is immunologically distinct from circulating influenza viruses. 
Rarely, person-to-person transmission of the novel virus in a large and immunologically susceptible 
population results in a pandemic.  
 
 
 
Figure 1.1 Diagram of an influenza A virion 
An influenza A virion consists of 2 surface 
glycoproteins, haemagglutinin (HA) and 
neuraminidase (NA), and M2 ion channel 
(M2) that are embedded in the viral 
envelope; the ribonucleoprotein complex, 
which consist of a viral RNA segment 
associated with the core viral nucleoprotein 
(NP) and 3 polymerase proteins (PA, PB1, 
PB2); and the matrix protein (M1), which is 
associated with both the viral envelope and 
ribonucleoprotein. Figure reproduced from 
Horimoto et al. (Horimoto and Kawaoka, 
2005). 
 
© 2005 Nature Publishing Group 
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cell-surface receptors and 
facilitates fusion between the 
viral envelope and endosomal 
membrane. It is the main target 
antigen of the humoral immune 
response in host animals.
NEURAMINIDASE
Type II integral membrane 
glycoprotein, which facilitates 
viral release from cells by 
removing sialic acid from 
sialyloligosaccharides on the 
cell and viral surface.
REVERSE GENETICS
A method that allows the 
production of viruses that 
possess genes derived from 
cloned cDNA.
PANDEMIC
Global influenza infection 
caused by the emergence of a 
virus with an HA subtype to 
which most of the human 
population lacks immunity.
REASSORTANT
A virus with gene segments 
derived from more than one 
virus, achieved by co-infection 
of a single cell by these viruses.
NA (N2) and a viral RNA polymerase gene segment, 
PB1 (polymerase basic 1), from an avian virus, with 
the other gene segments derived from a previously 
circulating human virus15,16. The 1968 virus had avian 
HA (H3) and PB1 segments in a background of human 
viral genes15,16. The acquisition of avian surface anti-
gens allowed these viruses to circumvent the human 
immune response. Why both of these pandemic strains 
also carried the gene that encodes PB1 from an avian 
virus remains unclear. In view of a recently identified 
North American swine virus, a triple REASSORTANT that 
combined swine, human and avian viral genes and 
possessed the genes that encode PB1 and HA from the 
same human virus17, one could argue that the genes 
that encode HA and PB1 interact functionally, either 
at a protein or nucleic acid level, in ways that enhance 
the replicative ability of hybrid viruses.
The Russian influenza H1N1 strain was essentially 
identical to those H1N1 strains that had circulated in 
humans in the 1950s (FIG. 2) REF. 18 , and it is thought 
likely that the virus was maintained in a freezer until 
it was somehow reintroduced into the general popula-
tion. The magnitude of this outbreak was limited, as most 
individuals over 27 years of age had some immunological 
memory to the virus.
Properties of avian influenza viruses
Influenza pandemics are caused by viruses that possess 
an HA molecule to which most of the population lacks 
immunity. Recently, purely avian influenza viruses, 
including the H5N1, H9N2 and H7N7 subtypes, have 
been directly transmitted to humans, raising concern 
over the possibility of a new influenza pandemic among 
the world’s immunologically naive populations. As the 
viruses responsible for pandemics in the past century 
were all characterized by the acquisition of HAs from 
avian viruses, with the exception of th  Russian influ-
enza virus, clues to the molecular changes that give rise 
to human pandemic strains can be found in the avian 
reservoir.
Avian influenza viruses can be sorted on the basis 
of virulence: highly pathogenic avian influenza (HPAI) 
viruses cause systemic lethal infection, killing birds as 
soon as 24 hours post-infection, and usually within 
one week, hereas low-p thog nic avian influenza 
(LPAI) viruses rarely gene ate outbreaks of severe 
disease in the field, and heir associatedmorbidity and 
mortality rates are lower than those of HPAI viruses4. 
Phylogenetic studies of avian influenza viruses have 
revealed two geographically separate sublineages 
(Eurasian and American), which probably reflects the 
separation of viruses owing to the distinct migratory 
patterns of the host birds in these two regions. Both 
HPAI and LPAI viruses are found within these two 
sublineages, indicating that viral pathogenicity is not 
determined by geographical distribution. Without 
exception, all of the HPAI viruses belong to the H5 or 
H7 subtype, for reasons that are still unclear. There do 
not seem to be any associations of specific NA subtypes 
with HPAI viruses.
Susceptibility and pathology. Many domestic and wild 
avian species are susceptible to influenza virus infection, 
although viruses that are highly pathogenic in one avian 
species might not be pathogenic in another19. For exam-
ple, ducks tend not to succumb to viruses that are lethal 
in chickens, even though virus can be detected in vari-
ous internal organs and in the blood of infected ducks. 
Among domestic avian species, chickens and turkeys 
are the most frequently involved in outbreaks of HPAI-
virus-related disease. The host factors that determine 
differences in susceptibility to avian influenza viruses 
in different avian species are unknown.
LPAI viruses replicate mainly in intestinal and res-
piratory organs, and are shed in the faeces of infected 
birds. Therefore, transmission of viruses through the 
faecal-contaminated-water–oral route is an impor-
tant mechanism of LPAI-virus dissemination among 
aquatic birds. High concentrations of HPAI viruses, 
which replicate systemically in poultry, are also shed 
in faeces. However, these viruses are more readily 
transmitted among birds in densely populated flocks 
by the nasal and oral routes through contact with 
virus-contaminated materials. LPAI viruses cause 
localized infections in the respiratory and/or intesti-
nal tract, resulting in mild or asymptomatic infection. 
In chickens infected with HPAI viruses, common 
symptoms include swelling of the microvascular endo-
thelium, multifocal haemorrhages and thrombosis19,20. 
HPAI viruses can replicate efficiently in vascular 
endothelial and perivascular parenchymatous cells, 
which aids viral dissemination and systemic infec-
tion. Additionally, involvement of the cardiovascular 
system is indicated, as HPAI antigens have been found 
in necrotic cardiac myocytes21.
Figure 1 | Schematic diagram of an influenza A virus 
virion. Two surface glycoproteins, haemagglutinin (HA) and 
neuraminidase (NA), and the M2 ion-channel protein are 
embedded in the viral envelope, which is derived from the host 
plasma membrane. The ribonucleoprotein complex comprises 
a viral RNA segment associated with the nucleoprotein (NP) 
and three polymerase proteins (PA, PB1 and PB2). The matrix 
(M1) protein is associated with both ribonucleoprotein and the 
viral envelope. A small amount of non-structural protein 2 is 
also present, but its location within the virion is unknown.
592 | AUGUST 2005 | VOLUME 3  www.nature.com/ reviews/micro
REVI EWS
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1.1.2  Transmission 
Influenza virus is highly infectious, associated with a basic reproduction numberi (R0) of 1.6-3.0 
(Truscott et al., 2012). The main mode of transmission is through large respiratory droplets (>5m) at 
close distance (Brankston et al., 2007), though influenza may spread through aerosolised particles 
expelled through sneezing or coughing (Tellier, 2009; Cowling et al., 2013) or direct contact with 
respiratory secretions through contaminated fomites (Morens and Rash, 1995). The typical incubation 
period is 2 days (range 1-4 days) (Cox and Subbarao, 1999).  
The risk of influenza transmission varies according to the setting. Increased mixing and contact among 
individuals, poor hygiene and individual factors such as susceptibility to infection and immunity from 
previous exposure may contribute to transmission (World Health Organization, 2010a). Influenza 
transmission has been evaluated in households, schools, hospitals, and confined environments such as 
nursing homes and military facilities (World Health Organization, 2010a). In observational studies of 
influenza transmission within households, the secondary attack rate (i.e. the probability that infection 
occurs among susceptible individuals after known contact with an infectious contact or source 
(Halloran, 2005)) ranged from 13 to 32% (Longini et al., 1982; Viboud et al., 2004; Hall et al., 1973; 
Philip et al., 1961) for seasonal influenza, and 3 to 38% during the 2009 influenza A(H1N1) pandemic 
(Lau et al., 2012). The countries, setting and study design varied substantially among these studies. 
Increased risk of transmission have been observed in young children (Casado et al., 2014; Petrie et al., 
2013; Viboud et al., 2004), contacts of infected young children (Viboud et al., 2004), and high number 
of susceptible occupants in the household (Longini et al., 1982). In a household cohort study in 
Vietnam, 25% (95% CI 21-30%) of influenza infection was thought to be attributable to household 
transmission (Cauchemez et al., 2014). Since children have a much higher attack rates than adults 
(World Health Organization, 2014c), schools are thought to be important settings for the spread of 
influenza. A Taiwanese study found that the R0 (the average number of secondary cases that result 
from one infected person) in schools were between 2.8 (aged 25-45 years) and 16.9 (aged 4-6 years), 
compared to an R0 of 1.2 to 2.4 in the community (Chen and Liao, 2008). Closed environments are 
associated with some of the highest rates of influenza transmission; attack rates of >40% have been 
reported in boarding schools (Smith et al., 2009; Rajatonirina et al., 2011), military facilities (Earhart et 
al., 2001), and nursing homes (Patriarca et al., 1987; Morens and Rash, 1995). Lastly, influenza 
outbreaks due to nosocomial transmission between healthcare workers and hospitalized patients have 
been reported (Balkovic et al., 1980; Horcajada et al., 2003; Taylor et al., 2014), thus highlighting the 
                                                        
i The number of secondary cases which one case would produce in a totally susceptible population [Dietz K. 
(1993) The estimation of the basic reproduction number for infectious diseases. Stat Methods Med Res 2: 23-41. 
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importance of compliance with infection control measures such as handwashing and use of face 
masks, in addition to vaccination in healthcare workers. 
1.1.3  Clinical Presentation 
In adults, influenza infection is characterised by sudden onset of fever, myalgia, malaise, headache, 
respiratory tract symptoms such as cough, sore throat, and rhinorrhoea, and occasionally vomiting 
and diarrhoea. In most people, it manifests as a self-limiting illness that resolves within a week. 
However, influenza can cause severe illness or death, particularly in certain at-risk populations (see 
Section 1.1.4.2). Pneumonia is by far the commonest complication, which can be categorised into 
primary viral pneumonia, secondary bacterial pneumonia, or mixed viral/bacterial pneumonia 
(Chertow and Memoli, 2013; Metersky et al., 2012) (see also Chapter 6). Streptococcus pneumoniae, 
Staphylococcus aureus, Haemophilus influenzae, and Streptococcus pyogenes are the most frequently 
identified bacterial co-pathogens (2009a; Martin-Loeches et al., 2011; Rice et al., 2012). Concomitant 
or subsequent bacterial infection causes a substantial proportion of influenza-related morbidity and 
mortality (Morens et al., 2008). Rarely, inﬂuenza has been associated with neurological (encephalitis 
(Santini et al., 2012; Cunha et al., 2012), transverse myelitis (Salonen et al., 1997), Guillain-Barre 
syndrome (Vellozzi et al., 2014), and Parkinsonism (Toovey et al., 2011)), musculoskeletal (e.g. 
myositis (Oba et al., 2000), rhabdomyolysis (Ayala et al., 2009)) and cardiac (e.g. myocarditis, 
pericarditis) (Estabragh and Mamas, 2013) complications. Moreover, influenza can exacerbate existing 
chronic medical conditions, such as chronic obstructive pulmonary disease (COPD) (De Serres et al., 
2009; Mohan et al., 2010) or ischaemic heart disease (Lichenstein et al., 2012; Warren-Gash et al., 
2011).  
1.1.4  Epidemiology of influenza in developed settings 
1.1.4.1  Characteristics of influenza outbreaks 
In temperate regions, distinct outbreaks occur predominantly in the winter months (Figure 1.2). The 
seasonality of influenza is less well defined in tropical and subtropical regions; influenza activity may 
occur throughout the year (Chapter 1.2) (Azziz Baumgartner et al., 2012). However, even in regions 
where annual winter epidemics occur, the timing, severity and distribution of viruses are highly 
variable. A myriad of factors are likely to contribute to this variability; these are summarized in Figure 
1.3.  
The WHO Global Influenza Surveillance and Response System (GISRS) is a network consisting of six 
WHO Collaborating Centres for Reference and Research on Influenza (US x2, UK, China, Japan, and 
Australia), in addition to 142 institutions from 112 countries (World Health Organization, 2014 ). GISRS 
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monitors the evolution of influenza viruses through collated surveillance data, and provides 
recommendations on vaccine composition twice yearly. Additionally, it acts as an alert mechanism for 
the emergence of influenza viruses with pandemic potential. The WHO estimates annual attack rates 
at 5–10% in adults and 20-30% in children (World Health Organization, 2014c), and annual epidemics 
are thought to result in around 3 to 5 million cases of severe illness, and around 250 000 to 500 000 
deaths worldwide (World Health Organization, 2014c). 
 
 
 
 
 
 
 
Figure 1.2  Influenza subtypes detected in the 2014-2015 influenza season 
From the WHO European Region, Global Influenza Surveillance and Response System (GISRS)  
(http://www.who.int/influenza/gisrs_laboratory/updates/summaryreport/en/). Note multiple influenza strains 
typically circulate concurrently in an influenza season. 
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Figure 1.3  Factors that determine the extent and severity of influenza outbreaks  
 
1.1.4.2 Risk groups for influenza 
Risk groups for influenza include individuals at increased risk of exposure, e.g. healthcare (Weber et 
al., 2010) or childcare workers (Cordell et al., 2004), in addition to those at higher risk of severe 
disease (e.g. hospitalisation or death), or complications. The latter include children < 5years (Poehling 
et al., 2006; Ampofo et al., 2006; Coffin et al., 2007; Zhou et al., 2012b; Chaves et al., 2014), the 
elderly (65 years) (Zhou et al., 2012b; Matias et al., 2014; Thompson et al., 2003; Quandelacy et al., 
2014; Van Kerkhove et al., 2011b), pregnant women (Neuzil et al., 1998; Dodds et al., 2007; Mosby et 
al., 2011) and those with underlying medical conditions, including chronic respiratory disease, 
signiﬁcant cardiovascular disease, chronic renal or liver disease, diabetes mellitus and 
immunodeﬁciency (Nicoll et al., 2008; Pebody et al., 2010; Quandelacy et al., 2014; Van Kerkhove et 
al., 2011b; Kunisaki and Janoff, 2009; Memoli et al., 2014). In many developed settings, influenza 
vaccines (see Section 1.1.5) are targeted at these vulnerable populations (England, 2013; Nokleby and 
Nicoll, 2010). In the US, the influenza vaccination policy has expanded to include all individuals aged 6 
months and over since 2010 (Fiore et al., 2010). In 2012, the World Health Organization (WHO) 
Strategic Advisory Group of Experts on Immunisation (SAGE) designated pregnant women as the 
highest priority group (2012). 
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1.1.4.3 Previous pandemics 
As discussed in Section 1.1.2, antigenic shift in an influenza A virus may give rise to a pandemic. 
Pandemics are characterised by the rapid dissemination of a new influenza A subtype, to which human 
populations have minimal or no immunity, has capacity for human-to-human transmission and causes 
serious disease (2012; Doshi, 2011). The first recognized influenza pandemic was in 1510 (Morens et 
al., 2010), thought to have originated from Asia, then rapidly spread to Africa and along trade routes 
to Europe. A first-hand account described “a ‘gasping oppression’ with cough, fever, and a sensation 
of constriction of the heart and lungs began to rage, seemingly everywhere at once” (Fernal, 2005). 
Major pandemics have occurred sporadically every 10-50 years since then (Morens et al., 2010). Over 
the past century, the most severe and extensive pandemic of 1918-19 was associated with up to 50 
million deaths (Patterson and Pyle, 1991; Johnson and Mueller, 2002). Less severe pandemics 
occurred in 1957, 1968, and most recently in 2009 (Table 1.1).  
The first reports of the influenza activity in 1918 came from Spanish wire news services, largely due to 
media blackout in allied countries and Germany during the First World War. As a result, the virus was 
erroneously believed to be the origin of the pandemic (hence “Spanish flu”) (Trilla et al., 2008). This 
pandemic was unique in many respects: firstly, case fatality rate was very high (>2.5% vs. <0.1% in 
other pandemics) (Marks and Beatty, 1976); one of the most striking aspects was the unusually high 
mortality in adults aged 20 to 40 years (~1000 per 100,000 persons), in addition to infants and the 
elderly (‘W’-shaped mortality curve) (Taubenberger and Morens, 2006). Secondly, most deaths were 
due to secondary bacterial pneumonia caused by common respiratory tract organisms, such as 
Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus (see also Chapter 
1.6.2.1) (1920; Jordan, 1923). Thirdly, three distinct waves of influenza activity occurred between 1918 
and 1919; the second of which caused widespread disease and high mortality rates (Taubenberger and 
Morens, 2006). Fourthly, most pandemics developed in Asia and spread to the rest of the world 
(Taubenberger and Morens, 2006), but the geographical origin of the 1918 virus remains unknown 
(Reid et al., 2004). Finally, recently published viral sequencing data suggest that the 1918 virus was 
derived from an avian-like influenza virus that was novel to humans, and not produced by 
reassortment from an existing strain that acquired new genes (Reid et al., 2004; Taubenberger et al., 
2005). To date, it remains unclear why the 1918 influenza pandemic was so fatal (Morens and 
Taubenberger, 2012). 
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1.1.4.4  Influenza surveillance 
Influenza activity is monitored globally by surveillance programmes, either in defined populations or in 
a limited number of sentinel sites. It involves systematically testing individuals that present to 
healthcare facilities with mild and severe acute respiratory symptoms for influenza (± other 
respiratory viruses). The purpose of surveillance is to estimate disease burden, describe influenza 
seasonality, determine circulating strains, monitor changes in antigenicity of viruses, guide the 
selection of strains for the annual influenza vaccine, as well as providing candidate viruses for vaccine 
production (World Health Organization, 2013b). The following standardised case definitions, as 
recommended by the WHO and the United States Centers for Disease Control and Prevention (CDC), 
allow comparisons between surveillance sites and countries (Pan American Health Organization & 
Centers for Disease Control and Prevention (PAHO-CDC), 2006): 
1) Influenza-like illness (ILI) 
 Sudden onset fever >38c  AND 
 Cough OR sore throat 
 Onset with 7 days 
2) Severe acute respiratory infection (SARI) 
Age <5 years: 
 Clinically suspected of having pneumonia or severe/very severe pneumonia 
Table 1.1  Influenza pandemics over the past century 
Time period Name Subtype How strain was derived Reproduction 
number (R) 
(Biggerstaff et al., 
2014) 
Median (IQR) 
Numbers of 
Deaths 
1918-19 Spanish flu  H1N1    An avian virus with HA(H1) that 
adapted to humans? 
(Taubenberger et al., 2005) 
1.80 (1.47-2.27) ~50 million 
1957-58 Asian flu  H2N2    Reassortment of an avian HA(H2), 
NA(N2), and PB1 viral segments + 
human viral genes (Subbe et al., 
2006) 
1.65 (1.53-1.70) ~1-2million 
1968-70 Hong Kong flu H3N2    Reassortment of avian HA(H3) + 
human viral genes (Subbe et al., 
2006) 
1.47 (1.30-1.70) ~ 1 million 
2009-10    Swine flu H1N1    Triple reassortment of human, 
swine, and avian viral genes 
(Garten et al., 2009) 
1.28 (1.19-1.37) ~284,000  
HA, haemagglutinin; NA, neuraminidase 
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 Requiring  hospital admission 
 Onset within 7 days 
(adapted from the programme for Integrated Management of Childhood illness (IMCI) 
(World Health Organization)) 
 
Age >5 years: 
 Sudden onset fever >38c  AND 
 Cough OR sore throat  AND 
 Shortness of breath OR difficulty breathing AND 
 Requiring hospital admission 
ILI surveillance monitors persons seeking care in outpatient facilities, whereas SARI surveillance 
captures persons with more severe illness that may require hospitalisation. As described in Section 
1.1.3, influenza causes a non-specific febrile illness that is difficult to distinguish from other respiratory 
infections. Clinical case definitions have to achieve a balance between sensitivity and specificity; a 
more sensitive definition will capture a larger proportion of all cases, but at the expense of testing a 
large number of cases caused by pathogens other than influenza. Conversely, a more specific 
definition will improve accuracy in capturing cases, but may miss a larger proportion of the total. The 
ILI and SARI definitions above demonstrated low sensitivity and specificity for influenza (Murray et al., 
2013). Following a global technical consultation by the WHO in 2011, sore throat was removed as a 
qualifying symptom, as several studies have suggested that it is negatively associated with influenza. 
In 2013, the case definitions were revised to (World Health Organization, 2013b): 
1) ILI 
An acute respiratory infection with: 
 Measured fever >38c  AND 
 Cough  
 Onset within 10 days 
2) SARI 
An acute respiratory infection with: 
 Measured fever >38c  AND 
 Cough  
 Onset within 10 days 
 Requires hospitalization 
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1.1.5  Influenza vaccination in adults 
1.1.5.1  Types of influenza vaccines  
Vaccination is the most effective way to prevent influenza disease and/or severe outcomes (World 
Health Organization, 2014c). Safe and effective influenza vaccines are available, in the form of 
inactivated influenza vaccine (IIV) and live-attenuated vaccines (LAIV). There are three types of 
inactivated vaccines: whole cell, split virus and subunit vaccines. ‘Split virus’ vaccines are prepared by 
disrupting whole viruses with organic solvents or detergents; ‘subunit’ vaccines contain highly puriﬁed 
HA and NA antigens prepared from disrupted virus particles. The puriﬁed viruses are then grown in 
chick embryos, chemically inactivated and further puriﬁed to produce the vaccine. IIV can be given as 
a single dose by intramuscular or intradermal injection to individuals aged 6 months or over (England, 
2013). 
LAIV is prepared using cold-adapted, live attenuated viruses from which reassortants with vaccine 
strain HA and NA antigens are generated. Also grown in embryonated hens’ eggs, LAIV is given 
intranasally to healthy children aged 2 to <17 years in the UK (Public Health England, 2015) (2 to 49 
years In the US (Grohskopf et al., 2015)). The decision for the preferential use of LAIV in children is 
based on superior efficacy of LAIV compared to IIV3 in young children <6 years (Belshe et al., 2007), 
with weaker evidence of superior efficacy in older children (Fleming et al., 2006). On the contrary, 
most comparative studies in adults have demonstrated either that LAIV and IIV were of similar efficacy 
(Treanor et al., 1999; Forrest et al., 2011) or that IIV was more efficacious (Ohmit et al., 2006; Ohmit et 
al., 2008; Monto et al., 2009). 
Current vaccines are trivalent (IIV3) or quadrivalent (IIV4) – the trivalent vaccine contains two strains 
of influenza A (A/H3N2 and A/H1N1) and one influenza B strain; the quadrivalent preparation contain 
an additional B virus (both B/Victoria and B/Yamagata lineages). The latter has been licenced in the UK 
since April 2013 (England, 2013). 
Due to antigenic drift, influenza vaccine formulation is updated twice-yearly (for the Northern and 
Southern Hemisphere) using virus strains predicted to circulate in the forthcoming winter from the 
global epidemiological surveillance (Grohskopf et al., 2015). Vaccine production takes around six 
months. Mismatches between vaccine strains and circulating strains occur occasionally, resulting in 
reduced efficacy (Bridges et al., 2000; Flannery et al., 2015), though a recent systematic review 
suggested that both IIV and LAIV can provide a degree of cross protection (vaccine efficacy (VE) 42-
75%) against non-matching circulating strains (Tricco et al., 2013).  
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1.1.5.2  Safety of influenza vaccines  
IIVs are considered safe in healthy adults (Vellozzi et al., 2009). Local injection site reactions are 
frequently reported, but systemic side effects such as fever, malaise and myalgia are uncommon 
(Jefferson et al., 2014a). A minor increase in the risk of Guillain-Barré syndrome (GBS) has been 
reported in older adults (estimated at 1 to 1.6 additional case per million persons vaccinated) (Juurlink 
et al., 2006; Salmon et al., 2013).  IIVs have also been found to be safe in pregnancy; no study to date 
has demonstrated an increased risk of maternal complications, or adverse foetal outcomes (Englund 
et al., 1993; Zaman et al., 2008; Naleway et al., 2014; Tamma et al., 2009). IIVs are contraindicated in 
individuals who have had a severe allergic reaction to eggs or a previous influenza vaccine, or GBS 
within 6 weeks of receiving an influenza vaccine (England, 2013). 
LAIV have been associated with mild transient upper respiratory tract symptoms, but no serious 
adverse events (Rudenko et al., 1996; Jefferson et al., 2014a). This vaccine is not recommended for 
pregnant women or adults with immunosuppression (England, 2013; Grohskopf et al., 2015), but is 
licensed for children aged 2-17 years with stable HIV infection receiving antiretroviral therapy (ART)  in 
the UK (England, 2013; Children's HIV Association, 2015).  
1.1.5.3  Vaccine efficacy in healthy adults 
Previous studies of influenza vaccines in healthy adults have estimated vaccine efficacy at between 70 
and 90% (Fiore et al., 2008). However, a comprehensive review in 2014 suggested that efficacy may be 
much lower (Jefferson et al., 2014a). The meta-analysis of randomised trials and observational studies 
found that IIV3 provided around 60% (95% confidence interval (CI) 53-66%] protection against 
virologically-proven inﬂuenza infection, with a number needed to vaccinateii (NNV) of 71 (95%CI 65-
80) (Jefferson et al., 2014a). The VE was similar when there was mismatch between the vaccine strains 
and circulating viruses (VE 55% (95% CI 41-66%), NNV 60 (95%CI 50-80) (Jefferson et al., 2014a). IIV4s 
are as effective as IIV3 based on non-inferior immunogenicity for the three shared antigens (Beran et 
al., 2013; Greenberg et al., 2013; Kieninger et al., 2013; Pepin et al., 2013; Tinoco et al., 2014). 
Additional benefit through protection against the additional influenza B strain has also been 
demonstrated (Beran et al., 2013; Kieninger et al., 2013; Pepin et al., 2013; Tinoco et al., 2014). 
However, the magnitude of this additional benefit is dependent on the circulating influenza B strain 
and the degree of cross protection between the B strains. 
Immune responses are often attenuated in the elderly and those with underlying conditions. However, 
vaccination can still protect against severe disease, complications such as bronchopneumonia, hospital 
admission and death (Mangtani et al., 2004; Baxter et al., 2010; Puig-Barbera et al., 2012; Ridenhour 
                                                        
ii This expresses the number of adults needed to be vaccinated to prevent one case of influenza. 
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et al., 2013; Kwong et al., 2013). As for LAIV, overall efficacy of 53% (95% CI 32-54%) has been 
reported, corresponding to a NNV of 39 (95%CI 32-54) (Jefferson et al., 2014a). As stated above, 
although LAIV appears to have better clinical efficacy than IIIV in children (Ambrose et al., 2008), 
studies in adults have shown that IIV is equivalent or more effective than LAIV (Edwards et al., 1994; 
Ohmit et al., 2006; Monto et al., 2009; Wang et al., 2009; Phillips et al., 2013). 
1.1.6  Treatment of seasonal influenza in healthy adults 
There are 2 classes of antiviral drugs for influenza: M2 protein inhibitors (amantadine, rimantadine), 
which are only active against influenza A, and neuraminidase inhibitors (NIs) (oral oseltamivir and 
inhaled zanamivir), which are active against influenza A and B. NIs are recommended as first-line 
antiviral treatment (World Health Organization, 2010d), as most of the currently circulating influenza 
A viruses are resistant to M2 inhibitors (2010).  
Oseltamivir given as post-exposure prophylaxis has been shown to be ~55% effective (95%CI 33-70%) 
in preventing symptomatic influenza, but had no effect on hospitalisation (Jefferson et al., 2014b). 
However, recent reviews on the effects of NI used as treatment on symptom duration and outcomes 
are conflicting. An updated Cochrane review of 46 randomised controlled trials (RCTs) challenged the 
value of antiviral use for influenza prevention and treatment as it reported only a modest reduction of 
illness duration (0.7 and 0.6 days with oseltamivir and zanamivir respectively), no effect on 
hospitalisation (relative risk 0.92, 95%CI 0.57-1.50), but an increased risk of gastrointestinal symptoms 
(Jefferson et al., 2014b). A more recent meta-analysis of RCTs (n=9) on oseltamivir use in adults with 
Influenza-like illness (ILI) demonstrated a similar reduction in symptom duration in those who received 
oseltamivir, but noted fewer lower respiratory tract complications requiring antibiotics (risk ratio (RR) 
0.56, 95%CI 0.52-0.75) and hospitalisations (RR 0.37, 95%CI 0.17-0.81) (Dobson et al., 2015). A 
separate meta-analysis of 78 studies on >29,000 hospitalised patients with 2009 H1N1 influenza 
infection reported 19% reduction of death in adults treated with NI at any time in hospital with 
influenza (adjusted odds ratio (aOR) 0.81, 95%CI 0.70-0.93), and if given within 48 hours of symptom 
onset, halved the risk of death compared to no treatment (aOR 0.50, 95%CI 0.37-0.67) (Muthuri et al., 
2014).  
There are numerous methodological reasons for the observed differences. Firstly, the Cochrane 
Review included studies that were statistically underpowered and were not designed to assess the 
effects of antivirals on severe influenza outcomes. On the other hand, the latter two studies were 
industry-funded, which may have introduced bias in study selection. Although Dobson et al. (Dobson 
et al., 2015) utilised individual patient data from all trials rather than aggregated study results, which 
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is the preferred approach for a meta-analysis (Lyman and Kuderer, 2005), only Roche-funded RCTs 
were included. With regards to the meta-analysis by Munthuri et al. (Muthuri et al., 2014), concerns 
have been raised regarding the inadequate handling of time-dependent bias (e.g. timing of treatment 
in relation to death, time between illness onset and presentation to care, and time between hospital 
admission and treatment initiation); the small proportion (19%) of available data included; and the 
lack of quality assessment of data (Kmietowicz, 2014; Jones et al., 2014; Antes and Meerpohl, 2014). 
At present, NIs are recommended in individuals with severe disease (e.g. requiring hospitalisation) or 
those at risk of complications (defined in Section 1.1.4.2, in addition to morbidly obese individuals) 
(World Health Organization, 2010d; National Institute for Health and Care Excellence, 2009). 
Oseltamivir can cause mild nausea and vomiting, and occasionally psychiatric and renal side effects. 
Bronchospasm and decline in respiratory function have been reported with zanamivir use in patients 
with asthma and COPD, hence it is contraindicated in this group.  
A promising agent on the horizon is nitazoxanide. Currently used as an anti-parasitic agent, it appears 
to have anti-influenza activity by blocking the maturation of viral HA at the post-translational level 
(Rossignol et al., 2009). In a recent randomized Phase 2b/3 trial, nitazoxanide was associated with a 
significant reduction in the median duration of symptom from 117 to 96 hours in patients with acute 
uncomplicated influenza (Haffizulla et al., 2014).  
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1.2  The Epidemiology of Influenza in sub-Saharan Africa  
As evident from Chapter 1.1, the substantial contribution of influenza to morbidity and mortality in 
the developed world is well described (World Health Organization, 2014c). In contrast, the 
epidemiology and burden of influenza in sub-Saharan Africa (SSA) are less well characterized. Lack of 
awareness of the disease, similarity of clinical presentation with other febrile illnesses such as malaria 
and bacterial pneumonia, inadequate diagnostic capacity, and prioritisation towards other high-
burden public health problems are likely contributory factors. As a result, the lack of epidemiological 
data was often interpreted as an absence of influenza disease (Yazdanbakhsh and Kremsner, 2009). 
However, since ~920 million people reside in SSA (Population Reference Bureau, 2014), and many 
countries in the region have high prevalence of co-morbidities, such as HIV, malaria and tuberculosis 
(TB), in addition to other factors common to low-resource settings, e.g. malnutrition and scarce health 
resources (Schoub, 2010), the illness burden is likely to be far greater than assumed.  
1.2.1  The impact of 1918 and 1968 influenza pandemics on SSA 
Published evidence suggests that the 1918 A(H1N1) and 1968 A(H3N2) pandemics had a significant 
impact on SSA. Sub-Saharan Africa missed the mild initial wave of the 1918 pandemic influenza 
A(H1N1) (Patterson, 1981). However, the severe second wave arrived in Freetown, Sierra Leone by an 
English ship, and also in East African coastal cities (Mombasa and Beira) by ships from Asia between 
August and September 1918, and rapidly spread from these locations through the continent via ship, 
river boat and railway (Patterson and Pyle, 1983). The rapidity of spread was attributed to wartime 
mobilisation of soldiers and labourers, and more importantly, the newly created colonial railway 
network (Patterson and Pyle, 1983). A death toll of 2.2 million in SSA was estimated, with a 
corresponding mortality rate of 23 per 1000 population (Johnson and Mueller, 2002), which is 
substantially higher than the global rate of 2.5 to 5 per 1000 population. This data also support the 
belief that the pandemic did not originate in Africa, since East and West Africa were infected 
separately, and the disease appeared to have been introduced at major ports (Patterson and Pyle, 
1983). 
A systematic review of published articles on human infection with the 1968 influenza A(H3N2) 
pandemic also reported high level of morbidity in all African regions (Ortiz et al., 2012). Community 
attack rates of ~20% were reported, comparable to studies from North America, Europe and Australia 
(Jackson et al., 2010). 22–64% of clinic patients and 8–72% of hospitalized patients tested by viral 
culture or serology had evidence of 1968 H3N2 virus infection (Ortiz et al., 2012).  
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1.2.2  Seasonal influenza epidemiology of SSA prior to 2009 Influenza A(H1N1) pandemic 
A systematic review of seasonal influenza epidemiology in SSA illustrated the scarcity of published 
data in the region (Gessner et al., 2011). It included 49 studies from 14 countries between 1980 and 
2009; the main findings are summarised in Table 1.2. Over half of the studies were from South Africa 
and Madagascar; both countries have served as WHO National Influenza Centres for over 30 years 
(McAnerney et al., 2012; Orelle et al., 2012). Seasonality trends, particularly outwith the southern 
African region, remain unclear. Eight studies described seasonal influenza outbreaks, several of which 
reported alarmingly high case fatality rates  (1.5-2.5%) (2003; 2002). Influenza diagnosis was made by 
viral culture, serology or immunofluorescence assay (IFA) by most studies; only two used molecular 
tests, such as polymerase chain reaction (PCR) (2003; Besselaar et al., 2004), which have superior 
sensitivity and are now considered the gold standard for respiratory viral diagnosis (Mahony, 2010). 
The review concluded that most countries in SSA had insufficient data to develop rational strategies 
for influenza control. Additionally, a number of important data gaps were highlighted, including 
influenza incidence and mortality; seasonality over a number of years; its contribution to adults 
hospitalised with ARI; interaction of influenza with malaria, tuberculosis and malnutrition; school and 
workplace absenteeism related to influenza; vaccine interventions; and economic burden of influenza 
(Gessner et al., 2011). Of note, a WHO-led consultation on the ‘Public Health Research Needs for 
Influenza in Africa’ in 2012 identified similar research objectives to the review authors (World Health 
Organization, 2012a).   
1.2.3  The impact of 2009 Influenza A(H1N1) pandemic on SSA 
During the initial months of the pandemic, a number of reports emerged from South Africa (Archer et 
al., 2009; Koegelenberg et al., 2010) and Madagascar (Rajatonirina et al., 2011; Rajatonirina et al., 
2012a; Rajatonirina et al., 2012b; Orelle et al., 2012), where the first imported cases of influenza 
A(H1N1)pdm09 were described on 14 June 2009 and 12 August 2009, respectively. 
In South Africa, 12,331 cases and 91 deaths were reported in the first 3 months of the pandemic 
(Archer et al., 2009). Amongst the deceased cases, the most common underlying conditions included 
HIV infection (17/32, 53%), pregnancy (25/45, 56% women of reproductive age), and active 
tuberculosis (TB) (7/72, 10%). Fatal cases had a significantly higher median age compared to non-fatal 
cases (34 vs. 15 years, p<0.01). A case series of 19 intensive care unit (ICU) admissions in Cape Town 
with confirmed influenza A(H1N1)pdm09 also found a high prevalence of risk factors for severe 
disease, including pregnancy (n = 6), type 2 diabetes mellitus (n = 6), obesity (n = 4), HIV infection (n = 
3), immunosuppressive therapy (n = 3) and active pulmonary TB (n = 2) (Koegelenberg et al., 2010).  13  
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Table 1.2  Summary of studies included in the systematic review of seasonal influenza epidemiology in SSA - 1980-2009 (Gessner et al., 2011)  
Characteristic  Studies (n) Countries (ref) Findings/Comments 
Seasonality 11   Kenya (Hazlett et al., 1988) 
  Madagascar (Ravaoarinoro et al., 
1982; Morvan et al., 1990; Rakoto-
Andrianarivelo et al., 1993) 
  Nigeria (Olaleye et al., 1989) 
  Senegal (Dosseh et al., 2000) 
  South Africa (McAnerney et al., 1994; 
Karstaedt et al., 2009) 
  The Gambia (Forgie et al., 1992; 
Mulholland et al., 1999) 
  Zambia (Mizuta et al., 1997) 
- Strong seasonal trend seen in Southern African countries 
(South Africa, Zambia and Madagascar) in cool, dry 
months [June to August], but year-round activity in 
Senegal. 
- 3 studies had <20 influenza-positive cases. 
 
Outbreak 8   DRC (2003) 
  Madagascar (Clerc et al., 1980; 
Cassel-Beraud et al., 1988; 2002; 
Soares et al., 2003) 
  Reunion island (Lassalle et al., 1998) 
  South Africa (Besselaar et al., 2004) 
  Zambia (Mizuta et al., 1995) 
- 2 studies were in schoolchildren (Besselaar et al., 2004; 
Mizuta et al., 1995); the others were of all ages. 
- Proportion of samples influenza-positive 6 to 95% (mean 
41%; median 28%). 
- High case fatality rates (CFR) were reported in DRC 
(1.5%) (2003) and Madagascar (2.5%) (2002). 
Proportion of outpatient 
respiratory illness associated 
with confirmed influenza (all 
ages) 
12   Cote D’Ivoire (Nichol et al., 1995) 
  Kenya (Gachara et al., 2006) 
  Madagascar (Ravaoarinoro et al., 
1982; Morvan et al., 1990; Rakoto-
Andrianarivelo et al., 1993; United 
Nations Development Programme, 
2014) 
  Nigeria (Olaleye et al., 1989) 
  Senegal (Dosseh and Rogier, 1996; 
Dosseh et al., 2000) 
  South Africa (Schoub et al., 1986; 
McAnerney et al., 1994) 
- 1-25% patients with ARI were influenza positive (mean 
9.5%; median 10%). 
- Surveillance period <12 months (n=3). 
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  Zambia (Mizuta et al., 1997) 
Proportion of inpatient adult 
respiratory illness associated 
with confirmed influenza 
2   Ethiopia (Aderaye, 1994) 
  Kenya (Scott et al., 2000) 
- 7/104 (7%) (Aderaye, 1994) and 14/281 (5%) (Scott et 
al., 2000) were positive for influenza. 
Incidence (children only) 1   South Africa (Madhi et al., 2000) - Influenza-associated hospitalisation 1268/100,000 in 
HIV-infected and 148/100,000 in HIV-uninfected 
children <2 years. 
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of the 19 patients died. Another case series of ICU admissions with A(H1N1) in Reunion Island 
between 2009 and 2010 also reported a high prevalence of co-morbidities (22/25, 88%) and 
mortality (12/25, 49%) (Gauzere et al., 2011). In Madagascar, 20% more deaths than expected were 
seen following the first wave of 2009 A(H1N1) pandemic, particularly from respiratory disease, with 
excess mortality in those aged >50 years (Rajatonirina et al., 2012b). 
As expected, very few laboratory-confirmed deaths due to influenza A(H1N1)pdm09 were reported 
to the WHO from the African region (n=168, April 2009 - August 2010) (World Health Organization, 
2010b). However, a modelling study of global mortality associated with the first 12 months of the 
pandemic estimated that 29% of the 201,200 respiratory deaths occurred in the region. The 
estimated mortality rate in the region (~7 per 100,000 population) was around 2 to 4 times higher 
than other regions (1.7-3.0 per 100,000) (Dawood et al., 2012).  
On the milder end of the disease spectrum, sero-epidemiological studies on influenza 
A(H1N1)pdm09 were performed on household cohorts in the Reunion Island (Dellagi et al., 2011), 
Mali (Koita et al., 2012) and Djibouti (Andayi et al., 2014), as part of the Cohorts for Pandemic 
Influenza (CoPanFlu) programme (Table 1.3). Seroprevalence was high across all three studies (27-
73%). Dellagi et al. (Dellagi et al., 2011) reported a 3-fold higher seroincidence of A(H1N1)pdm09 
infection than that estimated from clinical surveillance in the Reunion island cohort, indicating that 
around two thirds of infections in the community escaped medical detection. 
In all age groups, pre-pandemic HAI titres of >1/40 prevented seroconversion, and likely protected 
against infection. In all three studies, individuals aged <20 years were the most affected; the highest 
seroconversion rates were observed in this age group.  
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1.2.4  SSA since the 2009 Influenza A(H1N1) pandemic 
 
1.2.4.1  Influenza surveillance: 2010-2015 
The emergence of the influenza A(H1N1) pandemic in 2009, and to an extent the highly pathogenic 
avian influenza A(H5N1) in 2003 (World Health Organization, 2014a), led international organisations, 
such as the Centers for Disease Control and Prevention (CDC), WHO, and Institut Pasteur, to 
galvanise efforts with local health authorities and governments to strengthen epidemiological and 
laboratory surveillance capacity for influenza and other respiratory viruses in SSA (World Health 
Organization, 2012a; Steffen et al., 2011; World Health Organization, 2009c; Steffen et al., 2012). As 
of 2015, 22 of the 47 countries in SSA contribute routine influenza surveillance data to the WHO 
Global Influenza Surveillance and Response system (GISRS) (Figure 1.4) (World Health Organization, 
2015b). 
 
 
 
  
Table 1.3  Sero-epidemiological studies in SSA during the 2009 influenza A(H1N1) pandemic 
Study, 
year  
Country Study period Study population Seroprevalence 
HAI > 1:40 
Seroconversiona 
Dellagi et 
al., 2011  
Reunion 
Island 
July-Dec 2009 1687 individuals, 
772 households 
 <20yrs 29.8%b  
20-59yrs 35.6% b 
>60yrs 73.3% b 
<20yrs 63.2% 
20-59 39.4% 
>60yrs 16.7% 
Koita et 
al., 2012  
Rural Mali  202 individuals 4-19yrs 31.0% 
20-53yrs 27.8% 
4-19yrs 18.4% 
20-53yrs 12.2% 
Andayi et 
al., 2014  
Djibouti Oct 2010-Feb 2011 1045 individuals, 
324 households  
 <25yrs 35.9% 
>65yrs 29.5%   
 
HAI, haemagglutination inhibition assay 
aDefined as seronegative (HAI <1:40) to seropositive, or a 4-fold increase in HI titre between first and second paired serum 
sample, if first sample was seropositive ((HAI >1:40) 
bSerum sample obtained within the first two weeks of A(H1N1)pdm09 activity on Reunion Island, therefore represents 
baseline seroprevalence 
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To identify publications on influenza epidemiology in SSA published since 2009, a literature search 
was conducted using the same search terms as the review (Gessner et al., 2011): the National 
Library of Medicine was searched through PubMed for (“influenza” AND “Africa”) OR (“Africa” AND 
(“pneumonia” OR “acute respiratory infection”)) OR (“influenza” AND each individual sub-Saharan 
African country). The search was limited to human studies, studies that included adults, and studies 
published between 1 January 2010 and 31 July 2015.  
Over the 5.5-year period, 37 influenza surveillance studies from 25 countries were identified (Table 
1.4), reflecting the rapid expansion in surveillance activity as well as growing interest in influenza 
epidemiology in the region. A complete supplement was devoted to ‘Influenza in Africa’ in the 
Journal of Infectious Diseases in December 2012. The highest number of publications came from 
Kenya (n=8), South Africa (n=5), and Senegal (n=5), all of whom had surveillance platforms in place 
prior to the 2009 A(H1N1) pandemic. 
Most studies used the WHO- and CDC-recommended case definitions for ILI and SARI (Pan American 
Health Organization & Centers for Disease Control and Prevention (PAHO-CDC), 2006). However, the 
maximum time from symptom onset to recruitment varied from 3 (Njouom et al., 2010; 
Razanajatovo et al., 2011; McAnerney et al., 2012; Niang et al., 2012; Theo et al., 2012; Dia et al., 
2014b; Majanja et al., 2013) to 14 (Ahmed et al., 2012; Feikin et al., 2012c; Emukule et al., 2014) 
days, and hospitalization was not a requirement for some SARI definitions. A number of Kenyan 
studies used ‘acute respiratory infection’ (ARI), a variation of the SARI case definition, which  
 
 
Figure 1.4  The 22 SSA countries 
(dark green) that contribute 
influenza surveillance data ot 
the Global Influenza 
Surveillance and Response 
System (GISRS) in 2015  
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Table 1.4  Summary of influenza surveillance studies in SSA published since 2009 
  
Country 
  
Study 
  
Surveillance 
period 
  
Full 
years 
  
ILI sites 
  
SARI 
sites 
No. of specimens tested 
for influenza 
 No. of influenza-positive specimens     
Peak 
season   ILI (N) SARI (N)   Influenza + ILI (N,%) Influenza + SARI 
(N,%) 
  
North              
Sudan Enan et al., 2013  2010-2011a N  1b   400   64 (16)  Jan-Mar 
Central              
Cameroon Njouom et al., 
2010  
2007-2008 Y 7 -  238 -  70 (29) -  Nov-Dec 
Cameroon Njouom et al., 
2012  
2009 Y 14 -  561 -  158 (28) -  Jun-Jul; Oct-Nov 
DRC Muyembe 
Tamfum et al., 
2012 
2009-2011 N 5 2  3217 939  502 (16) 103 (11)  Jan-May 
Gabon Lekani-Douki et 
al., 2013 (Lekana-
Douki et al., 2013)  
2010-2011 Y 6 -  966 -  131 (14) -  Mar-May, Nov-Jan 
Gabon Lekani-Douki et 
al., 2014  
2010-2011 N 6 -   1041 -    119 (11) -    Oct-Mar 
Rwanda Nyatanyi et al., 
2012 
2008-2010 Y 6 6  945 971  276 (29) 101 (10)  Oct-Nov, Feb-Mar 
West              
Senegal Niang et al., 2012 
 
1996-2009 Y 2-13 -  9176 -  1233 (13) -  Jul-Sep 
Senegal Dia et al., 2014b 2009-2011 Y NS -  232 -  67 (29)   Sep-Nov 
Senegal Dia et al., 2014a  2012-2013 N 11 -  1427 -  317 (22)   Sept-Oct (Flu A);  
Jan-Aug (FluB) 
Cote d'Ivoire Kadjo  et al., 2012  2003-2010 Y 26 -  5074 -  969 (19) -  Mar-Sep 
Nigeria Dalhatu et al., 
2012 
2009-2010 N 4 4  2053 338  167 (8) 17 (5)  Year-round 
Senegal, Cape 
Verde, 
Mauritania, 
Guinea 
Dia et al., 2013 2009-2010 N NS -  Senegal 2264      
Cape Verde 498 
Mauritania 227  
Guinea 166 
-  Senegal 717 (32)  
Cape Verde 132 (27) 
Mauritania 42 (19) 
Guinea 20 (12) 
-  NS 
Niger Jusot et al., 2012 2009-2010 Y 10 10  320c  -  76c(24) -  Mar-May 
Niger Mainassara et al., 
2015 
2009-2013 Y 5 4  1176 952  146 (12) 54 (6)  Nov-Apr 
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ILI sites 
 
SARI 
sites 
 No. of specimens tested 
for influenza 
 No. of influenza-positive specimens   
Country Study Surveillance 
period 
Full 
years 
  ILI (N) SARI (N)   Flu+ ILI (N,%) Flu+ SARI (N,%)   Peak season 
West (continued)             
Togo Maman et 
al.,2014 (Maman 
et al., 2014)  
2010-2012 N 2 -  955 -  236 (25) -  Year-round  
Burkina Faso Tarnagda et al., 
2014 
2010-2012 N 6 -   881  -   58 (7) -    Oct-Mar (2010-11) 
Aug-Apr (2011-12) 
East              
Ethiopia Ayele et al., 
2012 
2008-2010 N 3 2  59 117  7 (12) 5 (4)  May-Jul 
Kenya Feikin et al., 
2012c 
2007-2009 Y - 7  - 2079  - 204 (10)  May-Oct 
Kenya Feikin et al., 
2012b 
2007-2010 Y           
Kenya Katz et al., 2012 2007-2010 Y Biweekly 
HH visits 
2  Urban 35652      
Rural 25799 
Urban 1197 
Rural 1641 
 -   Urban 319 (27)  
Rural 359 (22)  
 Year-round  
Kenya Ahmed et al., 
2012  
2007-2010 Y 2 2  1815 4449  252 (14) 516 (12)  May-Nov 
Kenya Katz et al., 2014 
(Katz et al., 2014)  
2007-2013 Y 11 11  14013 24762  2041 (15) 237 (10)  Year-round 
Kenya Majanja et al., 
2013 
2008-2011 N 8 -  11592 -  2073 (18) -  Year round  
Kenya Pretorius et al., 
2012 
2009-2010 N - 6  - 8173  - 704 (9)  Jun-Oct 
Kenya Emukule et al., 
2014 
2009-2012 Y 1 1  1508 4387  206 (14) 348 (8)  Year-round  
Madagascar Razanajatovo et 
al., 2011 
2008-2009 Y 9 -  313 -  97 (31) -  Year-round 
Tanzania Mmbaga et al., 
2012 
2008-2010 N 5 5  1083 695  89 (8) 51 (7)  Year-round 
Uganda Lutwama et al., 
2012 
2007-2010 N 10 5  2656 102  353 (13) 6 (6)  Jun-Oct 
South              
South Africa (McAnerney et 
al., 2012) 
1984-2008 Y 10-170 -   (2005-08) 5211 -    (2005-08) 1811 (35) -  May-Aug 
South Africa Cohen et al., 2013 2009-2011 N - 6  - 11925  - 1056 (9)  May-Sept 
South Africa Cohen et al. 2014 2009-2012 N - 6  - 16005  - 1239 (8)  May-Sept 
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ILI sites 
 
SARI 
sites 
 No. of specimens tested 
for influenza 
 No. of influenza-positive specimens   
Country Study Surveillance 
period 
Full 
years 
  ILI (N) SARI (N)   Flu+ ILI (N,%) Flu+ SARI (N,%)   Peak season 
South (continued)             
South Africa Budgell et al. 
2015 
2009-2012 N 205 6  9104 18293  NS (41) NS (8)  May-Sept 
South Africa Cohen et al., 
2015c  
2009-2012 N - 6  - 7067  - 621 (9)  May-Sept 
Zambia Theo et al, 2012 2008-2009 N 4 2   334 900   17 (5) 40 (4)   Jun-Aug  
Multiple countries             
Cameroon, 
Côte d'Ivoire, 
Madagascar, 
Niger, Senegal 
Heraud et al., 
2012 
 
2008-2009 Y NS 
 
 Senegal 1458 
Niger* 113          
Côte d’Ivoire 2473   
Cameroon 811 
Madagascar 3457 
  Senegal 409 (28)    
Niger 21 (19)                      
Côte d’Ivoire 547 (22)                    
Cameroon 212 (26) 
Madagascar 1417 (41) 
 2008: year-round 
activity in Côte 
d’Ivoire, Cameroon, 
and Madagascar; 
Senegal - Aug-Oct. 
2009: May-Nov for all 
countries except 
Madagascar = Jan-
Mar & May-Sep 
Cameroon, 
Cape Verde, 
Cote d'Ivoire, 
Ghana, Guinea, 
Mali, 
Mauritania, 
Niger, Nigeria, 
Senegal 
(Nzussouo et al., 
2012) 
2009-2010 N 110  Cameroon 470 
Cape Verde 498 
Cote d’Ivoire 1272 
Ghana 4032 
Guinea 98 
Mali 422 
Mauritania 127 
Niger 388 
Nigeria 1322 
Senegal 1546    
  Cameroon 165 (35) 
Cape Verde 133 (27)  
Cote d’Ivoire 492 (39) 
Ghana 883 (22) 
Guinea 12 (12) 
Mali 53 (13) 
Mauritania 31 (24) 
Niger 90 (23) 
Nigeria 123 (9) 
Senegal 599 (39) 
   
ILI, influenza-like illness; SARI, severe acute respiratory illness; DRC, Democratic Republic of Congo; Y, Yes; N, No; NS, not stated; HH, household. 
aEnrolled patients between January and March each year; bPatients with acute respiratory infection (undefined) were enrolled from a hospital. 
cIncludes both ILI & SARI patients; Published in Journal of Infectious Diseases ‘Influenza in Africa’ supplement.
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encompassed cough OR difficulty breathing OR chest pain AND documented axillary temperature 
>38.0C OR oxygen saturation <90% OR hospitalization (Feikin et al., 2012b; Katz et al., 2012).  In 
contrast to the studies in the earlier review (1980-2009), influenza was diagnosed using real-time 
reverse transcriptase polymerase chain reaction (rRT-PCR) in all studies except one (McAnerney et 
al., 2012).  
Most studies included all age groups, with the exception of Feikin et al. (>5 years) (Feikin et al., 
2012b), Cohen et al. (>5 years) (Cohen et al., 2015c), and Dia et al. (>50 years) (Dia et al., 2014b). 
The surveillance populations were predominantly young children (the median age was <5 years in 
22/30 studies). 14 studies included both ILI and SARI surveillance, 15 undertook ILI surveillance only, 
and 7 solely SARI surveillance. Just over half the studies had complete years of surveillance (table 
1.3); among those, influenza-PCR positivity ranged from 10 to 41% (median 24%) for ILI cases; and 4 
to 27% (median 9%) for SARI cases (Table 1.4). In studies that included both ILI and SARI surveillance, 
the detection rate of influenza was consistently higher in ILI compared to SARI cases.   
Seasonality is difficult to discern since all but 5 studies (Njouom et al., 2010; Razanajatovo et al., 
2011; Feikin et al., 2012c; McAnerney et al., 2012; Niang et al., 2012) included part of the influenza 
A(H1N1)pdm09 period, which disrupted seasonal patterns on the continent in 2009 and 2010. The 
available data suggest that countries in Southern Africa had clearly defined seasons – influenza 
activity was usually highest between May and September each year, in line with Southern 
Hemisphere winters. In contrast, seasonality is less clear-cut in the equatorial regions of the 
continent. Some have year-round activity, while in several countries in central and western Africa, 
influenza peaked in their corresponding rainy seasons (Niang et al., 2012; Kadjo et al., 2012; 
Nyatanyi et al., 2012).  
Most the surveillance studies overlapped with the 2009 A(H1N1) pandemic period (June 2009 to 
August 2010), hence were able to shed some light on the epidemiological impact of the pandemic. 
Consistent with the findings from the serosurveys (Section 1.2.3), several studies found that children 
and young adults aged <25 years had a higher risk of infection with A(H1N1)pdm09 compared to 
other age groups (Dia et al., 2013; Orelle et al., 2012; Cohen et al., 2014). This finding is supported 
by a global pooled analysis of 70,000 laboratory-confirmed hospitalized A(H1N1)pdm09 patients 
from 19 countries (including Madagascar and South Africa), which found the highest risk of 
hospitalization in patients aged <5 years and 5-14 years (relative risk (RR) 3.3 and 3.2, respectively, 
compared to the general population). However, the highest risk of death per capita was found in the 
age groups 50–64 (RR 1.5) and >65 years (RR 1.6) (Van Kerkhove et al., 2011b). Increased exposure 
or outbreaks at schools could explain the increased risk seen in older children and adolescents 
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(Rajatonirina et al., 2011; Orelle et al., 2012). 
In summary, substantial progress has been made to enhance influenza surveillance capacity in SSA, 
with an increasing number of countries, and sentinel sites conducting surveillance. These data show 
that, similar to other parts in the world, influenza is an important contributor to mild and severe 
acute respiratory disease in African individuals of all ages. Improved surveillance data on SARI have 
bettered our understanding of the role of influenza in hospitalised patients, a group that is especially 
pertinent from a clinical and public health perspective. The consistent detection of influenza in a 
higher percentage of ILI compared to SARI cases likely reflects the higher specificity of ILI case 
definition for influenza (Murray et al., 2013). 
Nevertheless, data are absent from approximately half the countries in SSA. A large proportion of 
published studies did not include complete years of surveillance. Influenza seasonality outside of 
Southern Africa remains unclear. Additional years of surveillance post 2009A(H1N1) pandemic may 
help to elucidate influenza transmission patterns in the equatorial regions (see also Section 1.2.5 on 
the challenges of influenza surveillance in SSA). 
1.2.4.2  Incidence estimates of influenza disease in SSA 
Since 2009, a number of studies have estimated the burden of influenza-associated medical 
attendances or hospitalisations (Table 1.5). Although slightly different case definitions for acute 
respiratory infection were used, the incidence rates for influenza-related hospitalisations were 
similar in the three Kenyan (Feikin et al., 2012b; Emukule et al., 2014; Fuller et al., 2013) and one 
South African study (Cohen et al., 2013). Cohen et al. (Cohen et al., 2013) demonstrated higher 
incidence of influenza-related hospitalisations in individuals aged 25-44 years compared to the 5-24 
and >45 age groups, which may be due to the underlying high HIV prevalence in this group. In 
contrast, Katz et al. (Katz et al., 2012) reported an incidence of influenza-associated medical 
attendances for acute lower respiratory tract infection (LRTI) of 1630 per 100,000 (95% CI 1500-
1700), which is ~40 time higher than the other two Kenyan studies. Although genuine variations in 
disease burden may exist, the substantial disparity may be partly explained by the inclusion of 
children <5years, which constituted a large proportion of the study population (mean age 9.8 years), 
and had considerably higher rates of acute respiratory illness. Moreover, the incidence measure was 
of influenza-associated medical attendances, rather than hospitalisations. It is likely that only a very 
small proportion of medical attendances would have resulted in hospital admission. 
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Table 1.5  Summary of studies that estimated influenza incidence in SSA 
  
Country 
  
Study 
  
Surveillance 
period 
  
Outcome 
 Age group 
(years) 
Per 100,000  
Adjustments Incidence 95% CI 
Kenya Feikin e al., 
2012c  
2007-2009 Influenza-associated respiratory 
illnessa hospitalisation 
 
>5  36.7 33.0-44.4 -  proportion of eligible patients who 
presented to hospital but not sampled  
- proportion of patients from whom swabs 
were taken but not tested for influenza  
Kenya Katz et al., 2012  2007-2010 Medically-attended influenza-
associated acute LRTIb 
All ages 1630 1500-1700 - proportion of eligible patients who 
presented to health facility but not 
sampled 
Kenya Fuller et al., 
2013 
2009-2011 Influenza-associated SARIc 
hospitalisation 
All ages 21-24 - - Provincial proportion of influenza-
positive SARI applied to provincial rates 
hospitalized SARI, and adjusted for 
prevalence of risk factors and health-
seeking behaviour 
Kenya Emukule et al., 
2014  
2009-2012 Influenza-associated SARIc 
hospitalisation 
>5  30 20-40 - proportion of eligible patients who 
presented to hospital but not sampled 
South 
Africa 
Cohen et al., 
2013  
2009-2011 Influenza-associated acute LRTId 
hospitalisation 
5-24  
25-44 
>45 
8-27 
58-68 
47-67 
- 
- 
- 
- proportion of eligible patients not 
enrolled 
             Abbreviations: CI = confidence interval; LRTI = lower respiratory tract infection; SARI = severe acute respiratory illness. 
              aDefined as cough, difficulty breathing or (if aged ≥ 5 years) pleuritic chest pain. 
                     bDefined as cough, difficulty breathing, or chest pain, and either axillary temperature >38.0°C or oxygen saturation <90%. 
                     cDefined as hospitalization with cough or difficulty breathing or pleural chest pain with an onset within the last 14 days. 
dDefined as hospitalization with sudden onset fever (>38.0°C) or reported fever, cough or sore throat, and shortness of breath or difficulty breathing, with onset within 7 days.    
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1.2.4.3  Risk factors for complications of seasonal influenza  
Beyond baseline demographics and clinical symptoms, few surveillance studies in SSA had recorded 
individual-level data to allow evaluation of risk factors for severe presentations of influenza. Only five 
studies have reported HIV status (Feikin et al., 2012b; Cohen et al., 2013; Emukule et al., 2014; Cohen 
et al., 2015b; Cohen et al., 2015a). Recent publications of surveillance data from South Africa found 
that HIV infection was strongly associated with severe influenza-related morbidity and mortality in 
SARI patients (Cohen et al., 2013; Cohen et al., 2015a; Tempia et al., 2015b). High prevalence of co-
infections with Mycobacterium tuberculosis (10%) and Streptococcus pneumoniae (7%), as well as 
underlying medical co-morbidities such as chronic lung or heart disease and diabetes (7%) was also 
found among influenza-positive patients (Cohen et al., 2013). Another study from South Africa in the 
pre-ART era, found that HIV-infected adults aged 25 to 54 years had a 150 to 200-fold increased risk 
influenza-associated death compared with the general population (Cohen et al., 2012a). 
A retrospective case control study in rural Kenya of 64 hospitalised patients >5 years of age with 
laboratory-confirmed influenza, and 190 age-, sex- and neighbourhood-matched healthy controls 
found that persons with HIV infection (adjusted odds ratio (aOR) 3.56, 95%CI 1.25-10.1) and chronic 
lung diseaseiii (aOR 6.83, 95%CI 1.37-34.0) were at greater risk of influenza-associated hospitalisation 
(Ope et al., 2011).  
The limited data from SSA to date suggest that HIV may be an important risk factor for severe 
presentations of influenza. The existing evidence on the impact of HIV infection on influenza illness is 
further explored in Chapter 1.4. 
1.2.5  Challenges of influenza surveillance in SSA 
From Section 1.2.3, it is clear that major strides have been made towards improving influenza 
surveillance in SSA and elucidating the regional burden of influenza. Nevertheless, there are still 
enormous challenges to obtaining good quality and representative surveillance data in the region. 
Surveillance capacities remain limited in certain SSA countries (Steffen et al., 2012). Outcome data are 
rarely reported. A recently published review on mortality associated with SARI patients enrolled in 
influenza surveillance found that few African countries systematically collect data on respiratory 
hospitalization outcomes. Only 11 of 23 (48%) surveyed countries systematically collected mortality 
data (McMorrow et al., 2015). Of 37,714 SARI patients included from 8 countries between 2009 and 
2012, 1073 deaths were reported of whom 57 tested positive for influenza (case fatality proportion 
(CFP) = 1.8%) (McMorrow et al., 2015).  
                                                        
iii Excluded active pulmonary tuberculosis or asthma. 
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In existing programmes, variability in surveillance methods, including case definitions, testing 
algorithms, age categorisations, methods of sample collection (nasopharyngeal (NP) aspirate, 
nasopharyngeal and/or oropharyngeal swabs) and consumables (e.g. type of viral transport medium) 
limits easy comparisons within and between countries. Secondly, many sentinel surveillance 
programmes have limited geographical representation, thus affecting generalizability of their findings. 
Thirdly, RT-PCR is now considered the gold standard for influenza diagnosis (WHO working group on 
polymerase chain reaction protocols for detecting subtype influenza A viruses, 2011). However, the 
requirements for reliable power source, access to reagents, consumables, trained technicians and 
skilled maintenance, in addition to robust sample transfer and storage systems, present significant 
logistical challenges to achieve high quality diagnostic standards in low-resource settings (Fields et al., 
2013). Fourthly, timely dissemination of surveillance data is often hindered by suboptimal data 
analysis and reporting mechanisms (Steffen et al., 2011). Furthermore, the sustainability of the current 
costly surveillance programmes is unclear. At present, many programmes are funded by external 
institutions, such as the CDC and Institut Pasteur, but this will not remain indefinite (Radin et al., 
2012). Active engagement and commitment from local governments are needed to sustain 
surveillance programmes in the long-term.  
1.2.6  Interventions against influenza  
In developed countries, annual vaccination (with IIV or LAIV, Chapter 1.1.5.1) is the cornerstone of 
influenza prevention (Monto, 2010; 2013). However, few countries in SSA have national influenza 
vaccine policies (Duque et al., 2014), and the requirement for annual vaccination is a major financial 
and logistical obstacle for many sub-Saharan African countries. A CDC survey in 2012 reported 
seasonal influenza vaccine availability in 14 of 31 (45%) surveyed African countries, in either the public 
or private sector (Duque et al., 2014). Only 2 SSA countries (Côte d’Ivoire and Mauritius) reported to 
have an active national public policy for influenza vaccination (Duque et al., 2014). Of note, South 
Africa has standing guidelines for the prevention and treatment of influenza but has yet to develop a 
national public policy regarding vaccination (Walaza and Cohen, 2015). 
Only a handful of studies have evaluated efficacy or effectiveness of IIV in Africa; and all were 
conducted in South Africa. A randomised double blind placebo-controlled trial of IIV3 in HIV-infected 
adults demonstrated vaccine efficacy of 75.5% (95%CI 9.2%-95.6%) (Madhi et al., 2011), which is 
comparable to that in developed settings (Anema et al., 2008). However, patients with underlying co-
morbidities and advanced immunosuppression (ART naïve with CD4 <100 cells/μL) were excluded. 
From an ILI surveillance programme between 2005 and 2009, age-adjusted vaccine effectiveness of 
IIV3 ranged from -14% (95%CI -100% to 35%) to 67% (95%CI 12%-90%) (Ntshoe et al., 2014). Low 
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vaccine coverage (approximately 4% among ILI cases) may have reduced the power to estimate 
vaccine effectiveness (Ntshoe et al., 2014). More recently, an RCT of IIV3 in HIV-infected and HIV-
uninfected pregnant women demonstrated partial clinical efficacy in both groups (VE in HIV-infected 
pregnant women 57.7%, 95%CI 0.2-82.1, HIV-uninfected pregnant women 50.4%, 95%CI  14.5-71.2) as 
well as in infants unexposed to HIV (VE 48.8%, 95%CI 11.6-70.4) (Madhi et al., 2014). LAIV is not 
recommended in immunosuppressed adults or pregnant women, thus unsuitable for widespread use 
in sub-Saharan Africa where HIV prevalence is high. Even if annual seasonal influenza vaccination 
became national policy, its implementation would be logistically challenging. There is currently no 
indigenous vaccine production in the region (Schoub et al., 2013). Additionally, the vaccine donation 
initiative that provided 2009 pandemic H1N1 vaccines also highlighted problems in timely vaccine 
procurement, distribution and uptake in the region (Schoub et al., 2013). 
Neuraminidase inhibitors (NI) is only available in limited quantities in some SSA countries (19/31 (65%) 
from a CDC survey (Duque et al., 2014)). NIs are most effective if administered within 48 hours of 
symptom onset (Aoki et al., 2003); though as discussed in Section 1.1.6, their widespread use outside 
at-risk groups in developed settings is being questioned (Jefferson et al., 2014b). At present, given the 
broad differential diagnosis of acute respiratory presentations in high HIV prevalence settings, lack of 
‘real-time’ viral testing, in addition to the restricted availability and prohibitive cost, the widespread 
and effective use of antivirals in the region is improbable. 
Estimation of vaccine and antiviral needs in SSA will depend on further evaluation of epidemiology and 
disease burden. In 2012, the WHO Strategic Advisory Group of Experts on Immunization (SAGE) 
designated pregnancy as the highest priority target group for vaccination (2012), and advised 
countries considering the introduction of seasonal influenza vaccination programme to evaluate 
influenza burden in at-risk populations to facilitate the development of evidence-based immunization 
policies based on country-specific priority target groups (2012). The relative priority of at-risk groups 
in SSA is likely to differ from that of developed settings. Furthermore, the development of a tailored 
response to influenza in Africa will require a better understanding of how influenza interacts with 
prevalent diseases such as HIV, TB and pneumonia; more data on circulating strains in the region to 
aid decision on the most appropriate vaccine formulation (Northern/Southern hemisphere 
formulations); and vaccine effectiveness studies in priority groups in Africa such as young children (<5 
years), pregnant women and HIV-infected individuals with advanced immunosuppression and co-
morbidities.  
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1.3  Contribution of Influenza and other respiratory viruses to the aetiology and 
outcome of adult pneumonia in sub-Saharan Africa 
1.3.1  Introduction 
Community-acquired pneumonia (CAP) is a leading cause of morbidity and mortality in all age groups 
worldwide (World Health Organization, 2008). The African continent bears a disproportionate burden, 
accounting for approximately 30% of the estimated 430 million episodes of lower respiratory tract 
infections (LRTI) each year (World Health Organization, 2008). Until recently, worldwide, pneumonia 
was largely attributed to bacterial pathogens, e.g. Streptococcus pneumoniae and Haemophilus 
influenzae (Welte et al., 2012; Peto et al., 2014). However, the advent of sensitive molecular tests 
(Ruuskanen et al., 2011; Lanaspa et al., 2014), emergence of severe acute respiratory syndrome 
(SARS), avian influenza A(H5N1) and 2009 pandemic influenza A(H1N1) virus, which often manifested 
as severe pneumonia, in addition to the recent discovery of novel respiratory viruses (e.g. bocavirus, 
coronaviruses NL63, HKU1, Middle East respiratory syndrome [MERS] and human metapneumovirus 
[hMPV]), have led to the growing recognition of viruses as major contributors to severe respiratory 
infections. 
Available data on the contribution of viruses to adult CAP are predominantly from studies in 
developed settings (Ruuskanen et al., 2011; Lanaspa et al., 2014), where up to a third of adult 
pneumonia were associated with viral infection (Jennings et al., 2008; Johansson et al., 2010; 
Lieberman et al., 2010; Jain et al., 2015). The epidemiology and viral aetiology of pneumonia in African 
adults are less well characterised (Ho, 2014), due to comparatively limited surveillance and diagnostic 
capacities, but are likely to substantially differ from developed settings for a variety of reasons. First, 
respiratory viruses tend to follow different seasonal patterns of activity. Epidemics of influenza occur 
during winter months in temperate regions, whereas emerging data from SSA indicate less distinct 
influenza peaks, particularly in equatorial regions (World Health Organization, 2014b) where a number 
of countries have reported year-round transmission (Dalhatu et al., 2012; Katz et al., 2012; Mmbaga et 
al., 2012). Secondly, high prevalence of HIV and other co-morbidities (e.g. tuberculosis and malaria) in 
SSA are likely to impact on the epidemiology and microbial aetiology of adult viral respiratory 
presentations (Joint United Nations Programme on HIV/AIDS, 2010). In contrast to the U-shaped age 
distribution seen in developed settings (Jokinen et al., 1993), several pneumonia aetiology studies in 
SSA have described a preponderance of younger adults (aged 15-45 years) (Scott et al., 2000; 
Tornheim et al., 2007). Thirdly, individuals with immunosuppression are at increased risk of severe 
disease. A study from South Africa described higher incidence of influenza-related hospitalization and 
mortality in HIV-infected compared with HIV-uninfected adults (also see Chapter 1.4) (Cohen et al., 
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2013). Lastly, targeted (Monto, 2010) or universal (Grohskopf et al., 2014) seasonal influenza 
vaccination is recommended in many developed settings, but few African countries have implemented 
national influenza vaccination programmes (Duque et al., 2014).  
1.3.2  Diagnosis of respiratory viral infections 
There is currently no gold standard for respiratory viral aetiology detection. Conventional methods, 
such as viral culture and immunofluorescence microscopy of respiratory specimens, or serological 
testing of acute and convalescent serum samples, have poor sensitivity (Gunson et al., 2005). Nucleic 
acid amplification tests (NAATs), such as PCR-based methods, have far greater sensitivity (Mahony, 
2010), are able to detect viruses that are difficult to culture (e.g. hMPV, coronaviruses NL63 and HKU1, 
and rhinovirus), can rapidly characterise new viral pathogens (Murdoch et al., 2010), and can yield 
results in a clinically relevant time frame. Studies in well-resourced settings have demonstrated higher 
microbial yield when conventional diagnostic techniques are augmented by NAATs (Templeton et al., 
2005; Jennings et al., 2008; Johansson et al., 2010; Diederen et al., 2009), the latter now form the 
backbone of respiratory viral testing in both well resourced and surveillances sites in low-income 
settings. 
A variety of upper and lower respiratory tract specimens have been used for aetiological studies of 
ARI, including nasopharyngeal aspirates (NPA) or washes; swabs from the nasopharynx or throat; 
expectorated or induced sputum; bronchoalveolar lavage (BAL) or transthoracic needle aspiration 
(Loens et al., 2009). Viral recovery varies according to specimen type. For the aetiological diagnosis of 
pneumonia, lower respiratory tract samples are preferred since they are taken from the site of 
infection (Murdoch et al., 2009; Karhu et al., 2014), but they are difficult to obtain without 
contamination from upper respiratory flora and are unavailable in many low resource settings. Viral 
diagnosis therefore mostly relies on upper respiratory specimens, but the high sensitivity of molecular 
tests complicates the interpretation of a positive result (Jansen et al., 2011). Aside from being the 
causative agent, a positive result may represent colonisation or post-infectious shedding. Thus, 
ascribing causality to every positive result may overestimate the contribution of respiratory viruses. 
Quantifying viral load (Bosis et al., 2008; Gerna et al., 2009) or ascertaining the background prevalence 
of asymptomatic nasopharyngeal viral infection in a control group (Feikin et al., 2012b; Levine et al., 
2012) may aid characterisation the pathogenic roles of detected viruses, but neither approach has 
commonly been used in aetiological studies.  
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1.3.3  Viral aetiology of acute respiratory infection in adults in sub-Saharan Africa 
Most aetiology studies undertaken in developed settings have focused on radiologically-confirmed 
pneumonia (Jennings et al., 2008; Templeton et al., 2005; Johansson et al., 2010; Diederen et al., 
2009; Saito et al., 2006; Lieberman et al., 2010; de Roux et al., 2006; Charles et al., 2008; Johnstone et 
al., 2008; Angeles Marcos et al., 2006). Given the inconsistent availability of chest radiographs in SSA 
health settings (Saito et al., 2012), a broader definition of pneumonia was adopted to include clinical 
evidence of LRTI with or without confirmed chest radiograph changes. Studies that evaluated viral 
aetiology in patients with mild respiratory symptoms (not requiring hospitalisation) were also included 
to assess the relative contribution of respiratory viruses in mild and severe ARI.  
To identify studies in SSA that had evaluated respiratory viruses in adults presenting with mild and 
severe ARI, a literature search using the PubMed database from inception till 15/03/2015 was 
conducted using the following search strategy: (“acute respiratory infection*”[All Fields] OR “acute 
respiratory illness*” [All Fields] OR “influenza-like illness*” OR “acute lower respiratory tract 
infection*” [All Fields] OR “pneumonia”[All Fields] OR “pneumonia”[MeSH Terms]) AND (“virus*”[All 
Fields] OR “viral”[All Fields]) AND (“Africa”[MeSH Terms] OR “Africa*”[All fields]). Only studies with 
patients aged five years and over were included. Those that exclusively examined for bacterial 
pathogens or a single virus (e.g. influenza surveillance) were excluded (Figure 1.5). 
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Nine studies were identified; four in patients with ILI (Razanajatovo et al., 2011; Kadjo et al., 2013; 
Lekana-Douki et al., 2014; Dia et al., 2014a), four in hospitalised patients with pneumonia or clinical 
LRTI (Joosting et al., 1979; Scott et al., 2000; Hartung et al., 2011; Pretorius et al., 2012), and one that 
included both outpatient and inpatient ARI patients (Feikin et al., 2012b) (Figure 1.5, Tables 1.7 and 
1.8). There were substantially more respiratory viral aetiology studies in young children (n=50) 
compared to adults, and a large proportion of excluded adult studies were reports from influenza 
surveillance following the 2009 A(H1N1) pandemic (Koegelenberg et al., 2010; Njouom et al., 2010; 
Barakat et al., 2011a; Barakat et al., 2011b; Byarugaba et al., 2011; Lahlou Amine et al., 2011; Van 
Kerkhove et al., 2011a; Archer et al., 2012; Barakat et al., 2012; Bulimo et al., 2012; Cohen et al., 
 
Figure 1.5  Identification and selection of studies that have evaluated viral aetiology of acute 
respiratory infection in adults in SSA 
RSV, respiratory syncytial virus; VZV, varicella zoster virus. 
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2012c; Dalhatu et al., 2012; Heraud et al., 2012; Katz et al., 2012; Lenzi et al., 2012; McAnerney et al., 
2012; Muyembe Tamfum et al., 2012; Niang et al., 2012; Orelle et al., 2012; Radin et al., 2012; Steffen 
et al., 2012; Theo et al., 2012; Venter et al., 2012; Byarugaba et al., 2013; Cohen et al., 2013; Matheka 
et al., 2013; Cohen et al., 2014; Katz et al., 2014; Meseko et al., 2014; Ntshoe et al., 2014; Tarnagda et 
al., 2014; Thiam et al., 2014; Wolter et al., 2014a; Cohen et al., 2015a; Cohen et al., 2015c; McMorrow 
et al., 2015).  
The nine included studies comprised 1753 non-hospitalised ILI patients, and 5746 hospitalised LRTI 
patients. There was substantial heterogeneity in the study populations, clinical case definitions of ‘ILI’ 
and ‘pneumonia’, and clinical specimens obtained for viral testing (Table 1.6). Four of the 9 studies did 
not include whole years of observation (Lekana-Douki et al., 2014; Scott et al., 2000; Hartung et al., 
2011; Pretorius et al., 2012), which may have resulted in the over- or underestimation of the burden 
of viral infections depending on the study period included and the seasonal peaks. Two studies 
conducted prior to 2000 used viral culture and serology (Joosting et al., 1979; Scott et al., 2000); the 
others utilised PCR-based methods. All studies tested for influenza A and B, adenovirus and RSV, and 
most also included parainfluenza viruses (PIV) and enterovirus. The more recent studies have 
encompassed testing for rhinovirus, coronaviruses, hMPV and bocavirus. HIV prevalence was high (49-
94%) among the 3 studies that reported serostatus (Scott et al., 2000; Hartung et al., 2011; Feikin et 
al., 2012b).  
One or more viral pathogens were detected in 37.7 to 84.2% of ILI patients (Razanajatovo et al., 2011; 
Kadjo et al., 2013; Lekana-Douki et al., 2014; Dia et al., 2014a; Feikin et al., 2012b), and 5.7 to 58% of 
hospitalised pneumonia patients (Joosting et al., 1979; Scott et al., 2000; Hartung et al., 2011; 
Pretorius et al., 2012; Feikin et al., 2012b) (Table 1.7). This is similar to that reported in contemporary 
studies in developed settings (Jennings et al., 2008; Templeton et al., 2005; Hohenthal et al., 2008; 
Johansson et al., 2010; Diederen et al., 2009; Saito et al., 2006; Lieberman et al., 2010), though 
proportions tested positive for virus are not strictly comparable due to the variable number of 
respiratory viruses tested among studies. 
With the exception of one Gabonese study (Lekana-Douki et al., 2014), influenza and rhinovirus were 
the most ubiquitous among the 5 studies that included non-hospitalised ILI patients (Razanajatovo et 
al., 2011; Kadjo et al., 2013; Lekana-Douki et al., 2014; Dia et al., 2014a; Feikin et al., 2012b). 
Adenovirus (2.2-12.1%), parainfluenza viruses (3.8-12.2%), RSV (1.9-7.5%), coronaviruses (2.3-11.3%), 
hMPV (0.9-6.1%) and enteroviruses (2.3-5.5%) were also frequently detected. Conversely, human 
bocavirus was rarely detected in patients with ILI.  
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Table 1.6  Characteristics of studies on viral aetiology in adults with ARI in SSA 
Study, year 
[Reference] 
Country Study 
period 
Setting Study 
population  
Case definition  Specimen Viral 
diagnostic test 
Non-hospitalised       
Razanajatovo et 
al, 2011  
Madagascar Jul 2008- 
Jun 2009 
Outpatient clinic-
based surveillance 
>5 years ILI (Fever >38.0 C and 
cough and >2 symptoms of 
sore throat, rhinorrhea, 
headache and muscular 
pain; symptoms < 3 days) 
NP & OP swabs rRT-PCR   
Feikin et al, 
2012b (Feikin et 
al., 2012b)  
Kenya  Mar 2007-
Feb 2010 
Population-based 
surveillance 
>5 years  ARI (cough or difficulty 
breathing or chest pain and 
temperature >38.0 C or 
oxygen saturation <90%)  
NP & OP swabs rRT-PCR  
Njouom et al., 
2012  
Cameroon Jan - Dec 
2009 
Outpatient clinic-
based surveillance 
>5 years ILI (Fever >38.0 C and 
cough or sore throat; 
symptoms < 5 days) 
NP & OP swabs rRT-PCR   
Lekana-Douki et 
al, 2014  
Gabon Mar 2010- 
Jun 2011 
Outpatient clinic-
based surveillance 
>5 years ILI (Fever >38.0 C and 
cough or sore throat) 
NP swab rRT-PCR   
Dia et al, 2014b  Senegal Jan 2009-
Dec 2011 
Outpatient clinic-
based surveillance 
>50 years ILI (Fever >38.0 C and 
cough or sore throat; 
symptoms < 5 days) 
NP & OP swabs rRT-PCR   
Hospitalised        
Joosting et al., 
1979  
South Africa May 1966-
Apr 1972 
Hospital-based 
observational study 
Black 
miners 
Acute respiratory disease 
(definition not stated) 
Throat swabs & 
serum  
Viral culture  & 
serology (HAI 
or 
complement 
fixation) 
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Scott et al., 2000  Kenya Mar 1994-
May 1996 
Hospital-based 
observational study 
>15 years Pneumonia (>2 symptoms 
of fever, cough, sputum, 
chest pain, SOB, or 
haemoptysis; symptoms 
<14 days; consolidation on 
CXR) 
Serum Complement 
fixation 
Hartung et al., 
2011  
Malawi Feb-Sept 
2006 
Hospital-based 
observational study 
>18 years Pneumonia (>1 symptom 
of cough, sputum, chest 
pain, SOB, chest pain or 
haemoptysis; CXR changes) 
+ admission to HDU 
BAL fluid rRT-PCR   
Feikin et al., 2012  Kenya  Mar 2007-
Feb 2010 
Population-based 
surveillance 
>5 years  ARI (cough or difficulty 
breathing or chest pain and 
temperature >38.0 C or 
oxygen saturation <90% or 
hospitalisation)  
NP & OP swabs rRT-PCR  
Pretorius et al., 
2012  
South Africa Feb 2009-
Dec 2010 
Hospital-based 
surveillance                   
(6 hospitals) 
>5 years SARI (fever; cough or sore 
throat; shortness or breath 
or difficulty breathing; 
symptoms <7 days) 
NP & OP swabs rRT-PCR 
HAI, haemaglutination inhibition assay; SOB, shortness of breath; CXR, chest radiograph (x-ray); HDU, high dependency unit; BAL, bronchoalveolar lavage; rRT-PCR, real-
time reverse transcriptase polymerase chain reaction; ARI, acute respiratory infection; NP, nasopharyngeal; OP,oropharyngeal; SARI, severe acute respiratory infection.  
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Table 1.7  Results of studies on viral aetiology in hospitalised adults with ARI in sub-Saharan Africa 
Study, 
year 
n HIV 
prevalence 
(%) 
Virology result 
>1 virus Influenza  Adenovirus Rhinovirus PIV 1-4 RSV hMPV Other 
Non-hospitalized          
Razanajatovo 
et al.,2011a 
159 NS 134 (84.2) Any: 52 (32.7) 
A: 45 (28.3) 
B: 7 (4.4) 
 
6 (3.8) 39 (24.5) Any: 6 (3.8) 
PIV1: 2 (1.3) 
PIV2: 0 (0) 
PIV3: 4 (2.5) 
12 (7.5) 1 (0.6) Bocavirus 0 (0) 
HCoV OC43 12 
(7.5); NL63 3 
(1.9); 229E 2 
(1.3); HKU1 1 
(0.6) 
Njouom et 
al, 2012b  
311 NS 176 (56.6) Any: 110 (35.4) 
A: 108 (34.7) 
B: 1 (0.3) 
C: 1 (0.3)  
- 36 (11.6) Any: 12 (3.9) 
PIV1: 4 (1.3) 
PIV2: 0 (0) 
PIV3: 6 (1.9) 
PIV4: 2 (0.6) 
6 (1.9) 11 (3.5) Enterovirus: 17 
(5.5) 
Lekana-
Douki et al., 
2014c 
231 NS 87 (37.7) Any:  23 (9.9) 
A(H1N1)pdm09:  
13 (5.6) 
B: 10 4.3)  
28 (12.1) 4 (1.7) Any 19 (8.2) 
PIV1: 4 (1.7) 
PIV2: 4 (1.7) 
PIV3: 9 (3.9)  
PIV 4: 2 (0.9)  
15 (6.5) 4 (1.7) Enterovirus 9 
(3.9) 
HCoV OC43: 2 
(0.9); NL63: 5 
(2.2); 229E: 0 (0); 
HKU1: 1 (0.6) 
 
Dia et al., 
2014d 
232 NS 150 (64.6) Any: 67 (28.9) 
A: 52 (22.4) 
B: 15 (6.5) 
5 (2.2) 40 (17.2) Any 13 (5.6) 
PIV1: 3 (1.3) 
PIV2: 0 (0) 
PIV3: 4 (1.7) 
PIV4: 6 (2.6) 
7 (3.0) 5 (2.2) Bocavirus 1 (0.4) 
Enterovirus 6 
(2.3) 
HCoV Any: 6 (2.3) 
Feikin et al., 
2012be 
820j 49% 237 (28.9) Any: 84 (10.2) 
22 (2.7) 
62 (7.5) 
84 (10.2) 108 (13.2) 
k 
Any: 100 (12.2) 
PIV1: 17 (2.1) 
PIV2: 28 (3.4) 
PIV3: 55 (6.7) 
59 (7.2) 50 (6.1)  
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Study, year n HIV 
prevalence 
(%) 
Virology results 
>1 virus Influenza Adenovirus Rhinovirus PIV 1-4 RSV hMPV Other 
Hospitalised           
Joosting et 
al., 1979f 
1012 NS 477 (47.1) Any: 384 (37.9) 
A: 287 (28.4) 
B: 87 (8.6) 
C: 10 (1) 
45 (4.4) - 17 (1.7) 8 (0.8) - Enterovirus – 1 
(0.1)  
Scott et al., 
2000bg  
281  52% 16 (5.7) 17 (5) 
A: 12 (4.3)                            
B: 2 (0.7) 
2 (0.7) - - 0 -  
Hartung et 
al., 2011h,  
51 94% 11 (21.6) 
 
A: 1 1 (9) 4 (36)  PIV1: 1 (9) 1 (9)  Bocavirus: 1 (9) 
HCoV OC43: 1 
(9); NL63: 1 (9) 
Feikin et al., 
2012be   
396J 49% 65 (16.4) Any: 37 (9) 
A: 29 (7) 
B: 8 (2) 
29 (7) 39 (35)k  22 (6.5)  
 
 
33 (8) 10 (3)  
Pretorius et 
al., 2012i  
4006 
m 
NS 5-24 years 
– 51% 
25-44 years 
– 33.8% 
45-64 years 
– 28.7% 
>65 years – 
24.2% 
Any – 343 (8.6) 
A(H3N2): 102 (2.5) 
A(H1N1): 104 (2.6) 
B: 137 (3.4) 
 
251 (6.3%) 653 (16) Any: 145 (3.4) 
PIV1: 12 (0.3) 
PIV2: 27 (0.7) 
PIV3: 96 (2.4) 
134 (3.3) 62 (1.5) Enterovirus: 63 
(1.6) 
HIV, human immunodeficiency virus; NS, not stated; PIV, parainfluenza virus; RSV, respiratory syncytial virus; hMPV, human metapneumovirus.  
a Tested for Influenza A & B, adenovirus, rhinovirus, PIV1-3, RSV, hMPV, coronavirus OC43, NL63, 229E & HKU1, and bocavirus. 
b Tested for Influenza A, B & C, rhinovirus, PIV1-3, RSV, hMPV, and enterovirus. 
c Tested for Influenza A & B, adenovirus, rhinovirus, PIV1-3, RSV, hMPV, coronavirus OC43, NL63, 229E & HKU1 and enterovirus. 
d Tested for Influenza A & B, adenovirus, rhinovirus, PIV1-4b, RSV, hMPV, coronaviruses, bocavirus, and enterovirus. 
e Tested for Influenza A & B, adenovirus, PIV 1-3, RSV, and hMPV (also rhinovirus, enterovirus and parechovirus from January 2009). 
f Tested for Influenza A, B & C, adenovirus, PIV1-3, RSV, herpesvirus, and enterovirus. 
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g Tested for Influenza A & B, adenovirus, and RSV.  
h  Tested for Influenza A & B, PIV 1-4, adenovirus, rhinovirus, RSV, hMPV, coronavirus OC43, NL63 & 229E,  and bocavirus. 
i Tested for Influenza A & B, adenovirus, PIV 1-3, RSV, hMPV, rhinovirus and enterovirus. 
j Only included patients aged >5 years in whom naso/oropharngeal specimens taken. 
jInclude enterovirus due to cross-reactivity on real-time transcriptase polymerase chain reaction (RT-PCR). 
m Only included patients aged >5 years 
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Five studies included hospitalised patients with clinical or radiologically-confirmed pneumonia 
(Joosting et al., 1979; Scott et al., 2000; Hartung et al., 2011; Pretorius et al., 2012; Feikin et al., 
2012b). The earliest study, conducted in black South African miners hospitalised with acute 
respiratory disease (definition not stated), demonstrated respiratory viral infection in 47% of cases 
using viral culture and serology (Joosting et al., 1979). In particular, a high proportion of influenza A 
(28%) was found. The protracted influenza epidemic was attributed to the close working conditions 
that facilitated transmission, and high staff turnover, which maintained a pool of susceptible 
individuals. In contrast, a viral pathogen was only detected in 5.7% adults with hospitalised 
pneumonia in Kenya (Scott et al., 2000), though serology was the only viral diagnostic method used 
to test for a small number of viruses.  
A prospective observational study in pneumonia patients admitted to a high dependency unit (HDU) 
at a tertiary referral hospital in Malawi found a viral pathogen in 11/51 patients (22%) (Hartung et 
al., 2011) – three were assigned a final diagnosis of viral pneumonitis, while the rest had an 
alternative diagnosis (pulmonary Kaposi’s sarcoma) or pathogen (e.g. TB) that was considered the 
primary cause for their severe respiratory presentation. Selection bias towards those that were less 
severely ill was likely in this study, since it was limited to patients who could tolerate a bronchoscopy 
(with resultant exclusion of 39% of eligible patients, primarily with severe hypoxia). Additionally, 
two-thirds of patients had symptoms for greater than 3 weeks, which likely explains the high 
proportions of Pneumocystis jirovecii pneumonia (PCP) (27%) and pulmonary TB (22%) seen.  
The most recent studies were derived from epidemiological surveillance in Kenya (Feikin et al., 
2012b) and South Africa (Pretorius et al., 2012). Both reported high detection rates of viral infection 
(16-51%); rhinovirus and influenza were again the most prevalent viruses, followed by adenovirus, 
RSV and parainfluenza viruses. Feikin et al. (Feikin et al., 2012b) also enrolled asymptomatic hospital 
controls. The authors identified significant association of influenza A and B, hMPV and RSV with 
hospitalised ARI. Conversely, rhinovirus, enterovirus, and adenovirus were equally common among 
cases and controls. Pretorius et al. (Pretorius et al., 2012), the largest study to date with greater than 
4,000 patients, demonstrated the highest prevalence of viruses in hospitalised SARI patients aged 5-
24 years (51%), compared to older age groups (25-44 years, 34%; 45-64 years, 29%; >65 years, 24%). 
There was little difference in the prevalence of individual respiratory viruses between ILI and 
pneumonia (Table 1.5).  
Outcome data were sparse – mortality of 10% and 22% were reported by two of the hospitalised 
pneumonia studies by Scott et al. (Scott et al., 2000) and Hartung et al. (Hartung et al., 2011); Feikin 
et al. (Feikin et al., 2012b) found a case fatality ratio of 6% in individuals aged >5 years with 
hospitalised ARI. However, none of the studies reported clinical outcome according to underlying 
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viral or bacterial aetiology. Additionally, there were limited data on high-risk groups such as 
individuals with HIV infection or other co-morbidities; although Feikin et al. described higher 
incidence rates of all tested respiratory pathogens in HIV-infected compared to HIV-uninfected 
adults (Feikin et al., 2012b).  
1.3.4  Detection of multiple viruses 
Viral co-infections are increasingly identified as a result of the enhanced diagnostic sensitivity of PCR 
tests compared to conventional methods (Mahony, 2010) and the development of multiplex assays 
that enable simultaneous detection of multiple viruses from a single specimen (Mahony et al., 2007). 
The presence of several viruses could indicate: i) two or more viruses are contributing to ARI 
pathogenesis; ii) >1 detected virus is an innocent bystander; or iii) one virus is the predisposing 
factor (such as by damaging the respiratory epithelium) for pneumonia by the second viral 
pathogen. Some studies, mainly in children, report increased disease severity with mixed viral 
infection (Drews et al., 1997; Greensill et al., 2003; Semple et al., 2005; Templeton et al., 2005), but 
others have not (Subbarao et al., 1989; Peng et al., 2009). Hence the clinical significance of 
detecting multiple viruses remains unclear. 
Among the included ILI studies, detection of >1 virus ranged from 4.7% (Njouom et al., 2012) to 
31.4% (Razanajatovo et al., 2011) of enrolled patients. Only two of the hospitalised pneumonia 
studies from Kenya and South Africa reported viral co-infection (Feikin et al., 2012b; Pretorius et al., 
2012). Pretorius et al. (Pretorius et al., 2012) found mixed viral infection in 17% of hospitalised 
pneumonia patients (including children <5 years), but were unable to correlate co-infection with 
clinical outcome due to the low number of specific co-infection combinations. The Kenyan 
surveillance study demonstrated no difference in co-infection between inpatients and outpatients 
(15 vs. 19%, p=0.51) (Feikin et al., 2012b). Similar prevalence of rhinovirus and adenovirus were also 
found in cases and healthy controls, implying that their identification in ARI cases may not be 
clinically significant (Feikin et al., 2012b). These findings highlight the difficulty in the clinical 
interpretation of positive PCR tests. In the majority of included ILI and LRTI studies, viruses were 
identified from upper respiratory tract specimens (table 1.4).  
1.3.5  Limitations of existing studies 
The existing viral aetiology studies in SSA suggest a high prevalence of viral pathogens in adults 
presenting with mild and severe ARI, in particular, influenza, rhinovirus, adenovirus, coronaviruses, 
parainfluenza viruses and RSV. Viral co-infections are not uncommon. However, there are wide 
variations in time period, study population, ARI definitions, clinical specimens, diagnostic methods, 
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and number of viruses tested. Key questions that need to be answered in SSA include the 
contribution of respiratory viruses to hospitalised pneumonia and mortality in high HIV prevalence 
settings, and the impact of HIV on the frequency and severity of viral respiratory infections. 
Moreover, concurrent recruitment of a control group to define the background prevalence of 
asymptomatic viral infections may aid interpretation of the significance of positive PCR results.  
1.4  The impact of HIV infection on Influenza Illness 
1.4.1  Overview 
HIV infection increases susceptibility to a number of respiratory infections, including bacterial 
pneumonia (de Gaetano Donati et al., 2000; Sogaard et al., 2008) and pulmonary tuberculosis 
(Sonnenberg et al., 2005; Wood et al., 2000). Although influenza is commonly identified in HIV-
infected adults with acute respiratory infection (Klein et al., 2007; Klein et al., 2010), little is known 
about the epidemiology of influenza in HIV-infected individuals.  Published evidence on the impact 
of HIV infection on the susceptibility and severity of seasonal and pandemic influenza illness, as well 
as on influenza virus shedding and transmission in both low and high HIV prevalence settings will be 
reviewed in this chapter. 
1.4.2  Susceptibility 
1.4.2.1  High-income countries  
Seasonal influenza. The only published data on the susceptibility of seasonal influenza in HIV-
infected adults in low HIV prevalence settings include three outbreak investigations of influenza A in 
residential drug rehabilitation facilities (Table 1.9); two in the United States (Cohen and Macauley, 
1989; Fine et al., 2001) and one in Italy (Boschini et al., 2006). The first two studies, conducted in the 
pre-ART era, found no association between HIV infection and ILI (Cohen and Macauley, 1989; Fine et 
al., 2001). Cohen and Macauley (Cohen and Macauley, 1989) described a non-significant difference 
in ILI incidence between 7 HIV-infected and 38 HIV-infected residents in Boston. Fine et al. (Fine et 
al., 2001) reported a higher incidence of ILI in HIV-infected, compared to HIV-uninfected individuals 
(52 vs. 25%), but the association was confounded by cigarette smoking. Both studies had a small 
sample size. In the third study, a 2004 influenza A(H3N2) outbreak in Italy, HIV-infected residents 
(n=171) were more likely to report ILI compared with HIV-uninfected residents (n=1140) (26 vs. 14%, 
RR 1.77, 95%CI 1.32–2.37) (Boschini et al., 2006). CD4 cell count and HIV viral load were not 
associated with the risk of ILI among HIV-infected persons. Although this study was larger than the 
other two, it did not describe or account for potential confounders, such as smoking. Of note, ILI, 
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Table 1.8  Studies that evaluated influenza susceptibility between HIV-infected and HIV-uninfected adults 
Author, year of 
publication 
Country N Period CD4 count 
(cells/µl) 
Influenza virus 
strain 
Outcome Outcome frequency 
Seasonal influenza        
Cohen & Macauley, 
1989  
United States 45 Mar 1988 NS A(H1N1) ILI – fever, chills, myalgia, sore 
throat & productive cough 
HIV+ 0/7 (0%) 
HIV- 14/38 (37%) 
Fine et al., 2001  United States 133 Nov-Dec 1996 92% CD4 
<300 
Median 141, 
range 6-437 
A(H3N2) ILI - temp >37.8c + cough or 
sore throat OR >1 respiratory 
symptom + laboratory-
confirmed influenza 
HIV+ 38/73 (52%) 
HIV- 15/60 (25%) 
Boschini et al, 2006  Italy 1311 Feb-Mar 2004 87% CD4 
>200 
A(H3N2) ILI – Fever (>38c) + >1 
constitutional symptom + >1 
respiratory symptom 
HIV+ 44/171 (26%) 
HIV- 165/1140 (14%) 
RR 1.77 (1.32-2.37) 
Pandemic infl.uenza A(H1N1) 
Campos-Loza et al., 
2010  
Mexico 832 Apr-Jun 2009 NS A(H1N1)pdm09 Laboratory-confirmed 
influenza (rRT-PCR) 
HIV+ 11/20 (55%) 
HIV- 120/812 (15%) 
OR 7.0 (2.8-17.3) 
Martinez et al., 
2011  
Spain 2106 Apr-Dec 2009 5% CD4 
<200 
A(H1N1)pdm09 Laboratory-confirmed 
influenza (rRT-PCR) 
HIV+ 56/623a (9%) 
Althoff et al., 2011  United States 1790 Mar-Sep 2009 39% CD4 
<200 
A(H1N1)pdm09 Seroincidenceb Incidence (per 100 PYs): 
HIV+ 33.4 (26.4-42.3) 
HIV- 29.7 (21.3-41.3) 
       aIRR 1.20 (0.79-1.82) 
Hung et al., 2013  Taiwan 1497 Sept-Nov 2009 11% CD4 
<200 
Median - 
446 
A(H1N1)pdm09 Seroprevalencec 
Seroincidenced 
Seroprevalence: 
HIV+ 137/931 (14.7%) 
HIV- 192/566 (33.9%) 
Seroincidence:  
HIV+ 85/907 (9.4%) 
HIV- 44/429 (10.3%) 
Garg et al., 2014  Thailand 368 May 2008-May 2009 
Apr-May 2010 
Jan-Mar 2011 
NS A(H1N1)pdm09 Seroincidence HIV+ 55/157 (35%) 
HIV- 71/211 (34%) 
NS, not stated; ILI, influenza-like illness; RR, risk ratio; rRT-PCR, real-time reverse transcriptase polymerase chain reaction; OR, odds ratio; HAI, haemagglutination 
inhibition assay; aIRR, adjusted incidence rate ratio. 
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a HIV status of all patients tested (n=2106) not described in the paper 
b>4-fold increase in HAI titres 
cHAI titre > 1:40 
d>4-fold increase in HAI titres or conversion from seronegative to HAI titres >1:40 in 2 sequential serum samples 
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rather than laboratory-confirmed influenza, was the outcome in all three studies. Overall, data on 
the impact of HIV infection on susceptibility to seasonal influenza are limited. 
2009 Pandemic influenza A(H1N1). The 2009-2010 A(H1N1) influenza pandemic provided an 
opportunity to further investigate susceptibility to influenza infection by HIV status. Five studies 
compared rates of influenza A(H1N1)pdm09 infection between HIV-infected and HIV-uninfected 
adults; two based on PCR testing and three on serology (Table 1.9). At an emergency department in 
Mexico City, 11/20 (55%) HIV-infected and 120/812 (15%) HIV-uninfected patients attending with ILI 
were positive for A(H1N1)pdm09 (p<0.001) (Campos-Loza et al., 2010). Of note, the HIV-infected 
patients were older (median age, 47 vs. 36 years, p=0.12), and more likely to be a smoker (63 vs. 
13%, p=0.001). A case series of adults presenting with acute respiratory illness in Barcelona, Spain 
found that 56/623 (9%) with confirmed influenza A(H1N1) infection were HIV-positive (Martinez et 
al., 2011). This suggested overrepresentation of HIV-infected patients as the proportion far 
exceeded the HIV prevalence in Catalonia (0.6%) (Centre d’Estudis Epidemiològics sobre les 
Infeccions de Transmissió Sexual i Sida de Catalunya (CEEISCAT), 2008) . Similar to the Mexican 
study, HIV-infected patients were older (mean age, 44 vs. 39 years, p=0.015), more frequently male 
(79 vs. 44%, p<0.001), and more likely to smoke (54 vs. 13%, p=0.001) than the HIV-uninfected 
patients, but were less likely to be pregnant (0 vs. 11%, p=0.008) or have chronic lung disease (5 vs. 
26%, p<0.001) (Martinez et al., 2011).  
Three serology studies, conducted in the US, Taiwan and Thailand, found no association between 
HIV status and seroprevalence or seroincidence of pandemic influenza A(H1N1). Althoff et al. 
(Althoff et al., 2011) demonstrated no difference in seroincidence of A(H1N1)pdm09 infection 
(defined as a >4-fold increase in A(H1N1)pdm09 hemagglutination inhibition (HAI) antibody titre in 
serum samples collected between March and September 2009, compared with the same months in 
2007 or 2008) between HIV-infected women with CD4 >350 cells/µl and HIV-uninfected women 
(incidence rates of 33.3 (95%CI 26.4-42.3) and 29.7 (95% CI, 21.3-41.3) per 100 person years (PYs), 
respectively. Comparatively fewer seroconversion events occurred in HIV-infected individuals with 
CD4 cell count <350 cells/µl in this study (16.9/100 PYs), which the authors suggested might have 
been due to an inability to mount an adequate antibody response in this group thus infections may 
have been missed (Althoff et al., 2011). A Taiwanese study found a significantly lower 
seroprevalence (HAI titre >1:40) in HIV-infected individuals, compared to HIV-uninfected patients 
(14.7 vs. 33.9%, p<0.001), though seroconversion rates were similar (85/907 (9.4%) and 44/429, 
10.3%), in HIV-infected and HIV-uninfected patients respectively, p=0.60) (Hung et al., 2013). Of 
note, being heterosexual and ART treatment was associated with seropositivity. The authors 
suggested the former could be related to increased exposure to children with influenza, whilst the  
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latter may be explained by the recovery of memory B-cell subpopulation associated with ART (Hung 
et al., 2013).Lastly, Garg et al. (Garg et al., 2014) collected paired serum specimens from 368 Thai 
men who have sex with men (MSM) before and during the 2009 influenza A(H1N1) pandemic, and 
found similar seroincidences among HIV-infected (n=157) and HIV-uninfected  (n=211) adults (35 vs. 
34%, p=0.78).   
In summary, the limited and heterogeneous available data do not suggest greater susceptibility to 
seasonal or pandemic influenza infection in HIV-infected adults than in HIV-uninfected persons. The 
role of CD4 cell count in influenza susceptibility remains unclear. Other risk factors for influenza 
infection, such as smoking, are often more prevalent in HIV-infected individuals (Arcavi and 
Benowitz, 2004), and need to be accounted for in studies assessing the relationship between HIV 
and influenza susceptibility. 
1.4.2.2  Low- or middle-income countries  
Largely due to a lack of diagnostic capability, few studies in high HIV prevalence settings, such as 
SSA, have estimated the incidence of influenza disease (Chapter 1.2.3.2), or evaluated the impact of 
HIV infection on influenza burden. Although influenza surveillance capacity on the African continent 
has expanded considerably over the past decade (Radin et al., 2012), few published studies have 
reported HIV status. Only two SSA studies have studied the impact of HIV infection on the burden of 
influenza disease, both from population-based surveillance. Feikin et al. (Feikin et al., 2012b) found 
that HIV-infected Kenyan adults with acute respiratory infection had a greater burden of both 
influenza A (incidence rates 4.49 [95%CI 2.80-6.18] vs. 1.42 [95%CI 1.04-1.80] per 100 person-years 
of observation (PYO) and influenza B (incidence rate 0.92 [95%CI 0.32-1.52] vs. 0.44 [95%CI 0.25-
0.63] per 100 PYO) compared to HIV-uninfected adults. Cohen et al. (Cohen et al., 2013) also 
reported a 4-8 times higher incidence of influenza-associated acute lower respiratory tract infection 
(LRTI) in HIV-infected persons in South Africa compared with HIV-uninfected persons. Both studies 
were predominantly comprised of children ((Feikin et al., 2012b) 59% 5-17 years; (Cohen et al., 
2013) 53% <5 years), and had considerable missing data on HIV status. Furthermore, only 36% of 
eligible patients in the Kenyan study had viral testing (Feikin et al., 2012b).  
1.4.3 Severity 
1.4.3.1  Defining severity  
Accurate attainment of influenza-associated mortality is difficult; influenza infection is rarely 
confirmed by laboratory diagnosis, and influenza-related deaths are often attributed to co-morbid 
conditions or secondary infections. Consequently, severity of influenza disease is often inferred from 
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hospitalisation, duration of hospital stay, admission to intensive care unit, or requirement for 
mechanical ventilation. 
1.4.3.2  High-income countries 
Seasonal influenza. Early studies on the severity of influenza illness in HIV-infected adults were 
predominantly based on anecdotal reports or ecological studies. Several case series early in the HIV 
epidemic described severe clinical presentation and prolonged hospitalisation among HIV-infected 
individuals admitted with influenza, but did not include HIV-uninfected comparators (Thurn and 
Henry, 1989; Safrin et al., 1990; Radwan et al., 2000). An ecological study from the US noted a 
correlation between trends in pneumonia-attributable deaths among 25–44 year-old adults and 
influenza seasonality in cities with high incidence of acquired immunodeficiency syndrome (AIDS) 
(1988).  
Several other US studies conducted before the advent of ART described excess influenza-associated 
morbidity and mortality in HIV-infected compared with HIV-uninfected persons (Table 1.9) (Neuzil et 
al., 1999; Lin and Nichol, 2001; Fine et al., 2001). Neuzil et al. (Neuzil et al., 1999) compared the 
incidence rates of acute cardiopulmonary hospitalisations and deaths among women enrolled in a 
Medicaid programme in the US between 1974 and 1993 during and around influenza seasons. 
Among those with high-risk conditions, HIV-infected women had the highest influenza-attributable 
risk of acute cardiopulmonary events (152 per 10,000 person-months, 95%CI 34-279). However, 
confidence intervals overlapped with estimates for other high-risk conditions, as HIV prevalence was 
only 0.02% (Neuzil et al., 1999). Lin et al. (Lin and Nichol, 2001) estimated excess deaths due to 
pneumonia or influenza in persons aged >13 years with AIDS from Cause-of-Death data from the 
National Center for Health Statistics. Patients with AIDS were found to have a 8.5 to 10.3-fold excess 
mortality attributable to pneumonia or influenza compared to the general US population, and 106-
161 times higher when restricted to adults aged 25–54 years (Lin and Nichol, 2001). It is notable that 
neither study accounted for other respiratory infections, e.g. pneumococcal pneumonia, which likely 
contributed to excess hospitalization and death in this population. Moreover, CD4 cell count in HIV-
infected populations was not available. The third study, the aforementioned outbreak investigation 
at a US drug rehabilitation centre (Chapter 1.4.2.1) (Fine et al., 2001), found more severe ILI 
presentation (as defined by illness duration >14 days, requiring an emergency department visit, or 
hospitalization) in HIV-infected, compared to HIV-uninfected residents (8/38 (21%) vs. 0/15). 
However, all 8 HIV-infected individuals with severe presentation were smokers, and 3 had additional 
co-morbidities, thus the independent effect of HIV on influenza severity was undeterminable.    
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Table 1.9  Studies that have evaluated severity of seasonal influenza between HIV-infected and HIV-uninfected adults in high-income countries 
Adapted from Sheth et al. 2011a  
Author, year of 
publication 
Country Study population Period Outcome Outcome frequency 
Neuzil et al., 1999 
(Neuzil et al., 1999)  
United 
States 
Women (15-64 years) 
enrolled in Tennessee 
Medicaid programme 
1974-1993 Influenza-attributable rates of 
acute cardiopulmonary 
hospitalisation and death during 
influenza season per 10,000 
person-months of observation 
Women with high risk (including HIV): 
15-45 years: 10.3 
45-64 years- 26.4 
Women with low risk: 
15-45 years: 2.0 
45-64 years- 2.9 
Lin & Nichol, 2001  United 
States 
 Persons with AIDS vs. 
general population >13 years 
from Multiple cause-of-death 
data 
1991-1994 Deaths due to pneumonia & 
influenza (P&I) during influenza 
seasons per 10,000 person-years 
of observation 
Persons with AIDS: 9.4-14.7 
General population: 1.1-1.2 
Fine et al., 2001  United 
States 
133 residents & staff at drug 
rehabilitation facility during 
an influenza A outbreak 
Nov-Dec 1996 Severe influenza – prolonged 
illness (duration >14 days), 
required hospital evaluation or 
admission. 
Prolonged illness: 
HIV+ 6 (16%), HIV- 0 
Emergency room evaluation: 
HIV+ 3 (8%) HIV- 0 
Hospitalisation: 
HIV+ 2 (5%) HIV- 0 
Skiest et al, 2001  United 
States 
43 cases of laboratory-
confirmed influenza 
diagnosed at an HIV clinic 
1997-1999 Influenza-associated pneumonia Pneumonia: 7 (16%) 
Mean CD4 340, viral load 3.34 log10 
copies/ml 
No pneumonia: 36 (84%) 
Mean CD4 346, viral load 3.25 log10 
copies/ml 
Neuzil et al., 2003  United 
States 
HIV+ adults (15-50 years) 
enrolled in Tennessee 
Medicaid programme 
1995-1999 Influenza-attributable 
hospitalisation rates during 
influenza seasons 
1995-96 (pre-ART): 48/1000 persons 
1996-99 (ART): 5/1000 persons 
Boschini et al., 2006  Italy 44 HIV+ and 154 HIV- 
residents at drug 
rehabilitation facility during 
an influenza A outbreak with 
ILI 
Feb-Mar 2004 ILI-related complications – e.g. 
pneumonia, bronchitis, sinusitis, 
meningitis, pharyngitis and 
tracheitis. 
Risk of complication related to ILI 
HIV+ OR 5.13 (95% CI 2.52-10.20) 
AIDS, acquired immunodeficiency syndrome; ART, highly active antiretroviral therapy; ILI, influenza-like illness. 
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Since the widespread introduction of ART, several more studies have assessed the relationship 
between HIV and influenza severity. In a case series of 43 HIV-infected adults with laboratory-
confirmed influenza from an HIV clinic in Texas, 7 (16%) had pneumonia (Skiest et al., 2001). The 
majority of patients had a CD4 cell counts of >200 cells/µl (74%) and were on ART (42/43). No 
significant difference in CD4 count or viral load were noted in patients with, and without pneumonia 
(Skiest et al., 2001). A second study by Neuzil et al (Neuzil et al., 2003) using the Medicaid database 
described a dramatic decline in influenza-attributable hospitalizations following the introduction of 
ART (from 48 to 5 hospitalisations per 1000 persons, for 1995 and 1996-1999 respectively), but CD4 
count was not reported. Lastly, in the above-mentioned outbreak investigation at the drug 
treatment centre in Italy (Chapter 1.2.3.2) (Boschini et al., 2006), HIV-infected residents with ILI had 
a higher risk of complications (such as pneumonia, bronchitis, otitis and meningitis) than HIV-
uninfected residents (OR 5.13, 95% CI: 2.52-10.20), though CD4 cell count and viral load were not 
associated with the risk of complications (Boschini et al., 2006).  
Although a number of studies, mostly from the pre-ART or early-ART era, suggest increased severity 
and mortality from seasonal influenza among HIV-infected individuals, these data should be 
cautiously interpreted. The case series were limited by small sample sizes, and failed to control for 
confounders, while results from ecological studies are prone to ecological fallacy. 
2009 Pandemic influenza A(H1N1). Initial reports on the 2009 H1N1 pandemic from North America 
and Europe found that the proportion of patients hospitalized with A(H1N1)pdm09 that were HIV-
infected (1-3.4%) (Kumar et al., 2009; Louie et al., 2009; Fuhrman et al., 2010; Peters et al., 2011) 
exceeded the prevalence of HIV infection in those regions (<0.5%) (UNAIDS, 2013). However, 
selection bias is possible since HIV-infected individuals were more likely to be tested and admitted if 
they presented with illness. 
Two cases series of HIV-infected patients had contrasting findings. Perez et al. (Perez et al., 2010) 
described mild clinical presentation in 30 Chilean HIV-infected patients with confirmed or suspected 
influenza A(H1N1)pdm09 infection. Most were on ART (93%) and with a mean CD4 cell count of 423 
cells/µl. Only 3 patients required hospital admission, and none died. The estimated incidence of 
1.74% was similar to that of the general population of Chile (2.1%) (Perez et al., 2010). In contrast, a 
study from Mexico reported high rates of hospitalisation (n=16, 53%) and death (n=6, 20%) among 
30 HIV-infected patients (median CD4 cell count 163 cells/µl) with confirmed influenza 
A(H1N1)pdm09 infection (Ormsby et al., 2011). Of note, 40% (n=12) had a concurrent opportunistic 
infection (OI); this sub-group had significantly lower median CD4 count (87 vs. 294 cells/µl, p=0.007), 
and a more complicated clinical course, as indicated by more prolonged admission (p=0.001), higher 
requirement for mechanical ventilation (p=0.009) and higher mortality (p=0.03) (Ormsby et al., 
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2011). These findings suggest that influenza may be more severe in HIV-infected patients with 
advanced HIV disease. Conversely, the severity of presentation may have been attributable to the OI 
rather than influenza. 
Studies that have compared the severity of clinical presentation of A(H1N1)pdm09 between HIV-
infected and HIV-uninfected persons have demonstrated similar clinical outcomes (Table 1.10). 
Campos-Loza et al. (Campos-Loza et al., 2010) reported similar rates of hospitalization (27 vs. 25%, 
p=0.81), severe disease (9 vs. 7%, p=0.68), and death (9 vs. 5%; p=0.86) in HIV-infected and HIV-
uninfected persons who presented to an emergency room in Mexico city with laboratory-confirmed 
pandemic influenza A(H1N1) infection. A study from Singapore that compared 11 HIV-infected 
persons (cases; median CD4 cell count 223 cells/ µl; 82% on ART) to 66 HIV-negative individuals (no 
comorbid conditions (n=33); with >1 comorbid condition (n=33)) with confirmed A(H1N1)pdm09 
infection found no significant differences between cases and either control groups with regards to 
duration of illness or hospitalisation, and proportion of patients that required hospitalization or 
intensive care unit (ICU) support (Isais et al., 2010). A multi-centre Spanish study that included 26 
HIV-infected (median CD4 count 604 cells/µl; 84% had undetectable viral load) and 559 HIV-
uninfected patients who were hospitalised with influenza A(H1N1)pdm09 also demonstrated similar 
clinical outcomes in the two groups (Riera et al., 2010). Another study of Spanish adults hospitalised 
with pandemic A(H1N1) found that respiratory complications, such as pneumonia (9 vs. 25%, in HIV-
infected and HIV-uninfected groups respectively) and respiratory failure (9 vs. 21%, respectively) 
were less common in the HIV-positive group (Martinez et al., 2011). Finally, comparable rates of ICU 
admission (29 vs. 34%) and death (13 vs. 13%) were found among HIV-infected and HIV-uninfected 
adults hospitalised with pandemic A(H1N1) in the US (Peters et al., 2011).  
Two large multi-country reports described the prevalence of immunosuppression among 
hospitalised and fatal cases of confirmed A(H1N1)pdm09. The first, by the French Institute for public 
health surveillance (Institut de Veille Sanitaire), included 684 influenza-associated deaths in 28 
countries. Underlying comorbidities were reported in 193 (28%) deaths, but HIV infection was not 
specifically listed (Vaillant et al., 2009). Sixteen patients had ‘‘immunodepression’’ and 19 had 
‘‘infectious diseases other than flu’’. The majority of countries that contributed data to this report 
had low HIV infection prevalence (<1%). A second report that included 70,000 patients with 
laboratory-confirmed A(H1N1)pdm09 patients from 19 countries, found that 
“immunocompromised” patients had substantially increased risks of hospitalization (risk ratio (RR) 
24.3, 95%CI 16.1-32.6) and death (RR 27.7, 95%CI 14.0-66.5), compared to patients with normal 
immune function (Van Kerkhove et al., 2011b).  Unfortunately, specific evaluation of HIV as a risk 
factor was not possible as most of the countries that contributed data had low HIV prevalence (with  
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Table 1.10  Reported rates of hospitalisation, ICU admission, mechanical ventilation and death by HIV status during the 2009 influenza A(H1N1) pandemic 
(Sheth et al., 2011) 
Author, year of 
publication 
Country HIV 
prevalence 
Study population 
 
Total 
n(%) 
Hospitalisation 
n(%) 
ICU admission 
n(%) 
Mechanical 
ventilation  n(%) 
Died 
n(%) 
HIV+ HIV- HIV+ HIV- HIV+ HIV- HIV+ HIV- HIV+ HIV- 
Campos-Loza et 
al., 2010  
Mexico 0.3% HIV+ & HIV- adults 
with LCII 
11 94 3 (27) 24 (25) 1 (9) 7 (7) 1 (9) 7 (7) 1 (9) 5 (5) 
Isais et al., 2010  Singapore 0.2% HIV+ adults & matched 
HIV- controls with LCII  
11 66 6 (55) 36 (55) 2 (0) 2 (3) NR  NR 0 (0) 0 (0) 
Riera et al., 2010  Spain 0.5% Hospitalised adults 
with LCII 
26 (4) 599 26 
(100) 
559  
(100) 
3 (12) 68 (12) 2 (8) 50 (9) 0 (0) 13 (2) 
Martinez et al., 
2011  
Spain 0.5% Adults presenting to 
ED with LCII 
56 (9) 168 15 
(27)* 
70 
(42)* 
NR NR 5 (9)* 36 
(21)* 
0 (0) 3 (2) 
Peters et al., 
2011  
US 0.45% Hospitalised adults 
with LCII 
31 (3) 877 31 
(100) 
877 
(100) 
9 (29) 300 (34) 6 (21) 223 
(28) 
4 (13) 118 
(13) 
NR, not reported; ICU, intensive care unit; LCII, laboratory-confirmed influenza infection 
*p<0.05 
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the exception of South Africa) (Van Kerkhove et al., 2011b). 
Lastly, a study from New York (HIV prevalence ~1.4% (New York City Department of Health and 
Mental Hygiene, 2014)) found that 7 (15%) of 47 confirmed deaths associated with 2009 H1N1 
influenza had HIV infection (Lee et al., 2010). In a separate analysis comparing hospitalised patients 
with confirmed A(H1N1)pdm09 who died (n=28) and survived (n=95), deceased patients had a 
significantly higher proportion of immunosuppression (HIV infection not specified) than those who 
survived (29 vs, 3%; p<0.05); though it should be noted that other underlying conditions, such as 
diabetes and cardiovascular disease, were also more prevalent among those who died (Lee et al., 
2010).  
In brief, with the exception of Ormsby et al. (Ormsby et al., 2011), which included patients with 
advanced immunosuppression, most studies with well-controlled HIV populations did not find 
increased severity and mortality related to pandemic influenza A(H1N1) in HIV-infected individuals. 
1.4.3.3  Low- or middle-income countries  
Contrary to the studies described above, a number of studies derived from countries with high 
prevalence of HIV infection strongly suggest increased severity and risk of death among HIV-infected 
individuals (Table 1.11). A retrospective case control study conducted within a hospital-based 
influenza surveillance programme in rural Kenya observed a greater risk of influenza-associated 
hospitalisation in HIV-infected persons compared with HIV-uninfected adults (adjusted odds ratio 
3.56, 95% CI 1.25-10.07) (Ope et al., 2011). A hospital-based influenza surveillance study in South 
Africa between 2009 and 2011 found that HIV-infected individuals had more prolonged hospital stay 
(>7 vs. <2 days, OR 4.5, 95% 2.1-9.5) and were more likely to die (OR 3.9, 95%CI 1.1-14.1) (Cohen et 
al., 2013). However, HIV status was only available for 78% of patients who had a positive influenza 
PCR, and only a third of HIV-infected individuals had available CD4 cell count data (60% had CD4 cell 
count <200 cells/µl) (Cohen et al., 2013).  
A case series of 91 adult deaths due to influenza A(pdm09) in South Africa found that 17 (53%) of 32 
patients with known serostatus were HIV-infected (Archer et al., 2009), which was substantially 
higher than the national HIV prevalence of 17.9% (UNAIDS, 2013). Data on CD4 cell counts and ART 
status were not available. Additionally, among the fatal cases, 10% had tuberculosis and over a 
quarter were pregnant. The relative contribution of HIV-associated immunosuppression to these 
deaths is therefore difficult to discern.  
Another South African study modelled seasonal and pandemic influenza-associated deaths among 
persons aged >5 years between 1998 and 2009 using monthly surveillance and mortality data 
(Tempia et al., 2015b). HIV-infected persons aged 5-64 years had an excess risk of influenza- 
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Table 1.11  Studies that have evaluated severity of seasonal influenza between HIV-infected and HIV-uninfected adults in low- or middle income 
countries 
Author, year of 
publication 
Country Study population Period CD4 (cells/µl) &  
ART status 
Severity outcome Effect of HIV  
Ope et al., 2011  Kenya 64 Cases: Influenza-related 
hospitalization in persons aged 
>5 years 
190 Controls: Age-, sex-, and 
neighbourhood-matched 
controls 
2006-2008 HIV+: cases 24.5%, 
controls 12.5%  
Mean CD4: cases 399, 
controls 387 
Influenza-associated 
hospitalisation 
aORa 3.56 (95%CI 1.25-10.1) 
Cohen et al., 2013  South 
Africa 
11925 individuals (aged >2 
days) enrolled with hospitalised 
acute LRTI 
2009-2011 60% CD4 <200b Prolonged hospital stay 
(>7 vs. <2 days) 
Death 
aORc 4.5 (95% 2.1-9.5) 
 
aORc 3.9 (95%CI 1.1-14.1) 
Archer et al, 2009  South 
Africa 
91 adults deaths with confirmed 
influenza A(H1N1) 
2009 NR Death 17/32 (53%) with known HIV 
status  
Tempia et al., 2015  South 
Africa 
Persons aged >5 years who died 1998-2009 NR Influenza-associated 
mortality rate  
Age-adjusted relative risk: 
7.9 (7.1-8.9) 
Cohen et al., 2015a  South 
Africa 
1376 individuals with influenza-
associated SARI 
2009-2013 50% on ARTd Case fatality proportion 
 
Mortality incidence 
HIV+ 22/419 (5%) 
HIV-  13/620 (2%)  
HIV+ 24.8/100000 PYs 
HIV- 1.7/100000 PYs 
IRR 20.4 (95%CI 15.0-27.8) 
CI, confidence interval; LRTI, lower respiratory tract infection; aOR, adjusted odds ratio; NR, not reported; SARI, severe acute respiratory infection; PYs, person years; IRR, incidence rate ratio. 
aAdjusted for chronic lung disease, HIV status, cattle and chicken ownership. 
bAvailable for 33% HIV-infected individuals 
cAdjusted for age, underlying medical condition excluding tuberculosis and HIV, pneumococcal co-infection, influenza type, duration of hospitalisation and death. 
dAvailable for 50% HIV-infected individuals 
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associated death compared to HIV-uninfected persons (age-adjusted relative risk: RR 7.9, 95%CI 7.1-
8.9). Case fatality proportion (CFP) was higher in HIV-infected, compared with HIV-negative individuals 
(22/419 (5%) vs. 13/620 (2%) respectively, p=0.006) enrolled with influenza-positive SARI in a 
surveillance programme in South Africa between 2009 and 2013 (Cohen et al., 2015a). CD4 cell count 
was available for <30% HIV-infected individuals; CFP was higher in those with severe 
immunosuppression (CD4 <200 cells/µl) compared to those without severe immune compromise (16 
vs. 4% respectively, p=0.012). Among 251 (59%) HIV-infected individuals with data on ART status, 126 
(50%) reported receiving ART, but no difference in CFP was observed among those receiving or not 
receiving ART (5 vs. 7%, p=0.39). Adjusting for age, mortality rate was 20 times (95%CI 15.0-27.8) 
higher in HIV-infected individuals than HIV-uninfected individuals (Cohen et al., 2015a).  
In studies undertaken high HIV prevalence settings, a clear association between HIV infection and 
influenza-associated severe morbidity and mortality is emerging. Nevertheless, studies with 
comprehensive HIV data, and further understanding of the impact of CD4 and ART treatment are 
needed. 
1.4.4  Shedding 
The quantity of viral shedding is generally accepted as a proxy measure of infectiousness (Bell et al., 
2006), thus comparison of influenza virus shedding between HIV-infected and HIV-uninfected 
individuals would help inform infection control measures and influenza prevention and treatment 
guidelines for this population. Data comparing influenza virus shedding in adults with and without HIV 
infection have yet to be published. In healthy individuals, the average duration of viral shedding is 
around 5 days, but can last up to 10 days (Carrat et al., 2008). Studies on patients with other forms of 
immunosuppression suggest that prolonged shedding of seasonal influenza virus (Klimov et al., 1995; 
Boivin et al., 2002; Weinstock et al., 2003; Gooskens et al., 2009) and influenza A(H1N1)pdm09 virus 
(2009b; Hill-Cawthorne et al., 2010) can occur for months, and has been shown to be associated with 
antiviral resistance.  
A pilot study that compared influenza viral load by rRT-PCR serially up to 28 days patients with ILI was 
presented at the Options for the Control of Influenza VIII Conference (Hellferscee et al., 2013). No 
differences were observed in the duration (median 9 days, range 2-14 days) and magnitude of 
influenza virus shedding between enrolled HIV-infected (n=2) and HIV-uninfected (n=9) patients. 
However, the lack of association may be due to the small number of patients enrolled. The final results 
of this ongoing study are awaited. 
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1.4.5  Transmission 
Few studies have evaluated the impact of HIV infection on influenza transmission dynamics. A study 
from a population-based influenza surveillance programme in an urban slum in Nairobi, Kenya, 
compared rates of ILI among household contacts of HIV-infected individuals, and household members 
of exclusively HIV-negative households (Wong et al., 2015). The presence of an HIV-infected person in 
the household was found to be a risk factor for ILI in non-HIV-infected household contacts (RR 1.44, 
95%CI 1.06-1.94), and the risk increases with the number of HIV-infected persons in the household 
(Wong et al., 2015). However, this analysis did not account for the HIV status of the household 
contacts. Moreover, almost two-thirds of adults in households labelled as exclusively HIV-negative 
were not tested, which would have resulted in misclassification. 
A retrospective cohort study of 176 influenza index cases and their 874 household contacts from the 
same surveillance programme in Kenya, examined the association between the HIV status of influenza 
index cases and the risk of developing secondary ILI among household contacts (Judd et al., 2015). 
Household contacts of HIV-infected influenza index cases were twice as likely to develop ILI, compared 
to household contacts of HIV-negative index cases (adjusted relative risk 2.36, 95%CI 1.19-4.66) (Judd 
et al., 2015). However, being an HIV-infected household contact of the index case was not significantly 
associated with the development of secondary ILI, compared with being an HIV-negative household 
contact. Influenza virus shedding data for the index cases was not available to substantiate the 
authors’ hypothesis that HIV-infected index cases may shed virus for longer and at higher titres. 
Secondly, HIV status was not available for 62% index cases and 48% household contact, thus limiting 
the representativeness of the study population if those who were tested were systematically different 
from those who were not tested. 
1.4.6  Summary 
The impact of HIV infection on the susceptibility and severity of influenza illness appears to differ in 
low HIV-prevalence and HIV-prevalence settings. In regions with low prevalence of HIV infection, HIV 
infection does not appear to significantly increase susceptibility or severity to seasonal influenza 
infection, though many of the included studies were anecdotal reports or ecological studies that did 
not account for potential confounders such as smoking or comorbidities. Several studies suggest that a 
greater proportion of persons hospitalized with confirmed H1N1pdm virus infections are HIV-infected 
compared with the general population. However, increased propensity to test and hospitalise HIV-
infected individuals who present with illness may result in overrepresentation of HIV-infected persons 
in the studies. Among patients hospitalized with pandemic influenza A(H1N1) in low HIV prevalence 
settings, severity of presentation and clinical outcomes appear to be equivalent among HIV-infected 
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and HIV-uninfected adults, especially in settings where the majority of patients are receiving ART and 
do not have severe immunosuppression.  
In contrast, data from one Mexican study that included a high proportion of patients with advanced 
HIV disease (Ormsby et al., 2011), and studies emerging from countries with high HIV prevalence 
(Feikin et al., 2012b; Cohen et al., 2013; Ope et al., 2011; Archer et al., 2009; Tempia et al., 2015b) 
suggest that influenza susceptibility, severity, as well as risk of death may be increased among HIV-
infected persons. This is likely due to more advanced immunosuppression, poorer virological control, 
in addition to a higher prevalence of other comorbidities, such as tuberculosis. To date, the majority of 
studies from high HIV prevalence settings have derived from South Africa, and information on CD4 cell 
count and ART status have been incomplete. 
Further prospective studies in high HIV prevalence settings that comprehensively record CD4 cell 
counts, ART use, and co-morbid conditions are therefore needed, to evaluate the impact of these 
factors on the relationship between HIV infection and severity of influenza. Such data may allow 
policymakers to make informed decisions about targeted annual influenza immunization, which are 
currently unavailable in many high HIV prevalence countries (Chapter 1.5). 
1.5  Influenza Vaccination in HIV-infected Adults 
1.5.1  Current guidelines 
From Chapter 1.4, the limited available evidence suggests that HIV-infected individuals experience 
greater susceptibility and severity of influenza illness compared to the general population, particularly 
in high HIV prevalence settings. Hence annual seasonal influenza vaccination is recommended for HIV-
infected individuals by many national immunisation guidelines, including the UK (Geretti et al., 2008; 
National Advisory Committee on Immunization (NACI), 2014; Grohskopf et al., 2015). In South Africa, 
the only sub-Saharan African country with published immunisation guidelines, inactivated vaccines are 
recommended in HIV-infected individuals with CD4 cell count >100 cells/L (Walaza, 2014).  
As described in Section 1.1.5.1, two types of influenza vaccines are available: inactivated and live-
attenuated vaccines (IIV & LAIV). As with other live virus vaccines, LAIV is not recommended in HIV-
infected adults (Geretti et al., 2008; National Advisory Committee on Immunization (NACI), 2014; 
Grohskopf et al., 2015). HIV-infected persons are also advised to avoid close contact with anyone who 
has received LAIV for 7 (Grohskopf et al., 2015) to 21 (Geretti et al., 2008) days after receipt, due to 
the theoretical risk for transmission of the live-attenuated vaccine virus. 
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1.5.2  Evidence of efficacy in HIV-infected adults  
1.5.2.1  Vaccine immunogenicity  
Vaccine-induced antibody responses are lower in HIV-infected persons compared to HIV-negative 
controls (Miotti et al., 1989; Kroon et al., 1994; Iorio et al., 1997; Fowke et al., 1997; Nelson et al., 
1988; Amendola et al., 2001; Crum-Cianflone et al., 2011; Parmigiani et al., 2013; Yanagisawa et al., 
2011; Nunes et al., 2015), and are correlated with CD4 count (Fowke et al., 1997; Fuller et al., 1999; 
Kroon et al., 2000; Tebas et al., 2010; Tiu et al., 2011; Yamanaka et al., 2005).  Several studies 
examining the effect of ART on influenza vaccine immunogenicity have found higher seroprotection 
rates in patients on ART for 6 months or more compared to those not on treatment (Launay et al., 
2011; Durier et al., 2013). Moreover, HIV-infected patients with CD4 counts >300 cells/L while on 
ART appear to have humoral and cellular responses to inﬂuenza vaccination similar to those of healthy 
controls (Kroon et al., 1998).  
The use of higher or booster doses of inactivated vaccines, in addition to adjuvanted preparations 
have been explored as strategies to enhance immunogenicity in HIV-infected persons. Additional or 
higher doses of inactivated vaccines (IIV3 and monovalent 2009 pandemic A/H1N1 (pAH1N1) vaccine) 
in HIV-infected adults have resulted in improved serconversion rates in some studies (Bickel et al., 
2011; Nielsen et al., 2012; Santini-Oliveira et al., 2012; McKittrick et al., 2013; El Sahly et al., 2012; 
Cooper et al., 2012) but not in others (Cooper et al., 2011; Miotti et al., 1989; Kroon et al., 1994; Iorio 
et al., 1997; Hatakeyama et al., 2011; Lagler et al., 2012), though most of the studies that 
demonstrated no difference in immunogenicity were conducted in the pre-ART era (Miotti et al., 1989; 
Kroon et al., 1994; Iorio et al., 1997) or were non-randomised (Miotti et al., 1989; Kroon et al., 1994; 
Iorio et al., 1997; Hatakeyama et al., 2011; Lagler et al., 2012). A number of studies have also 
demonstrated improved humoral responses associated with adjuvanted seasonal IIV3 (Iorio et al., 
2003) and pandemic A/H1N1 vaccine compared with non-adjuvanted preparations (Ho et al., 2011; 
Launay et al., 2011; Durier et al., 2013). Current guidelines recommend a single standard dose of IIV 
only (i.e. 15μg of haemagglutinin antigen per strain in each 0.5ml dose).  
1.5.2.2  Clinical efﬁcacy  
A recent Cochrane Review that included 116 studies on TIVs reported an overall efficacy of 60% [95% 
CI 53-66%] in preventing laboratory-confirmed inﬂuenza in healthy adults (see also Section 1.1.5.3) 
(Demicheli et al., 2014). In contrast, data on the clinical efﬁcacy of inﬂuenza vaccination in HIV-
infected adults are limited. A pooled clinical efficacy of 85% [95% CI 22-97%] was reported in a recent 
systematic review and meta-analysis of two randomised placebo-controlled trial (RCT) (Tasker et al., 
1998; Madhi et al., 2011) and three observational studies (Fine et al., 2001; Ranieri et al., 2005; 
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Yamanaka et al., 2005) (Table 1.12 & 1.13). However, no significant effect on all-cause pneumonia, 
hospitalisation or mortality was found (Remschmidt et al., 2014). The majority of included studies 
were conducted in the pre-ART or early-ART era, with the exception of Madhi et al. (Madhi et al., 
2011). Of note, this randomised trial of IIV3 in South African adults excluded patients with CD4 cell 
count <100 cells/L and naïve to ART and those with co-morbidities (Madhi et al., 2011). 
Only one RCT of IIV3 has been published in HIV-infected pregnant women. The study, which included 
149 pregnant women from South Africa (mean age - 26 years), demonstrated a vaccine efficacy of 58% 
(95%CI 0.2-82%), but only 27% (p=0.60) among the infants of the participants (Madhi et al., 2014). 
Table 1.12  Characteristics of studies included in the systematic review on influenza vaccination in HIV-
infected adults (Remschmidt et al., 2014) 
Study, year of 
publication 
Setting, 
country 
Age (years)  
(mean or range) 
N vaccinated 
CD4 count/l 
N unvaccinated 
CD4 count/l 
Vaccine type 
Randomised placebo-controlled trial 
Tasker et al., 
1999  
Outpatient 
military 
clinic, USA 
33 55 
n=5 <200  
47 
n=8 <200 
Whole virion 
A/Johannesburg/33/94 
A/Texas/36/91 
B/Harbin/07/94 
Madhi et al., 
2011  
Outpatient 
clinic, South 
Africa 
34 255  
Median 340a 
251 
Median 356a 
IIV3, Mutagrip 
Cohort study      
Fine et al., 
2001b  
Outbreak at 
residential 
facility, USA 
19-62 42 
n=6 <100  
29 
n=8 <100 
A/Nanching/933/95 
A/Texas/36/91 
B/Harbin/07/94 
Ranieri et al., 
2005 
Outpatient 
clinic, Italy 
20-69 90  
n=12 <200 
55  
n=16 <200 
Virosomal adjuvanted, 
Inflexa V 
Yamanaka et 
al., 2005  
Outpatient 
clinic, Japan 
40-41 262 
n=51 <200 
66  
n=9 <200 
Subunit 
A/New Caledonia/20/99 
A/Panama/2007/99 
B/Shanton/7/87 
aPatients naïve to antiretroviral therapy with CD4 cell count <100 per microlitre (l) were excluded. 
bPublished as a case-control study, but only the cohort of HIV-infected persons were included. 
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Table 1.13  Included studies in the systematic review on influenza vaccination in HIV-infected adults: Risk factors for influenza-related outcomes 
in vaccinated vs. non-vaccinated individuals (Remschmidt et al., 2014) 
 
Study, 
year of publication 
Risk ratio (95% confidence interval) 
Laboratory-
confirmed influenza  
Influenza-like 
illness 
Any respiratory 
illness 
Pneumonia 
(all cause) 
Hospitalisation 
(all cause) 
Mortality  
(all-cause) 
Randomised placebo-controlled trial 
Tasker et al., 1999  0.04 (0.00-0.68) - 0.59 (0.36-0.99) Not estimable
a Not estimablea - 
Madhi et al., 2011 0.24 (0.07-0.85) 1.08 (0.47-2.50) 0.84 (0.57-1.23) 0.33 (0.01-8.02) 0.98 (0.20-4.83) 0.49 (0.04-5.39) 
Cohort study 
Fine et al., 2001  - 0.73 (0.47-1.13) - 
 
- 0.23 (0.05-1.06) - 
Ranieri et al., 2005  - 0.22 (0.12-0.38) - 
 
Not estimablea Not estimablea - 
Yamanaka et al., 
2005  
0.29 (0.15-0.56) - - - - - 
aNo cases 
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1.5.2.3  Vaccine safety 
Inactivated inﬂuenza vaccine are safe and well tolerated in HIV-infected individuals (Zanetti et al., 
2002), including pregnant women (Madhi et al., 2014; Abzug et al., 2013). As described in Section 
1.1.5.2, injection site reactions are the most frequent side effects. Systemic side effects are 
uncommon, and include fever, malaise, myalgia, arthralgia and allergic reactions (most likely due to 
hypersensitivity to residual egg protein). Guillain–Barré syndrome has been reported very rarely; no 
association with seasonal or H1N1 pandemic vaccine has been found (Demicheli et al., 2014).  
There have been concerns that vaccine-induced CD4 cell activation might promote HIV replication 
(Clouse et al., 1989). Minor CD4 count and viral load fluctuations have been described following 
vaccination with IIV3 (Ho, 1992; O'Brien et al., 1995; Rosok et al., 1996; Staprans et al., 1995; Fuller 
et al., 1999; Gunthard et al., 2000; Tasker et al., 1998) and adjuvanted pA/H1N1 vaccine (Calmy et 
al., 2012; Kelly et al., 2012), but not thought to be clinically relevant. No negative long-term sequelae 
have been demonstrated (Sullivan et al., 2000).  
 
1.5.3  Summary  
IIV is safe, and is recommended for HIV-infected individuals in many developed settings. Limited 
available evidence suggest that it is immunogenic and efficacious among HIV-infected individuals 
without significant immunosuppression. However, further studies are needed to evaluate the 
immunogenicity and clinical efficacy of IIV among HIV-infected individuals with advanced 
immunosuppression (CD4 cell count <100 cells/µl) and those with co-morbidities, which will be 
applicable to a substantial proportion of the HIV-infected population in SSA. 
1.6  Interactions between respiratory viruses and Streptococcus pneumoniae  
1.6.1  Overview 
The first observation that viral infections predisposed to bacterial pneumonia was made by René 
Laënnec, the French physician who invented the stethoscope, in 1803 (Laënnec, 1819). He noted an 
increase in the prevalence of pneumonia following an influenza epidemic. It is now recognised that a 
substantial proportion of influenza-related morbidity and mortality is due to concurrent or 
secondary bacterial infection, particularly with Streptococcus pneumoniae and Staphylococcus 
aureus (Morens et al., 2008). Other respiratory viruses, including adenovirus, rhinovirus, respiratory 
syncytial virus (RSV), and parainfluenza viruses may also predispose to secondary infections, but 
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evidence of such interactions is lacking. In this chapter, current literature on the association 
between respiratory viruses, with a predominant focus on influenza, and S. pneumoniae infection 
will be reviewed. 
1.6.2  The epidemiology of respiratory viruses and Streptococcus pneumoniae  
1.6.2.1  Pandemic influenza 
The devastating impact of influenza and pneumococcal co-infection was brought into focus by the 
1918 influenza pandemic, which was associated with up to 50 million deaths globally (Chapter 
1.1.4.3). Recent reviews of epidemiological, histological, and microbiological evidence from the 
pandemic suggest that the majority of severe illness and deaths were attributable to secondary 
bacterial pneumonia (Morens et al., 2008; Brundage and Shanks, 2007). Most deaths occurred 7 to 
14 days after onset of influenza symptoms (Mills et al., 2004). Histopathological examination of lung 
tissue sections from 68 influenza victims demonstrated evidence of severe acute bacterial 
pneumonia in most cases. In the same study, over 90% lung tissue from 96 fatal cases were culture-
positive for >1 bacterium; S. pneumoniae was the most frequently isolated organism, followed by 
Streptococcus pyogenes and S. aureus (Morens et al., 2008). Moreover, a review of lung-tissue and 
autopsy studies found that bacteria were more likely to be isolated from patients with influenza-
associated pneumonia (mean 16%), particularly in those who died (40%), than those without 
pneumonia (<1%) (Chien et al., 2009). S. pneumoniae comprised 71% of positive cultures.  
The subsequent pandemic in 1957-58 was associated with lower mortality. Nevertheless, 
pneumonia accounted for a higher proportion of deaths in 1957-58 (44%) than in the preceding 
inter-pandemic years (~20%, range 4–44%) (Trotter et al., 1959; Dauer, 1958; Collins and Lehmann, 
1951). S. aureus was the predominant bacterium identified in pneumonia patients in this pandemic 
(Hers et al., 1958; Robertson et al., 1958; Martin et al., 1959). The shift in microbiological aetiology 
may have been due to temporal changes in bacterial circulation, but may also have been a 
consequence of widespread penicillin use, resulting in fewer penicillin-susceptible organisms, 
including pneumococci. However, the predominant pathogen reverted to S. pneumoniae during the 
1968 pandemic (Bisno et al., 1971; Burk et al., 1971), suggesting that antibiotics were not the sole 
cause for the microbiological changes. It is therefore more likely that strain-related differences in the 
virus or the bacterial co-pathogens are responsible for the aetiological shifts between pandemics. 
The emergence of the 2009 pandemic influenza A(H1N1) provided a further opportunity to study the 
role of bacterial co-infections in influenza morbidity/mortality in the context of widespread use of 
broad-spectrum antibiotics. In studies of severe or fatal cases of A(H1N1)pdm09, bacterial co-
infection was identified in 25 to 50% cases (2009a; Dominguez-Cherit et al., 2009; Estenssoro et al., 
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2010; Mauad et al., 2010; Shieh et al., 2010), with S. pneumoniae and S. aureus as the commonest 
pathogens identified. Those with bacterial co-infection were associated with increased severity and 
mortality (Rice et al., 2012; Palacios et al., 2009; Dhanoa et al., 2011; Cohen et al., 2012 ).  
1.6.2.2  Seasonal influenza 
 A number of ecological studies have evaluated the association between influenza circulation and all 
invasive pneumococcal disease (IPD) during non-pandemic periods, with variable findings. Several 
US surveillance studies reported significant correlation between influenza activity and IPD 
occurrence (Kim et al., 1996; Talbot et al., 2005). A Swedish study between 1994 and 2004 estimated 
that 6-10% of annual IPD burden were influenza-related, with a lag time of 1 to 3 weeks for IPD 
following peaks in influenza incidence (Grabowska et al., 2006). In contrast, Zhou et al. (Zhou et al., 
2012a) found substantial variation in the strength of association of invasive pneumococcal 
pneumonia incidence with influenza activity across seasons from 1994-2005; strength of association 
was highest when A(H3N2) was the predominant strain (Zhou et al., 2012a). Recent studies from the 
US (Walter et al., 2010) and Canada (Kuster et al., 2011) found that seasonality and time lag of 
pneumococcal disease was only partially related to influenza seasonality. These findings suggest that 
the impact of influenza on the epidemiology of pneumococcal pneumonia may differ during 
pandemic and non-pandemic periods. However, the studies did not distinguish pneumococcal 
pneumonia from other forms of invasive disease, such as bacteremia without pneumonia. 
Moreover, the majority of studies did not control for the underlying seasonality of either pathogen. 
In temperate regions, peaks in influenza and S. pneumoniae disease activity occur in winter, but 
similar seasonality is also observed in a wide range of infectious, environmental, and social factors 
(Kim et al., 1996; Watson et al., 2006). Unadjusted analyses of seasonally-correlated phenomena 
could result in overestimation of temporal associations (Bowie and Prothero, 1981). 
1.6.2.3  Other respiratory viruses 
Due to the availability of nucleic acid amplification techniques for identifying respiratory viral 
infections (Chapter 1.3.2), data on the frequency and outcomes of co-infections that involve other 
respiratory viruses are emerging. Contemporary pneumonia aetiology studies suggest that co-
infections with bacteria and respiratory viruses other than influenza, including adenovirus, 
rhinovirus, RSV, coronaviruses, and parainfluenza viruses, are common (4-28%) (Angeles Marcos et 
al., 2006; Jennings et al., 2008; Johnstone et al., 2008; Templeton et al., 2005; Luchsinger et al., 
2013; Damasio et al., 2015).  
With regards to the impact of co-infection on illness severity, studies from Sweden (Johansson et al., 
2011) and the Netherlands (Templeton et al., 2005) found that mixed viral-bacterial infection was 
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correlated with a more severe presentation (pneumonia severity index (PSI) (Fine et al., 1997) risk 
class IV/V) in adults with CAP. In the Dutch study, severe pneumonia was significantly associated 
with rhinovirus as well as coronaviruses OC43 and 229E (Templeton et al., 2005). Jennings et al. 
(Jennings et al., 2008) demonstrated increased disease severity (CURB65 score >2 (Lim et al., 
2003)and PSI class IV/V) specifically in mixed rhinovirus-pneumococcal co-infection among adults 
with CAP in New Zealand. A retrospective case control study from Korea also found that preceding 
viral infection, particularly with rhinovirus, hMPV, RSV and parainfluenza viruses, was associated 
with increased severity (higher PSI score) of pneumococcal pneumonia (Yoon et al., 2014).  
Conversely, viral-bacterial co-infections was not associated with increased illness severity in adult 
pneumonia cohorts from Chile (Luchsinger et al., 2013) and Brazil (Damasio et al., 2015). Choi et al. 
(Choi et al., 2012) demonstrated a high prevalence of respiratory viruses in Korean adults with 
community- and hospital-acquired pneumonia requiring ICU admission (rhinovirus (24%), 
parainfluenza virus (21%), human metapneumovirus (hMPV) (18%), influenza virus (17%), and RSV 
(14%)), but patients with viral-bacterial co-infections had similar mortality to those with single agent 
infection. 
1.6.2.4  Limitations of diagnostic tests for Streptococcus pneumoniae 
One of the key limitations of epidemiological studies evaluating the association between respiratory 
viruses and S. pneumoniae is the absence of a gold standard for pneumococcal detection. Current 
pneumococcal diagnostic tests lack sensitivity (Klugman et al., 2008); diagnostic yield have been 
reported to be <30% for blood culture and 57% for sputum culture (Roson et al., 2000). The recent 
advent of the BinaxNOW S. pneumoniae antigen (BinaxNOW-SP, Alere, USA) shows promise. It is an 
immunochromatographic membrane test (ICT) that tests for the presence of pneumococcal C-
polysaccharide in urine. A meta-analysis of 27 studies estimated a pooled sensitivity of 74% and 
specificity of 97% for the diagnosis of adult pneumococcal pneumonia using ICT (Sinclair et al., 
2013). Similar sensitivity and specificity have been reported in HIV-infected adults (Boulware et al., 
2007) and critically ill patients (Lasocki et al., 2006) from well-resourced settings. However, 
limitations of this assay include cross-reaction with certain alpha-hemolytic streptococci 
(Streptococcus mitis and Streptococcus oralis) (Klugman et al., 2008), and poor specificity in young 
children due to high rates of asymptomatic nasopharyngeal (NP) carriage (Dowell et al., 2001; Hamer 
et al., 2002). In contrast, specificity of ICT was unaffected in a study of Thai women with a high 
prevalence of pneumococcal carriage (25%) (Turner et al., 2011). 
There is also growing interest in the use of quantitative molecular techniques to diagnose 
pneumococcal pneumonia. Quantitative real-time PCR (qRT-PCR) with specific gene targets, such as 
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pneumococcal autolysin (lytA) (Carvalho Mda et al., 2007), has been used to measure bacterial load 
of S. pneumoniae in blood (Kee et al., 2008; Peters et al., 2009; Rello et al., 2009), sputum (Yang et 
al., 2005), and NP specimens (Albrich et al., 2012). Pneumococcal detection rates are reportedly 2-5 
times higher using blood qRT-PCR compared to blood culture (Resti et al., 2010; Wolter et al., 2014a; 
Rello et al., 2009), and bacterial load appears to correlate with clinical severity and mortality (Rello 
et al., 2009; Wolter et al., 2014b). However, only 10-25% of adults with pneumococcal pneumonia 
are bacteraemic (Feldman and Anderson, 2011; Said et al., 2013b). Respiratory specimens are more 
accessible, though good quality sputum samples are difficult to obtain, and discrimination between 
infection and colonisation is challenging. Several studies have evaluated the clinical utility of qRT-
PCR on NP specimens of adults with CAP. Albrich et al. (Albrich et al., 2012) demonstrated good 
correlation between quantitative lytA RT-PCR on NP swabs and quantitative NP cultures, and 
suggested that an NP pneumococcal density cut-off of >8000 copies/mL could differentiate between 
clinical disease and asymptomatic carriage. Adeldaim et al. (Abdeldaim et al., 2008) evaluated a qRT-
PCR based on gene fragment Spn9802 on NP specimens, and reported a clinically significant cut-off 
of 104 DNA copies/mL. The findings from these two studies support the hypothesis of a critical 
colonisation density (around 103-104/mL), which when exceeded, leads to an increased risk of micro-
aspirations and subsequent lower respiratory tract infection (Greenberg et al., 2011; Albrich et al., 
2012). 
Lastly, sequential infections are difficult to capture; the preceding influenza infection has often 
resolved, or viral shedding has ceased, by the time the patient presents with secondary bacterial 
pneumonia (Weinberger et al., 2012).  
1.6.2  Vaccine probe studies 
The introduction of a 7-valent pneumococcal conjugate vaccine (PCV7) has resulted in a significant 
decline in invasive disease caused by vaccine serotypes in vaccinated children, as well as impressive 
herd protection of unvaccinated adults (Centers for Disease Control and Prevention, 2005; Millar et 
al., 2008). This efficacious vaccine has been used as a probe to explore the role of Streptococcus 
pneumoniae in the aetiology of influenza-associated pneumonia (Simonsen et al., 2011; Madhi and 
Klugman, 2004). Children that received a 9-valent PCV (PCV9) in a randomised, double-blind trial in 
South Africa had a 45% lower hospitalisation rate of seasonal influenza-related pneumonia, 
compared to children that were not vaccinated (Madhi and Klugman, 2004). PCV9 was also 
associated with reductions in hospitalisations for pneumonia associated with adenovirus, RSV and 
parainfluenza 1-3 by 31% (Madhi and Klugman, 2004), and hMPV by 58% (Madhi et al., 2006). A US 
study also found that states with higher PCV vaccination coverage had significantly fewer influenza-
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associated pneumonia hospitalisations among children (Simonsen et al., 2011). The impact of PCV on 
reducing the burden of confirmed virus-associated pneumonia provides further evidence of the role 
of superimposed pneumococcal infection as a cause of severe pneumonia.   
1.6.3  Are respiratory viral infections required for pneumococcal transmission? 
Since nasopharyngeal pneumococcal colonisation, the first step in the development of invasive 
disease (Gray et al., 1980; Bogaert et al., 2004), is asymptomatic, coryza related to viral upper 
respiratory infections may be crucial for the transmission of pneumococcus from the posterior 
nasopharynx (Klugman et al., 2009). A prospective study of factors associated with the spread of 
respiratory diseases among British families found increased pneumococcal colonisation during 
clinical upper respiratory illness (Brimblecombe et al., 1958). It is likely that coryza facilitates mucous 
sampling of S. pneumoniae, thereby enhances detection. However, it also allows easier transmission 
through direct spread by coughing or sneezing or via fomite contamination (Brimblecombe et al., 
1958). A recent study in rural Kenya has also demonstrated an association between NP 
pneumococcal colonisation and coryza (adjusted odds ratio 2.29, 95%CI 1.48-3.56) (Abdullahi et al., 
2008). 
 
1.6.4 Pathogenic mechanisms underlying the interaction between respiratory viruses and 
S. pneumoniae  
1.6.4.1  Influenza and S. pnuemoniae 
The synergistic interaction between Influenza and S. pneumoniae have been shown in a number of 
animal models (Berendt et al., 1975; Peltola and McCullers, 2004; Seki et al., 2004). Pre-exposure of 
squirrel monkeys to influenza A(H3N2) virus significantly increased blood pneumococcal load (from 
55 to 30,000 colonies/mL) (Berendt et al., 1975). Similarly, pneumococcal load in the lungs of 
influenza A pre-exposed monkeys were >100,000 compared to 90 colonies/mL in monkeys exposed 
to S. pneumoniae alone. Murine studies also established the importance of the order of exposure to 
the two pathogens – mice that were sequentially challenged by influenza virus, followed by 
pneumococcus 7 days later all died (McCullers and Rehg, 2002; Peltola and McCullers, 2004). 
Conversely, mice challenged with influenza virus 7 days after pneumococcal exposure did not result 
in fatal outcome, and mice that were simultaneously infected with both pathogens had a higher 
mortality (60%) than mice infected with either influenza or pneumococcus alone. In a different 
study, lungs of influenza-exposed mice had higher density of pneumococci following pneumococcal 
challenge (LeVine et al., 2001). Sequential influenza-pneumococcal infection was also associated 
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with increased pulmonary neutrophil infiltrates, as well as higher levels of IL-1 and TNF-, 
compared to mice inoculated solely with S. pneumoniae.  
A transmission model in ferrets also demonstrated that influenza infection increased susceptibility 
to pneumococcal acquisition in terms of the percentage of ferrets infected and the distance over 
which they could acquire infection (McCullers et al., 2010). Moreover, these influenza-mediated 
effects on colonisation, transmission, and disease were pneumococcal strain-specific. 
Murine models have also helped to expand our understanding of the pathogenic processes by which 
influenza infection increases susceptibility to pneumococcal colonisation and subsequent disease 
(McCullers, 2006; Short et al., 2012). The hypothesised mechanisms, summarized in Table 1.14, 
include viral-mediated changes to the respiratory tract that facilitate pneumococcal binding, as well 
as alterations of the innate immune response that result in diminished ability to clear 
pneumococcus, and amplification of host immunopathology. The precise contribution of the various 
pathogenic mechanisms described remains uncertain, but it is clear that the processes are complex 
and multifactorial. 
1.6.4.2  Other respiratory viruses and S. pnuemoniae 
In vitro and animal models have also shown synergistic interactions between S. pneumoniae and 
viruses other than influenza. As these viruses share common virulence traits with influenza viruses, 
many of the mechanisms for synergy are expected to be similar (Table 1.14). Adenovirus, RSV and 
hMPV enhance in vitro adherence of S. pneumoniae to respiratory epithelial cells (Hakansson et al., 
1994; Kukavica-Ibrulj et al., 2009; Hament et al., 2004).  
Preceding hMPV infection has also been shown to increase pneumococcal load in mice, and is also 
associated with increased levels of inflammatory cytokines and chemokines, as well as greater 
expression of Toll-like receptor 2 (TLR2), TLR6, TLR7, and TLR13 in the lungs of co-infected mice 
(Kukavica-Ibrulj et al., 2009). Co-infection with RSV has been shown to up-regulate the expression of 
key pneumococcal virulence genes, including pneumolysin (Smith et al., 2014). Lastly, parainfluenza 
viruses encode a neuraminidase, which promotes pneumococcal binding in a similar manner to that 
of influenza (Alymova et al., 2005).  
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Table 1.14  Pathogenic mechanisms underlying the interaction between influenza and S. pneumoniae, as demonstrated in animal models 
Pathogenic 
mechanism 
Details on the effect of influenza infection on pneumococcal disease Outcome 
Epithelial damage - Viral destruction of respiratory epithelium (Harford and Hara, 1950) - Increase exposure of S. pneumoniae to binding sites in 
the basement membrane  
Reduced activity in 
airway protection 
mechanism 
- Impaired ciliary function (Pittet et al., 2010) 
- Obstruction of small airways due to disruption of surfactant, increased 
mucinous secretions and influx of inflammatory cells (Harford and Hara, 
1950; Loosli et al., 1975) 
- Decrease mechanical clearance of S. pneumoniae  
- Improve conditions for bacterial growth 
- Reduce oxygen and carbon dioxide diffusion capacity 
(Horner and Gray, 1973) 
Increased receptor 
availability/ bacterial 
adherence 
-  Cleavage of sialic acid by viral or bacterial neuroaminidases (NAs) 
from cell surface glycoconjugates (McCullers and Bartmess, 2003) 
*Parainfluenza viruses (Alymova et al., 2005) 
- Pro-inflammatory cytokines up-regulate expression of cellular 
receptors (Peltola and McCullers, 2004)    *Adenovirus (Lai et al., 2014), 
RSV (Hament et al., 2004) & hMPV (Kukavica-Ibrulj et al., 2009) 
-  Deposition of fibrin and fibrinogen deposition during regenerative 
process following viral infection  
- Expose cryptic cell receptors for pneumococcal 
binding in lower airways (McCullers, 2006) 
- Promote adherence of S. pneumoniae 
 
- Provide further attachment sites for bacteria 
Down-regulation of 
innate immune 
response 
- Interferon- production by T cells (Sun and Metzger, 2008)  
 
 
-  Desensitization of alveolar macrophages to bacterial Toll-like receptor 
(TLR) ligands such as flagellin (TLR5), lipopolysaccharide (TLR4) and 
lipotechoic acid (TLR2) (Didierlaurent et al., 2008) *hMPV (Kukavica-
Ibrulj et al., 2009) 
- Increased pulmonary levels of alternatively activated macrophages 
(AAMs) in murine lungs at days 7-14 post influenza virus infection 
(Didierlaurent et al., 2008) 
- Induced Type 1 interferons impair CXCL1/2 production (Shahangian et 
al., 2009) 
- IFN1 production also inhibits CCL2 production reduced recruitment of 
-  Down-regulate alveolar macrophage scavenger 
receptors (MARCO) on macrophages that are involved 
in phagocytosis of unopsonized pneumococci 
- Reduce chemokine production, NF-B activation and 
consequently impaired neutrophil recruitment 
 
-  AAMs have poorer bactericidal activity than pro-
inflammatory macrophages  
-  Reduce neutrophil chemotaxis  
-  Reduce recruitment of monocytes/macrophages 
 
-  Suppress inflammatory response to secondary 
pneumococcal infection 
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monocytes/macrophages (Nakamura et al., 2011) 
- Increased glucocorticoids levels 
Bacterial 
enhancement of 
inflammation 
- Pneumococcal cell wall, pneumolysin and pyruvate oxidase SpxB 
(Cockeran et al., 2001; Spellerberg et al., 1996) 
- Induce cell damage and inflammation 
*Denote viral pathogens that have demonstrated similar pathogenic mechanism to influenza virus in facilitating pneumococcal infection. 
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1.6.5  Rationale for evaluating the association between respiratory viruses and 
pneumococcal density 
Existing evidence from epidemiological and experimental studies support the biological plausibility 
that preceding respiratory viral infections, particularly with influenza, increase susceptibility to 
bacterial pneumonia. Since pneumococcal disease is preceded by nasopharyngeal pneumococcal 
carriage (Bogaert et al., 2004), another potential mechanism by which respiratory viruses predispose 
to pneumococcal disease may be by increasing carriage density to reach the ‘critical’ level, with 
subsequent lower respiratory tract invasion (Albrich et al., 2012). Few epidemiological studies have 
evaluated the impact of respiratory viral infection on pneumococcal carriage density. A case control 
study of paediatric hospitalised LRTI in Vietnam found significantly higher NP pneumococcal load in 
children with viral co-infections than children without co-infection (Vu et al., 2011). Wolter et al. 
(Wolter et al., 2014b) also demonstrated higher pneumococcal colonization density, and in turn, 
increased invasive disease, in individuals with respiratory viral co-infection within a severe acute 
respiratory illness (SARI) surveillance programme in South Africa. However, both studies were cross-
sectional, therefore unable to assess the dynamic relationship between onset of viral infection and 
NP pneumococcal carriage. If this hypothesis was true, it will have important implications for 
populations with high pneumococcal carriage, such as young children and HIV-infected individuals 
(Gill et al., 2008; Abdullahi et al., 2012).  
We therefore plan to investigate the relationship between respiratory viral infections and NP 
pneumococcal carriage density in a region with a high prevalence of HIV infection and pneumococcal 
carriage. The aim is to determine whether adults with confirmed respiratory viral infection have 
increased density of NP pneumococcal carriage (Chapter 6). 
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1.7  Malawi 
1.7.1  Demographic and health indicators 
Malawi is located in Southeast Africa, with a population of around 15.9 million as of 2012 (UNdata, 
2014), and is estimated to exceed 26 million by 2030 (Population Reference Bureau, 2012). The 
average life expectancy at birth is 54.9 years for males, and 55.2 years for females (UNdata, 2014). 
Malawi has a young population with a median age of 17; 46% are under 15 years of age (Population 
Reference Bureau, 2012). One of the poorest countries in the world, Malawi has a gross domestic 
product (GDP) of US$355 per capita and is ranked 174th of 187 countries according to the Human 
Development Index (United Nations Development Programme, 2014). The economy is 
predominantly agricultural, with around 90% of the population living in rural areas. A substantial 
proportion of Malawians rely on subsistence farming, and therefore are vulnerable to natural 
disasters, such as drought or heavy rain. 
Blantyre, the commercial and finance centre, is situated in the South of Malawi (Figure 1.6). It has a 
population of 1.3 million, around two-thirds of which reside in urban dwellings. Healthcare is free at 
the point of delivery. The government health care system in Blantyre consists of the Queen Elizabeth 
Central Hospital (QECH), the largest referral hospital in the country that provides secondary and 
tertiary care to the population of greater Blantyre (see also Chapter 2.1.1), and 18 health centres 
that are under the jurisdiction of the District Health Office. Additionally, there are a number of 
private hospitals and clinics that are run by non-governmental organisations (NGO) but the number 
of inpatient beds available is very small.  
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Figure 1.6  Map of Malawi and 
location of Blantyre (red dot) 
 
 
Malawi is characterized by a heavy burden of disease as evidenced by high mortality rates in both 
children (infant & under-five mortality, 66 & 112/1000 live births) and adults (maternal mortality 
675/100,000 live births) (National Statistics Office (NSO) and ICF Macro, 2011), as well as high 
prevalence of diseases such as tuberculosis, malaria, HIV (Section 1.7.2), and other tropical diseases. 
Despite this, Malawi has only 1.9 physicians per 100,000 population, constituting one of the lowest 
physician densities in the world (World Health Organization, 2009b). 
1.7.2 HIV epidemic in Malawi 
Adult HIV prevalence in Malawi has been declining steadily since reaching a peak of 16.4% in 1999 
(Government of Malawi, 2014). In 2010, the national adult HIV prevalence was reported as 10.6% 
(National Statistics Office (NSO) and ICF Macro, 2011), with significant gender and geographical 
variation (Figure 1.7). Women have higher prevalence than men, and prevalence is twice as high in 
urban compared to rural settings. In urban Blantyre, prevalence is reported to be as high as 18.5% in 
a household HIV self-testing study (Choko et al., 2011); Heterosexual contact is the principal mode of 
HIV transmission in Malawi (88%), while mother-to-child transmission of HIV accounts for around 
10% of all new HIV infections (Government of Malawi, 2014). 
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Figure 1.7  Prevalence of HIV infection in Malawi, by A) sex; B) urban or rural 
distribution(National Statistics Office (NSO) and ICF Macro, 2011). 
MDHS, Malawi Demographic and Health Survey. 
 
A free national programme to provide combined antiretroviral therapy (cART) for those living with 
HIV infection has been available in Malawi since 2004, following a grant from the Global Fund to 
Fight AIDS, TB and Malaria. As of December 2013, the total number of patients alive on ART was 
472,865 (Government of Malawi, 2014). Using the previous ART eligibility criteria of CD4 <350 
cells/mm3 or WHO Clinical Stage 3 and 4, ART coverage in Malawi in 2013 was estimated at 83% (up 
from 65% in 2012) (Government of Malawi, 2014). However, the CD4 threshold for ART initiation 
was changed to <500 cells/mm3 in 2014 (Malawi Ministry of Health, 2014) in line with the revised 
WHO guidelines (World Health Organization, 2013a). This has been fully implemented, thus 
increasing the pool of eligible patients. The initial first-line treatment had been a combination of 
stavudine, lamivudine and nevirapine, but was updated to tenofovir, lamivudine and efavirenz in 
July 2013 (Ministry of Health, 2008; Malawi Ministry of Health, 2014). Malawi was also one of the 
first countries to introduce lifelong ART for pregnant and breastfeeding women to prevent mother-
to-child transmission (PMTCT) (Option B+) in 2011 (WHO Regional Office for Africa, 2014). Between 
2011 and 2013, Option B+ increased ART coverage among HIV-infected pregnant women from 40 to 
61% (Government of Malawi Ministry of Health, 2011; Government of Malawi Ministry of Health, 
2013). However, ART uptake and retention remain a challenge. In a study of ~22,000 women who 
started Option B+ between October 2011 and March 2012, 17% women were lost to follow-up 6 
months after ART initiation (Tenthani et al., 2014). More recently, the Malawi Ministry of Health 
reported that 77%, 72% and 71% of women who started ART as part of Option B+ were retained on 
treatment at six, 12, and 24 months after initiation, respectively (Government of Malawi Ministry of 
Health, 2014). 
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1.7.3  Acute respiratory infections in Malawi 
There are scanty published data on acute respiratory infections in Malawian adults. Several reports 
in the pre-HIV era described ARI as the most common cause of adult admission in Malawi (Harries et 
al., 1988; Harries et al., 1990). More recently, a study at QECH from January 2010 to July 2011 
identified both upper and lower respiratory infection as top ten diagnoses in the adult medical 
wards (SanJoaquin et al., 2013). Pneumonia was the commonest cause of admission (1149/7103, 
16%). Of those patients, 85% had HIV infection with 10% inpatient mortality (SanJoaquin et al., 
2013). However, the epidemiology and aetiology of ARI presentations in this setting have not yet 
been comprehensively described. 
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1.8  Aims and objectives 
The aim of this thesis is to examine the relationship between HIV infection and influenza, in a high 
HIV prevalence setting. The main hypothesis is that HIV-infected adults are at an increased risk of 
influenza infection and experience greater severity of disease, compared to HIV-uninfected adults. 
Thus policy makers should consider HIV-infected individuals as a priority group when devising 
influenza control strategies in Malawi and other similar high HIV prevalence settings. 
Key research questions that will be addressed include:  
1. What is the epidemiology and burden of influenza in adults in an urban setting in Malawi? 
2. Does HIV increase susceptibility to influenza infection? 
3. What is the contribution of influenza to hospitalized lower respiratory tract infection (LRTI) in 
Malawian adults? 
4. What are the clinical predictors of influenza in patients admitted with LRTI in Malawi? 
5. Is HIV infection associated with increased severity of influenza-related respiratory 
presentation? 
6. Does infection with influenza or other respiratory viruses predispose to secondary 
pneumococcal pneumonia by  increasing risk of acquisition and nasopharyngeal density of 
Streptococcus pneumoniae?  
This thesis sets out to address the above questions using the following studies:  
1. Sentinel hospital-based surveillance of influenza and other respiratory viruses in adults 
presenting with mild and severe acute respiratory presentations (Q1) 
2. Recruitment of a prospective cohort of HIV-infected and HIV-uninfected individuals to 
measure the incidence of influenza-confirmed illness episodes over a 2-year period (Q1&2) 
3. A case control study of adults presenting with mild and severe influenza-related respiratory 
presentations in Blantyre, Malawi (Q3-5) 
4. A cross-sectional and case control study nested within the prospective cohort (Q6) 
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CHAPTER 2.   GENERAL METHODS 
             
 
This chapter discusses methodological aspects that are common to the studies described in Chapters 
3 to 6, including study sites, laboratory procedures, data management and ethical considerations. 
Methods pertaining to each study – namely study design, population, clinical definitions, 
procedures, sample size, statistical analysis and timescale, will be discussed under the individual 
chapters. 
2.1  Study sites 
2.1.1  Queen Elizabeth Central Hospital  
The Queen Elizabeth Central Hospital (QECH) is the largest government inpatient health facility 
(1250 beds) in Malawi, and is the referral centre for patients in the Southern Region. It provides 
secondary and tertiary care to the population of greater Blantyre (around 1.3 million), including 
internal medicine, general surgery, paediatrics, obstetrics and gynaecology, anaesthetics and 
radiology, in addition to specialised surgical specialties such as orthopaedics, Ear Nose and Throat, 
neurosurgery, and ophthalmology departments. A recently published paper on the electronic 
inpatient data collection system for adult inpatients (Surveillance Programme of Inpatients and 
Epidemiology (SPINE)) (SanJoaquin et al., 2013) reported over 7000 adult medical admissions at 
QECH between January 2010 and July 2011; median age was 37 years, 50% were male, 74% were 
HIV-positive (21% previously undiagnosed). The median stay in hospital was 5 days, and in-hospital 
mortality was 15% (SanJoaquin et al., 2013). 
2.1.1.1 Adult Emergency Trauma Centre (AETC) 
The current Adult Emergency Trauma Centre has been in operation since the beginning of 2012. Its 
facilities include a triage area, resuscitation area, and a short stay ward. On average, around 200 
adults (range 100-250) attend daily, of which on average 20 to 30 result in medical admissions.   
2.1.1.2 Antiretroviral treatment (ART) and Voluntary Counselling and Testing (VCT) Clinics 
The ART clinic at QECH was founded initially as a fee-paying clinic in 2000, but has been providing 
ART free of charge to children and adults since 2004 as part of the Ministry of Health scale-up 
programme (van Oosterhout et al., 2005; van Oosterhout et al., 2007). Between 2004 and 2011, 
around 16,000 individuals were initiated on ART at the QECH clinic (Sloan et al., 2013). Currently, 
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~10,000 registered patients are alive and on treatment, of whom 9176 are on first-line ART 
treatment, and 560 are on second line therapy (July 2015). 
The VCT service is located adjacent to the ART clinic. Trained counsellors provide HIV counselling and 
testing to approximately 40 walk-in patients daily.  
2.1.2  Gateway Clinic 
The Gateway clinic is a primary care clinic located close to QECH, run by the Ministry of Health 
Blantyre District Health Office (DHO). It was opened in October 2013 in response to growing 
pressures on the AETC at QECH, which had become overburdened with patients with primary care 
issues due to the lack of a district hospital and primary care services within Blantyre. The clinic has 
one consultation room (subdivided into two consultation areas using a screen), a short stay area, a 
laboratory where point-of-care tests, e.g. urinary pregnancy test and malaria rapid diagnostic test 
(RDT), are performed, and a pharmacy. The clinic also provides an HIV VCT service. The BASH-FLU 
study began recruitment at this clinic in January 2014. Recognition of the lack of space for patient 
consultation led to the donation of a container by MLW that has been refurbished into two clinic 
rooms, one of which is used for conducting research activities.  
Since its opening, the number of patients attending the Gateway clinic has steadily increased. It 
currently sees up to 300 walk-in patients daily.  
2.1.3  Malawi-Liverpool-Wellcome Trust (MLW) Clinical Research Programme 
MLW is a clinical research programme that conducts laboratory, clinical, epidemiological and social 
science research on health problems affecting Malawi and sub-Saharan Africa. Established in 1995, 
the programme is part of the University of Malawi College of Medicine (COM) and has close links 
with the University of Liverpool and The Liverpool School of Tropical Medicine (LSTM) through the 
Liverpool-Glasgow Wellcome Trust Centre for Global Health Research (Wellcome Trust Liverpool 
Glasgow Centre for Global Health Research). It has also established collaborative links with 
numerous research institutions worldwide. Since 2003, it has been recognised as one the Wellcome 
Trust’s Major Overseas Programme. 
MLW is located within the grounds of QECH, with field research sites around urban Blantyre, 
Chikwawa and Thyolo. The programme hosts a large number of local and international PhD and 
Masters Students, as well as post-doctoral researchers. It also provide operational support, including 
administration, finance, information technology, human resources, data management, laboratory, in 
addition to ordering and storage of research consumables. Most MLW fellows with a clinical 
General methods 
 77 
background contribute to clinical duties, as well as undergraduate and postgraduate teaching 
programmes at QECH.  
The research activities of MLW are focused under four main themes: Malaria, HIV and tuberculosis, 
Non-communicable diseases, and Microbes, immunity and vaccines. 
 
 
Figure 2.1  Study sites of influenza surveillance and BASH-FLU study within Blantyre, Malawi 
2.2  Laboratory Procedures 
2.2.1  Sample registration and storage 
With the exception of the haemagglutination inhibition (HAI) assay (see section 2.2.9), all clinical 
specimens collected from study participants were processed at the MLW or COM-MLW laboratories. 
Both laboratories participate in the UK National External Quality Assessment Scheme (NEQAS). 
Each study specimen was labelled with a pre-printed laboratory specimen barcode and the 
participant’s unique study barcode (section 2.3), with a corresponding laboratory specimen 
submission form that contained the same details, in addition to the participant’s name and date of 
birth. This allowed treating clinicians to access to the results from the Laboratory Information 
Management System (LIMS) in a timely fashion. Laboratory test results were subsequently linked to 
the participants’ demographic information by their unique study number.  
Nasopharyngeal/oropharyngeal and serum samples were stored for batch processing at a later date. 
Stored specimens were anonymised (identifiable by laboratory specimen number and patient study 
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number only) and indexed in accordance with regulatory requirements for human specimen storage. 
They may be stored for up to five years after the end of the study, after which they will be destroyed 
in accordance to Category II waste procedure of the University of Liverpool protocol. Specific 
consent was sought for the storage and transfer of nasopharyngeal/oropharyngeal specimens to the 
United Kingdom (University of Liverpool and/or Liverpool School of Tropical Medicine laboratories), 
and serum specimens to the United States (CDC laboratory, Atlanta). A COMREC Material Transfer 
Agreement was completed and approved. 
2.2.2  HIV test 
HIV status of study participants were determined using rapid HIV tests as per WHO-recommended 
algorithm and national guidelines (figure 2.2 (World Health Organization, 2004)); Alere DetermineTM 
HIV-1/2 assay (Alere Medical Co. Ltd., Chiba, Japan) was used as the initial screening test, and Uni-
GoldTM Recombigen HIV test (Trinity BioTech, Wicklow, Ireland) as the confirmatory test.  
 
 
 
Figure 2.2  Algorithm for use of rapid HIV tests (World Health Organization, 2004) 
General methods 
 79 
2.2.3  CD4+ cell count 
CD4+ T-cell counts were performed on a FACScount flow cytometer (Becton Dickinson, BD 
Biosciences, San Jose, USA).  
2.2.4  Blood culture 
5 to 10 millilitres of blood were collected in a single aerobic blood culture bottle containing the 
manufacturer’s standard culture medium and incubated in a BACTEC 9050 blood culture system 
(Becton Dickenson, BD Biosciences, San Jose, USA) for up to 7 days at the MLW microbiology 
laboratory (Gordon et al., 2001; Everett et al., 2011).  
2.2.5  Sputum tests for tuberculosis 
2.2.5.1  Sputum smear for acid-fast bacilli (AFB)  
Sputum specimens were processed at the COM-MLW TB laboratory. Samples were smeared onto a 
glass slide and allowed to air-dry then heat-fixed. Slides were then examined for acid-fast bacilli 
(AFB) after staining with Auramine. All Auramine-positive smears were confirmed with Ziehl-Neelsen 
staining. Each slide was examined by two independent readers.   
 
2.2.5.2 Sputum culture 
Sputum was incubated in liquid medium for up to 6 weeks using the BACTEC960 Mycobacterial 
Growth Index Tube (MGIT; Becton Dickinson, BD Biosciences, San Jose, USA) system, which exploits 
the fluorescence of an oxygen sensor to detect growth of mycobacteria in culture. A positive and a 
negative control were included with each batch.  
2.2.5.3 Gene Xpert 
Xpert MTB/RIF test was also performed on sputum in patients suspected to have pulmonary TB in 
the cohort and case control studies. It is an automated molecular test for Mycobacterium tuberculosis 
Table 2.1   Grading of sputum AFB smear 
(International Union Against Tuberculosis and Lung Disease, 2000) 
AFB count  Recording/Reporting 
No AFB in >100 fields Negative 
1 to 9 AFB per 100 fields Specify the actual number of AFB per 100 fields  
10-99 AFB per 100 fields + 
1 to 10 AFB per fields ++ 
>10 AFB per field  +++ 
AFB, acid-fast bacilli  
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(Mtb) and resistance to rifampicin, using a nested rRT-PCR assay to amplify a portion of the rpoB 
gene containing the 81 base pair “core” region. The probes are able to differentiate between the 
conserved wild-type sequence and mutations in the core region that are associated with rifampicin 
resistance (Boehme et al., 2010). The MTB/RIF test platform (GeneXpert, Cepheid) integrates sample 
processing and PCR in a single-use disposable cartridge containing all reagents required for bacterial 
lysis, nucleic acid extraction, amplification, and amplicon detection, in addition to a sample 
processing control to control for adequate processing of the target bacteria and to monitor the 
presence of inhibitor(s) in the PCR reaction.  The only manual step is the addition of a bactericidal 
buffer to sputum before transferring a defined volume to the cartridge. The cartridge is then 
inserted into the GeneXpert device, which provides results within 2 hours. 
2.2.6  BinaxNOW Urinary Antigen for Streptococcus pneumoniae 
BinaxNOW® Streptococcus pneumoniae Antigen test (Alere North America, Freehold, US) was 
performed on unconcentrated urine specimens in patients enrolled with hospitalized LRTI, and a 
subset of participants in the cohort study according to manufacturer’s instructions. It is a point-of-
care immunochromatographic (ICT) assay for the detection of pneumococcal soluble antigen. Recent 
meta-analyses of adult studies reported sensitivity and specificity of 74-75% and 94-97% respectively 
(Said et al., 2013a; Sinclair et al., 2013; Horita et al., 2013; Boulware et al., 2007).  
2.2.7  Nasopharyngeal and oropharyngeal samples for respiratory pathogen testing 
In the cohort study (Chapter 4), paired nasopharyngeal and oropharyngeal specimens were taken 
using flocked swabs (FLOQswabs, Copan Diagnostics, Brescia, Italy). For nasopharyngeal sampling, 
the swab is inserted along the floor of the nose to the posterior nasopharynx, and withdrawn with a 
rotating motion after a maximum of 5 seconds. The swab tips were placed in 3mls Universal 
Transport Medium (UTM, Copan Diagnostics, Brescia, Italy) and 1ml aliquots are stored in 
cryovials. It is recognised that the type of swab and operator technique can affect microbial yield. 
Flocked swabs have been shown to be equivalent or superior to Dacron or Rayon swabs with regards 
to the sensitivity of microbial detection, and the quantity of organism recovered (Daley et al., 2006; 
Hernes et al., 2011). They have also demonstrated superiority in the recovery of pneumococci from 
the nasopharynx (Dube et al., 2013). A Kenyan study found no appreciable increase in sensitivity in 
taking two swabs at the same time-point, compared to one (Abdullahi et al., 2007), and current 
WHO guidelines recommend a single swab (Satzke et al., 2013). We therefore opted for a single 
nasopharyngeal sample only. This was also more acceptable to our participants, who had to undergo 
nasopharyngeal sampling up to 10 times over the study period. 
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In the influenza surveillance (Chapter 3) and case control study (Chapter 5), 1 ml aliquots of 
nasopharyngeal aspirates were placed in UTM and skim-milk triptone glucose glycerol (STGG) 
respectively.  UTM aliquots were stored at -80C, and batch-tested for influenza and other 
respiratory pathogens by rRT-PCR at the MLW molecular laboratory. Total nucleic acids were 
extracted from 300μl aliquots of each specimen with the Qiagen BioRobot Universal System using 
the QIAamp One-For-All nucleic acid kit (Qiagen ltd., Manchester, UK) by the MLW molecular 
diagnostic staff.  
Detection of respiratory viruses and bacteria 
5 or 10 μl of nucleic acid extract was used in each qRT-PCR reaction. The CDC Human Influenza qRT- 
PCR diagnostic panel (CDC Influenza division) detecting influenza A and B, influenza A subtyping kit 
(CDC Influenza division) detecting seasonal A(H1), seasonal A(H3), and pandemic 2009A(H1) (World 
Health Organization, 2009a; Selvaraju and Selvarangan, 2010), and a real-time multiplex PCR assay, 
Fast-track Diagnostics (FTD) Respiratory 33  kit (Fast-track Diagnostics Ltd., Luxembourg) (Table 
2.2) were used (Bierbaum et al., 2014; Driscoll et al., 2014), in combination with the AgPath one-step 
qRT-PCR reagents (Applied Biosystems, California, USA). PCR conditions were according to the 
manufacturer’s instructions. Appropriate negative and positive control specimens were run 
alongside each reaction. Samples with cycle threshold (Ct) value <33 were recorded as positive. 
Table 2.2  Pathogens included in the FTD Respiratory 33 multiplex PCR, and their determined 
clinical significance 
Viral (potentially pathogenic) Adenovirus 
Bocavirus 
Coronavirus OC43, NL63, 229E, HKU1 
Enterovirus/parechovirus 
Influenza A, B, C 
Human metapneumovirus A & B 
Parainfluenza viruses 1, 2, 3, 4 
Respiratory syncytial virus (RSV) A & B 
Rhinovirus 
Atypical bacteria (potentially 
pathogenic) 
Bordetella pertussis 
Chlamydia pneumoniae 
Legionella species 
Mycoplasma pneumoniae 
Pneumocystis jirovecii 
Commensal bacteria in the 
nasopharynx 
Haemophilus influenzae species & type B 
Moraxella catarrhalis 
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2.2.8  Nasopharyngeal samples for quantitative lyt-A PCR for Streptococcus pneumoniae  
The nasopharyngeal density of S. pneumoniae was measured in a sub-study of the BASH-FLU cohort 
study (Chapter 6), utilising real-time PCR targeting the autolysin-encoding lytA gene (Carvalho Mda 
et al., 2007; Albrich et al., 2012). LytA is a single-copy gene present in all encapsulated and non-
encapsulated pneumococci. The assay does not cross-react with other mitis group streptococci (Greve 
and Moller, 2012). Total nucleic acids were extracted from 300ul universal transport medium (UTM) 
with combined nasopharyngeal and oropharyngeal specimens. The QIAamp One-For-All nucleic acid 
kit (Qiagen) was used with the Qiagen BioRobot Universal System following the standard protocol 
provided by the manufacturer. Five µl of the extracted nucleic acids were used in the quantitative LytA 
PCR assay. PCR primers and cycling conditions were used as described in Carvalho et al (Carvalho 
Mda et al., 2007). A standard curve for quantification was generated using paired tenfold serial 
dilutions of DNA extracted from a reference bacterial culture, spanning 7x102-7x109 genomic copies 
per millilitre (copies/ml). DNA concentrations of these standards were measured using the Qubit 
DNA BR assay kit (Life Technologies). Sample density was reported as the qPCR concentration in 
copies/ml as calculated from the standard curve.  
2.2.9  HAI assay  
Serum specimen will be transferred to the laboratory at the Infiuenza Division of the National Center 
for Immunization and Respiratory Diseases, CDC, in Atlanta, Georgia, US, for processing of HAI assay. 
The results of this test will not be reported in this thesis. 
2.3  Data management 
Data for this study were collected in accordance with the ethical principles of Good Clinical Practice 
(GCP), as defined by the International Conference on Harmonisation guidelines. MLW Standard 
Operating Procedures were adhered to in relation to data handling and consent.  
Each participant was assigned a unique study number at enrolment. Data collection forms for a 
particular participant were linked by a scannable barcode containing this number. Data were 
Streptococcus pneumoniae 
Staphylococcus aureus 
Pathogens of unknown significance 
in the nasopharynx therefore 
excluded from analysis 
Cytomegalovirus 
Klebsiella pneumoniae 
Salmonella species 
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collected on paper-based case record forms (CRFs) (Appendix 8.3-8.5) and converted to electronic 
form using Intelligent Character Recognition (ICR) scanning software (Cardiff TeleForm Version 
10.7, Vista, CA). The software highlights data entries that are ambiguous or are outwith a pre-
determined range, which were verified by the data officer or principal investigator. The verified data 
was subsequently exported to a Microsoft Access database on a secure server at MLW.  No patient-
identifiable information is kept on the electronic database, which is password-protected and access 
is restricted to the principal investigator. Data files were exported to Stata 12.1 (Statacorp, USA) for 
analysis. The paper CRFs were stored in locked filing cabinets in the MLW research office that were 
accessible only to the members of the study team.  
The patient/guardian consent form and the participant tracking form contain the only sources of 
person-identifiable information. The latter contain the subjects’ name, contact details and the 
unique study number, in order to provide a link with the anonymised clinical data. Both were kept in 
a secured locked cabinet held separately from the CRF hard copies.  
The paper CRFs will be stored in the MLW archives for up to 5 years following study completion, 
after which time they will be destroyed. 
2.4  Statistical analysis 
Statistical analysis plans are described in the Methods section of the individual studies. All analyses 
were undertaken using STATA 12.0 (StataCorp, College Station, USA). Missing observations were 
included in the analysis of each study by creating missing value categories. For tables where 
denominators are not included, the numbers of missing values for individual variables are detailed in 
Appendix 8.4. 
2.5  Ethical considerations 
Ethical approval for the sentinel influenza surveillance was obtained from the College of Medicine 
Research Ethics Committee (COMREC), University of Malawi (P.07/10/958) and the Centers for 
Disease Control and Prevention (CDC) through an ethical reliance. The BASH-FLU cohort and case 
control studies were approved by the Research Ethics Committees of the Liverpool School of 
Tropical Medicine, UK (12.43) and COMREC (11/12/1310). Written informed consent was obtained 
from all participants or their guardians. Patient and guardian consent forms are in the appendix. 
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CHAPTER 3.  The epidemiology and risk factors for influenza in 
Malawian adults presenting with acute respiratory infection: a 
sentinel surveillance study 
             
 
 
3.1  Introduction 
Influenza is an important cause of acute respiratory disease worldwide; annual attack rate is 
estimated to be between 20 to 30% in children and 5 to 10% in adults, and an annual mortality of up 
to 500,000 (World Health Organization, 2014c). Although thought to be considerable, the 
epidemiology and burden of influenza in most SSA countries, particularly life-threatening lower 
respiratory disease, are poorly characterised (Chapters 1.2 & 1.3). The lack of diagnostic capacity, 
similarity of influenza presentation with other common febrile illnesses such as malaria and bacterial 
pneumonia, and prioritisation of other high-burden public health problems are likely contributory 
factors. A recent systematic review concluded that most SSA countries had insufficient 
epidemiological data to develop rational strategies for influenza prevention and control (Gessner et 
al., 2011). It is unsurprising therefore that while the World Health Organisation (WHO) recommends 
seasonal influenza vaccine for at-risk groups, such as young children, pregnant women, and HIV-
infected individuals (2012), few countries in the region have implemented these recommendations 
or have a national public policies (Duque et al., 2014). 
Since the 2009 influenza A(H1N1) virus (influenza A(H1N1)pdm09) pandemic, governments and 
international agencies, such as the CDC and WHO, have strengthened surveillance capacity for 
influenza and other respiratory viruses in SSA (Steffen et al., 2012). Emerging data suggest that 
influenza is prevalent in both mild and severe acute respiratory presentations (Chapter 1.2), and 
may be associated with a greater mortality compared to developed settings (Cohen et al., 2012c). 
Data from South Africa suggest increased incidence of hospitalisation and mortality in HIV-infected 
individuals, which has considerable implications for many high HIV prevalence SSA countries (Cohen 
et al., 2013; Cohen et al., 2015a). However, outside South Africa and Kenya, there are scant 
epidemiological data, and where available, surveillance activities have largely focused on children 
(Dalhatu et al., 2012; Lutwama et al., 2012; Niang et al., 2012; Muyembe Tamfum et al., 2012; Katz 
et al., 2012; Mmbaga et al., 2012; Theo et al., 2012; Cohen et al., 2013; Dia et al., 2013; Katz et al., 
2014; Cohen et al., 2014; Emukule et al., 2014), are predominantly based on outpatients, and lack 
individual-level information to evaluate risk factors for influenza or severe influenza presentations. 
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With the support of the CDC, sentinel hospital-based surveillance for influenza and other respiratory 
viruses was established in January 2011, at Queen Elizabeth Central Hospital (QECH) in Blantyre, 
Malawi. In a high HIV prevalence setting (SanJoaquin et al., 2013), we utilised clinical and molecular 
techniques to define the contribution of influenza and other respiratory pathogens to acute 
respiratory presentations in Malawian adults and characterise the risk factors associated with 
influenza-related respiratory presentations in the post-influenza A(H1N1)pdm09 period. 
3.2  Methods 
3.2.1  Study design 
This was a sentinel surveillance study of adults presenting to QECH with mild and severe acute 
respiratory illness.  
3.2.2   Study site 
Active, prospective respiratory virus surveillance was introduced at QECH in January 2011. Patients 
were enrolled from the Adult Emergency Trauma Centre (AETC) (Chapter 2.1.1).  
3.2.3  Study population 
All patients aged 15 years and over who presented to the AETC during weekdays were eligible. 
Consecutive patients that fulfilled the case definitions were recruited. A maximum of 4 patients who 
met the case definition for ILI, and 4 patients with SARI were enrolled during weekdays. ILI 
recruitment was conducted in 2011 only.  
The following adapted WHO case definitions (World Health Organization, 2013b) were used: 
Influenza-like illness (ILI) 
 Reported or recorded fever (>38C) 
 > 2 of the following: cough, sore throat, myalgia, headache, OR diarrhoea/vomiting  
 Symptom for 7 days or fewer 
 
Severe acute respiratory illness (SARI) 
 Reported OR recorded fever (>38C) 
 Cough OR sore throat 
 Shortness of breath OR difficulty breathing 
 Symptoms for 7 days or fewer 
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 Hospitalisation was not a requirement 
 
3.2.4  Study procedures  
3.2.4.1  Staff 
The following staff were employed to maintain the study cohort: 
 2 study nurses: responsible for screening for eligible patients at the triage area in AETC; consent 
and enrolment of patients; obtaining clinical specimens, including nasopharyngeal aspirate, 
blood and sputum; instituting appropriate management, e.g. administering intravenous fluids 
or antibiotics; and completion of paper and electronic copies of screening and enrolment logs.  
 1 clinical officer: responsible for assessing eligibility, consent and enrolment of patients; clinical 
assessment and management of patients; conducting necessary clinical procedures, e.g. pleural 
aspiration; aiding study nurses in obtaining clinical specimens. 
 1 laboratory messenger: responsible for transporting clinical specimens from AETC to the 
MLW/COM laboratories. 
 1 molecular laboratory technician: responsible for aliquoting, storage and processing combined 
nasopharyngeal specimens, as part of a team of technicians in the core diagnostic laboratory. 
In addition to screening and enrolment of study participants, study staff also contributed to routine 
clinical activities at the AETC. 
3.2.4.2  Enrolment 
ILI and SARI patients were recruited daily between 8am to 3pm in the AETC. Recruitment hours were 
limited by the necessity of clinical samples to reach the laboratory by 3pm for processing. Persons 
that met the eligibility criteria who were willing to consider participation in the study received a 
patient information document. Written informed consent was obtained.  
Demographic and clinical information were obtained from study participants using a structured 
questionnaire (Appendix 8.3.1). Data collected included demographic details, clinical presentation, 
pregnancy status, history of pneumococcal conjugate or influenza vaccination, preceding antibiotic 
use, and smoking status. Physiological parameters at presentation were also recorded. 
3.2.4.3  Laboratory investigations 
The investigations that were performed on enrolment are listed in Table 3.1 (see Chapter 2.2 for 
details on individual tests). 
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Table 3.1   Laboratory investigations undertaken in sentinel surveillance 
Investigations ILI SARI 
Venous blood    
 Malaria rapid diagnostic test X X 
 Rapid HIV test (if status unknown)  X 
 Blood culture  X 
Nasopharyngeal aspirate   
 Influenza PCR (CDC H1N1 kit) X X 
 Multiplex PCR for 33 respiratory pathogens                            
(Fast-track Diagnostics)  
 X 
 
3.2.5  Statistical analysis 
Between January 2011 and March 2013, demographic and clinical data on enrolled adults were 
entered through a touch screen electronic data collection system – the Surveillance Programme of 
Inpatients and Epidemiology (SPINE) (SanJoaquin et al., 2013). In April 2013, this was migrated to a 
scannable paper-based case report form using optical recognition software (Cardiff TeleForm 
Version 10.7, Vista, CA, USA).  
Logistic regression was used to calculate odds ratios (OR) and 95% confidence intervals to compare 
clinical variables between influenza-positive and influenza-negative patients. Monthly proportions of 
influenza positivity among SARI patients were plotted against meteorological parameters (mean 
monthly temperature, rainfall and relative humidity obtained from the Department of Climate 
Change and Meteorological Services in Blantyre) to assess potential associations.  
The incidence of adult hospital-attended influenza-positive SARI per 100,000 persons was estimated 
using the number of enrolled SARI cases who tested positive for influenza, adjusting for the 
recruited proportion of all SARIs that attended QECH each month as the numerator (SanJoaquin et 
al., 2013), divided by census estimates of Blantyre population aged >15years (National Statistics 
Office (NSO), 2008) and multiplied by 100,000, with Poisson confidence intervals (CIs).  
To identify factors associated with influenza positivity and clinical severity (defined as Modified Early 
Warning Score (MEWS) >4 (Subbe et al., 2001) (Table 3.2) among SARI patients, multivariable 
Poisson models with robust error estimates were constructed (log binomial convergence failure 
occurred (Williamson et al., 2013; Chen et al., 2014)). Covariates with a p-value of <0.2 on 
univariable analysis were assessed for significance in the multivariable analysis using backwards-
stepwise selection. Risk ratios (RR) and 95% CIs were reported. 
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3.3  Results 
3.3.1  Demographic and clinical characteristics of the surveillance population 
From 1 January 2011 to 31 December 2013, 1705 patients (579 ILI (2011), and 1126 SARI patients 
(2011-2013)) aged 15 years and over were enrolled. Demographic characteristics and influenza 
results are described in Table 3.3. The median ages of SARI and ILI cases were 28.6 years (range 15–
71 years) and 32.9 years (range 15-88 years) respectively. 301 (52%) ILI and 489 (43.4%) SARI 
patients were male. Twenty-eight pregnant women were enrolled (9 with ILI and 19 with SARI). HIV 
status was available for 1109 (98.5%) SARI patients, of whom 558 (50.3%) were HIV-infected. Very 
few patients (1.4% ILI and 1.2% SARI) reported receipt of influenza vaccination in the previous year. 
Overall, 95 (16.4%) ILI cases and 163 (14.5%) SARI cases were positive for influenza viruses (18.3% 
(2011); 9.6% (2012); 16.1% (2013), Table 3.3). Annual cycles of influenza activity were observed 
(Figure 3.1), but timing of peak detection varied year to year. In 2011, influenza activity had a 
bimodal peak – in April and July. In 2012, influenza was detected between March and June only. In 
contrast, influenza was detected throughout 2013, but peaked in January and February. Increased 
influenza activity was predominantly seen between January and June (proportion of influenza- 
positive SARI patients: January to March 19.5%, April to June 18%, July to September 12.3%, and 
October to December 5%). Influenza activity was lowest in the hot, dry months, while the peaks 
were associated with high relative humidity, but not with rainfall or low temperature (Figures 3.1 to 
3.3). Influenza A(H1N1)pdm09, A(H3N2) and influenza B circulated in all three years; influenza  
Table 3.2  Modified Early Warning Score (MEWS) 
 3 2 1 0 1 2 3 
SBP(mmHg) <70 71-80 81-100 101-199  >200  
Heart rate 
(beats/min) 
 <40 41-50 51-100 101-110 111-129 >130 
Respiratory rate 
(breaths/min) 
 <9  9-14 15-20 21-29 >30 
Temperature 
(c) 
 <35 
 
 35-38.5  >38.5  
AVPU score    Alert Reacting 
to voice 
Reacting 
to pain 
Unresponsive 
SBP, systolic blood pressure; AVPU, “Alert, voice, pain, unresponsive” 
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A(H1N1)pdm09 dominating in 2011 (39.1%) and 2013 (49.4%), while seasonal influenza A(H3N2) was 
the most prevalent in 2012 (48.6%).  
Table 3.3  Demographic characteristics and influenza PCR results for adults enrolled with 
ILI and SARI, 2011-2013 (N=1705) 
Characteristic 2011 2011-2013 
ILI (n=579) 
n (%) 
SARI (n=1126) 
n (%) 
Gender  
   Male 
 
301 (52.0) 
 
489 (43.4) 
Age (median, IQR) 28.6 (23.5-35.2) 32.9 (26.6-42) 
HIV status a.b 
   Positive 
 Pregnancy (Female only) 
   Yes 
   No   
 
    N/A  
(n=278) 
9 (3.2) 
269 (96.8)    
 
558 (50.3) 
(n=637) 
19 (2.7) 
618 (97.3)  
Current smoker 37 (6.6) 29 (2.8) 
Antibiotics in the past two week 
Reported Influenza vaccination in past yearc 
63 (10.9) 
8 (1.4) 
482 (46.5) 
13 (1.2) 
Influenza-PCR positive  
  Year   
    2011 
    2012 
    2013  
  Type/subtype 
   Influenza A 
      Pandemic A(H1N1) 
      Seasonal A(H3N2) 
      A(un-subtyped)d 
    Influenza B 
    Influenza A & B co-infection 
Other respiratory viruses identifieda 
   None 
   1 
   >2 
95  (16.4) 
 
95  (16.4) 
- 
- 
(n=95) 
 
43 (45.3) 
33 (34.7) 
3 (3.2) 
15 (15.8) 
1 (1.0) 
 
- 
- 
163 (14.5) 
 
46 (18.3) 
35 (9.6) 
82 (16.1) 
(n=163) 
 
61 (37.4) 
47 (28.8) 
1 (0.6) 
50 (30.7) 
3 (1.8) 
 
717 (63.7) 
285 (25.3) 
124 (11.0) 
ILI, influenza-like illness; SARI, severe acute respiratory illness; N/A, not applicable; IQR=inter-
quartile range; PCR=polymerase chain reaction 
The number of missing observations in each variable is detailed in Appendix 8.4.1; individuals with 
missing data were excluded from the denominator in percentage calculations. 
aHIV test and multiplex-PCR for 33 respiratory pathogens were only performed on SARI patients 
bHIV result – missing in 17 SARI patients. 
cThere is no routine influenza vaccination programme in Malawi. 
dInfluenza A sample with CT values <40 which could not be subtyped. 
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Figure 3.1   Relationship between influenza positivity in enrolled adults with SARI, and monthly relative humidity, 2011-2013 (N=1126) 
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Figure 3.2   Relationship between influenza positivity in  enrolled adults with SARI, and monthly temperature, 2011-2013 (N=1126) 
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Figure 3.3   Relationship between influenza positivity in enrolled adults with SARI, and monthly rainfall, 2011-2013 (N=1126) 
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Malaria antigen test results were available for 562 (97.1%) ILI and 911 (80.9%) SARI patients; 3% of 
adults recruited with ILI or SARI had a positive malaria RDT; none were influenza positive.  
Compared with influenza negative patients with SARI, headache was more (90.1 vs. 83.7%, OR 1.79 
(95%CI 1.02-3.13), p=0.04) while rhinorrhoea was less (7.5 vs. 13.9%, OR 0.50 (95% CI 0.27-0.92, 
p=0.03) commonly reported among influenza positive patients. No other clinical differences by 
aetiology were found (Table 3.4).  
 
 
3.3.2  Incidence of hospital-attended influenza-associated SARI 
The incidence of hospital-attended influenza-associated SARI for Blantyre was estimated at 16.8 
(95%CI 13.8-19.8) in 2011, 9.7 (95% CI 7.4-11.9) in 2012, and 16.9 (95%CI 14.0-19.8) in 2013, per 
100,000 persons aged 15 years and over. 
3.3.3  Prevalence of other respiratory viruses 
Respiratory viruses other than influenza were identified in almost a third of enrolled SARI patients 
(32.2%, n=363) (Figure 3.4). The most ubiquitous were rhinovirus (n=149, 13.2%), RSV (n=48, 4.2%), 
adenovirus (n=47, 4.1%) and coronavirus OC43 (n=47, 4.1%). 253 (22.5%) had a single virus isolated, 
whereas co-detections were found in 150 (13.3%) adults.  
 
Table 3.4  Clinical characteristics of enrolled adults with SARI by influenza status (N=1126) 
Characteristic Number of cases (%)      OR (95% CI) P-value* 
Influenza PCR +ve 
(n=163) 
Influenza PCR –ve 
(n=963)  
 
Symptoms 
Fever >38c 
Cough 
Sore throat 
Headache 
Rhinorrhoea 
Myalgia 
Vomiting/diarrhoea 
 
138/162 (85.2) 
149/152 (98.0) 
95/150 (63.3) 
137/152 (90.1) 
12/161 (7.5) 
129/152 (84.9) 
19/151 (12.6) 
 
770 (80.5) 
866/892 (97.1) 
592/890 (66.5) 
747/893 (83.7) 
132/950 (13.9) 
750/885 (84.7) 
173/892 (16.5) 
 
1.39 (0.88-2.23) 
1.49 (0.45-4.99) 
0.87 (0.61-1.25) 
1.79 (1.02-3.13) 
0.50 (0.27-0.92) 
1.02 (0.63-1.64) 
0.73 (0.44-1.22) 
 
0.16 
0.52 
0.45 
0.04 
0.03 
0.94 
0.23 
Signs 
Systolic BP <90mmHg 
HR >120/minute 
RR >30/minute 
Oxygen saturation <90% on air 
 
27/152 (17.5) 
67/153 (44.0) 
   76/151 (50.3)  
      22/154 (14.0) 
 
114/892 (12.8)                      
340/892 (38.1) 
401/886 (45.3) 
104/894 (11.6) 
 
1.44 (0.91-2.30) 
1.27 (0.90-1.80) 
1.23 (0.87-1.74) 
1.25 (0.76-2.08) 
 
       0.12                  
0.18 
0.24 
0.37 
PCR, polymerase chain reaction; OR, odds ratio; BP, blood pressure; HR, heart rate; RR, respiratory rate 
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3.3.4  Factors associated with influenza positivity in SARI patients 
Results from multivariable analysis (Table 3.5) indicate that, among SARI patients, non-pregnant 
women were more likely than men to be positive for influenza (adjusted risk ratio (aRR) 1.45, 95%CI 
1.08-1.98). However, pregnant women had an almost three-fold increased risk of influenza infection, 
compared to men (aRR 2.82, 95%CI 1.41-5.83, p=0.007). A sub-analysis restricted to women of 
childbearing age (CBA) (15 to 45 years, n=505) with SARI was performed (Table 3.6). HIV prevalence 
was substantially lower in pregnant compared to non-pregnant women of CBA (21 vs. 54%, 
p=0.005). However, pregnant women were nearly twice as likely to be influenza positive than non-
pregnant women, after adjustment for HIV status, recruitment year and viral co-infections (31 vs. 
15%, aRR 1.84, 95%CI 0.99-3.43, p=0.05). 
 
 
Figure 3.4  Influenza and respiratory viruses detected in enrolled adults with SARI, 2011-2013 
(N=1126) 
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Table 3.5  Factors associated with influenza PCR positivity in enrolled adults with SARI, 2011-2013 (N=1126) 
Characteristic Number of cases with 
+ve influenza-PCR (%) 
Univariablea  Multivariablea,b 
RR (95% CI) P-value*  RR (95% CI) P-value 
Sex 
  Male 
  Female 
Age group (years) 
  15-24 
  25-34 
   > 35 
HIV status 
  Negative 
  Positive 
           
58/489 (11.9) 
105/636 (16.5) 
 
40/230 (17.4) 
59/414 (14.3) 
62/472 (13.2) 
 
96/551 (17.5) 
60/558 (10.8) 
 
1 
    1.39 (1.03-1.88) 
 
1.32 (0.92-1.91) 
1.08 (0.78-1.51) 
1 
 
1 
0.61 (0.46-0.83) 
 
 
0.03 
 
0.33 
 
 
 
 
<0.001 
  
 
 
 
1.35 (0.90-1.90) 
1.06 (0.76-1.47) 
1 
 
1 
0.59 (0.43-0.80) 
 
 
 
 
0.65 
 
 
 
 
<0.001 
Medical history  
  Malaria RDT - negative 
                         - positive 
 Recent antibiotics – no 
                                   – yes 
  Pregnancy – male (not applicable) 
                      – non-pregnant female 
                      – pregnant female 
  Current smoking – no 
                                 – yes 
 
138/882 (15.6) 
       0/28 (0) 
86/580 (14.8) 
73/501 (14.6) 
58/494 (11.7) 
99/612 (16.2) 
6/19 (31.6) 
140/945 (14.8) 
12/102 (11.8) 
 
 
- 
1 
0.99 (0.74-1.33) 
1 
1.37 (1.02-1.86) 
2.70 (1.33-5.44) 
1 
0.79 (0.46-1.38) 
 
 
- 
 
0.93 
 
 
0.02 
 
0.41 
  
 
 
 
 
1 
1.45 (1.08-1.98) 
2.82 (1.41-5.63) 
 
 
 
 
 
 
 
 
 
0.007 
 
 
Year of surveillance 
   2011 
   2012 
   2013 
 
46/251 (18.6) 
35/366 (9.6) 
82/509 (16.1) 
 
1.91 (1.27-2.89) 
1 
1.69 (1.16-2.49) 
 
 
 
0.003 
  
2.38 (1.56-3.63) 
1 
1.69 (1.14-2.49) 
 
 
 
<0.001 
Viral co-infections 
  None 
  >1 other respiratory virus 
 
124 /717 (17.3) 
39/408 (9.6) 
 
1 
0.55 (0.39-0.78) 
 
 
 0.001    
  
1 
0.51 (0.36-0.73) 
 
  
<0.001 
PCR, polymerase chain reaction; RR, risk ratio; CI, confidence interval; RDT, rapid diagnostic test 
a Generalised linear model using Poisson distribution with robust error estimates.  
bBackward stepwise approach, including a priori confounders (age, sex, HIV status and year of surveillance) and all variables with p<0.20 in 
univariate analysis.  
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Influenza-positive adults with SARI were less likely to be HIV-infected (aRR 0.59; 95%CI 0.43-0.80, 
p<0.001) or have co-detection with an additional respiratory virus (aRR 0.51; 95%CI 0.36-0.73, 
p<0.001). Small numbers prohibited the evaluation of specific viral co-detection combinations with 
influenza.  
3.3.5  Factors associated with clinical severity among SARI patients 
 422 (37.5%) SARI patients had clinically severe disease (MEWS score >4). No inpatient deaths were 
recorded, though patient follow-up after enrolment was incomplete. In the multivariable analysis 
(Table 3.7), HIV infection (aRR 1.58, 95%CI 1.23-2.04), and PCR-detected P. jirovecii (aRR 1.61, 95%CI 
1.05-2.47) were associated with clinical severity. Influenza positivity was not associated with clinical 
severity. However, HIV infection predicted severity in both influenza-positive (RR 2.30, 95%CI 1.33-
3.99) and influenza-negative (RR 1.46, 95%CI 1.13-1.89) SARI patients. Other viral aetiology (e.g. 
hMPV, parainfluenza 2) did not predict severity. Smoking was reported in 102 (9.7%) individuals, but 
was not associated with severity.  
  
Table 3.6  Sub-analysis of factors associated influenza PCR positivity in females of childbearing 
age (15-45 years) with SARI, 2011-2013 (N=505) 
Characteristic Number of 
cases with +ve 
influenza-PCR 
(%) 
Univariablea  Multivariablea,b 
RR (95% CI) P-
value* 
 RR (95% CI) P-value* 
Pregnant  
  No 
  Yes 
 
74/486 (15.2) 
6/19 (31.6) 
 
1 
2.06 (1.03-4.14) 
 
 
0.04 
  
1 
1.84 (0.99-3.43) 
 
 
0.05 
HIV status 
  Negative 
  Positive 
 
51/237 (21.5) 
27/262 (10.3) 
 
1 
0.61 (0.46-0.83) 
 
 
<0.001 
  
1 
0.45 (0.29-0.70) 
 
 
<0.001 
Year of surveillance 
   2011 
   2012 
   2013 
 
22/126 (17.5) 
12/162 (7.4) 
46/216 (21.3) 
 
2.36 (1.21-4.58) 
1 
2.88 (1.58-5.25) 
 
 
 
<0.001 
  
2.82 (1.48-5.41) 
1 
2.45 (1.35-4.45) 
 
 
 
<0.001 
Viral co-infections 
  None 
  >1 other respiratory virus 
 
62/304 (20.4) 
18/200 (9.0) 
 
1 
0.44 (0.27-0.72) 
 
 
 0.001    
  
1 
0.42 (0.26-0.69) 
 
  
<0.001 
RR, risk ratio; CI, confidence interval 
aGeneralised linear model using Poisson regression with robust error estimates 
bAdjusted for all variables in the model 
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Table 3.7  Factors associated with clinical severity in adults with SARI, 2011-2013 (N=1126) 
Characteristic Number of cases 
with clinical 
severity (n=422) 
(%) 
Univariableb  Multivariableb,c 
RR (95% CI) P-value  RR (95% CI) P-value 
Sex 
  Male 
  Female 
Age group 
  15-24 
  25-34 
   > 35 
HIV – Negative 
        – Positive 
           
105/489 (21.5) 
133/636 (20.9) 
 
46/231 (19.9) 
87/419 (20.8) 
105/476 (22.1) 
91/551 (16.5) 
143/558 (25.6) 
 
1 
0.97 (0.77-1.22) 
 
1 
1.04 (0.76-1.43) 
1.11 (0.81-1.51) 
1 
1.55 (1.23-1.96) 
 
 
0.81 
 
 
 
 
 
<0.001 
  
1 
0.88 (0.70-1.11) 
 
1 
0.96 (0.68-1.35) 
1.00 (0.73-1.39) 
1 
1.58 (1.23-2.04) 
 
 
0.27 
 
 
 
0.95 
 
<0.001 
Medical history  
 Pregnancy  - No 
                      - Yes 
 Recent antibiotics     - No 
                                       - Yes 
 Current smoker         - No 
                                      - Yes 
 
 
236/1107 (21.3) 
2/19 (10.5) 
134/548 (24.5) 
101/483 (20.9) 
224/946 (23.7) 
14/102 (13.7) 
 
1 
0.49 (0.13-1.84) 
1 
0.85 (0.68-1.07) 
1 
0.58 (0.35-0.96) 
 
 
0.29 
- 
0.18 
 
0.03 
 
 
  
 
Malaria RDT  - Negative 
                         - Positive 
Influenza PCR - Negative 
                          - Positive 
 
213/883 (24.1) 
6/28 (21.4) 
198/962 (20.6) 
40/163 (24.5) 
 
1 
0.89 (0.43-1.82) 
1 
1.19 (0.89-1.60) 
 
 
0.75 
 
0.24 
  
 
 
 
 
 
 
Viral co-infections 
  No 
  Yes 
 
198/976 (20.3) 
40/150 (26.7) 
 
1 
1.31 (0.98-1.76) 
 
 
0.07 
   
Respiratory pathogens 
Adenovirus   - Negative 
                        - Positive 
Bocavirus   - Negative 
                     - Positive 
Coronavirus  
  OC43    - Negative 
                - Positive  
  NL63     - Negative 
                - Positive  
  229E     - Negative 
                - Positive 
 HKU1     - Negative 
                - Positive 
Enterovirus - Negative 
                      - Positive 
hMPV     - Negative 
                - Positive 
Parainfluenza 
   1  - Negative 
       - Positive 
   2  - Negative 
       - Positive 
   3  - Negative 
       - Positive 
   4  - Negative 
 
228/1076 (21.2) 
10/47 (21.3) 
232/1099 (21.1) 
6/24 (25.0) 
 
225/1074 (21.0) 
13/49 (26.5) 
227/1086 (20.9) 
11/37 (29.7) 
227/1088 (20.9) 
11/35 (31.4) 
 
 
236/1091 (21.6) 
2/32 (6.3) 
224/1089 (20.6) 
14/34 (41.2) 
 
230/1095 (21.0) 
8/28 (28.6) 
231/1105 (20.9) 
7/18 (38.9)  
234/1100 (21.3) 
4/23 (17.4) 
233/1095 (21.3) 
 
1 
1.00 (0.57-1.76) 
1 
1.18 (0.59-2.39) 
 
1 
1.27 (0.78-2.05) 
1 
1.42 (0.86-2.37) 
1 
1.51 (0.91-2.49) 
1 
0.85 (0.43-1.67) 
1 
0.28 (0.08-1.11) 
1 
2.00 (1.32-3.04) 
 
1 
1.36 (0.75-2.47) 
1 
1.86 (1.03-3.36) 
1 
0.82 (0.33-2.01) 
1 
 
 
0.99 
 
0.64 
 
 
0.33  
 
0.18 
 
0.11 
 
0.63 
 
0.07 
 
0.004 
 
 
0.31 
 
0.04 
 
0.66 
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3.4  Discussion 
Our data substantiate the emerging evidence from the African region that the contribution of 
influenza to life-threatening respiratory disease, although previously under-recognised, is 
considerable (Radin et al., 2012). Comprehensive hospital-based sentinel surveillance in our high HIV 
seroprevalence, malaria-endemic African setting has illustrated influenza as an important 
contributor to mild (16.4%) and severe (14.6%) acute respiratory illnesses in adults. In the 
immediate post-pandemic period, influenza A(H1N1)pdm09 was the predominant strain in Malawi in 
2011 and 2013, but was largely absent in 2012. Our data also highlight the strong association 
between pregnancy and influenza in SSA. Furthermore, around a quarter of influenza-positive adults 
with SARI presenting to hospital have severe disease, and that HIV infection is a predictor of severity 
in both influenza positive and influenza negative cases.  
The identification of pregnancy as a potential risk factor for influenza has considerable public health 
importance. While epidemiological evidence from developed settings suggest that pregnant women 
are at increased risk for severe illness and death (Mosby et al., 2011; Van Kerkhove et al., 2011b), 
thus a priority group for influenza vaccination (2012), the association between pregnancy and 
influenza has not been described in SSA outside a pandemic. This finding has important implications 
in the region with the highest fertility rate (The World Bank, 2014). It is possible that pregnant 
women are a healthier group compared to non-pregnant women, thus the higher risk seen in this 
       - Positive 
RSV - Negative 
       - Positive 
Rhinovirus  - Negative 
                     - Positive 
5/28 (17.9) 
226/1075 (21.0) 
12/47 (25.0) 
201/974 (20.6) 
37/149 (24.8) 
0.84 (0.38-1.87) 
1 
1.18 (0.72-1.97) 
1 
1.20 (0.89-1.63) 
0.67 
 
0.50 
 
0.24 
Chlamydia pneumoniae  
- Negative 
- Positive 
Legionella species 
- Negative 
- Positive 
Mycoplasma pneumoniae 
- Negative 
- Positive 
Pneumocystis jirovecii 
- Negative 
- Positive 
 
234/1107 (21.1) 
4/16 (25.0) 
 
189/944 (20.0) 
27/129 (20.9) 
 
233/1099 (21.2) 
5/24 (20.8) 
 
205/1047 (19.6) 
11/26 (42.3) 
 
1 
1.18 (0.50-2.78) 
 
1 
1.05 (0.73-1.50) 
 
1 
0.98 (0.45-2.16) 
 
1 
2.16 (1.36-3.44) 
 
 
0.70 
 
 
0.81 
 
 
0.97 
 
 
0.001 
  
 
 
 
 
 
 
 
 
 
1 
1.61 (1.05-2.47) 
 
 
 
 
 
 
 
 
 
 
 
0.03 
RR, risk ratio; CI, confidence interval; RDT, rapid diagnostic test; PCR, polymerase chain reaction; hMPV, human 
metapneumovirus; RSV, respiratory syncytial virus. 
a As defined by a MEWS score of >4   
b Generalised linear model using Poisson distribution with robust error estimates.  
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group may be due to the greater contribution of influenza to SARI relative to other pathogens.   
Over half of enrolled adults with SARI were HIV-positive, and HIV infection independently predicted 
clinical severity in both influenza positive and influenza negative cases. HIV is a risk factor for severe 
pneumonia (Mwachari et al., 2006; Feldman et al., 2009; Sogaard et al., 2008; Torres et al., 2013); 
indeed several SSA hospital pneumonia aetiology studies reported a high prevalence of HIV infection 
(26-94%) (Scott et al., 2000; Hartung et al., 2011; Koulla-Shiro et al., 1996). Furthermore, recent 
studies from Kenya (Ope et al., 2011) and South Africa (Cohen et al., 2013) have suggested an 
increased risk of influenza-related hospitalisation in HIV-infected persons.  
Influenza was less commonly identified in HIV-infected compared to HIV-uninfected adults with 
SARI. This has also been described in HIV-infected children (Madhi et al., 2000) and adults (Cohen et 
al., 2015c) in South Africa, and likely reflects the different spectrum of organisms affecting HIV-
infected adults (Park et al., 2001), with greater relative contribution of opportunistic pathogens such 
as P. jirovecii, S. pneumoniae and M. tuberculosis (Raju et al., 2012; Benito et al., 2012), rather than a 
lower absolute risk (i.e. the converse of pregnancy). Although we were able to ascertain HIV status 
for the majority of enrolled SARI patients (98.5%), our study was not powered to evaluate the 
impact of HIV infection on the burden and severity of influenza infection, particularly across CD4 cell 
strata. This association will be evaluated in the studies described in this thesis (Chapters 4 and 5).  
The minimum incidence estimates of hospital-attended influenza-positive SARI (9.6 to 16.9 per 
100,000 adult population) were lower than other published estimates from Kenya (30 (Emukule et 
al., 2014) and 36.7 (Feikin et al., 2012b) per 100,000) and South Africa (71-260 per 100,000 (in HIV-
infected patients) and 5-44 per 100,000 (in HIV-uninfected patients)) (Cohen et al., 2013). These 
differences may be due to a genuine difference in disease burden, but may also in part be due to 
heterogeneous methodologies. All three previous African studies included children aged 5-14 years, 
a group that typically has higher annual rates of influenza infection (Feikin et al., 2012b; Cohen et al., 
2013). Variations in health-seeking behavior and thresholds for hospital admission between the sites 
are also likely contributory factors. Moreover, ours are likely to represent minimum estimates, since 
our surveillance only detects individuals that access care at QECH. There are numerous reasons why 
access to QECH may not occur: patients may have presented to other healthcare facilities or a 
traditional healer; they may not consider their symptoms severe enough to warrant care; may be 
too ill or too poor to attend; or may have died prior to presentation (Desmond et al., 2013).  
There is increasing recognition that, viruses such as rhinovirus, adenovirus, hMPV, parainfluenza 
viruses, and coronaviruses can cause clinically severe disease (Arden et al., 2005; Choi et al., 2012; 
Fry et al., 2011; Cao et al., 2014). Although other respiratory viruses were prevalent in patients with 
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SARI, and detection of multiple viruses was not uncommon, influenza tended to occur in isolation. 
Studies that have evaluated the association between viral co-infection and disease severity have 
yielded mixed results (Drews et al., 1997; Greensill et al., 2003; Semple et al., 2005; Templeton et al., 
2005; Subbarao et al., 1989; Peng et al., 2009). We identified two or more viral pathogens in 13% 
adults with SARI, and found a non-significant trend towards increased severity in adults with viral co-
infection (26.7% vs. 20.3% with MEWS >4). Further understanding of the interactions and 
contribution of these viruses to severe respiratory disease will help to narrow the focus on pertinent 
targets for vaccine and antiviral development.  
A number of limitations need to be considered. First, we conducted hospital-based surveillance at a 
single site. While there are no other large inpatient facilities in Blantyre, we have not sampled from 
elsewhere in Malawi. Secondly, data on whether household contacts were unwell or also recruited 
in the study were not captured. We were therefore unable to account for potential household 
clustering. Thirdly, co-morbidities were poorly recorded, thus we were unable to evaluate chronic 
lung disease as a potential risk factor for influenza, or adjust for underlying co-morbidities in the 
multivariable analysis for clinical severity. Furthermore, data on hospitalisation and mortality were 
not systematically captured. Instead, we utilised the MEWS score as a surrogate marker for clinical 
severity. The score has been widely used in developed healthcare settings to identify patients at risk 
of deterioration, and a threshold of greater than four is predictive of inpatient mortality (Subbe et 
al., 2001). It has also been validated in other African settings (Burch et al., 2008; Rylance et al., 2009; 
Wheeler et al., 2013).  
Vaccination with inactivated influenza vaccine (IIV) is safe, and effective in HIV-infected adults 
(Madhi et al., 2011), as well as pregnant women (both HIV-infected or uninfected) in Africa (Madhi 
et al., 2014). Moreover, vaccination of pregnant women also confers protection to their young 
infants less than 6 months of age (Madhi et al., 2014; Zaman et al., 2008), who respond poorly to 
vaccination (Englund et al., 2010). At present, IIV is unavailable through the public sector in Malawi 
and many similar African countries. Difficulties encountered by the vaccine donation initiative in the 
procurement, distribution and uptake of A(H1N1)pdm09 vaccine highlight the potential challenges 
of implementing annual vaccination (Schoub et al., 2013). Nevertheless, a targeted adult vaccination 
programme may utilise existing health infrastructure, namely HIV care and antenatal services.  
In conclusion, there is a substantial burden of previously unstudied influenza-related severe 
respiratory disease in Malawian adults, a finding likely to be generalizable to other SSA urban areas. 
Surveillance for influenza and other respiratory viruses, with specific focus on severe disease in 
pregnant women and HIV-infected individuals, and greater effort to capture outcome data, is critical 
to further characterise disease burden in these high-risk groups. Annual vaccination is indicated for 
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both groups under current WHO recommendations, with pregnant women designated the highest 
priority (2012). Moreover, the GAVI Alliance are considering funding routine influenza immunization 
of pregnant women at first antenatal visit in 2018 (GAVI the Vaccine Alliance, 2013), many of whom 
in SSA, will be HIV-infected. How, when and who to administer vaccine remains a considerable 
challenge. 
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CHAPTER 4.  Incidence of Laboratory-confirmed Influenza Illness 
Among HIV-infected and HIV-uninfected Adults in Malawi: A 
Prospective Cohort Study 
             
 
 
4.1  Introduction 
Influenza infection and its complications are leading causes of morbidity and mortality worldwide 
(World Health Organization, 2014c). Immunocompromised persons, including those with HIV 
infection, are considered to be at greater risk of influenza-associated morbidity and mortality, thus 
are a priority group for annual seasonal influenza vaccination in many developed settings (Geretti et 
al., 2008; Grohskopf et al., 2014; National Advisory Committee on Immunization (NACI), 2014). 
However, influenza vaccine is not available in most sub-Saharan African countries (Duque et al., 
2014). In 2009, the WHO highlighted the urgent need for more data on the burden of influenza in 
African countries and its effects on immunosuppressed persons due to the high prevalence of HIV 
infection in the region (World Health Organization, 2012a). Emerging data from surveillance 
programmes in SSA (Radin et al., 2012), including Malawi (Chapter 3), suggest that influenza is 
prevalent in adults with acute respiratory illness. However, few published studies have reported HIV 
status. 
Data on the impact of HIV infection on susceptibility to influenza infection have been limited to 
several outbreak investigations (Cohen and Macauley, 1989; Fine et al., 2001; Boschini et al., 2006), 
in addition to several case series (Campos-Loza et al., 2010; Martinez et al., 2011) and serology 
studies (Althoff et al., 2010; Hung et al., 2013; Garg et al., 2014) from the recent 2009 A(H1N1) 
pandemic (Chapter 1.4). All were conducted in low HIV prevalence settings with conflicting results.  
Two recently published surveillance studies from Kenya (Feikin et al., 2012b) and South Africa 
(Cohen et al., 2013) reported higher incidence of influenza infection in HIV-infected persons, 
compared to HIV-uninfected persons. However, they had incomplete data on HIV status (missing 
from 31% (Feikin et al., 2012b) and 22% (Cohen et al., 2013) enrolled participants, respectively), as 
well as CD4+ cell count and antiretroviral treatment. Additionally, both studies included children and 
adults, and did not include individual-level data to account for potential confounding factors.  
We therefore conducted a prospective cohort study in an urban SSA setting with a high HIV 
prevalence, to examine the impact of HIV infection on the incidence of laboratory-confirmed 
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influenza illness, while controlling for possible confounders and defining additional risk factors that 
increase influenza burden in Malawian adults.   
 
4.2  Methods 
 
4.2.1  Study design 
This was a prospective cohort study of HIV-infected, and HIV-uninfected adults, with a follow-up 
period of two years (Figure 4.1).  
 
 
 
Figure 4.1  Overview of study site, study population, and active and passive surveillance 
ART-antiretroviral treatment; VCT-voluntary counselling and testing; RV-routine review 
4.2.2   Study site 
Patients were enrolled from the ART and VCT clinics at QECH (Section 2.1.1.2). The study clinic was 
located within the VCT clinic (Chapter 2.1.2, figure 2.1). Study staff were present between 8am and 
5pm on weekdays.  
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4.2.3  Study population 
Adults aged >18 years were recruited from the ART and VCT clinics at QECH between April 2013 and 
January 2014. The following eligibility criteria were applied: 
Inclusion criteria 
 Aged 18 years or over 
 Intending to stay in Blantyre in the next year 
 Willing to attend QECH for scheduled and illness visits 
 Willing to undergo an HIV test (if status unknown) 
 Able to give informed consent (personally or by legal proxy) 
Exclusion criteria 
 Acute active lung disease (including acute pneumonia, suspected TB not on treatment, and 
intensive phase of tuberculosis treatment) 
 Terminal illness (e.g. metastatic malignancy, terminal AIDS) 
 Previous influenza vaccination 
 Another household member already enrolled in study 
Persons that met the eligibility criteria who were willing to consider participation in the study 
received a patient information document (in Chichewa or English). Written informed consent was 
obtained from the patient/guardian.   
4.2.4  Study procedures  
4.2.4.1  Staff 
The following staff were employed to maintain the study cohort: 
 1 nurse coordinator: responsible for consent and enrolment of participants during recruitment 
period; taking the majority of clinical specimens, including naso-/oropharyngeal swabs, blood 
and urine; conducted routine reviews; and was in charge of coordinating participant follow-up 
and field worker visit schedule.  
 1 clinical officer: responsible for consent and enrolment of participants during recruitment 
period; aided nurse coordinator in obtaining clinical specimens; and conducted routine reviews 
and clinical assessment of participants attending with ILI episodes. 
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 2 qualified HIV testing counsellors/ field workers: performed sensitisation talks at ART/VCT 
clinic and HTC counselling during recruitment period; trained in nasopharyngeal and 
oropharyngeal swab sampling; and conducted home visits of defaulted participants. 
 1 molecular laboratory technician: responsible for aliquoting, storage and processing combined 
nasopharyngeal & oropharyngeal specimens, as part of a team of technicians in the core 
diagnostic laboratory. 
4.2.4.2  Enrolment 
Demographic and clinical information, in addition to exposure to risk factors for influenza were 
obtained from study participants using a structured questionnaire (appendix 8.4). Data collected 
included: demographic details; clinical history (including co-morbidities, previous history of 
tuberculosis or pneumonia, pregnancy, history of pneumococcal conjugate vaccination, and HIV 
history); smoking and alcohol use; household characteristics (including household size, number of 
young children in household, number of rooms in dwelling); and socioeconomic status. The latter 
was defined by highest level of education attained (none, primary, secondary or tertiary), 
employment (yes or no), asset ownership (ownership of mobile phone, radio, refrigerator, bed and 
car/motorbike), food security (frequency of difficulty accessing food), access to water (type and 
distance water supply from dwelling) and type of sanitation facility. 
Baseline clinical examination was performed to determine body mass index (BMI), oxygen 
saturation, evidence of chronic lung disease, in addition to the WHO clinical staging for HIV (if the 
participant was HIV-reactive). 
A sticker was placed in the participant’s health passport (figure 4.2) to identify them as a participant 
of the BASH-FLU cohort study; as a record of their study identification number; and to provide 
contact details in case the participant wished to contact the study team. 
 
 Figure 4.2  Sticker that identifies the 
individual as a BASH-FLU cohort 
study participant 
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4.2.4.3  Active and passive surveillance 
The follow-up period was from the date of enrolment until 31 March 2015. Follow-up consisted of 
active and passive surveillance. Participants were reimbursed for their transport costs. 
Active surveillance 
Routine reviews (i.e. active surveillance) for the first year of the study took place monthly (x3) 
between April and July (thought to be peak influenza season from surveillance data 2011-2012). 
However, year-round influenza transmission was found in 2013 (Chapter 3.3), hence active 
surveillance was modified to 4-monthly visits in the second year of follow-up (figure 4.1). At each 
visit, participants were screened for influenza-like symptoms within the past 4 weeks, and 
nasopharyngeal and oropharyngeal swabs were obtained. The purpose of active surveillance was to 
ascertain the prevalence of asymptomatic carriage of influenza virus.  
Passive surveillance 
During the study period, participants were instructed to attend study clinic as soon as possible if 
they developed influenza-like symptoms. These were defined as reported or documented fever 
(>38C) and > 2 of the following symptoms: cough, rhinorrhoea, sore throat, myalgia, headache and 
vomiting/diarrhoea. A leaflet detailing the above symptoms was given to participants to take home 
at enrolment.  
 
 
  
Figure 4.3  A) The study clinical officer conducting a routine review of a participant at the 
study clinic; B) obtaining a nasopharyngeal specimen 
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The study clinical officer assessed ill participants at the study clinic from 8am to 5pm during weekdays. 
Outwith these times, participants were advised to attend their local health centre or AETC if they were 
severely unwell, and inform the study team through the study phone. Any participant that was admitted 
to QECH was assessed by the study clinical officer at the earliest opportunity.  
Data collected during the illness episodes included clinical presentation, physical examination, 
investigations, details of any hospital admission, outcome and final diagnosis. 
4.2.4.4  Laboratory investigations 
The investigations that were performed on enrolment, routine visits and influenza-like illness 
episodes are listed below (see Section 2.2 for details of individual tests): 
 
HIV testing was performed by trained counsellors in the study team. Participants that were newly 
diagnosed with HIV infection were referred for HIV care at the QECH ART clinic or their local health 
centre. 
4.2.4.5  Participant follow-up default procedures 
If a participant failed to attend a routine appointment, the study nurse attempted to contact 
him/her by telephone to arrange a further appointment. If the subject failed to attend within 2 
Table 4.1  Laboratory investigations undertaken in the cohort study 
Visit Specimen type & test 
Enrolment Venous blood 
-  Rapid HIV test (if status unknown) 
-  CD4+ cell count 
Routine review  
(active surveillance) 
Nasopharyngeal & oropharyngeal swabs 
-  Influenza PCR (CDC H1N1 kit) 
-  Quantitative lytA PCR for Streptococcus pneumoniae 
Venous blood 
- Rapid HIV test (repeated annually in HIV-negative cohort) 
Urine (in a subset of patients, December 2014 – March 2015) 
- BinaxNOW S. pneumoniae urinary antigen 
Influenza-like illness episode 
(passive surveillance) 
Venous blood 
- Malaria rapid diagnostic test 
- Blood culture 
-  Haemagglutination inhibition (HAI) assay  
(convalescent sample take 4-6 weeks after ILI episode) 
Nasopharyngeal & oropharyngeal swabs 
- Influenza PCR (CDC H1N1 kit) 
-  Quantitative lytA PCR for Streptococcus pneumoniae 
Sputum 
- Smear microscopy for AFB and culture 
Chest X-Ray 
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weeks of the telephone contact, a field worker visited them at their home. Failure to locate the 
participant following 2 home visits led to one further attempt to locate them through local health 
surveillance assistants (HSA) or church. Thereafter, they were deemed lost to follow-up. 
If a participant died, the study team attempted to ascertain whether the individual had influenza-like 
symptoms prior to death from his/her guardian or household contacts. 
4.2.5  Sample size calculations 
This study was powered for the primary outcome of incidence rate ratio (IRR) of laboratory-
confirmed influenza illness by HIV status. No published data on influenza incidence in adults in SSA 
settings were available at the time of study inception. A cumulative incidence of 4 per 100 person 
years was estimated in the HIV-uninfected cohort. Assuming a 20% loss-to follow-up, a sample size 
of 608 individuals (with an HIV+: HIV- ratio of 60:40) was estimated to provide 80% power to detect 
an incidence rate ratio (IRR) of 3.0 or greater (i.e. to detect three times higher rate of influenza in 
HIV-infected vs. HIV-uninfected individuals). 
4.2.6  Statistical analysis 
For the descriptive comparison of baseline characteristics of the HIV-infected and HIV-uninfected 
cohorts, chi-square test was used to compare categorical variables; continuous variables were 
summarised using means and medians and compared using a Student independent-samples t-test or 
Wilcoxon rank-sum test as appropriate for the distribution properties of each variable.  
The at-risk period commenced on day of enrolment and continued to the end of study (31 March 
2015). All analyses were based on person-years observed to death, default or end of follow-up. In 
cases of default, follow-up was censored at the date of relocation from Blantyre, date of withdrawal 
of consent, or date of most recently attended clinic visit. 
A Poisson regression model was used to estimate an incidence rate ratio (IRR) for the effect of HIV 
infection on influenza infection. For recurrent events (i.e. ILI events or recurrent influenza events), a 
population average Poisson regression model using generalised estimating equations (GEE) was 
constructed to account for clustering of ILI events in a participant. An exchangeable correlation 
matrix was specified.  Additional Poisson regression models were performed with stratification of 
HIV-infected cohort by ART status (on or not on ART at enrolment) or CD4+ count (>350 or <350 
cells/µl at enrolment), using the HIV-negative cohort as baseline. 
The multivariable models adjusted for age and sex a priori, in addition to other exposures that 
potentially confounded the association between HIV and influenza illness. With few outcome events, 
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we adjusted for a maximum of three covariates to keep the number of events per model variable 
(EPV) at ~10, in order to avoid unreliable coefficients and biased estimates that have occurred in 
models with EPV <10 (Peduzzi et al., 1996). Thus three separate multivariable models were 
constructed, all of which contained HIV: model A included the age and sex, the a priori confounders, 
model B included the other risk factors, namely household crowding and food security, and model C 
included all variables from A and B for comparison. 
In addition to consideration of confounding, it was necessary to investigate some relationships for 
interactions. We hypothesised that the relationship between HIV and influenza might differ by food 
security. Consequently, a Poisson regression model was constructed with an interaction term for 
food security divided into two groups (difficulty obtaining food: never or sometimes vs. often or 
always). A likelihood ratio test compared the model with an interaction term with one without. 
4.2.7  Study timescale 
 
 
 
Figure 4.4  Timescale of cohort study 
 
There were two periods of recruitment of cohort participants – i) April to June 2013, and ii) October 
to December 2013. The original aim had been to recruit the entire cohort (n=608) prior to the onset 
of peak influenza season in 2013. However, due to the combination of a three-month delay to the 
start of the study, under-recruitment of participants in the planned recruitment period (309 had 
been recruited up to end of June 2013), and subsequent finding of year-round influenza activity in 
Blantyre, a second period of recruitment was undertaken between October and December 2013.  
The sub-study on the association between respiratory viral infection and nasopharyngeal carriage of 
S. pneumoniae is described in Chapter 6.  
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4.3  Results 
4.3.1  Baseline characteristics of HIV-infected and HIV-uninfected cohort 
Between April 2013 and January 2014, 655 individuals were screened for the cohort study. 608 
participants were recruited, of whom 360 (59%) had HIV infection (Figure 4.5). The baseline 
characteristics of the HIV-infected and HIV-uninfected cohorts are summarised in Table 4.2. 
 
 
 
 
 
 
 
 
Figure 4.5  Flow diagram of cohort study recruitment 
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Table 4.2  Demographic, clinical, household and socioeconomic characteristics of the 
cohort participants (N=608) 
 
 
HIV-infected 
cohort 
HIV-uninfected 
cohort 
p-valuea 
 n=360 (59%) n=248 (41%)  
Gender (male) 113 (31) 111 (45) 0.001 
Age (years) – median (IQR) 37 (31-45) 31 (25-39)  <0.001 
Medical history 
  Asthma 
  Chronic lung disease 
  Heart failure 
  Chronic renal disease 
  Chronic liver disease 
  Diabetes 
  Pregnant at enrolment 
  Previous pulmonary tuberculosis 
  Pneumonia in past 5 years 
  Smoking - current 
                   - previous 
  Drinks alcohol  
 
18 (5) 
1 (0.3) 
2 (0.6) 
0 (0) 
2 (0.6) 
2 (0.6) 
4 (1) 
90 (25) 
59 (16) 
11 (3) 
42 (12) 
44 (12) 
 
8 (3) 
0 (0) 
1 (0.4) 
0 (0) 
0 (0) 
2(0.8) 
4 (2) 
6 (2) 
13 (5)  
4 (2)  
19 (8) 
35 (14) 
 
0.29 
- 
0.80 
- 
0.24 
0.70 
0.02 
<0.001 
<0.001 
0.14 
 
0.47 
  BMI (kg/m2)c – median (IQR) 
   <18.5 
  > 18.5  
21.9 (19.7-24.7) 
38 (10.6) 
322 (89.4) 
22.0 (19.9-25.6) 
17 (6.9) 
231 (93.1) 
0.15 
 
0.18 
Housing characteristics 
  Children <5 years in household (n) 
     0 
     1   
     >2 
  Individuals aged >5years in household (n) 
     0-2 
     3-4 
     >5 
Crowding indexb  
    <1.5 
    1.5-2.9 
     > 2.5 
  Toilet 
     None/non-VIP toilet 
     VIP/flush toilet 
 Water supply 
     River/stream/borehole 
     Public tap/standpipe 
     Piped to dwelling 
 Principal cooking fuel 
     Firewood 
     Charcoal 
     Electricity 
 
 
219 (61) 
115 (32) 
25 (7) 
 
88 (25) 
162 (45) 
108 (30) 
 
110 (30) 
144 (40) 
106 (30) 
 
327 (91) 
32 (9) 
 
75 (21) 
212 (60) 
67 (19) 
 
77 (22) 
244 (68) 
36 (10) 
 
 
132 (54) 
82 (33) 
32 (13) 
 
56 (23) 
91 (37) 
100 (41) 
 
                 66 (27) 
95 (38) 
87 (35) 
 
205 (83) 
43 (17) 
 
 44 (18) 
131 (53) 
71 (29) 
                    
49 (20) 
166 (68) 
30 (12) 
 
 
 
 
0.03 
 
 
 
0.03 
 
 
0.33 
 
0.002 
 
 
 
0.02 
 
 
 
0.66 
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In keeping with the demographic of the HIV epidemic in Malawi (Chapter 1.7.2), the HIV-infected 
cohort had a higher proportion of females and were older, compared to the HIV-uninfected cohort. 
The prevalence of chronic co-morbidities (reliant on self-reporting, in addition to checking the health 
passport) and smoking in both cohorts were low, though unsurprisingly a significantly higher 
proportion of HIV-infected participants reported a past history of tuberculosis (25% vs. 2%, p<0.001) 
and pneumonia in the past 5 years (16% vs. 5%, p<0.001). 
The HIV-uninfected cohort had larger household sizes (both number of children <5, as well as 
individuals >5 years of age). However, the crowding index, derived from the total household size 
divided by the number of living rooms, did not differ between the two groups.  There were also no 
significant differences in education level or asset ownership. The HIV-uninfected cohort had better 
sanitation facilities, water supply and food security.  
Socioeconomic status   
  Highest level of education 
     Never attended 
     Primary 
     Secondary – without MSCE 
     Secondary – with MSCE/ Tertiary 
  Employment 
     No formal employment (incl. students) 
     Vocational/manual/farming 
     Street seller 
     Sales/shop/service worker 
     Professional 
  Asset ownershipc 
     1-2 
     3 
     4-5 
  Food securityd – difficulties obtaining food 
    Never 
    Sometimes 
    Often/always 
 
 
18 (5) 
152 (42) 
138 (38) 
51 (15) 
 
87 (24) 
35 (10) 
119 (33) 
90 (25) 
29 (8) 
 
141 (39) 
151 (42) 
68 (19) 
 
137 (38) 
149 (42) 
70 (20) 
 
 
10 (4) 
89 (36) 
93 (38) 
56 (22) 
 
78 (31) 
25 (10) 
55 (23) 
72 (29) 
16 (6) 
 
83 (33) 
113 (46) 
52 (21) 
 
133 (54) 
86 (35) 
28 (11) 
 
 
 
 
 
0.10 
 
 
 
 
 
0.05 
 
 
 
0.36 
 
 
 
<0.001 
IQR, interquartile range; VIP, ventilated improved pit; MSCE, Malawi School certificate of Education 
aChi-square or Fisher’s exact test for categorical variables; Wilcoxon rank sum test for continuous 
variable. 
The number of missing observations in each variable is detailed in Appendix 8.4.2; individuals with 
missing data were excluded from the denominator in percentage calculations.  
bTotal number of household members divided by the number of living rooms in household (kitchen 
or bathroom not included). 
cNumber of the following assets owned in household: working refrigerator, radio, mobile phone, bed 
and car/motorbike. 
dSometimes (1-2 times/month), often (up to once a week), always (every day)  
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Among the 360 enrolled HIV-infected individuals, the majority (85%) were diagnosed prior to the 
study (Table 4.3). Around two-thirds of the cohort were on ART at enrolment; most had been on ART 
for over 12 months. A further 47 (13%) were commenced on ART over the duration of the study. The 
relatively good immune reconstitution in this cohort is reflected in the median CD4+ cell count of 
390 cells/µl (IQR 244-547).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.3  Clinical characteristics of the HIV-infected cohort 
 N (%) 
CD4+ at enrolmenta – median, IQR 390 (244-547) 
WHO clinical stage 
  1 
  2 
  3 
  4 
 
138 (38) 
84 (23) 
130 (36) 
8 (2) 
Previously tested HIV-positive 307 (85) 
On ART  
  At enrolment 
  Commenced during study 
 
234 (65) 
47 (13)  
ART regimen at enrolmentb (n=234) 
  Stavudine, lamivudine, nevirapine (1A) 
  Zidovudine, lamivudine, nevirapine (2A) 
  Stavudine, lamivudine, nevirapine (3A) 
  Tenofovir, lamivudine, efavirenz (5A) 
  Tenofovir, lamivudine, nevirapine (6A) 
  Tenofovir, lamivudine, atazanavir/ritonavir (7A) 
 
83 (36) 
28 (12) 
2 (1) 
110 (47) 
3 (1) 
7 (3) 
 Duration on ART at enrolment (n=234) 
  <3months 
  3-12 months 
  >12 months 
 
7 (3) 
36 (15) 
191 (82) 
On co-trimoxazole prophylaxis 
  At enrolment 
 
239 (67) 
IQR-interquartile range; ART-antiretroviral treatment 
The number of missing observations in each variable is detailed in Appendix 
8.4.2; individuals with missing data were excluded from the denominator in 
percentage calculations.  
aMissing for 3 HIV-infected participants 
bRegimen 1A had been the first line treatment in Malawi at the start of the 
recruitment period, but this was switched to 5A in July 2013 (Ministry of 
Health, 2011). Patients who were taking 1A were switched to 5A after July 
2013. 
Prospective Cohort Study of HIV-infected and HIV-uninfected adults 
 
 
 114 
4.3.2  Routine visits (active surveillance)  
Between 1 April 2013 and 31 March 2015, 3094 routine reviews were conducted in 573 cohort 
participants (Figure 4.6). This included successful home visits by the field workers if participants had 
failed to attend 2 clinic appointments. Of note, intensive active surveillance during what was initially 
believed to be peak influenza season (January to June) was revised to 4-monthly reviews in the 
second year of follow up, as data that emerged from sentinel surveillance at QECH (Chapter 3) 
suggested year-round influenza transmission (see also Chapter 4.2.4.3). This explains the few visits 
that took place between September and November 2013, and high attendances from January to 
April 2014.  
Symptoms of acute ILI (Chapter 4.2.4.3) were reported during 4 routine visits; these were recorded 
as ILI episodes. Furthermore, ILI symptoms within 4 week of review were reported in 40 visits (37 
participants), but the participants did not contact study staff or attend the study clinic for review at 
the time of illness. 
 
 
Figure 4.6  Number of routine review attendances by cohort participants per month, April 2013–
March 2015 
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4.3.3  Cohort study follow-up 
Among the 608 enrolled participants, 121 (19.9%, 71 HIV-infected, 50 HIV-uninfected) exited the 
study before the end date (Figure 4.7). Around half of the exited participants (n=61) had relocated 
out of Blantyre; 25 had withdrawn from the study, mainly due to reluctance to undergo repeated 
nasopharyngeal sampling; there were 11 deaths (10 HIV-infected (2.8%); 1 HIV-uninfected (0.4%)); 
and 25 participants were lost to follow-up. None of the deceased had reported respiratory 
symptoms or had attended the study clinic with an ILI episode in the 2 weeks prior to death.  
There were no differences in the proportion of participants that exited the study or were loss-to-
follow-up among the HIV-infected and HIV-uninfected cohorts. Total person-time follow-up was 
520.1 and 347.8 person-years (PYs) in the HIV-infected and HIV-uninfected cohorts respectively. 
 
 
 
 
Figure 4.7  Progress of cohort study participants, April 2013  –  March 2015 
 
4.3.4  Influenza-like illness episodes (passive surveillance)  
4.3.4.1  ILI attendances 
348 illness attendances fulfilled the ILI criteria during the study period; 229 were in 130 (36.1%) HIV-
infected participants, and 119 in 78 (31.5%) HIV-uninfected participants. HIV-infected participants 
were more likely to present with multiple ILI episodes (Figure 4.8). The incidence of ILI attendance 
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was 442 and 341 per 1000 PYs in HIV-infected and HIV-uninfected participants respectively, 
providing an incidence rate ratio (IRR) of 1.21 (95%CI 0.99-1.48, p=0.07). 
4.3.4.2  Pre-hospital treatment 
Antibiotic use within 2 weeks of ILI attendance was reported In 31 (8.9%) episodes (HIV-infected - 
23); HIV-uninfected - 8)). Antibiotics included penicillins (n=18), cotrimoxazole (excluding 
prophylaxis) (n=7), tetracyclines (n=1), erythromycin (n=1) and ciprofloxacin (n=1). 14 participants 
(HIV-infected - 9; HIV-uninfected - 5) had also taken antimalarials prior to ILI visit 
(artemether/lumefantrine (LA) (n=9), quinine (n=2), and Fansidar (n=2).  
 
 
 
 
Figure 4.8  Total number of ILI attendances by cohort participants, April 2013–March 2015 
 
4.3.4.3  Clinical presentation 
The clinical characteristics of the ILI presentations, by HIV status, are summarised in Table 4.4. HIV-
infected participants reported shortness of breath (11.3 vs. 4.3%, p=0.03) and diarrhoea (15.7 vs. 
8.6%, p=0.07) with higher frequency compared to HIV-uninfected participants, and were more likely 
to have a documented fever (9.2 vs. 1.7%, p=0.009), tachycardia (11 vs 0%) and upper respiratory 
tract findings (12.6 vs. 5.1%, p=0.03). The prevalence of other symptoms and clinical signs were 
similar in the two groups. Most ILI presentations were mild; only five (1.4%) episodes resulted in 
hospital admission, 2 of which were associated with a positive influenza PCR (Table 4.5). 
Furthermore, no deaths resulted from the ILI episodes. 
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Table 4.4  Clinical characteristics of participants presenting with ILI, April 2013–March 
2015 (N=348) 
Characteristic HIV-infected 
participants 
HIV-uninfected 
participants 
p-valuea 
 (n=229) (n=119)  
Clinical presentation 
   Cough 
   Sore throat 
   Rhinorrhoea 
   Myalgia 
   Nausea/vomiting 
   Shortness of breath 
   Diarrhoea 
   Headache 
 
167 (72.6) 
123 (53.5) 
201 (87.4) 
192 (83.5) 
25 (10.9) 
25 (11.3) 
36 (15.7) 
196 (85.2) 
 
85 (72.7) 
59 (50.4) 
101 (86.3) 
99 (84.6) 
10 (8.6) 
5 (4.3) 
10 (8.6) 
102 (87.2) 
 
0.99 
0.59 
0.78 
0.79 
0.50 
0.03 
0.07 
0.62 
Clinical signs 
  Temperature >38c 
  Heart rate >120 beats/min 
  Respiratory rate >30 breaths/min 
  Oxygen saturation <90% 
  Upper respiratory tract signsb 
  Lower respiratory tract signsc 
 
21 (9.2) 
11 (4.8) 
5 (2.2) 
3 (1.3) 
29 (12.6) 
5 (2.2) 
 
2 (1.7) 
0 (0) 
0 (0) 
0 (0) 
6 (5.1) 
1 (0.8) 
 
0.009 
0.02 
0.17 
0.55 
0.03 
0.67 
Hospital admission 5 (2.2) 0 (0)  
The number of missing observations in each variable is detailed in Appendix 8.4.2; individuals 
with missing data were excluded from the denominator in percentage calculations.  
aChi-squared or Fisher’s exact test 
binclude redness or pus in throat, cervical lymphadenopathy or sinus tenderness. 
cinclude crepitations, bronchial breathing, pleural rub, wheeze or signs consistent with pleural 
effusion. 
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4.3.4.4  Investigation results 
Among 348 ILI episodes, 29 (8.3%) were found to be positive for influenza PCR (table 4.6); 24/229 
(10.5%) in HIV-infected participants, and 5/119 (4.2%) in HIV-uninfected participants. Of the HIV-
infected participants with a positive influenza PCR, two-thirds (n=16) had influenza B, the rest had 
influenza A(H3N2). In contrast, three HIV-uninfected participants had influenza A(H3N2), and two 
had influenza B.  Figure 4.9 illustrates the frequency of ILI presentation and the type and subtype of 
influenza positive samples over the study period. There were no recurrent influenza events. 
143/348 (41.1%) had at least 1 respiratory virus (including influenza) detected (Table 4.6). Rhinovirus 
was the most ubiquitous, followed by influenza and coronavirus NL63. There were no differences in 
the prevalence of respiratory viruses among HIV-infected and HIV-uninfected cohorts, though the 
numbers of individual viruses detected were small.  
With regards to other investigations, RDT for malaria was positive in 10 (2.9%) ILI episodes; 2 had 
bacteraemia (both Salmonella species), and none were positive for acid-fast bacilli on sputum 
microscopy, or subsequent culture for Mycobacterium tuberculosis.   
 
Table 4.5  Investigation results and outcome of the hospitalised ILI episodes (n=5) 
Sex 
(age, 
years) 
HIV 
status 
PCR result Blood 
culture 
CXR AFB Days of 
admission 
Outcome 
F, 25 + Influenza B 
hMPV 
No growth Lobar 
consolidation 
– 13 Discharged 
F, 32 +  No growth Diffuse 
bilateral 
infiltrates 
– 4 Discharged 
F, 36 + Influenza A(H3) No growth Patchy bi-
basal 
infiltrates  
ND 6 Discharged 
F, 33 + Legionella 
species 
No growth Normal – 3 Discharged 
F, 31 + Mycoplasma 
pneumoniae 
Salmonella 
typhimurium 
Diffuse 
bilateral 
infiltrates 
ND 12 Discharged 
PCR, polymerase chain reaction, CXR, chest x-ray; AFB, sputum microscopy for acid-fast bacilli; hMPV, human 
metapneumovirus; ND, not done. 
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Table 4.6  Investigation results of participants presenting with ILI, April 2013–March 
2015 (N=348) 
Investigation HIV-infected 
cohort 
HIV-uninfected 
cohort 
p-valuea 
 (n=229) (n=119)  
Influenza-PCR positive 
   Influenza type/subtype 
     A(H3) 
     B 
24 (10.5) 
 
8 (3.9) 
16 (7.0)   
5 (4.2) 
 
3 (3.4) 
2 (1.7) 
0.04 
 
0.89 
0.049 
Other respiratory viruses    
 Adenovirus 
 Bocavirus 
 Coronavirus - 0C43 
                        - NL63 
                        - 229E 
                        - HKU1 
 Enterovirus 
 Human metapneumovirus 
 Parainfluenza virus 1 
 Parainfluenza virus 2 
 Parainfluenza virus 3 
 Parainfluenza virus 4 
 Rhinovirus 
 RSV 
3 1.3) 
2 (0.9) 
4 (1.8) 
15 (6.6) 
7  (3.1) 
6 (2.6) 
3 (1.3) 
6 (2.6) 
1 (0.4) 
0 (0) 
3 (1.3) 
2 (0.9) 
32 (14.2) 
8 (3.5) 
5 (4.2) 
0 (0) 
3 (2.5) 
9 (7.6) 
2 (1.7) 
2 (1.7) 
0 (0) 
3 (2.5) 
1 (0.9) 
0 (0) 
3 (2.5) 
1 (0.9) 
14 (11.9) 
3 (2.5) 
0.09 
0.55 
0.69 
0.82 
0.72 
0.72 
0.55 
1.00 
1.00 
- 
0.42 
1.00 
               0.55
 0.76 
At least 1 respiratory virus 97 (42.4) 46 (38.7) 0.51 
Multiple viral co-detection 17 (7.4) 5 (4.2) 0.24 
S. pneumoniae colonisation 104 (45.6) 50 (42.4) 0.57 
Other aetiology identified 
   Malaria RDT positive 
   Blood culture positiveb 
     Sputum positive for AFB 
 
5 (2.2) 
2/50 (4.0) 
0/6 (0) 
 
5 (4.2) 
0/22 (0) 
0/2 (0) 
 
0.27 
1.00 
- 
PCR, polymerase chain reaction; RSV, respiratory syncytial virus; RDT, rapid diagnostic test; 
AFB, acid-fast bacilli 
The number of missing observations in each variable is detailed in Appendix 8.4.2; individuals 
with missing data were excluded from the denominator in percentage calculations.  
aChi-squared or Fisher’s exact test 
b Salmonella typhimurium (n=1), Salmonella typhi (n=1) 
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4.3.4.5  The impact of HIV infection on influenza incidence 
The HIV-infected cohort had 24 independent laboratory-confirmed influenza episodes over 520 PYs, 
and the HIV-uninfected cohort had 5 episodes over 348 PYs (Table 4.7). This equated to incidence 
rates of 46.0 (95%CI 30.8-68.6] vs. 14.5 (95%CI 6.0-34.7) per 1000PYs respectively, and a crude 
incidence rate ratio (IRR) for the effect of HIV infection of 3.21 (95% CI 1.22-8.41, p=0.02). To 
evaluate the impact of HIV infection, we sought to control for covariates that may potentially 
confound the relationship between HIV and influenza. In the univariable analysis, past history of 
pneumonia, high crowding index (denotes number of persons per sleeping room, used as proxy for 
household crowding), greater distance to water supply, lower education level, unemployment, and 
poor food security were associated with influenza infection. Results from a simulation study suggest 
that evaluation of less than 10 events per variable (EPV) in regression models may lead to biased and 
less precise estimates (Peduzzi et al., 1996). As there were only 29 outcome events, we decided to 
include a maximum of 3 covariates in a multivariable model. Three multivariable models were 
constructed (Table 4.8).  
Multivariable model A included the a priori confounders, age and gender, in addition to HIV 
infection. The effect of HIV infection on influenza incidence did not change substantially after 
adjustment for age and sex (aIRR 3.01 (95%CI 1.11-8.21, p=0.02). For model B, HIV infection was 
included, along with up to two significant covariates using backwards stepwise regression. 
Household crowding and food insecurity were found to be independent risk factors for influenza 
infection, and the effect estimate for HIV infection was similar to model A (aIRR 2.94, 95%CI 1.11-
7.80). In the final multivariable model (C), all five covariates from models A and B were included. The 
effect estimates from this model did not differ substantially from the first two; after adjusting for 
age, gender, household crowding and food security, HIV-infected adults still had an approximately 
three times increased rate of influenza infection compared to HIV-uninfected adults (aIRR 2.75 
[1.02-7.44], p=0.03). Pearson’s goodness-of-fit tests for all three models suggest reasonable fit with 
the data (Table 4.8). 
Although none of the deceased participants reported respiratory symptoms (according to informal 
verbal autopsy) or had a documented ILI visit prior to death, we performed a sensitivity analysis 
including participant death as an influenza outcome event (10 in HIV+ & 1 in HIV- participants, Figure 
4.7). Thus this analysis included 34 laboratory-confirmed influenza illness or death in the HIV-
infected cohort, and 6 in the HIV-uninfected cohort, equating to incidence rates of 63.4 (95%CI 45.1-
89.2] vs. 17.2 (95%CI 7.8-38.4) per 1000PYs respectively. Crude IRR for the effect of HIV infection 
was 3.68 (95% CI 1.54-8.78, p=0.002). In multivariable analysis, aIRR was 2.99 (95%CI 1.22-7.34), 
after adjusting for age, gender, household crowding and food insecurity (multivariable model C). 
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Table 4.7  Risk factors for laboratory-confirmed influenza illness among cohort participants (N=608) 
Characteristic Number 
influenza +ve 
ILI episodes 
(n=29) 
PYFU IR (per 1000 
PYFU) (95%CI) 
Univariablea  Multivariable Ca.e 
 IRR (95% CI) P-value  IRR (95% CI) P-value 
Gender 
  Male 
  Female 
Age group (years) 
  18-29 
  30-39 
   > 40 
HIV status 
  Negative 
  Positive 
           
10 
19 
 
5 
13 
11 
 
5 
24 
 
319 
549 
 
239 
326 
303 
 
348 
520 
 
31.4 (16.9-58.3) 
34.6 (22.1-54.2) 
 
20.9 (8.7-50.2) 
39.9 (23.2-68.7) 
36.3 (20.1-65.6) 
 
14.5 (6.0-34.7) 
46.0 (30.8-68.6) 
 
1 
1.21 (0.52-2.84) 
 
1 
1.73 (0.60-4.97) 
1.33 (0.43-4.05) 
 
1 
3.21 (1.22-8.41) 
 
 
0.66 
 
 
 
0.30 
 
 
0.02 
  
1 
0.88 (0.40-1.93) 
 
1 
1.55 (0.54-4.43) 
1.42 (0.47-4.28) 
 
 1 
2.75 (1.02-7.44) 
 
 
0.74 
 
 
 
0.70 
 
 
0.03 
Medical history 
  Previous pulmonary TB 
  Previous pneumonia 
  Low BMI (<18.5 kg/m2) 
Housing characteristics 
 Children <5 yrs in household 
    0 
    1 
    >2 
 Individual >5 yrs in household 
    0-3 
    3-4 
    >5 
Crowding indexb 
    <1.5 
    1.5-2.4 
    >2.5 
Water source 
  River/stream/borehole 
 
4 
6 
3 
 
18 
8 
3 
 
 
5 
10 
14 
 
4 
16 
9 
 
8  
 
142 
110 
74 
 
497 
288 
81 
 
 
196 
356 
313 
 
245 
340 
282 
 
184 
 
28.2 (23.3-51.1) 
54.3 (24.4-120.9) 
40.3 (13.0-125.0) 
 
36.2 (22.8-57.5) 
27.8 (13.9-55.6) 
37.3 (12.0-115.5) 
 
 
25.5 (10.6-61.3) 
28.1 (15.1-52.3) 
44.7 (26.5-75.4) 
 
16.3 (6.12-43.5) 
47.1 (28.8-76.8) 
32.0 (16.6-61.5) 
 
43.5 (21.8-87.1) 
 
0.82 (0.28-2.43) 
1.86 (0.75-4.57) 
0.81 (0.25-2.68) 
 
1 
0.77 (0.33-1.77) 
1.03 (0.30-3.50) 
 
 
1 
1.10 (0.38-3.22) 
1.76 (0.63-4.87) 
 
1 
2.88 (0.96-8.62) 
1.95 (0.60-6.35) 
 
2.72 (0.72-10.26) 
 
0.87 
0.14 
0.73 
 
 
 
0.80 
 
 
 
 
0.41 
 
 
 
0.11 
 
0.25 
  
 
 
 
 
 
 
 
 
 
 
 
 
1 
3.41 (1.12-10.36) 
2.06 (0.62-6.83) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0.056 
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  Public tap/standpipe 
  Piped to dwelling 
Distance from water supply 
  <200 metres 
  >200 metres 
18 
3 
 
20 
9 
486 
188 
 
705 
156 
37.0 (23.3-58.8) 
16.0 (5.2-49.5) 
 
28.4 (18.3-44.0) 
57.7 (30.0-110.9) 
2.31 (0.68-7.86) 
1 
 
1 
2.02 (0.92-4.45) 
 
 
 
 
0.08 
 
 
 
 
 
 
 
 
 
Sanitation facility 
  No/non-VIP toilet 
  VIP /flush toilet 
 
27 
2 
 
769 
98 
 
35.1 (24.1-51.2) 
20.5 (5.1-81.9) 
 
1.71 (0.41-7.20) 
1 
 
0.43 
   
Principal cooking fuel 
  Electricity 
  Charcoal 
  Firewood 
 
3 
18 
7 
 
94 
572 
193 
 
32.0 (10.3-99.3) 
33.2 (21.2-52.0) 
36.3 (17.3-76.1) 
 
1 
1.04 (0.31-3.52) 
1.14 (0.29-4.41) 
 
 
 
0.97 
   
Socioeconomic status 
Highest level of education 
  Never attended/primary 
  Secondary/tertiary 
 
 
 
18 
11 
 
 
 
378 
488 
 
 
47.6 (30.0-75.6) 
22.5 (12.5-40.7) 
 
 
1 
0.47 (.22-1.00) 
 
 
 
 
0.05 
 
   
Employment 
  No 
  Yes 
 
 
13 
16 
 
 
 
 
262 
606 
 
 
49.6 (28.8-85.4) 
26.4 (16.2-43.1) 
 
 
 
1 
0.53 (0.26-1.11) 
 
 
 
 
0.09 
 
 
   
Assets ownedc 
   0-2 
   3 
   4-5 
 
15 
8 
6 
 
308 
386 
175 
 
48.8 (29.4-80.9) 
20.7 (10.4-41.5) 
34.4 (15.4-76.5) 
 
 
1.42 (0.55-3.65) 
0.60 (0.21-1.74) 
1 
 
0.26 
   
Difficulty obtaining foodd 
  Never 
  Sometimes  
  Often/always 
 
10 
7 
12 
 
386 
338 
138 
25.9 (13.9-48.2) 
20.7 (9.9-43.5) 
87.2 (49.5-153.6) 
 
1 
0.80 (0.30-2.10) 
3.35 (1.45-7.76) 
 
 
 
0.005 
  
1 
0.71 (0.27-1.88) 
3.09 (1.30-7.36) 
 
 
 
0.006 
ILI, influenza-like illness; PYFU, person-years follow-up; IR, incidence rate; IRR, incidence rate ratio; CI, confidence interval; TB, tuberculosis; BMI, body mass index; VIP, 
ventilated improved pit 
aIRRs estimated for the incidence of laboratory-confirmed influenza using Poisson regression 
bTotal number of household members divided by the number of living rooms in household (kitchen or bathroom not included). 
cNumber of the following assets owned in household: working refrigerator, radio, mobile phone, bed and car/motorbike. 
dSometimes (1-2 times/month), often (up to once a week), always (every day) 
eAdjusted for gender, age group, HIV status, crowding index and food security 
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Table 4.8  Multivariable analyses of risk factors for laboratory-confirmed influenza infection among cohort participants (N=608) 
Characteristic IR of laboratory-
confirmed influenza  
(per 1000 PYFU) 
(95%CI) 
 Multivariable Aa,b  Multivariable Ba,c  Multivariable Ca,d 
IRR (95% CI) P-value  IRR (95% CI) P-value  IRR (95% CI) P-value 
Gender 
  Male 
  Female 
Age group 
  18-29 
  30-39 
   > 40 
HIV status 
  Negative 
  Positive 
 
31.4 (16.9-58.3) 
34.6 (22.1-54.2) 
 
20.9 (8.7-50.2) 
39.9 (23.2-68.7) 
36.3 (20.1-65.6) 
 
14.5 (6.0-34.7) 
46.0 (30.8-68.6) 
  
1 
0.97 (0.44-2.12) 
 
1 
1.42 (0.44-2.12) 
1.23 (0.41-3.70) 
 
1 
3.01 (1.11-8.21)  
 
 
0.94 
 
 
 
0.80 
 
 
0.02 
  
 
 
 
 
 
 
 
1 
2.94 (1.11-7.80) 
 
 
 
 
 
 
 
 
 
0.02 
  
1 
0.88 (0.40-1.93) 
 
1 
1.55 (0.54-4.43) 
1.42 (0.47-4.28) 
 
 1 
2.75 (1.02-7.44) 
 
 
0.74 
 
 
 
0.70 
 
 
0.03 
Crowding indexe 
    <1.5 
    1.5-2.4 
    >2.5 
 
16.3 (6.12-43.5) 
47.1 (28.8-76.8) 
32.0 (16.6-61.5) 
     
1 
3.27 (1.09-9.80) 
1.97 (0.60-6.42) 
 
 
 
0.06 
  
1 
3.41 (1.12-10.36) 
2.06 (0.62-6.83) 
 
 
 
0.056 
Difficulty obtaining foodf 
  Never 
  Sometimes  
  Often/always 
 
25.9 (13.9-48.2) 
20.7 (9.9-43.5) 
87.2 (49.5-153.6) 
     
1 
0.71 (0.27-1.86) 
2.99 (1.27-7.06) 
 
 
 
 
 
0.007 
  
1 
0.71 (0.27-1.88) 
3.09 (1.30-7.36) 
 
 
 
0.006 
Pearson’s goodness-of-fit 
test 
   0.07   0.42   0.12 
IR, incidence rate; PYFU, person-years follow-up; IRR, incidence rate ratio; CI, confidence interval 
aIRRs estimated for the incidence of laboratory-confirmed influenza using Poisson regression 
bAdjusted for gender, age group and HIV status. 
cAdjusted for HIV status, crowding index and food security 
dAdjusted for gender, age group, HIV status, crowding index and food security 
eTotal number of household members divided by the number of living rooms in household (kitchen or bathroom not included). 
fSometimes (1-2 times/month), often (up to once a week), always (every day) 
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4.3.4.6  Other risk factors for influenza  
Those who lived in a household with 1.5-2.4 persons per sleeping room was associated with an increased risk 
of influenza, compared to those in households with <1.5 persons/sleeping room (aIRR 3.27, 95%CI 1.09-9.80). 
However, the increased risk was not observed in participants who lived in household with crowding index 
>2.5 (aIRR 1.97, 95%CI 0.60-6.42). 
Participants who reported frequent (once a week or more) difficulties accessing food had a three-fold 
increased risk of influenza infection, compared to those who never had difficulties in food access (aIRR 2.99, 
95%CI 1.27-7.06 – model B). Low BMI was not associated with influenza infection. 
We also assessed covariates for potential effect modification of the impact of HIV on influenza illness. Among 
those that reported difficulty obtaining food once a week or more (often/always), the risk of influenza was 
almost 10-times greater in HIV-infected individuals (IRR 9.50, 95%CI 1.27-70.99) than HIV-uninfected 
individuals. Conversely, in those with no or infrequent difficulty obtaining food, the association between HIV 
and influenza disappears (IRR 1.18, 95%CI 0.32-4.39). This suggests an interaction between food insecurity 
and HIV (p-value for interaction, 0.01). Effect modification was not demonstrated with the other variables. 
4.3.4.7  Effects of CD4+ count and antiretroviral treatment status on influenza incidence 
To explore the effect of CD4+ T-lymphocyte cell count on influenza incidence, the HIV-infected cohort was 
stratified by their CD4+ count at enrolment (<200 or >200 cells/µl) (Table 4.8). We opted to adjust for a priori 
confounders only (age and gender) since the study was not powered for this stratified analysis. Using HIV-
uninfected cohort as baseline, HIV-infected participants with CD4+ count <200 cells/µl at enrolment had 
nearly twice the incidence of influenza compared to HIV-infected participants with CD4+ >200 cells/µl 
(Incidence rate 40.5/ 1000 PYs, aIRR 2.59, 95%CI 0.92-7.27) vs. 79.1/1000 PYs, aIRR 5.50, 95%CI 1.68-18.02), 
compared to HIV-negative participants (incidence rate 14.5/1000 PYs). However, when restricted to the HIV-
infected sub-group (Table 4.10), the association does not reach statistical significance (IRR 1.95, 95%CI 0.78-
4.92). The effect of HIV on influenza did not differ by antiretroviral treatment status (Table 4.9 & 4.10). 
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Table 4.9  The effect of CD4+ count at enrolment and antiretroviral treatment status on incidence rates of laboratory-confirmed influenza illness (N=608)  
Characteristic Number 
influenza 
+ve ILI 
episodes 
(n=29) 
PYFU IR (per 1000 
PYFU) (95%CI) 
Univariable  Multivariablea,b  Multivariablea,c 
 IRR (95% CI) P-
value 
 IRR (95% CI) P-
value 
 IRR (95% CI) P-
value 
Gender 
  Male 
  Female 
Age group 
  18-29 
  30-39 
   > 40 
CD4+ categoryd 
  HIV-negative 
  CD4+ > 200 cells/µl 
  CD4+ < 200 cells/µl 
           
10 
19 
 
5 
13 
11 
 
5 
14 
10 
319 
549 
 
239 
326 
8303 
 
348 
316 
202 
 
31.4 (16.9-58.3) 
34.6 (22.1-54.2) 
 
20.9 (8.7-50.2) 
39.9 (23.2-68.7) 
36.3 (20.1-65.6) 
 
14.5 (6.0-34.7) 
40.5 (25.5-64.3) 
79.1 (35.5-176) 
 
1 
1.21 (0.52-2.84) 
 
1 
1.73 (0.60-4.97) 
1.33 (0.43-4.05) 
 
1 
2.81 (1.04-7.58) 
5.50 (1.68-18.02) 
 
 
0.66 
 
 
 
0.30 
 
 
 
0.02 
  
1 
1.06 (0.48-2.35) 
 
1 
1.42 (0.49-4.09) 
1.28 (0.43-3.86) 
 
 1 
2.59 (0.92-7.27) 
5.11 (1.53-17.11) 
 
 
0.74 
 
 
 
0.70 
 
 
 
0.02 
  
1 
0.96 (0.44-9.20) 
 
1 
1.39 (0.48-4.03) 
1.17 (0.38-3.65) 
 
 
 
 
 
 
0.92 
 
 
 
0.89 
ART treatment status 
  HIV-negative 
  HIV+ – on ART 
  HIV+ – not on ART 
 
5 
17 
7 
 
348 
350 
170 
 
14.5 (6.0-34.7) 
48.6 (30.2-78.1) 
41.1 (19.6-86.2) 
 
1 
3.37 (1.24-9.15) 
2.86 (0.91-9.00) 
 
 
 
0.03 
  
 
   
1 
3.20 (1.11-9.20) 
2.73 (0.85-8.72) 
 
 
 
0.055 
ILI, influenza-like illness; PYFU, person-years follow-up; IR, incidence rate; IRR, incidence rate ratio; CI, confidence interval; ART, antiretroviral treatment 
aIRRs estimated for the incidence of laboratory-confirmed influenza using Poisson regression 
bAdjusted for gender, age group and CD4+ categories 
cAdjusted for gender, age group and ART treatment status 
dCD4+ result missing for 3 HIV-infected participants 
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4.3.4.8  The impact of HIV infection on influenza incidence, accounting for the number of ILI attendances 
Lastly, we explored how a higher number of ILI attendances in the HIV-infected cohort than HIV-uninfected 
cohort affected the observed impact of HIV infection on laboratory-confirmed influenza illness (thus in this 
scenario the assumption is that HIV-infected persons were more likely to attend with ILI, rather than having 
greater propensity to develop ILI compared to HIV-uninfected persons). Logistic regression models using 
generalised estimating equations (GEE) were constructed, to account for the number of ILI attendances by 
cohort participants (table 4.10). Compared with the effect estimates derived from the Poisson regression 
models (Table 4.8), the population average odds ratios were marginally lower and confidence intervals 
broader, which were expected. Importantly, the elevated risk of influenza illness in HIV-infected participants 
compared to HIV-uninfected participants persisted (Model A: aOR 2.39, 95%CI 0.93-6.19; model B: aOR 2.54, 
95%CI 1.00-6.47). 
 
 
 
 
 
 
Table 4.10  The effect of CD4+ count at enrolment and antiretroviral treatment status on incidence 
rates of laboratory-confirmed influenza illness among HIV-infected participants (N=360) 
Characteristic  Number 
influenza +ve 
ILI episodes 
(n=29) 
PYFU IR (per 1000 PYFU) 
(95%CI) 
Univariablea 
 IRR (95% CI) P-value 
CD4+ categoryb 
  > 200 cells/µl 
  < 200 cells/µl 
 
14 
10 
 
316 
202 
 
40.5 (25.5-64.3) 
79.1 (35.5-176) 
 
1 
1.95 (0.78-4.92) 
 
 
0.18 
ART treatment status 
  Yes 
  No 
 
17 
7 
 
350 
170 
 
48.6 (30.2-78.2) 
41.1 (19.6-86.2) 
 
1.18 (0.49-2.85) 
1 
 
0.71 
 
ILI, influenza-like illness; PYFU, person-years follow-up; IR, incidence rate; IRR, incidence rate ratio; CI, 
confidence interval; ART, antiretroviral treatment 
aIRRs estimated for the incidence of laboratory-confirmed influenza using Poisson regression 
bCD4+ result missing for 3 HIV-infected participants 
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 Table 4.11  Risk factors for laboratory-confirmed influenza illness, accounting for the number of ILI attendances, April 2013-March 2015 
(N=608) 
Characteristic Univariable  Multivariable Aa,b  Multivariable Ba,c 
OR (95% CI) P-value  OR (95% CI) P-value  OR (95% CI) P-value 
Gender 
  Male 
  Female 
Age group 
  18-29 
  30-39 
   > 40 
HIV status 
  Negative 
  Positive 
 
1 
1.21 (0.57-2.58) 
 
1 
2.05 (0.70-6.02) 
2.09 (0.70-6.25) 
 
1 
2.75 (1.02-7.41) 
 
 
0.62 
 
 
 
0.37 
 
 
0.045 
  
1 
1.14 (0.54-2.39) 
1 
1.58 (0.53-4.70) 
1.56 (0.53-4.59) 
 
 
 1 
2.39 (0.93-6.19) 
 
 
0.73 
 
 
 
0.70 
 
 
0.07 
  
 
 
 
 
 
 
 
1 
2.54 (1.00-6.47) 
 
 
 
 
 
 
 
 
 
0.05 
Crowding indexd 
    <1.5 
    1.5-2.4 
    >2.5 
 
1 
2.71 (0.90-8.20) 
1.47 (0.46-4.71) 
 
 
 
0.12 
  
 
   
1 
3.60 (1.08-11.98) 
1.20 (0.36-4.03) 
 
 
 
0.02 
Difficulty obtaining foode 
  Never 
  Sometimes  
  Often/always 
 
1 
0.72 (0.27-1.91) 
2.13 (0.92-4.90) 
 
 
 
0.05 
  
 
   
1 
0.66 (0.25-1.71) 
2.60 (1.06-6.41) 
 
 
 
0.03 
OR, odds ratio; CI, confidence interval 
aOdds ratios estimated by population average model using generalised estimating equation (GEE). 
bAdjusted for gender, age group and HIV status. 
cAdjusted for HIV status, crowding index and food security. 
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4.4  Discussion 
This prospective cohort study has demonstrated that HIV-infected adults have an almost three times 
increased susceptibility to influenza infection, compared to HIV-uninfected adults. Among HIV-
infected adults, there was a trend toward a higher risk of influenza among those with an enrolment 
CD4+ cell count of <200 cells/µl, but ART status had no impact. Household crowding and food 
insecurity were also independent risk factors for influenza infection. Furthermore, food insecurity 
may potentiate the impact of HIV on influenza. We did not find any significant associations between 
age, gender, previous history of pneumonia or tuberculosis, smoking, education, sanitation access, 
or exposure to young children in the household and risk of influenza.   
Previous studies of HIV and risk of influenza, largely comprising anecdotal reports or retrospective 
studies in low HIV prevalence settings, have had contradictory findings (Chapter 1.4). However, our 
results support findings from Kenya and South Africa that clearly demonstrate an increased influenza 
incidence in HIV-infected individuals (Feikin et al., 2012b; Cohen et al., 2013). Our incidence rates of 
laboratory-confirmed influenza illness were similar to that reported by Feikin et al. (54.1 vs. 18.6 per 
1000 PYsiv, in HIV-infected and HIV-uninfected persons aged >18 years respectively, crude rate ratio 
~2.91) (Feikin et al., 2012b). In contrast, Cohen et al. (Cohen et al., 2013) focused on influenza-
associated LRTI hospitalisations rather than ILI, therefore had substantially lower incidence 
estimates despite including all ages (1.97-2.28 (HIV+) vs. 0.26-0.54 (HIV-), per 1000 PYsi, relative risks 
4.2-7.5). Both studies derived their incidence estimates from population-based surveillance, which 
lack precise denominators from which to calculate disease burden. Feikin et al. (Feikin et al., 2012b) 
estimated aetiology-specific incidence by applying the proportion of each aetiology to ARI incidence 
adjusted for health-seeking patterns; sampling bias could have affected the pathogens detected, 
since viral testing was only performed in 36% enrolled patients. Lastly, neither study accounted for 
potential confounders, nor had complete HIV data. Thus this Malawian cohort study provides strong 
evidence that HIV is an important risk factor for influenza infection.  
Our HIV-infected cohort had a similar median age to that reported from a cross-sectional study 
undertaken at the QECH ART clinic  (37 vs. 39 years) (van Oosterhout et al., 2005), but we had a 
higher proportion of females (69 vs. 55% (van Oosterhout et al., 2005)). This could have been due to 
recruitment bias, if women were more likely to present to the study clinic for eligibility screening. 
However, the implementation of new guidelines to initiate lifelong ART for all HIV-infected pregnant 
and breastfeeding women irrespective of WHO clinical stage or CD4+ cell count (Option B+) in 2011 
                                                        
iv Person-years adjusted to allow comparison with our incidence rates. 
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(Malawi Ministry of Health, 2011) likely contributed to the increased proportion of women attending 
HIV services. Since a large proportion of HIV-infected participants were recruited from the ART clinic, 
two-thirds were on ART at enrolment, and most had been taking ART for over 12 months. Viral load 
was not available in our study, but the median CD4+ cell count of 390 cells/l implies that our HIV-
infected cohort may have better-controlled HIV disease compared to the Malawian adult HIV 
population. The overall mortality rate of the HIV-infected cohort (2.8%) was also lower than that 
reported in other African settings (Geng et al., 2015; Boulle et al., 2014).  
Acknowledging the limited number of influenza events, we found a significant excess of influenza B 
infection among the HIV-infected cohort (16/24 (67%) in HIV+ vs. 2/5 (40%) in HIV-, p=0.049, Table 
4.6). This echoes the findings of a South African surveillance study that also observed an association 
with HIV infection in patients with hospitalised influenza B infection (Cohen et al., 2014). It is unclear 
why influenza B infection may be more common in HIV-infected individuals, but if confirmed, may 
imply that quadrivalent inactivated vaccines that contain both influenza B strains may yield better 
clinical efficacy in HIV-infected adults. 
Household crowding, as measured by the number of persons per sleeping room in the household, 
was associated with increased risk of influenza infection. This may reflect transmission among 
household members at close proximity. A recent review suggested that influenza virus was 
predominantly transmitted at close range through large droplets generated by coughing, sneezing or 
talking (Chapter 1.1.2) (Brankston et al., 2007). Crowding may also be related to greater exposure to 
young children in the household, though the number of children under 5 years of age was not 
associated with influenza susceptibility. Household crowding has not been evaluated as a risk factor 
for influenza in adults, but has been implicated as a risk factor for ARI (Cardoso et al., 2004; Murray 
et al., 2012; Ram et al., 2014) and influenza (Doshi et al., 2015) in young children. Crowding has been 
suggested as a link between social behaviour and seasonality (Lofgren et al., 2007). Murray et al. 
(Murray et al., 2012) postulated that rainfall increases time spent indoors, intensifying close contact 
in crowded households, with subsequent increased transmission of respiratory pathogens. We did 
not evaluate meteorological data in this study, but no association was found between rainfall and 
influenza activity in our sentinel surveillance (Chapter 3.3). 
It is intriguing that food insecurity emerged as a risk factor for influenza. Although linked with 
respiratory infections in young infants (Ohemeng et al., 2015), as well as increased incident 
opportunistic infections and hospitalisation in Ugandan adults (Weiser et al., 2012b), an association 
between food insecurity and influenza has not been previously described. Food insecurity can, but 
does not necessarily, lead to malnutrition (Kadiyala and Rawat, 2013) and low weight (Singh et al., 
2014; Kac et al., 2012). In our cohort, 20% HIV-infected, and 11% HIV-uninfected participants 
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reported frequent difficulty obtaining food, but only 11% and 7% respectively, were underweight 
(BMI <18.5 kg/m2); we did not find an association between low BMI and food insecurity or increased 
risk of influenza. Although poverty is one of the major causes, food insecurity is a complex 
phenomenon that is linked to lower standards of education, unemployment, lack of access to 
sanitation (Food and Agricultural Organization of the United Nations (FAO), 2000), in addition to 
socioeconomic factors that we have not measured (Jones et al., 2013). It is also inextricably linked 
with HIV infection (Gillespie and Kadiyala, 2005); among HIV-infected persons, it has been associated 
with non-adherence to ART (McKinney et al., 2014; Hong et al., 2014; Weiser et al., 2014), as well as 
poorer HIV control (Weiser et al., 2014; Feldman et al., 2015). Conversely, food insecurity 
significantly declines with increasing ART duration (Weiser et al., 2012a; Palar et al., 2012). Our 
analysis indicated effect modification between food insecurity and HIV; severe food insecurity 
amplified the effect of HIV on influenza risk. Given the small numbers involved (severe food 
insecurity was reported in 12 HIV+/influenza+ vs. 1 HIV-/influenza+ participants), these results 
require cautious interpretation, but merit further exploration, given the opportunities for 
intervening in nutritional support. 
Other than influenza, we identified a host of other respiratory viruses among the ILI episodes, 
including rhinovirus, coronaviruses, hMPV, adenovirus, RSV, parainfluenza viruses, enterovirus, and 
bocavirus. Viral co-infections were found in approximately 5% of ILI episodes. With the exception of 
adenovirus, which was more frequently identified in HIV-uninfected individuals, there was no 
difference in the prevalence of other respiratory viruses detected between ILI samples from HIV-
infected and HIV-uninfected individuals. As with influenza, incidence and disaggregated risk factors 
can be calculated. However, some of tested viruses, such as adenovirus, rhinovirus/enterovirus and 
bocavirus, are commonly identified in well individuals (Feikin et al., 2012b; Jansen et al., 2011; 
Garcia-Garcia et al., 2008), whereas asymptomatic carriage is uncommon for influenza A & B, RSV, 
hMPV, parainfluenza viruses and coronaviruses (Falsey et al., 2006; Feikin et al., 2012b; Kumar et al., 
2008). Hence the clinical relevance of positive test results for these other viruses is difficult to 
discern. We plan to evaluate these results in context of asymptomatic nasopharyngeal samples that 
we have concurrently collected over the 2-year follow-up period (Chapter 7.5). The samples have yet 
to be processed, and will not be reported in this thesis. 
This study has several strengths: to the best of our knowledge, it is the only longitudinal study to 
investigate the rates of influenza and its associations in a well-described cohort of HIV-infected and 
HIV-uninfected persons. Secondly, it was a prospective study with detailed characterisation of the 
clinical presentation and viral aetiology of ILI episodes, and the follow-up period included more than 
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one influenza season. Furthermore, we were able to investigate associations adjusted for key 
potential confounders.  
This study did have several limitations. Cohort participants were recruited from the ART and VCT 
clinics at QECH, thus may have differed to the general population of Blantyre. Another observational 
study conducted at the same VCT clinic found significant differences in educational attainment and 
occupation between enrolled HIV-infected and uninfected patients (Kelly et al., 2014). In our cohort, 
the number of persons in the household (aged <5 and >5 years), sanitation facility, water supply and 
food insecurity differed significantly by HIV status (Table 4.2) We attempted to adjust for potential 
confounding by HIV status in the multivariable analysis. Although recruiting HIV-uninfected 
individuals in the community rather than at VCT clinic could have generated a more representative 
cohort, it seems unlikely that this would have better sampled individuals who didn’t ordinarily 
present for HIV testing. Secondly, patient retention was our priority; it was felt that participants 
recruited close to the study clinic was more likely to return for review.  
Under-ascertainment of ILI episodes, and therefore influenza cases, was likely. During routine 
reviews, 40 participants had admitted to symptoms in keeping with ILI but had not attended for 
review (Chapter 4.3.2). Many cited mild illness and financial constraints for non-attendance, which 
we attempted to mitigate by reimbursement of transport costs. Nonetheless, a healthcare utilisation 
study of QECH ART clinic attenders found that many do not seek medical care for perceived mild 
illness (Masangalawe et al., 2011). If non-presentation of ILI occurred equally in the HIV-infected and 
HIV-uninfected cohorts, then influenza burden would have been underestimated in both groups, and 
the observed effect would have been biased towards the null. We found that HIV-infected 
participants attended with ILI more frequently than HIV-uninfected participants (adjusted IRR 1.21), 
which implied either that HIV-infected individuals experienced more ILI events than HIV-uninfected 
individuals, or HIV-infected patients were more likely to present to the study clinic if they 
experienced an ILI. It is difficult to speculate which of the two scenarios was more likely. However, 
the latter would constitute a form of selection bias given the differential ascertainment of outcome 
data between exposure categories. We therefore performed an alternative analysis that accounted 
for the number of ILI attendances by cohort participants. As expected, the effect estimates derived 
from the population average model were slightly smaller with wider confidence intervals than the 
Poisson regression analysis, but the effect of HIV infection on influenza persisted.  
A major source of bias in cohort studies is loss to follow-up. We employed a number of measures to 
encourage routine and illness attendances, and to minimise loss to follow-up. At enrolment, cohort 
participants were given comprehensive education on the purpose of the study and importance of 
attendance, reinforced by written information to take home. Since physical addresses are not 
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available in Blantyre (few street names and house numbers), we obtained detailed maps and 
directions to patients’ dwellings, as well as contact numbers for the participant, guardian or 
relative/neighbour. A dedicated study contact number was given to all participants to allow ease of 
contact of study staff. Regular contact was maintained with participants through clinic visits and 
telephone. Furthermore, proactive field workers conducted home visits if participants failed to 
attend routine reviews; visits occasionally took place early morning or at weekends to increase 
likelihood of locating the participant. Around 20% participants exited the study prior to the end date, 
which is equivalent to the rates of loss to follow-up in other longitudinal studies in Blantyre (French 
et al., 2010). Importantly, attrition rates were similar between the HIV-infected and HIV-uninfected 
cohorts, and the reason for study exit was known for the majority of exited participants. Around half 
had relocated out of Blantyre, thus highlighting the difficulties of conducting a longitudinal study in 
an urban population. Only 14 (3.9%) HIV-infected and 11 (4.4%) HIV-uninfected participants were 
untraceable. 
The risk of misclassification of HIV status was low as HIV testing were performed by experienced HTC 
counsellors and the tests used are associated with >99% sensitivity and specificity (World Health 
Organization, 2004). Additionally, HIV-uninfected participants were retested annually in case they 
seroconverted.  
Although molecular assays are highly sensitive and specific, misclassification of influenza status 
could have occurred. False positive result is rare, but false negatives can occur from poor specimen 
collection or handling, or if the patient had stopped shedding virus (Centers for Disease Control and 
Prevention, 2015a). This was minimised by rigorous training of study team on specimen collection 
and handling, and advising participants to attend for review as soon as ILI symptoms develop. 
Furthermore, any misclassification was likely to be non-differential to HIV status and unlikely to 
skew the results.  
The HIV-infected and HIV-uninfected cohorts were unmatched on any characteristics. This was 
primarily to allow us to assess the effect of age, gender and other factors on influenza risk, but also 
matching on age or sex would have been challenging. In a cohort study, the exposed and unexposed 
groups should be as similar as possible with respect to all factors that may be related to the 
outcome, except the exposure of interest (Hennekens and Buring, 1987). In our study, a number of 
important differences between the two cohorts could have potentially confounded the association 
between HIV and influenza. In particular, the HIV-infected participants had a higher prevalence of 
previous tuberculosis and pneumonia, smaller household size, poorer water supply and sanitation 
facility, and were more likely to report food insecurity. These variables were included after careful 
review of existing literature, and evaluated as potential confounders in the multivariable analysis. 
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With few outcome events, we adjusted for a maximum of three covariates to avoid unreliable 
coefficients and biased estimates that can occur in models with events per variable (EPV) <10 
(Peduzzi et al., 1996). Thus three separate multivariable models were constructed, all containing 
HIV. The crude and adjusted effect estimates of HIV on influenza do not vary substantially, indicating 
little confounding by the included variables. However, we were limited in the number of variables 
we could include in a multivariable model, thus residual confounding is possible. We found a trend 
towards a higher risk of influenza among those with a low enrolment CD4+ cell count (<200 cells/µl), 
while ART status had no effect. However, the study was not powered for these stratified analyses.   
Lastly, information on additional potential confounders would have been useful. For example, 
indoor air pollution may be an independent risk factor for influenza infection. Biomass fuel is 
extensively used in Blantyre (Piddock et al., 2014); the association between biomass fuel exposure 
and respiratory infection in young children is well established (Kirkwood et al., 1995), but has not 
been evaluated in adults. Data were collected on the principal type of fuel used in household, which 
did not differ by HIV status. However, we did not measure the magnitude of current air pollution 
exposure, which would have been a major additional undertaking. The association between biomass 
exposure and adult pneumonia is currently the subject of another research project in Blantyre.  
This study therefore adds to the scant body of literature from high HIV prevalence settings that HIV-
infected adults have an increased susceptibility to influenza infection, compared to HIV-uninfected 
adults. Although most of the influenza cases were mild, our findings have important public health 
implications. HIV-infected individuals, aside from having increased risk of influenza infection and 
therefore higher disease burden, may also have a substantial role in community and nosocomial 
influenza transmission. In particular, they may increase transmission to other HIV-infected 
individuals in overcrowded ART clinics and hospital wards, where up to 75% patients have HIV 
infection (SanJoaquin et al., 2013). Furthermore, given the synergistic interaction between influenza 
and Streptococcus pneumoniae (McCullers, 2006), this may be a potential mechanism for the higher 
risk of bacterial pneumonia (Sogaard et al., 2008) and IPD (Nuorti et al., 2000; Harboe et al., 2014) 
observed among HIV-infected persons. Consequently, preventative strategies against influenza in 
this risk group may be especially pertinent.  
Influenza vaccines, the most effective preventative tool against influenza, are not widely available in 
most SSA countries, and require annual administration. Thus policymakers will likely require further 
detailed evidence of the impact of HIV infection on influenza, particularly severe disease (Chapter 5), 
as well as mortality, prior to consideration of HIV-infected adults as a target group for immunisation. 
As regards HIV and influenza susceptibility, several unanswered questions remain. The impact of the 
degree of immunosuppression, and duration of antiretroviral treatment on the risk of influenza 
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illness remain unclear. The contribution of environmental and socioeconomic factors to influenza 
risk, particularly the interaction between HIV and food insecurity, require further elucidation. A 
population-based household cohort study would be an appropriate study design to address these 
questions. A random sample generated from the population will increase representativeness of the 
cohort. Secondly, active surveillance (e.g. involving visit by field worker visit once or twice weekly) 
will allow more accurate ascertainment of influenza burden, as persons with ILI who would not seek 
healthcare or are prevented to do so due to financial or time constraints, or cultural preferences can 
be captured. Furthermore, it will provide the opportunity to assess the complex transmission 
dynamics of influenza. A large cohort study is costly and logistically difficult to perform, but cost 
efficiency can be optimised by concurrently evaluating a number of other respiratory pathogens, 
including bacteria, tuberculosis and atypical organisms, and their interactions with influenza. 
In conclusion, HIV-infected Malawian adults have a greater burden of influenza illness than HIV-
uninfected adults, particularly in those with advanced immunosuppression. Household crowding and 
food insecurity also emerged as previously unrecognised risk factors for adult influenza infection. 
Further evaluation of the effect of the degree of immunosuppression and duration of antiretroviral 
treatment will build a more complete picture of the effect of HIV on influenza susceptibility. The 
findings of this study, if accompanied by evidence of increased disease severity (Chapter 5), will 
present a strong case to policymakers to consider targeted influenza vaccination policy in HIV-
infected adults in Malawi and other similar high HIV prevalence settings. The interaction between 
HIV and food insecurity also warrants further exploration. 
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CHAPTER 5.   Severe and Mild Influenza-Related Respiratory 
Presentations in Malawian Adults: a Case Control Study 
             
 
5.1  Introduction 
Pneumonia is the commonest reason for adult hospital admission in SSA, with an estimated 4 million 
episodes and 200,000 deaths annually (Scott et al., 2012). As a result of limited surveillance and 
diagnostic capacity until recently, the contribution of influenza to adult pneumonia in SSA has not 
been well characterised (Chapter 1.3). The few studies that have evaluated viral aetiology in adult 
pneumonia in SSA detected influenza in 2 to 38% cases (Joosting et al., 1979; Scott et al., 2000; 
Hartung et al., 2011; Feikin et al., 2012b; Pretorius et al., 2012). However, the studies comprised 
diverse study populations, pneumonia definitions, as well as viral diagnostic tests. Thus the precise 
contribution of influenza to pneumonia remains unclear. 
Existing literature that have evaluated the impact of HIV infection on the severity of influenza 
presentation have demonstrated conflicting findings (Chapter 1.4). In low HIV prevalence settings, 
HIV infection did not appear to significantly increase severity of influenza. Conversely, recent studies 
from high HIV prevalence settings in SSA have shown increased risk of hospitalisation (Ope et al., 
2011), prolonged duration of hospital stay (Cohen et al., 2013), and higher mortality (Cohen et al., 
2013; Tempia et al., 2015b; Cohen et al., 2015a) in HIV-infected persons compared to HIV-uninfected 
persons, though HIV status, CD4+ cell count and ART treatment status were not comprehensively 
ascertained. The disparity in the observed impact of HIV on disease severity and mortality from 
influenza may be explained by more advanced immunosuppression in HIV-infected individuals, 
poorer access to ART, in addition to higher prevalence of co-morbid conditions, such as tuberculosis, 
pregnancy or malnutrition in HIV-infected adults in SSA compared to other regions, but requires 
further evaluation. 
As described in Chapter 1.5, annual seasonal influenza vaccination is currently unavailable in much 
of SSA (Duque et al., 2014); most countries have neither the resources nor the infrastructure to 
implement this. Thus demonstrating an important contribution of influenza to hospitalised 
pneumonia, and defining risk factors for severe influenza presentation, are critical information to 
build a case for policymakers and international organisations to devise targeted influenza 
immunization policy, and identify appropriate priority groups to target in SSA.  
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We therefore conducted a case control study of adults presenting with severe (cases, hospitalized 
lower respiratory tract infection) and mild (controls, influenza-like illness) influenza illness to 
examine the role and impact of HIV as a risk factor for severe influenza-related respiratory 
presentation in Malawian adults, and to identify other risk factors prominent in this setting. 
5.2  Methods 
5.2.1  Study design 
A case control study design was chosen to evaluate the association between HIV infection and 
severity of influenza presentation in adults since severe influenza-associated lower respiratory tract 
infection is a relatively rare outcome. It allowed efficient recruitment of ‘cases’ in the timeframe 
required to complete this study. Additionally, ILI patients were chosen over healthy community adult 
controls as the control group for two main reasons: first, to enrich for influenza-positivity in the 
control group; second, it was felt that ILI patients presenting to government primary and secondary 
care facilities were more likely to be from the same population from which cases were derived. We 
wished to examine age and gender as potential risk factors for severe influenza. Hence cases and 
controls were unmatched. An overview of cases and controls and the population from which they 
were derived are illustrated in figure 5.1. 
 
 
  
 
Figure 5.1  Overview of case control study design 
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5.2.2  Study site 
Both potential cases and controls were enrolled from QECH at the start of the study. However, as a 
result of reorganisation of the health system in Blantyre, primary care patients were redirected to 
the Gateway Clinic. Following ethical approval, recruitment of patients with ILI took place at the 
Gateway clinic (Chapter 2.1.2) from January 2014.  
5.2.3  Study population 
 
5.2.3.1  Definition of cases and controls 
Cases 
Adults (aged >18 years) presenting to QECH with lower respiratory tract infection (LRTI) AND 
requiring hospitalisation AND influenza PCR-positive from a nasopharyngeal specimen. 
Controls  
Adults (aged >18 years) presenting to QECH or Gateway Clinic with influenza-like illness (ILI) AND not 
requiring hospitalisation AND influenza PCR-positive from a nasopharyngeal specimen. 
5.2.3.2 Eligibility criteria 
Hospitalized LRTI 
Inclusion criteria 
 Reported fever OR recorded fever (>38°C oralv) 
 Reported cough OR chest pain OR breathlessness OR haemoptysis  
 Crepitations OR pleural rub OR bronchial breathing OR signs suggestive of pleural effusion 
on clinical examination 
 Require hospitalisation 
Exclusion criteria 
 Pre-admission diagnosis of terminal illness (e.g. metastatic malignancy) 
 Current anti-tuberculous treatment 
 Admission to hospital >24 hours prior to recruitment 
 Symptoms for 14 days or greater 
 Prior hospitalisation within last 4 weeks 
 Suspected concurrent meningitis 
 Prior participation in the study 
                                                        
v Obtained using SureTemp Plus 690 electronic thermometer. 
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Rationale for the inclusion/exclusion criteria  
Previous studies on pneumonia or LRTI have required the presence of infiltrates on chest radiograph 
(Templeton et al., 2005; de Roux et al., 2006; Jennings et al., 2008; Luchsinger et al., 2013). Since the 
availability of chest radiographs were variable at QECH, we opted for a clinical definition of LRTI – 
which comprised fever, > one respiratory symptoms and > one clinical sign suggestive of LRTI. In 
terms of exclusion criteria, the exclusion of patients who had been hospitalised for >24 hours, and 
prior hospitalisation within 4 weeks was to ensure that the detected influenza was community-
acquired rather than due to nosocomial transmission. This study co-recruited patients with another 
study that aimed to define the aetiology of community-acquired pneumonia and factors associated 
with 30-mortality and treatment outcome (see section 5.2.5), hence patients that were deemed 
unlikely to live beyond 30 days, patients whose respiratory symptoms may have been due to 
another focus of infection (e.g. concurrent meningitis), as well as those on active TB treatment were 
excluded. 
ILI 
Inclusion criteria 
 Reported fever OR recorded fever (>38°C) 
 > 2 of the following: cough, sore throat, rhinorrhoea, myalgia, vomiting/diarrhoea OR 
headache 
 Symptoms for 7 days or fewer 
 Not requiring hospitalization for ILI presentationvi 
Exclusion criteria 
 Pre-admission diagnosis of terminal illness (e.g. metastatic malignancy) 
 Current anti-tuberculous treatment 
 Prior hospitalisation within last 4 weeks 
 Suspected concurrent meningitis 
 Prior participation in the study 
Rationale for the inclusion/exclusion criteria  
The inclusion criteria for ILI were identical to that used in the influenza surveillance at QECH 
(Chapter 3.2.3). Moreover, since the control group should be from the same study population from 
which cases are derived, the exclusion criteria that were applicable to hospitalised LRTI patients 
were also applied to enrolled patients with ILI. 
                                                        
iiMay be hospitalized for an alternative indication e.g. fracture. 
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5.2.4  Related studies  
The case control study recruited patients at QECH with acute respiratory symptoms alongside two 
other studies: the Malawian Adult Lower Respiratory Tract Infection Severity, Aetiology and 
Outcome (MARISO) study (COMREC reference P.11/12/1309) and the H1N1 sentinel influenza 
surveillance (P.07/10/958). The MARISO study, a prospective cohort study nested within this case 
control study, conducted more detailed clinical investigations and follow-up in a subset of patients 
with hospitalised LRTI. Eligibility criteria for adult LRTI were identical in the MARISO and BASH-FLU 
studies. There was also a significant overlap between hospitalized LRTI patients and patients with 
severe acute respiratory illness (SARI) recruited by the influenza surveillance. The overlap among the 
three studies is represented in Figure 5.2. Staff employed by the three studies were integrated into a 
single Acute Respiratory Infection Studies team. Recruitment procedures and laboratory 
investigations were streamlined to avoid obtaining duplicate clinical specimens and additional 
burden from participants. Depending on the fulfilment of eligibility criteria and daily recruitment 
target of each study, patients were recruited into one, two, or all three studies. Separate patient 
information leaflets were available for the three studies, but a joint informed consent procedure 
was completed (Appendix 8.3.3). 
 
 
 
 
Figure 5.2  Recruitment overlap among BASH-FLU, MARISO and H1N1 
surveillance studies 
N.B. size of box in this diagram does not represent the relative proportion of 
patients recruited.  
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5.2.5  Study procedures  
5.2.5.1  Staff 
The following GCP-trained staff were employed to recruit for the BASH-FLU case control study, 
MARISO study and H1N1 influenza surveillance (i.e. the Acute Respiratory Infection studies): 
 3 study nurses: responsible for screening for eligible patients at the triage area in AETC, medical 
wards and the Gateway clinic; consent and enrolment of patients; obtaining clinical specimens, 
including nasopharyngeal aspirate, blood, sputum and urine; instituting appropriate 
management, e.g. administering intravenous fluids or antibiotics; and completion of paper and 
electronic copies of screening and enrolment logs.  
 3 clinical officers: responsible for assessing eligibility, consent and enrolment of patients; clinical 
assessment and management of patients; conducting necessary clinical procedures, e.g. pleural 
aspiration; aiding study nurses in obtaining clinical specimens. 
 1 laboratory messenger: responsible for transporting clinical specimens from the area of 
recruitment (AETC, medical ward or Gateway clinic) to the MLW/COM laboratories. 
 1 molecular laboratory technician: responsible for aliquoting, storage and processing 
nasopharyngeal specimens, as part of a team of technicians in the core diagnostic laboratory. 
In addition to screening and enrolment of study participants, study staff also contributed to routine 
clinical activities at the AETC and Gateway Clinic during their working hours. 
  
Figure 5.3  Recruitment activities by study nurses in the Adult Emergency Trauma Centre 
A) One of the study nurses at the triage desk in AETC, B) Study nurses performing baseline observations 
and screening for eligible patients at the triage area. 
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5.2.5.2  Enrolment 
Recruitment of ILI patients took place at the Gateway clinic between 8 and 11 am on weekdays. 
Hospitalised LRTI patients were recruited daily between 8am to 3pm in AETC; the study team also 
screened for eligible patients in the medical wards every morning that had been admitted in the 
preceding 24 hours. Recruitment hours were limited by the necessity of clinical samples to reach the 
laboratory by 3pm for processing. 
Persons that met the eligibility criteria who were willing to consider participation in the study 
received a patient information document, and written informed consent was sought. A proportion of 
hospitalised LRTI patients were unable to provide informed consent at initial assessment due to 
confusion or clinical instability. In order to recruit a representative study population with 
hospitalized LRTI, these patients were recruited on the basis of proxy consent provided by an 
accompanying guardian (using a separate guardian consent form – Appendix 8.3.3). In the absence 
of a guardian, patients unable to give informed consent were not recruited. Formal consent from the 
patient was requested when they had recovered to the extent that they were able to have 
reasonable comprehension and retention of the information related to the study. If consent was 
denied at this stage, the participant’s record was deleted from the study database.  
Data were obtained from study participants and/or their guardian using a structured questionnaire 
(Appendix 8.3.3). Information collected included: demographic details; clinical presentation; medical 
history (including co-morbidities, previous history of tuberculosis or pneumonia, pregnancy, HIV and 
vaccination history); smoking and alcohol use; household characteristics (including household size, 
number of young children in household, number of rooms in dwelling and cooking fuel used); and 
socioeconomic status. The latter was defined by education, occupation, asset ownership, food 
security, and access to water and sanitation facilities. 
Detailed clinical examination was performed to ascertain physiological parameters at presentation, 
nutritional status (body mass index (BMI) and mean upper arm circumference (MUAC)), mental 
status (AVPU score), upper and lower respiratory tract signs, other relevant systemic findings, as 
well as WHO clinical staging for HIV (if the participant was HIV-reactive). Of note, the same CRFs are 
completed for ILI and hospitalised LRTI patients, but the groups are differentiated by their 
designated study barcodes (section 2.3): hospitalised LRTI patients have barcodes beginning with 
2200XXX (XXX is their study number), whereas ILI patients have barcodes beginning with 3300XXX. 
In addition to clinical assessment of patients and completing study documents, the study clinical 
officers were also responsible for completion of hospital admission documents, entering patients’ 
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clinical details in their health passport, and formulation of onward management plans. Empirical 
treatment was administered by the study nurses. 
5.2.5.3  Laboratory investigations 
The investigations that were performed on patients with ILI and hospitalised LRTI at recruitment are 
listed below (see Section 2.2 for details of individual tests):  
Table 5.1  Laboratory investigations undertaken in the case control study 
Investigations ILI Hospitalised LRTI 
Venous blood    
 Malaria rapid diagnostic test X X 
 Rapid HIV test (if status unknown) X X 
 CD4+ cell count  X X 
 Blood culture  X 
Nasopharyngeal & oropharyngeal swabs   
 Influenza PCR (CDC H1N1 kit) X X 
 Multiplex PCR for 33 respiratory pathogens                            
(Fast-track Diagnostics)  
 X 
 Quantitative lytA PCR for S. pneumoniae  X 
Sputum   
 Smear microscopy for AFB & culture  X 
 GeneXpert MTB/RIF  X 
Urine   
Rapid urinary antigen test for S. pneumoniae (BinaxNOW)  X 
Chest X-Ray   X 
 
All laboratory tests were done at the MLW or University of Malawi College of Medicine laboratories 
(Chapter 2.2). With the exception of PCR results on nasopharyngeal specimens, results of the above 
investigations were relayed back to patients and the clinical team looking after them as soon as they 
were available. HIV testing was performed by the MLW laboratory, and results were fed back to the 
participants by HTC-trained study staff. Patients that were newly diagnosed with HIV infection were 
referred for HIV care at the QECH ART clinic or their local health centre. 
5.2.5.4  Follow-up 
No formal follow-up was conducted beyond recruitment. However, the study team conducted daily 
morning ward rounds of enrolled patients at QECH to feedback clinically-relevant laboratory test 
results to the clinical team, obtain digital images of chest radiographs, and record duration of 
admission and patient outcome. Timing of hospital discharge was at the discretion of the clinical 
team.  
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5.2.6  Sample size calculations 
In a Kenyan case control study, the OR of having HIV infection was 3.6 (95%CI 1.3-10.1) in 
hospitalised patients with influenza (cases) compared to healthy adults (controls) (Ope et al., 2011). 
A lower effect estimate was thought likely in this study since our controls were patients with ILI. 
With an estimated HIV prevalence of 37.5% in adults with ILI from preliminary influenza surveillance 
data (Garg et al., 2012), and a case: control ratio of 1:2, a sample size of 57 cases and 114 controls 
provided 80% power to detect risk factors with an odds ratio of 2.5 or greater. Based on estimated 
influenza prevalence of 10% and 16.4% in adults presenting to QECH with hospitalized LRTI and ILI 
respectively, this would involve recruitment of approximately 570 adults with hospitalized LRTI and 
695 adults with ILI. Patient recruitment was discontinued once the target number of cases and 
controls are recruited. 
5.2.7  Statistical analysis 
In the descriptive comparison of baseline characteristics between enrolled hospitalised LRTI and 
mild ILI patients, as well as influenza-positive cases and controls, chi-square tests was used to 
compare categorical variables. Student independent-samples t-tests or Wilcoxon rank-sum tests 
were used to compare continuous variables, depending on the distribution properties of the 
variable.  
Multivariable analyses were implemented to identify i) clinical predictors of influenza among 
hospitalised LRTI patients; and ii) risk factors for severe influenza presentation (i.le. being a case). A 
log binomial regression model was used to compute risk ratios (RR) and 95% confidence intervals for    
factors predicting influenza-associated LRTI.  
The analysis of risk factors for severe influenza presentation was restricted to cases and controls. 
HIV infection and month of recruitment were included a priori in the multivariable model; the latter 
due to the discordant timing of recruitment of hospitalized LRTI and ILI patients (Figure 5.6).  Since 
cases and controls were unmatched, unconditional logistic regression models were used to estimate 
odds ratios for the effect of HIV (primary exposure of interest) and other risk factors for severe 
influenza presentation. In both multivariable models, covariates with a p-value <0.10 on univariable 
analysis were assessed in the multivariable model using stepwise backwards elimination. Factors 
with two-sided p-values of <0.05 were considered significant. 
Population attributable fractions (PAF) of modifiable risk factors for severe influenza were also 
estimated. PAF provides an estimate of the proportion of hospitalised influenza cases that would 
theoretically be prevented if the exposure was removed, assuming a causal relationship between 
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the exposure and outcome (Rockhill et al., 1998). The PAFs and confidence intervals for the risk 
factors for severe influenza were derived from the prevalence of exposure in cases and adjusted OR 
from the multivariable logistic regression model using the punafcc command in Stata 12.0 (Newson, 
2013), which is based on the formulae by Greenland and Drescher (Greenland, 1993). As individual 
risk factors may interact in their impact on overall risk of disease, PAFs for multiple risk factors can 
add up to greater than 100%. 
5.2.8  Study timescale 
Study staff were recruited and trained in March and April 2013. Recruitment of hospitalised LRTI and 
ILI patients commenced in AETC on 15 May 2013, and at the Gateway Clinic (ILI patients only) from 
27 January 2014. Patient recruitment was completed on 28 February 2015. 
5.3  Results 
Between May 2013 and February 2015, 1645 patients were screened for eligibility for hospitalised 
LRTI and 846 for ILI, with subsequent recruitment of 518 and 642 patients respectively (Figure 5.4). 
Recruitment was discontinued prior to reaching target sample size due to time constraints. Due to 
the strict eligibility criteria for hospitalized LRTI, a large proportion of screened patients were 
deemed ineligible for study inclusion (n=1109, 68.5%); the predominant reasons for exclusion were 
illness duration greater than 14 days, lack of focal chest signs, and the absence of fever. Eligible and 
non-eligible individuals had similar sex distribution (59 vs. 64% male, p=0.08) (Figure 5.5). However, 
ineligible individuals were slightly older with a median age 35 years and a higher proportion of 
individuals aged > 40years (40% vs. 31%. P=0.01).   
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Figure 5.4  Flow diagram of case control study recruitment 
aSome excluded for multiple reasons 
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Figure 5.5  Age and gender distribution among eligible and ineligible individuals 
screened for hospitalised LRTI 
 
Recruitment progress over the 22-month period is illustrated in Figure 5.6. The number of 
participants recruited each month varied from 11 to 37 for hospitalised LRTI, and 1 to 68 for ILI. Few 
ILI patients were recruited between September and December 2013 due to health system 
reorganisation in Blantyre that resulted in the diversion of patients with primary care issues away 
from AETC (Chapter 5.2.3). Enrolment numbers improved from January 2014 after the recruitment 
site of ILI patients was changed to the Gateway Clinic.  
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Figure 5.6  Monthly patient recruitment in the BASH-FLU case control study 
 
5.3.1  Baseline characteristics of hospitalised LRTI and ILI patients  
The baseline characteristics of the patients enrolled with hospitalised LRTI and mild ILI are 
summarized in Table 5.2. Compared to patients with ILI, those recruited with hospitalised LRTI were 
more likely to be male (62 vs. 42%) and were older (median age 35 vs. 32 years). Since QECH is a 
tertiary referral hospital, it is unsurprising that 61% of LRTI patients had attended another health 
facility prior to admission, with a similar proportion reporting pre-hospital antibiotic consumption.  
The LRTI patients also had a substantially higher HIV prevalence (77 vs. 30%), and had more 
advanced immunosuppression among those with HIV-infection (median CD4+ count 101 vs. 313 
cells/µl). The prevalence of chronic co-morbidities in both groups were low, though a higher 
proportion of hospitalised LRTI patients had reported a previous history of tuberculosis and 
pneumonia within the past 5 years. 
In terms of household characteristics, there were no differences in household crowding or exposure 
to young children (<5 years). However, patients with ILI had better sanitation (encompassing 
sanitation facility, water source, as well as distance to water source), level of education, asset 
ownership, and reported less food insecurity.  
The presenting symptoms and clinical examination findings of the two groups are summarized in 
Table 5.3. The majority of symptoms, with the exception of headache, rhinorrhoea and sore throat, 
were more commonly reported among hospitalised LRTI patients. Additionally, a higher proportion  
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Table 5.2  Demographic, clinical, household and socioeconomic characteristics of adults enrolled 
with hospitalised LRTI and mild ILI, Queen Elizabeth Central Hospital and Gateway Clinic, 
Blantyre, May 2013-February 2015 (N=1160) 
Characteristic Hospitalised  
LRTI 
ILI p-valuea 
 (n=518) (n=642)  
Demographic  
Gender  
   Male 
 
 
323 (62.4) 
 
 
273 (42.5) 
 
 
<0.001 
Age (median, IQR) 
Age group 
  18-29 
  30-39 
   > 40 
34.8 (29.6-42.2) 
 
138 (26.6) 
227 (43.8) 
153 (29.5) 
31.9 (25.4-43.0) 
 
278 (43.3) 
165 (25.7) 
199 (31.0) 
<0.001 
 
 
 
<0.001 
Pre-hospital/clinic attendance & treatment 
  Attended another health facilityb 
  Antibiotics within 2 weeks  
  Antimalarials within 2 weeks 
  Traditional medicines within 2 weeks 
 
312 (60.8) 
309 (60.7) 
83 (16.3) 
39 (7.7) 
 
62 (9.8) 
70 (11.1) 
13 (2.1) 
2 (0.3)  
 
<0.001 
<0.001 
<0.001 
<0.001 
HIV prevalence 
     Known HIV+ at enrolment 
     On ART at enrolment 
396 (76.6) 
246/396 (62.1) 
188/233 (80.7) 
193 (30.2) 
92/189 (48.7) 
68/87 (78.2) 
<0.001 
<0.001 
0.62 
CD4+ cell count (cells/µl)c 
  median, IQR 
 
101 (46-196) 
 
313 (167-450) 
 
<0.001 
Medical history 
  Chronic lung disease 
  Chronic cardiac disease  
  Hypertension 
  Cancer 
  Chronic kidney disease 
  Chronic liver disease 
  Stroke 
  Previous history of tuberculosis  
  Pneumonia in past 5 years 
  Pregnant 
  Smoking – current 
  Alcohol 
 
18 (3.6) 
2 (0.4) 
9 (1.8) 
5 (1.0) 
1 (0.2) 
1 (0.2) 
5 (1.0) 
90 (17.5) 
113 (22.1) 
2/191 (1.1) 
58 (11.3) 
135 (26.4) 
 
15 (2.4) 
1 (0.2) 
19 (3.0) 
1 (0.2) 
0 (0) 
0 (0) 
1 (0.2) 
45 (7.1) 
46 (7.2) 
10/363 (2.8) 
39 (6.1) 
78 (12.2) 
 
0.23 
0.59 
0.19 
0.09 
0.44 
0.44 
0.99 
<0.001 
<0.001 
0.19 
<0.001 
<0.001 
Household and socioeconomic  
Children <5years 
    0 
    1 
    >2 
Crowding indexd 
    <1.5 
    1.5-2.4 
    >2.5 
Water supply 
     River/borehole/well 
 
 
296 (57.7) 
156 (30.4) 
61 (11.9) 
 
174 (35.0) 
203 (40.9) 
120 (24.1) 
 
150 (29.2) 
272 (52.9) 
 
 
381 (59.7) 
195 (30.6) 
62 (9.7) 
 
219 (35.8) 
258 (42.2) 
135 (22.1) 
 
134 (21.0) 
308 (48.3) 
 
 
 
 
0.48 
 
 
 
0.71 
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     Public tap/standpipe 
     Piped to dwelling/plot 
Distance from water supply 
     <200m 
     >200m 
Sanitation 
    None/non-VIP toilet 
    VIP toilet 
    Flush toilet 
Principal cooking fuel 
     Firewood 
     Charcoal 
     Electricity 
Highest level of education 
     Never attended school 
     Primary 
     Secondary/Tertiary 
92 (17.9) 
 
182 (35.4) 
332 (64.5) 
 
284 (55.3) 
188 (36.6) 
42 (8.2) 
 
140 (27.2) 
325 (63.2) 
49 (9.5) 
 
49 (9.7) 
274 (53.9) 
185 (36.4) 
196 (30.7) 
 
272 (42.6) 
366 (57.4) 
 
260 (40.8) 
252 (39.6) 
125 (19.6) 
 
129 (20.2) 
421 (66.1) 
87 (13.7) 
 
52 (8.2) 
266 (41.7) 
320 (50.2) 
<0.001 
 
 
0.01 
 
 
 
<0.001 
 
 
 
0.006 
 
 
 
<0.001 
Employment status 
     Unemployed 
 
68 (13.2) 
 
91 (14.3) 
 
0.61 
Asset ownershipe 
     0 
     1 
     2 
     3 
     4-5 
 
84 (16.3) 
106 (20.6) 
122 (23.7) 
158 (30.7) 
35 (8.7) 
 
75 (11.8) 
112 (17.6) 
165 (25.9) 
206 (32.3) 
80 (12.5) 
 
 
 
 
 
0.04 
Food security – difficulty obtaining food 
    Never 
    Sometimes 
    Often/always 
 
247 (48.0) 
226 (44.0) 
41 (8.0)  
 
367 (57.5) 
250 (39.2) 
31 (3.3)  
 
 
 
<0.001 
Season of recruitment 
   Jan-Mar  
   Apr-Jun 
   Jul-Sep 
   Oct-Dec 
 
99 (19.1) 
100 (19.3) 
161 (31.1) 
158 (30.5) 
 
204 (31.8) 
180 (28.0) 
156 (24.3) 
102 (15.9) 
 
 
 
 
<0.001 
LRTI-lower respiratory tract infection; ILI-influenza-like illness; IQR-interquartile range; PCV, pneumococcal 
conjugate vaccine; VIP, ventilated improved pit latrine  
The number of missing observations in each variable is detailed in Appendix 8.4.3; individuals with missing 
data were excluded from the denominator in percentage calculations.  
achi-squared test for categorical variables /Wilcoxon rank sum test for continuous variables  
bIncludes attendance to other hospital, health centre, private clinic, traditional healer or pharmacy 
cCD4+ count not available for 45 hospitalised LRTI and 13 ILI patients 
dTotal number of household members divided by number of rooms in house (excluding kitchen and 
bathroom) 
eNumber of the following assets owned in household: working refrigerator, radio, mobile phone, bed and 
car/motorbike.  
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Table 5.3  Clinical characteristics of adults enrolled with hospitalised LRTI and mild ILI, May 
2013-February 2015 (N=1160) 
Characteristic Hospitalised  
LRTI 
Mild ILI p-valuea 
(n=518) (n=624)  
Symptoms 
   Cough 
   Sputum 
   Shortness of breath 
   Chest pain 
   Myalgia 
   Headache 
   Rhinorrhoea 
   Sore throat 
 
506 (98.6) 
406 (79.1) 
492 (95.9) 
501 (97.9) 
405 (79.0) 
233 (45.4) 
83 (16.2) 
122 (23.8) 
 
612 (95.9) 
111 (17.4) 
93 (14.6) 
259 (40.6) 
516 (80.9) 
504 (79.0) 
529 (82.9) 
395 (61.9) 
 
0.03 
<0.001 
<0.001 
<0.001 
0.42 
<0.001 
<0.001 
<0.001 
   Nausea/vomiting 
   DIarrhoea  
   Weight loss 
   Night sweats  
   Skin rash 
83 (16.2) 
81 (15.9) 
310 (60.4) 
331 (64.7) 
38 (7.4) 
22 (3.5) 
25 (3.9) 
18 (2.8) 
17 (2.7) 
17 (2.7) 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
Physiological parameters at enrolment 
   Disorientationb 
   Temperature >38c or <35c 
   Systolic blood pressure <90mmHg  
   Diastolic blood pressure <60mmHg 
   Heart rate >120 or <40 beats/min 
   Respiratory rate >30/min 
   Oxygen saturation <90% 
   Unable to stand 
7 (1.4) 
256 (49.4) 
96 (18.7) 
132 (25.7) 
222 (43.2) 
231 (46.1) 
113 (22.0) 
97 (18.9) 
3 (0.5) 
48 (7.5) 
10 (1.6) 
20 (3.1) 
23 (3.6) 
4 (0.6) 
7 (1.1) 
1 (0.2) 
0.11 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
   BMI (kg/m2)  – median (IQR) 
     <18.5 
     18.5-24.9 
      >25 
   MUAC (mm) – median (IQR) 
19.9 (18.2-21.7) 
147(29.7) 
329 (66.5) 
19 (3.8) 
250 (220-260)   
21.7 (19.7-24.3) 
67 (10.5) 
437 (68.5) 
134 (21.0) 
255 (240-270) 
<0.001 
 
 
<0.001 
<0.001 
 Clinical signs 
   Red throat 
   Pus in throat 
   Cervical lymphadenopathy 
   Sinus tenderness 
 
11 (2.1) 
1 (0.2) 
40 (7.8) 
1 (0.2) 
 
38 (6.0) 
1 (0.2) 
5 (0.8) 
3 (0.5) 
 
0.001 
1.00 
<0.001 
0.63 
   Crepitations 
   Bronchial breathing 
   Effusion 
   Pleural rub 
   Wheeze 
436 (84.8) 
188 (36.6) 
85 (16.5) 
141 (27.4) 
20 (3.9) 
18 (2.8) 
7 (1.1) 
0 (0) 
0 (0) 
4 (0.6) 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
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of LRTI patients had physiological parameters consistent with clinical instability (e.g. systolic blood 
pressure <90mmHg or oxygen saturation <90%), thus supporting greater severity of clinical 
presentation in this group.  
  
   Finger clubbing 
   Pale conjunctivae 
   Oral candidiasis 
   Kaposi’s sarcoma lesions 
   Jaundice 
   Hepatomegaly  
   Splenomegaly 
   Pedal oedema 
27 (5.3) 
29 (5.6) 
34 (6.6) 
16 (3.1) 
7 (1.4) 
25 (4.9) 
17 (3.3) 
14 (2.8) 
0 (0) 
1 (0.2) 
2 (0.3) 
0 (0) 
1 (0.2) 
2 (0.3) 
2 (0.3) 
3 (0.5) 
<0.001 
<0.001 
<0.001 
<0.001 
0.01 
<0.001 
<0.001 
0.002 
LRTI, lower respiratory tract infection; ILI-influenza-like illness; BMI, body mass index, MUAC, mid 
upper arm circumference; mm-millimetres; IQR-interquartile range. 
The number of missing observations in each variable is detailed in Appendix 8.4.3; individuals with 
missing data were excluded from the denominator in percentage calculations.  
aChi-square or Fisher’s exact test 
bDisorientated in time, place or person 
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5.3.2  The contribution of influenza to hospitalised LRTI and ILI  
Influenza was identified in 56 (10.8%) patients with hospitalised LRTI and 88 (13.7%) patients with 
ILI. Figure 5.6 illustrates the number and proportion of enrolled hospitalised LRTI and ILI patients 
with a positive influenza PCR, including the type and subtype of influenza. Seasonal influenza 
A(H3N2) and influenza B, but not influenza A(H1N1)pdm09, were identified during the study period. 
 
 
 
A. Hospitalised lower respiratory tract infection 
 
B. Influenza-like illness 
Figure 5.7  Number and percentage of A) hospitalised LRTI (n=56), and B) ILI (n=88) patients with a 
positive influenza PCR per month, including influenza type and subtype, May 2013-February 2015 
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5.3.3  Aetiology and outcome of hospitalised LRTI at QECH 
5.3.3.1  Aetiology 
From the diagnostic tests that were performed (Chapter 5.2.5.3), one or more aetiological agents 
were identified in 381 (67%) of 518 patients admitted with LRTI (Table 5.4). Respiratory viruses were 
detected by rRT-PCR from NPA from approximately a third of patients (n=177, 34.2%); the most 
commonly identified were influenza A and B (n=56, 10.8%), adenovirus (n=39, 7.7%), coronavirus 
229E (n=22, 4.4%), and rhinovirus (n=22, 4.4%). Among those with > 1 respiratory virus detected on 
NPA, 39 (22.3%) had viral co-detection.  Figure 5.8 illustrates the seasonal distribution of respiratory 
viruses other than influenza that have 10 or more positive samples over the study period, detected 
from nasopharyngeal specimen by rRT-PCR.  
A bacterial aetiology, including atypical organisms, was found in 203 (39%) hospitalised LRTI patients 
(Table 5.4). Legionella species (n=96, 18.6%) and Streptococcus pneumoniae (n=95, 18.3%) were the 
most frequently detected bacteria. S. pneumoniae was grown on blood culture in 4 patients (3 of 
whom also had a positive urinary antigen test), and was diagnosed by urinary antigen test alone in 
91 patients. S. pneumoniae demonstrated no obvious seasonal patterns (Figure 5.9), whereas 
detection of Legionella species peaked in December 2013, followed by sustained activity from June 
2014 to February 2015. Bacteraemia with Gram-negative organisms was also common (including 
Salmonella species (n=14; Salmonella typhi (n=8), non-typhoidal Salmonella (n=6)), Escherichia coli 
(n=2), Burkholderia cepacia (n=1), and Enterobacter cloacae (n=1)). Atypical pathogens were 
detected in a small proportion of patients (Bordetella pertussis (n=7), Chlamydia pneumoniae (n=2), 
Mycoplasma pneumoniae (n=7)).  
S. pneumoniae was identified from nasopharyngeal aspirate by RT-PCR in 284 (55.1%) patients, 
which likely represents colonisation. Of note, urinary antigen for S. pneumoniae was positive for 
73/233 (31.3%) of patients with a positive PCR on NPA, versus 21/189 (11.1%) who had a negative 
PCR. 
Among the 389 patients that submitted sputum, pulmonary tuberculosis was diagnosedvii in 93 
(23.9%) patients (by smear microscopy (n=43), liquid culture (n=59) or GeneXpert (n=58)). Malaria 
rapid diagnostic test was positive in 7 (1.4%) patients; 5 of which had an additional microbial agent 
detected (virus (n=3), bacteria (n=1), TB (n=1)). The overlap in aetiological diagnoses is illustrated in 
Figure 5.10. Mixed pathogen infections were common (n=113, 21.8%). Specific pathogen 
combinations are shown in Tables 5.5 to 5.8. 
                                                        
vii Patients could have been diagnosed with >1 method. 
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Table 5.4  Aetiology of adults with hospitalised LRTI at QECH (n=518) 
Investigation N (%) 
Aetiology undetermined 167 (32.2) 
NPA – respiratory viruses  (n=517) 
 > 1 respiratory virus 
   Influenza A & B 
   Adenovirus 
   Bocavirus 
   Coronavirus OC43 
                          NL63 
                          229E  
                          HKU1 
   Enterovirus 
   Human metapneumovirus 
   Influenza C 
   Parainfluenza virus 1 
   Parainfluenza virus 2 
   Parainfluenza virus 3 
   Parainfluenza virus 4 
   Rhinovirus 
   Respiratory syncytial virus 
   > 2 respiratory viruses 
 
177 (34.2) 
56 (10.8) 
40 (7.7) 
15 (2.9) 
10 (1.9) 
7 (1.4) 
22 (4.3) 
5 (1.0) 
5 (1.0) 
11 (2.2) 
6 (1.2) 
2 (0.4) 
7 (1.4) 
7 (1.4) 
3 (0.6) 
22 (4.3) 
9 (1.7) 
39 (7.5) 
NPA - atypical pathogens (n=517) 
   Bordetella pertussis 
   Chlamydia pneumoniae 
   Legionella species 
   Mycoplasma pneumoniae 
    Pneumocystis jirovecii 
 
6 (1.1) 
   2 (0.4) 
96 (18.6) 
7 (1.3) 
7 (1.3) 
NPA - Streptococcus pneumoniae colonization (n=517) 284 (55.1) 
 Blood culture 
   Streptococcus pneumoniae 
   Staphylococcus aureus 
   Escherichia coli 
   Salmonella species 
   Burkholderia cepacia 
   Enterobacter cloacae 
  Contaminants (e.g. Bacillus sp., Micrococcus sp., 
coagulase negative Staphylococcus) 
25/509 (4.9)b 
4 
2 
3 
14  
1 
1 
15 
 
Tuberculosis (diagnosed by smear microscopy 
/culture/Gene Xpert) 
93/389 (23.9) 
Urinary S. pneumoniae antigen - positive 94/421 (22.3) 
Malaria RDT - positive 7/488  (1.4) 
Outcome 
Duration of admissionb (days) – median (IQR) 
Required admission to HDUc  
Inpatient mortality 
 
6 (3-8) 
72/477 (15.1) 
52 (10.0) 
LRTI, lower respiratory tract infection; NPA, nasopharyngeal aspirate; RDT, rapid 
diagnostic test; IQR, interquartile range; HDU, high dependency unit 
aExcludes contaminants 
bDischarge date missing in 16 participants; cMissing in 41 participants  
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Figure 5.8  Monthly distribution of respiratory viruses other than influenza A and B (with n>10) 
detected by rRT-PCR, among patients with hospitalized LRTI, May 2013-February 2015  
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                2013                                                               2014                                                                                                 2015 
Figure 5.9  Monthly distribution of Legionella species detected by rRT-PCR (n=518) and 
Streptococcus pneumoniae, detected by urinary antigen test (n=421), among patients with 
hosptialised LRTI, May 2013-February 2015 
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Figure 5.10  Overlap of aetiological diagnoses among adults enrolled with hospitalised LRTI 
(N=518) 
One or more aetiological agents were detected in 351 patients.   
Patients with positive malaria rapid diagnostic test (n=7) not represented in this Venn diagram; 3 had co-
detection with virus, 1 with bacteria and 1 with TB. 
Respiratory viruses were identified by CDC influenza PCR and multiplex PCR for 33 respiratory pathogens 
(FastTrack Diagnostics).  
Bacterial aetiology were identified by positive blood culture or positive urinary antigen for Streptococcus 
pneumoniae (Alere BinaxNOW). Atypical pathogens were identified by multiplex PCR for 33 respiratory 
pathogens (FastTrack Diagnostics).  
Tuberculosis was diagnosed by smear microscopy, culture, or GeneXpert. 
Venn diagram was generated using eulerAPE version 3. 
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virus  
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Bacteria or 
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bacteria 
(n=68) 
Virus + TB 
(n=19) Virus + 
bact + 
TB (n=8) 
Tuberculosis 
(n=47) 
Aetiology 
undetermined 
(n=167) 
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Table 5.5  Specific bacteria & virus combinations in adults with hospitalised LRTI (N=68) 
Bacterial organism Virus(es) N 
E. cloacae Coronavirus 229E 1 
Salmonella species Coronavirus NL63 1 
S. pneumoniae (n=26) Adenovirus 
Coronavirus 43 
Coronavirus 229 
hMPV 
Influenza 
Influenza + adenovirus 
Influenza + hMPV 
Influenza + bocavirus + coronavirus 229 
Parainfluenza virus 1 
Parainfluenza virus 2 
Parainfluenza virus 2 + rhinovirus 
Parainfluenza virus 3 
Parainfluenza virus 4 
Rhinovirus 
RSV 
3 
1 
1 
3 
6 
1 
1 
1 
1 
1 
1 
2 
1 
2 
1 
S. aureus Influenza 2 
B. pertussis Enterovirus 
Rhinovirus 
1 
1 
Legionella species 
(n=22) 
Adenovirus 
Adenovirus + coronavirus OC43 
Adenovirus + hMPV 
Bocavirus 
Coronavirus OC43 
Coronavirus OC43 + rhinovirus 
Coronavirus OC43 + parainfluenza virus2 + RSV 
Enterovirus 
Enterovirus + rhinovirus 
Influenza 
Influenza + RSV 
Parainfluenza virus 1 
Parainfluenza virus 2 
Parainfluenza virus 3 
Parainfluenza virus 4 
4 
1 
1 
1 
1 
1 
1 
1 
1 
5 
1 
1 
1 
1 
1 
M. pneumoniae Parainfluenza virus 2 1 
Salmonella typhi Rhinovirus 
RSV 
1 
1 
S. pneumoniae + 
B. pertussis 
Rhinovirus 1 
S. pneumoniae + 
Legionella species 
Adenovirus 
Coronavirus OC43 
Coronavirus 229E 
Coronavirus HKU1 
Rhinovirus 
RSV 
1 
1 
1 
1 
1 
1 
Legionella species  + 
M. pneumoniae 
Bocavirus 1 
hMPV, human metapneumovirus; RSV, respiratory syncytial virus 
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Table 5.6  Specific TB and virus combinations in adults with hospitalised 
LRTI (N=19) 
Virus(es) N 
Adenovirus  
Adenovirus + coronavirus 229E 
Bocavirus + RSV 
Coronavirus OC43 
Coronavirus NL63 + rhinovirus 
Coronavirus 229E 
hMPV 
hMPV + parainfluenza virus 3 
Influenza 
Influenza + parainfluenza virus 3 + rhinovirus 
Rhinovirus 
6 
1 
1 
1 
1 
2 
1 
1 
3 
1 
1 
hMPV, human metapneumovirus; RSV, respiratory syncytial virus 
 
 
Table 5.7  Specific TB and bacteria combinations in adults with 
hospitalised LRTI (N=18) 
Bacterial organism N 
Legionella species 
M. pneumoniae 
S. pneumoniae 
Legionella species + S. pneumoniae 
8 
1 
6 
3 
 
 
 
Table 5 8  Specific TB, bacteria and virus combinations in adults with 
hospitalised LRTI (N=7) 
Bacterial organism Virus(es) N 
Burkholderia cepacia Coronavirus 229E 1 
Chlamydia pneumoniae Adenovirus 1 
Legionella species Parainfluenza virus 3 1 
Salmonella species Adenovirus + parainfluenza virus 2 
+ parainfluenza virus 4 
1 
S. pneumoniae Adenovirus 
Rhinovirus 
1 
1 
Legionella species + 
Mycoplasma 
pneumoniae 
Adenovirus 1 
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5.3.3.2  Outcome 
The median duration of hospital stay was 6 days (range 1-75 days). In terms of clinical outcomeviii: 72 
(13.9%) patients required admission to the high dependency unit, WHO-recommended anti-
tuberculous chemotherapy was started in 104 (20.1%) patients; and 18 (3.5%) were treated for 
Pneumocystis jirovecii (PCP) with intravenous co-trimoxazole during their admission. 52 (10%) 
patients died, 46 (88.5%) of whom were HIV-reactive. 
5.3.3  Clinical predictors of influenza among hospitalized LRTI patients  
Factors that may predict a diagnosis of influenza among patients admitted with hospitalised LRTI 
were explored (Table 5.9). Univariable analysis revealed that being female (risk ratio (RR) 1.66, 95%CI 
1.01-2.71, p=0.045), and symptom duration less than 7 days (RR 1.81, 95%CI 1.11-2.95) was 
associated with an influenza diagnosis. Conversely, those that had a laboratory-confirmed diagnosis 
of tuberculosis were less likely to have influenza. No particular symptoms or signs of clinical 
instability were associated with influenza. Additionally, influenza was not associated with inpatient 
mortality. On multivariable analysis, the strong negative association with tuberculosis persisted (RR 
0.33, 95%CI 0.12-0.89, p=0.01), as did a weak association with shorter symptom duration (<7 days vs. 
7-14 days, RR 1.62, 95%CI 0.99-2.65, p=0.06).  
 
                                                        
viiiNumber of patients with missing values: HDU status (n=41), inpatient TB treatment (n=18), inpatient PCP 
treatment (n=21), and inpatient mortality (n=12). 
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Table 5.9  Predictors of laboratory-confirmed influenza in adults with hospitalised LRTI, May 2013-February 2015 (N=518) 
Characteristic  N (%) Influenza PCR+  
(N=56) 
 Univariablea   Multivariablea,c 
 RR (95% CI) p-value  RR (95% CI) p-value 
Demographic  characteristics 
Gender  
  
 
Male 
Female 
 
28/323 (8.7) 
28/195  (14.4) 
  
1 
1.66 (1.01-2.71) 
 
 
0.045 
  
 
 
 
Age group (years) 
 
18-29 
30-39 
>40 
 17/138 (12.3) 
22/227 (9.7) 
17/153 (11.1) 
             1.11 (0.59-2.09) 
0.87 (0.48-1.59) 
1 
0.73 
 
 
  
 
 
 
 
Underlying medical conditions 
HIV status 
 
 
Negative 
Positive 
 
17/121 (14.1) 
39/396 (9.9) 
  
1 
0.70 (0.41-1.19) 
 
 
0.21 
  
 
 
 
Previous history of tuberculosis   No 
Yes 
46/424 (10.9) 
10/90 (11.1) 
 1 
1.02 (0.54-1.95) 
 
0.94 
   
Pneumonia past 5 years 
 
No  
Yes 
39/399 (9.5) 
17/11 (15.0) 
 1 
1.58 (0.92-2.69) 
 
0.11 
   
Malnutrition (BMI <18.5) No 
Yes 
41/348 (11.8) 
12/147 (8.1) 
 1 
0.69 (0.38-1.28) 
 
0.22 
   
Season 
   
 
Jan-Mar 
Apr-Jun 
Jul-Sep 
Oct-Dec 
16/99 (16.2) 
15/100 (15.0) 
12/161 (7.5) 
13/158 (8.2) 
 1.96 (0.99-3.91) 
1.82 (0.91-3.67) 
0.91 (0.43-1.92) 
1 
 
 
 
0.06 
  
 
 
 
 
 
Clinical presentationb 
Symptom duration (days) 
   
 
<7 
 7-14 
 
26/166 (15.7) 
30/346 (8.7) 
  
1.81 (1.11-2.95) 
1  
 
0.02 
  
1.62 (0.99-2.65) 
1 
 
 
0.06 
Symptoms 
Cough 
   
 
No 
Yes 
 
0/7 (0) 
56/506 (11.1) 
  
 
- 
 
 
- 
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Sputum 
   
No 
Yes 
7/107 (6.5) 
49/406 (12.1)  
 1 
1.84 (0.86-3.96)  
 
0.12 
   
Shortness of breath 
 
No 
Yes 
4/21 (19.1) 
52/482 (10.6)  
 1 
0.55 (0.22-1.39)  
 
0.21 
   
Chest pain 
   
No 
Yes 
1/11 (9.1) 
55/501 (11.0)  
 1 
1.21 (0.18-7.96)  
 
0.85 
   
Myalgia 
 
No 
Yes 
8/108 (7.4) 
48/405 (11.9)  
 1 
1.6 (0.78-3.28)  
 
0.20 
   
Headache 
 
No 
Yes 
28/280 (10.0) 
28/233 (12.0)  
 1 
1.20 (0.73-1.97)  
 
0.47 
   
Rhinorrhoea 
 
No 
Yes 
42/430 (9.8) 
14/83 (16.9)  
 1 
1.73 (0.99-3.02)  
 
0.07 
   
Sore throat No 
Yes 
38/391 (9.7) 
18/122 (14.8) 
 1 
1.52 (0.90.-2.56) 
 
0.12 
   
Co-infections 
> 1 other respiratory virus 
   
 
No 
Yes 
 
41/384 (10.7) 
15/134 (11.1) 
  
1 
1.05 (0.60-1.83) 
 
 
0.87 
   
Bacteria 
 
No 
Yes 
35/308 (11.4) 
21/210 (10.0)  
 1 
0.88 (0.53-1.47)  
 
0.62 
   
Tuberculosis  No 
Yes 
Don’t knowc 
  43/297 (14.5)  
4/92 (4.4) 
9/129 (7.0) 
 1 
0.30 (0.11-0.81) 
0.48 (0.24-0.96) 
 
 
0.004 
 1 
0.33 (0.12-0.89) 
0.51 (0.25-1.01) 
 
 
0.01 
S. pneumoniae carriage No 
Yes 
20/225 (8.9) 
36/379 (12.9) 
 1 
1.45 (0.87-2.44) 
 
0.15 
   
Outcome 
Died during inpatient stay  
 
No 
Yes 
 
53/454 (11.7) 
3/52 (5.8) 
  
1 
0.49 (0.16-1.53) 
 
 
0.22 
   
RR, risk ratio; CI, confidence interval; BMI, body mass index 
aLog binomial regression 
bNo associations were demonstrated between physiological parameters (Temperature <35 or >38c, systolic BP<90mmHg, diastolic BP<0mmHg, heart rate >120 or 
<40/minute, respiratory rate >30/min, oxygen saturation <90%, and disorientation) and influenza positivity. 
c No sputum submitted.; dAdjusted for symptom duration at presentation and current tuberculosis. 
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5.3.4 Risk factors for severe influenza presentation 
A total of 56 cases and 88 controls were enrolled (Section 5.3.2). The demographic characteristics of 
cases and controls are shown in Table 5.10. Influenza A virus was identified in 30 (53.6%) cases and 
35 (39.8%) controls; all were subtype A(H3N2) except one control (unsubtyped). Of note, both 
influenza A(H3) and B were identified in two controls. No difference was observed in age and sex. 
Thirty-nine (69.6%) cases and 26 (29.6%) controls were HIV-reactive (p<0.001). HIV-infected cases 
had more advanced immunosuppression (median CD4+ count 140 vs. 265 cells/µl, p=0.03) and were 
more likely to be on ART treatment at enrolment (35.7 vs. 9.1%, p<0.001) compared to HIV-infected 
controls. Cases were more likely to be underweight and a higher proportion of cases reported 
previous tuberculosis and pneumonia within the past 5 years.  
Cases and controls did not differ in terms of household exposure to children <5 years or crowding. 
However, cases were more likely to be exposed to children who had received pneumococcal 
conjugate vaccine. Controls had better sanitation, level of education, and food security.  
In the univariable analysis (Table 5.11), HIV infection, reported history of tuberculosis, pneumonia 
within past 5 years, being underweight, month of recruitment, type and distance from water supply, 
sanitation facility, lower education level, and food insecurity were all associated with being a case. 
Two multivariable models were constructed; model A included influenza regardless of type/subtype, 
whereas model B incorporated the type of influenza as a covariate. Month of recruitment was 
deemed an a priori confounder, due to the seasonal discrepancy in the recruitment of hospitalised 
LRTI and ILI patients (Figure 5.5). In multivariable model A, HIV infection was strongly associated 
with severe influenza presentation (adjusted odds ratio (aOR) 4.98, 95%CI 2.09-11.88, p<0.001). 
Additionally, those that reported pneumonia within the past 5 years (aOR 6.49, 95%CI 2.00-21.07, 
p<0.001), those with poor sanitation facility, i.e. having no toilet or a non-ventilated improved pit 
(VIP) latrine toilet (aOR 3.14, 95%CI 1.25-7.84, p=0.01), and frequent difficulty accessing food (aOR 
20.85, 95%CI 1.97-221.16, p=0.01) were also at increased risk of severe influenza.  
Significant risk factors remained the same in multivariable model B as Model A (Table 5.11). 
However, in this model, cases were over 5 times more likely to have influenza type A compared to B 
(aOR 5.33, 95%CI 1.88-15.10, p<0.001).  
Possible interaction between HIV infection and food security was explored. The effect of HIV on the 
risk of severe influenza was similar in those who report no food insecurity (OR 6.03, 95%CI 2.23-
16.32), and those who report food insecurity “sometimes, often or always” (OR 4.93, 95%CI 1.62-
14.99). No effect modification was demonstrated (p=0.58).  
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Table 5.10  Description of influenza-positive cases and controls 
Characteristic  Cases Controls p-valuea 
 n=56 n=88  
Influenza type 
     Influenza A PCR positive 
     Influenza B PCR positive 
 
30 (53.6) 
26 (46.4) 
 
35 (38.9) 
55 (61.1) 
 
 
Month of recruitment 
     Jan-Mar 
     Apr-Jun 
     Jul-Sep 
     Oct-Dec 
 
16 (28.6) 
15 (26.8) 
12 (21.4) 
13 (23.2) 
 
49 (55.7) 
18 (20.5) 
9 (10.2) 
12 (13.6) 
 
 
 
 
0.01 
Gender  
   Male 
 
28 (50.0) 
 
43 (48.9) 
 
0.89 
Age, years (median, IQR) 
Age group, years 
  18-29 
  30-39 
   > 40 
35.9 (28.1-43.4) 
 
17 (30.4) 
22 (39.3) 
17 (30.4) 
31.9 (26.4-42.2) 
 
36 (40.9) 
25 (28.4) 
27 (30.7) 
0.13 
 
 
 
0.32 
HIV status 
  HIV-reactive 
 
39 (69.6) 
 
26 (29.6) 
 
<0.001 
  CD4+ count (cells/µl) -median, IQR 
  On ART at enrolment 
140 (87-268) 
20/39 (51.3) 
265 (161-341) 
8/26 (30.8) 
0.03 
0.10 
Medical history 
  Previous history of tuberculosis  
  Pneumonia in past 5 years 
  Pregnant 
  BMI <18.5 (kg/m2) 
  Smoking (current) 
  Alcohol 
 
10 (17.9) 
17 (30.9) 
0/28 (0) 
12 (22.6) 
5 (8.9) 
8 (14.3) 
 
5 (5.7) 
7 (8.0) 
1/45 (2.2) 
9 (10.2) 
7 (8.0) 
8 (9.1) 
 
0.01 
<0.001 
1.00 
0.05 
0.59 
0.33 
Household and socioeconomic factors 
Children <5 years in household 
    0 
    1 
    >2 
Crowding indexb 
    <1.5 
    1.5-2.4 
    >2.5 
Water supply 
     River/borehole/well 
     Public tap/standpipe 
     Piped to dwelling/plot 
Distance to water supply  
     <200 metres 
     >200 metres 
Sanitation facility 
     None/non-VIP toilet 
     VIP/flush toilet 
Principal cooking fuel 
     Firewood 
 
 
31 (55.4) 
19 (33.9) 
6 (10.7) 
 
16 (36.4) 
20 (45.5) 
8 (18.2) 
 
15 (26.8) 
32 (57.1) 
9 (16.1) 
 
15 (26.8) 
41 (73.2) 
 
34 (60.7) 
22 (39.3) 
 
14 (25.0) 
 
 
55 (62.5) 
22 (25.0) 
11 (12.5) 
 
18 (26.5) 
31 (45.6) 
19 (27.9) 
 
19 (21.6) 
40 (45.5) 
29 (33.0) 
 
37 (42.0) 
41 (58.0) 
 
37 (42.1) 
51 (57.9) 
 
14 (15.9) 
 
 
 
 
0.51 
 
 
 
0.83 
 
 
 
0.08 
 
 
0.06 
 
 
0.03 
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     Charcoal 
     Other 
35 (66.1) 
5 (8.9) 
55 (62.5) 
19 (21.6) 
 
0.62 
Highest level of education 
   Never attended school 
    Primary 
    Secondary/Tertiary 
 
5 (9.1) 
34 (61.8) 
16 (29.1)  
 
15 (17.1) 
28 (31.8) 
45 (51.1) 
 
 
 
0.002 
Employment  
    Unemployed 
 
5 (8.9) 
 
10 (11.4) 
 
0.64 
Asset ownershipc 
    0-1    
    2-3 
    4-5 
 
22 (39.3) 
29 (51.8) 
5 (8.9) 
 
29 (33.0) 
47 (53.4) 
12 (13.6) 
 
 
 
0.59 
Difficulty accessing food 
    Never 
    Sometimes    
    Often/always 
 
28 (50.0) 
21 (37.5) 
7 (12.5)  
 
58 (65.9) 
29 (33.0) 
1 (1.1)  
 
 
 
0.008 
IQR, interquartile range; BMI, body mass index, PCV, pneumococcal conjugate vaccine; VIP, ventilated 
improved pit latrine 
aChi-square or Fisher’s exact test 
bTotal number of household members divided by number of rooms in house (excluding kitchen and 
bathroom)  
 cNumber of the following assets owned in household: working refrigerator, radio, mobile phone, bed 
and car/motorbike. 
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Table 5.11  Risk factors for severe influenza presentation in influenza PCR positive cases and controls, May 2013-February 2015 
Characteristic Casesa Controlsb Univariablec   Multivariable A c,d  Multivariable Bc,e 
 n=56  n=88 OR (95% CI) p-
value 
 OR (95% CI) p-
value 
 OR (95% CI) p-
value 
Gender  
   Male 
 
28 (50.0) 
 
43 (48.9) 
 
0.96 (0.49=1.88) 
 
0.89 
  
 
 
 
  
 
 
 
Age group (years) 
  18-29 
  30-39 
  >40 
 
17 (30.4) 
22 (39.3) 
17 (30.4) 
 
36 (40.9) 
25 (28.4) 
27 (30.7) 
 
0.75 (0.32-1.73) 
1.40 (0.61- 3.22) 
1 
 
 
 
0.32 
  
 
 
 
  
 
 
 
 
Month of recruitment 
  Jan-Mar 
  Apr-Jun 
  Jul-Sep 
  Oct-Dec 
 
16 (28.6) 
15 (26.8) 
12 (21.4) 
13 (23.2) 
 
49 (55.7) 
18 (20.5) 
9 (10.2) 
12 (13.6) 
 
1 
2.55 (1.05-5.20) 
4.08 (1.45-11.46) 
3.32 (1.25-8.72) 
 
 
 
 
0.01 
  
1 
3.36 (1.13-9.95) 
6.34 (1.69-23.80) 
3.60 (1.07-12.10) 
 
 
 
 
0.01 
  
1 
5.15 (1.58-16.81) 
11.69 (2.54-53.8) 
2.89 (0.82-10.12) 
 
 
 
 
0.003 
HIV status 
  HIV-reactive 
 
39 (69.6) 
 
26 (29.6) 
 
5.47 (2.63-11.36) 
 
<0.001 
  
4.98 (2.09-11.88) 
 
<0.001 
  
6.72 (2.56-17.66) 
 
<0.001 
Previous history of 
tuberculosis  
10 (17.9) 5 (5.7) 3.61 (1.16-11.20) 0.03       
Pneumonia past 5 years 17 (30.9) 7 (8.0) 5.18 (1.98-13.53) 0.001  6.49 (2.00-21.07) 0.001  6.43 (1.95-21.25) 0.001 
Malnutrition (BMI <18.5) 12 (22.6) 9 (10.2) 2.57 (1.00-6.60) 0.05       
Water supply 
   River/borehole/well 
   Public tap/standpipe 
   Piped to dwelling/plot 
 
15 (26.8) 
32 (57.1) 
9 (16.1)  
 
19 (21.6) 
40 (45.5) 
29 (33.0)  
 
2.54 (0.93-6.98) 
2.58 (1.07-6.22) 
1 
 
0.07 
      
Distance from water 
supply 
   <200 metres 
   >200 metres 
 
 
15 (26.8) 
41 (73.1) 
 
 
37 (42.1) 
51 (57.9) 
 
 
1 
1.98 (0.96-4.10) 
 
 
 
0.07 
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Sanitation facility 
  None/non-VIP toilet  
  VIP/ flush toilet 
 
34 (60.7) 
22 (39.3) 
 
37 (42.1) 
51 (57.9) 
 
2.13 (1.08-4.22) 
1 
 
0.03 
  
3.14 (1.25-7.84) 
1 
 
0.01 
  
3.64 (1.38-9.55) 
1 
 
0.006 
Highest level of education 
  None 
  Primary 
  Secondary & above 
 
5 (9.1) 
34 (61.8) 
16 (29.1) 
 
15 (17.1) 
28 (31.8) 
45 (51.1) 
 
1 
 3.64 (1.18-11.27) 
1.07 (0.33-3.41) 
 
 
 
0.002 
     
 
 
 
 
 
 
Difficulties obtaining food 
   Never 
   Sometimes 
   Often/always 
 
28 (50.0) 
21 (37.5) 
7 (12.5) 
 
58 (65.9) 
29 (33.0) 
1 (1.1) 
 
1 
1.50 (0.73-3.08) 
14.4 (1.70-123.65) 
 
 
 
0.007 
  
1 
1.15 (0.47-2.84) 
20.85 (1.97-221.16) 
 
 
 
0.01 
  
1 
1.26 (0.48-3.26) 
48.43 (3.72-631.34) 
 
 
 
0.002 
Influenza type 
   Influenza A virus 
   Influenza B virus 
 
30 (53.6) 
26 (46.4) 
 
33 (38.4) 
53 (61.6) 
 
1.85 (0.94-3.66) 
1 
 
0.08 
     
5.33 (1.88-15.10) 
1 
 
<0.001 
Hosmer-Lemeshow test       0.30   0.92 
OR, odds ratio; CI, confidence interval; BMI, body mass index; pneumococcal conjugate vaccine; VIP, ventilated improved pit latrine 
aInfluenza-PCR positive hospitalised LRTI 
bInfluenza-PCR positive ILI 
cUnconditional logistic regression 
dAdjusted for HIV status, history of pneumonia within 5 years, month of recruitment,   sanitation facility, and food security 
eAdjusted for HIV status, history of pneumonia within 5 years,  month of recruitment,  sanitation facility, food security, and influenza type 
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5.3.4.1  Effect of CD4+ and HIV treatment status 
To explore the roles of CD4+ T-lymphocyte cell count and ART treatment status, a sub-analysis 
restricting to HIV-infected cases and controls was performed (Table 5.12). There was a suggestion 
that patients with a CD4+ cell count <200 cells/µl had increased severity of influenza, compared to 
those with CD4+ >200 cells/µl (OR 2.72, 95%CI 0.97-7.60, p=0.06), but the association was not 
statistically significant. No association was found between ART treatment status and influenza 
severity. Stratified analysis by duration of ART treatment was not possible due to the small numbers 
included.  
 
 
5.3.4.2  Population attributable fraction 
The adjusted PAFs (aPAF) (Table 5.13) were computed using multivariable model A (Table 5.11). In 
our study population, the highest proportion of cases of hospitalized influenza can be attributed to 
HIV infection (aPAF 56.7%, 95%CI 42.3-67.4) and poor sanitation (aPAF 40.9%, 95%CI 20.5-56.0). In 
contrast, despite the observed strong effect, frequent difficulty accessing food only accounted for 
12% (95%CI 10.6-13.6) of cases, due to the low prevalence in our population.  
  
Table 5.12  The effect of CD4+ cell count and HIV treatment status on the risk of severe 
influenza presentation, restricted to HIV-infected cases and controls (N=65) 
Characteristic Casesa Controlsb Univariablec  
 n=39 n=26 OR (95% CI) p-value 
CD4+ cell count (cells/µl) 
  >200  
  <200 
 
16 (41.0) 
23 (59.0) 
 
17 (58.9) 
9 (34.6) 
 
1 
2.72 (0.97-7.60) 
 
 
0.06 
Antiretroviral therapy  
  No 
  Yes  
 
20 (51.3) 
19 (48.7)  
 
18 (69.3) 
8 (30.8) 
 
1 
2.14 (0.75-6.07) 
 
 
0.15 
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5.4  Discussion  
Lower respiratory tract infections are the leading cause of adult hospital admission in sub-Saharan 
Africa (SSA) (Scott et al., 2012). Bacteria such as Streptococcus pneumoniae and Mycobacterium 
tuberculosis (Mtb) are key causative organisms in the region (Scott et al., 2000; Nyamande et al., 
2007). However, the contribution of respiratory viruses, such as influenza, have not been well 
characterised (Ho, 2014). This prospective case control study confirms influenza as an important 
contributor to hospitalised lower respiratory tract infection in Malawian adults. Importantly, in the 
context of a high HIV prevalence setting, HIV-infected adults were five times as likely to have severe 
influenza than HIV-uninfected adults. Patients with advanced immunosuppression (CD4+ <200 
cells/l) are at particular risk. In fact, over 50% of hospitalised influenza cases were attributable to 
HIV infection. We also found that those who reported a history of pneumonia within five years, poor 
sanitation, frequent difficulty accessing food and who had infection with influenza A virus were at 
increased risk of severe influenza disease.  
Whilst studies in low HIV prevalence settings have produced conflicting data regarding HIV as a risk 
factor for severe influenza disease, our findings corroborate with the handful of studies from SSA 
that have demonstrated increased severity of influenza presentation in HIV-infected persons 
(Chapter 1.4.3.3). A retrospective case control study in rural Kenya found a 3.5 times increased risk 
of influenza-associated hospitalisation in HIV-infected persons aged >5 years than HIV-uninfected 
individuals (Ope et al., 2011). The study district had a similar HIV prevalence to Blantyre, but the 
proportion of cases and controls that were HIV-infected were comparatively lower than ours (24.5 
vs. 12.5%, respectively). This is likely due to their inclusion of older children (aged 5-17 years), which 
Table 5.13  Population attributable fraction of modifiable risk factors for severe influenza 
Characteristic % exposed 
among 
cases 
      Adjusted  Adjusted PAF  
(95%CI) OR (95% CI) p-value 
Being HIV-infected 69.6 4.98 (2.09-11.88) <0.001 56.7% (42.3-67.4) 
Sanitation facility 
  None/non-VIP toilet  
  VIP/ flush toilet 
 
60.7 
39.3 
 
3.14 (1.25-7.84) 
1 
 
0.01 
 
40.9% (20.5-56.0) 
- 
Difficulties obtaining food 
   Never 
   Sometimes 
   Often/always 
 
50.0 
37.5 
12.5 
 
1 
1.15 (0.47-2.84) 
20.85 (1.97-221.16) 
 
 
 
0.01 
 
- 
       6% (-40.9-38.0) 
12.0% (10.3-13.7) 
OR, odds ratio; CI, confidence interval; PAF, population attributable fraction 
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comprised two-thirds of their study population, as well as their use of health individuals, rather than 
patients with ILI, as controls. When restricted to those aged >18 years (22/64 cases and 64/190 
controls), the HIV prevalence among their cases and controls were more comparable to our study 
population (59 vs. 24%, corresponding to a crude odds ratio of 4.53). The study may have been 
particularly prone to recall bias, since cases were interviewed weeks to months after the illness 
event (Ope et al., 2011).  
Cohen et al. (Cohen et al., 2013) also reported a 4 to 8-fold greater incidence of influenza-related 
hospitalisation among HIV-infected individuals enrolled in sentinel surveillance in South Africa. HIV-
infected individuals also had more prolonged hospitalisation and higher mortality. However, no 
difference in case fatality ratio (CFR) was demonstrated between those with CD4 cell count <200 or 
>200 cells/l (Cohen et al., 2013). Both these previous studies were limited by substantial missing 
data with regards to HIV status, degree of immunosuppression and ART treatment status. Hence this 
case control study, conducted exclusively in adults, with well-defined cases and controls, near 
complete ascertainment of HIV status, CD4 cell count and ART use, and estimates of PAF, provides 
the most robust data to date that HIV is a key risk factor for severe influenza presentation in a high 
HIV prevalence setting. Moreover, patients with CD4 count <200 cells/l had an almost 3-fold 
greater risk of severe presentation compared to those with CD4+ >200 cells/l, which has not been 
previously described.  
We did not find any association between ART treatment status and influenza severity, even though 
most of the HIV-infected patients reportedly on ART had been taking it for over 12 months. In 
industrialised settings, the introduction of ART coincided with a dramatic decline in influenza-
attributable hospitalisations (Neuzil et al., 2003), and was associated with improved survival 
following pandemic influenza A(H1N1) infection (Ormsby et al., 2011). However, similar to our 
finding, this beneficial effect has not been reported in high HIV prevalence settings. Cohen et al. 
(Cohen et al., 2015c) observed no difference in CFR among HIV-infected individuals with influenza-
positive SARI who were or were not receiving ART. Jambo et al. (Jambo et al., 2012) also found poor 
reconstitution of influenza-specific CD4+ T-cell response in HIV-infected Malawian adults with Stage 
III/IV disease following 12 months of ART, despite a marked reduction in viral load and rise in CD4+ 
count (Jambo et al., 2012). These results suggest that ART may not protect HIV-infected participants 
from influenza-related complications. Alternatively, several years of ART may be required before 
sufficient pathogen-specific immune reconstitution is achieved. Thus the impact of ART on the 
relationship between HIV and influenza severity requires further evaluation, particularly in light of 
the recent revision of CD4+ threshold for initiating ART from 350 to 500 cells/l in 2013 (World 
Health Organization, 2013a). 
Severe and Mild Influenza-related Respiratory Presentations in Malawian Adults: a Case Control Study 
 171 
CD4+ T-cells are an essential component of the defence against influenza infection (Thomas et al., 
2006), thus cell-mediated immune defects in the lungs in HIV-infected individuals may be a potential 
mechanism for increased severity of influenza virus. Jambo et al. (Jambo et al., 2011) found impaired 
pulmonary antigen-specific CD4+ T-cell response to influenza in asymptomatic HIV-infected 
Malawian adults. The authors also demonstrated a loss of influenza-specific proliferative CD4+ T-cell 
responses in patients with early, as well as advanced HIV disease (Jambo et al., 2012), implying that 
the loss of influenza-specific immunity occurs early in HIV infection prior to total CD4 T-cell 
depletion, rendering HIV-infected individuals vulnerable to influenza infection, but also to secondary 
bacterial infection such as pneumococcal pneumonia, particularly in an area of intense 
pneumococcal exposure such as Malawi (Everett et al., 2011).  
Bacterial co-infections could have contributed to the severity of influenza presentation in the HIV-
infected group. Epidemiological evidence and murine models suggest that influenza predisposes to 
invasive bacterial infections, particularly Streptococcus pneumoniae (McCullers and Rehg, 2002; 
McCullers, 2006; McNamee and Harmsen, 2006; Brundage, 2006). Among individuals with 
hospitalised LRTI in South Africa, both influenza and HIV infection were associated with increased 
blood pneumococcal load (Wolter et al., 2014a), as well as invasive pneumococcal pneumonia 
(Wolter et al., 2014b). Cohen et al. (Cohen et al., 2013) observed an increased risk of pneumococcal 
co-infection among HIV-infected individuals with influenza-associated LRTI. Although none of our 
influenza cases had documented pneumococcal bacteraemia, 11/46 (24%) had a positive 
pneumococcal urinary antigen test.  
Aside from HIV infection, several other risk factors for severe influenza were identified (Figure 5.11). 
Firstly, patients who reported a pneumonia episode within the past 5 years had a greater risk of 
severe influenza. We believe previous history of severe respiratory infection partly mediates the 
effect of HIV on influenza severity (red arrow in Figure 5.9), since HIV is associated with increased 
risk of bacterial pneumonia (Sogaard et al., 2008). However, a past episode of severe respiratory 
infection could also act as a proxy for chronic lung disease, thus in itself an independent risk factor 
for severe influenza. Chronic lung disease is a known risk factor of severe outcomes due to influenza 
infection (Ope et al., 2011; Pebody et al., 2010; Van Kerkhove et al., 2011b), and has been identified 
as a priority group for vaccination in industrialised countries (England, 2013; Grohskopf et al., 2014). 
Previous pulmonary TB was associated with influenza severity in the univariable, but not the 
multivariable analysis. This was thought be to due to confounding by its association with HIV 
infection. Of note, we were unable to assess whether current TB infection was associated with 
influenza severity, as ILI patients were not investigated for TB. However, this was unlikely, as 
TB/influenza co-infection was only identified in 4 of 518 hospitalised LRTI patients (Table 5.9).  
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Cases were also found to be associated with poor (or unimproved (World Health Organization and 
UNICEF, 2015)) sanitation and food insecurity. The link between poor sanitation and infection is well 
known (Mara et al., 2010). Although the effect estimate for poor sanitation was lower than that for 
the other risk factors (aOR 3.14), it emerged as the second most important risk factor for severe 
influenza in our analysis (PAF 40.9%), due to the high prevalence of cases with unimproved 
sanitation (61%). Food insecurity can lead to low weight; an association between malnutrition and 
increased severity of infections has been described in children (Jones and Berkley, 2014), though not 
in adults. In our study, those that reported frequent difficulty accessing food, but not those with low 
BMI, were at significantly greater risk of severe influenza presentation. Although the two variables 
are closely related, low weight is not only due to inadequate dietary intake, but also malabsorption 
and an increased metabolic rate in HIV-infected adults (Hommes et al., 1991; Melchior et al., 1991). 
Food insecurity remains strongly associated with severe influenza following adjustment for HIV 
status, suggesting it is an independent risk factor, and may be associated with underlying 
unmeasured socioeconomic factors. In contrast to the cohort study, we did not demonstrate any 
interaction between HIV and food security on the effect of influenza severity. However, as few 
patients reported ‘often’ or ‘always’ having difficulties obtaining food, interaction was evaluated 
 
 
Figure 5.11  Factors associated with severe influenza presentation 
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with food security as a binary variable. This would have limited our ability to assess for effect 
modification on the more severe end of the food insecurity spectrum.  
Influenza A (all subtype H3N2) was associated with increased disease severity compared to influenza 
B. This may be partly due to the discrepant recruitment of hospitalised LRTI and ILI cases; influenza 
A(H3N2) was prevalent in the months where more hospitalised LRTI cases were recruited (see 
Figures 5.6 and 5.7). We attempted to minimise selection bias by controlling for month of 
recruitment. Influenza B virus is commonly perceived to cause milder infection than influenza A, 
though available literature have inconsistent findings. A large US viral surveillance study from 1976 
to 1999 found that the highest influenza-related mortality rates occurred during A(H3N2)-
predominant seasons (Thompson et al., 2003). Esposito et al. (Esposito et al., 2011) also reported 
more LRTI presentations, as well as higher rate and duration of hospitalisation in Italian children 
aged <15 years with A(H3N2) compared to A(H1N1) and B infections between 2007 and 2009. During 
the pandemic period, A(H1N1) was found to cause more severe disease than A(H3N2) and B in a 
population-based influenza hospitalization surveillance study in the US (Chaves et al., 2013). A multi-
centre study from Korea reported increased rate of hospitalisation and duration of hospital stay in 
patients infected with influenza A(H3N2) compared to B in the post-pandemic period, but this was 
confounded by the higher proportion of elderly and patients in co-morbidities among those with 
A(H3N2) infection (Wie et al., 2013). Conversely, several studies found similar clinical characteristics 
and outcome among outpatients (Irving et al., 2012) and hospitalised patients (Su et al., 2014; 
Gutierrez-Pizarraya et al., 2012) with confirmed influenza A and B infections, though two of the 
three studies did not distinguish between A subtypes (Irving et al., 2012; Su et al., 2014). It is likely 
that the comparative severity of influenza A and B viruses in any given season will depend on the 
virulence of the circulating strain, as well as the degree of antigenic drift from the previous season, 
which in turn will affect the impact of population immunity. 
One or more aetiological agents were identified in two-thirds of patients with hospitalised LRTI. 
Influenza was detected in 11% of adults enrolled with hospitalised LRTI at QECH, which is 
comparable to the proportions reported in pneumonia studies from developed settings (mean 
influenza positivity 7.5%, range 3.0-18.7%) (Angeles Marcos et al., 2006; Charles et al., 2008; 
Johnstone et al., 2008; Saito et al., 2012; Jennings et al., 2008; Diederen et al., 2009; Johansson et 
al., 2010; Templeton et al., 2005; Hohenthal et al., 2008; Lieberman et al., 2010; Lim et al., 2001; 
Lauderdale et al., 2005; Almirall et al., 2007; Ruiz et al., 1999). Other respiratory viruses were also 
prevalent. Overall, around one third of patients were positive for at least 1 respiratory virus 
(including influenza) and viral co-infection was found in 7.5% cases. The isolation of Legionella 
species in almost 20% of LRTI is surprising. The incidence of Legionella reported from several 
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pneumonia cohorts from South Africa has ranged from 1.7 to 8.7% (Potgieter and Hammond, 1992; 
Maartens et al., 1994; Mpe et al., 2001; Nyamande et al., 2007). Odera and Anzara (Odera and 
Anzala, 2009) found Legionella pneumophila in 9% of adult pneumonia patients in Nairobi, though a 
large proportion was associated with air conditioner exposure. Other pneumonia series in SSA have 
not identified any Legionella infection (Feldman et al., 1989; Scott et al., 2000; Hartung et al., 2011). 
In these studies, the presence of Legionella was evaluated using direct fluorescent antibody or 
urinary antigen. Although PCR on a throat swab has been shown to correlate with serology and 
urinary antigen results (Ramirez et al., 1996), the significance of identifying Legionella from the 
nasopharynx is unclear. It may represent the causative organism, but may also reflect asymptomatic 
carriage or environmental contamination. We plan to evaluate this further by performing urinary 
Legionella antigen test on stored specimens. 
In contrast, the proportion of patients with proven pneumococcal pneumonia in our study (18%) 
was lower than that reported in other SSA pneumonia cohorts (25-46% (Koulla-Shiro et al., 1996; 
Scott et al., 2000; Yoshimine et al., 2001; Charalambous et al., 2003; Nyamande et al., 2007; Albrich 
et al., 2012)), most of whom had similarly high prevalence of HIV infection. This may be partly due to 
the fact that around 20% patients were unable to provide a urine specimen for the BinaxNOW 
antigen test. Additionally, only four patients had S. pneumoniae bacteraemia. The low blood culture 
yield may be attributable to the high prevalence of pre-hospital antibiotic utilisation (61%). This has 
prompted a 4th year medical student project to evaluate pre-hospital antibiotic utilisation in Blantyre 
(analysis pending). Lastly, M. tuberculosis was identified in a quarter of patients that submitted 
sputum. This reflects the high incidence of TB in Malawi (Bank, 2015), and is in keeping with studies 
from other high TB prevalence settings that have confirmed Mtb as a key contributor to acute 
community-acquired pneumonia (Scott et al., 2000; Nyamande et al., 2007). Thus patients with 
respiratory symptoms should be screened for TB regardless of symptom duration. 
The clinical manifestation of influenza-associated LRTI was indistinguishable from other causes of 
LRTI, rendering the rationalisation of antimicrobial therapy by clinical assessment difficult. Influenza-
positive patients did have shorter symptom duration (<7 days), and were less likely to have TB co-
infection. There have been concerns that influenza virus infection may play a role in the 
development of active TB disease either directly after exposure to Mtb or through reactivation of 
latent Mtb infection, particularly in TB-endemic countries (de Paus et al., 2013). However, consistent 
with our findings, most of the studies that have evaluated both influenza and tuberculosis have not 
found an association (Bradshaw et al., 2008; de Paus et al., 2013; Oei and Nishiura, 2012; Roth et al., 
2013). The exception is Walaza et al. (Walaza et al., 2015), who reported an increased mortality 
among patients with influenza and TB co-infection in South Africa, compared to those with TB 
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infection alone. However, this only applied in patients with symptoms >7 days, and their sample size 
was small. 
This study has a number of limitations. Firstly, recall bias could not be entirely discounted but was 
unlikely, since both cases and controls were ill at enrolment. Secondly, the main exposure of interest 
(HIV status) was objectively measured, and differential recall of other risk factors of interest (e.g. 
household exposure to young children, household and socioeconomic characteristics) between cases 
and controls was also unlikely.  
Few eligible participants refused enrolment (2.8% hospitalized LRTI and 1.8% ILI patients), thus 
unlikely to have resulted in selection bias. However, Berkson’s bias (Berkson, 1946) could have 
occurred if HIV-infected participants had an increased propensity to present to hospital with severe 
respiratory symptoms than HIV-negative individuals, and secondly, if the study clinician was more 
likely to admit an individual with acute respiratory illness that was HIV-infected. We tried to 
minimise the latter firstly by rigorous training of study staff to follow standard operating procedures 
and manage patients according to standardised hospital protocols (Sloan and Zijlstra, 2012). 
Secondly, the eligibility criteria for hospitalized LRTI were strict. Furthermore, the HIV status was 
unknown to the study clinician at the time of assessment for the majority of patients (300 (58%) 
hospitalized LRTI; 549 (86%) ILI).  
RT-PCR tests for influenza are very sensitive and specific (Mahony, 2010). However, as the average 
duration of influenza virus shedding is 5 days (Carrat et al., 2008), LRTI patients who presented with 
longer symptom duration may have ceased shedding virus at the time of enrolment, thus 
erroneously categorised as influenza negative. If this misclassification occurred equally in HIV-
infected and HIV-uninfected patients, the effect of HIV on severity would have been 
underestimated. However, if the likelihood of influenza detection given infection differed according 
to HIV status, for example, if influenza virus shedding occurred for longer duration in HIV-infected 
persons, this differential misclassification could have biased the effect estimate away from null. At 
present, the impact of HIV infection on the duration and magnitude of influenza virus shedding is 
unclear, but is under evaluation in ongoing studies in South Africa (Hellferscee et al., 2013) and 
Malawi (Chapter 1.4.4). 
Although HIV was the primary exposure of interest, we assessed a number of additional risk factors 
for severe influenza. When evaluating multiple variables, it is possible that a significant association 
was discovered by chance, when a true association does not exist. We tried to mitigate this in two 
ways: firstly, all variables included in the analysis were carefully considered after consulting existing 
literature, as possible confounders of the association between HIV and influenza severity, or 
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potential risk factors for severe influenza. Secondly, since there were only 56 cases, we included a 
maximum of five variables in the multivariable analysis to avoid biased estimates and over-
adjustment (Peduzzi et al., 1996). On the other hand, by limiting the number of variables we 
included in our model, residual confounding was possible. Moreover, the small number of cases and 
controls certain continuous variables, such as age group, required broad categorisation. This may 
have limited the ability to adequately adjust for age, therefore a small, linear association between 
age and influenza severity could have been missed.  
Lastly, due to time constraints, recruitment was discontinued after 22 months in February 2015, and 
therefore did not take place over 2 full calendar years. Taking into account the seasonal patterns in 
influenza activity in Blantyre, this likely resulted in an underestimation of the contribution of 
influenza to both ILI and hospitalised LRTI, as March and April months typically have high influenza 
activity.   
This study confirms a prominent aetiological role for influenza in mild and severe acute respiratory 
illness in Malawian adults. Since pneumonia is the commonest cause of adult medical admissions at 
QECH (SanJoaquin et al., 2013), constituting 1 in 6 primary diagnosis, effective preventative 
strategies against influenza could substantially reduce the burden of ARI in Malawi and other similar 
settings with overstretched health systems. Moreover, HIV infection increases the risk of severe 
influenza presentation; greater than 50% severe influenza cases is attributable to HIV infection. This 
finding is especially important in SSA, a region with 25 million people living with HIV (UNAIDS, 2013).  
Several interventions may reduce influenza burden in HIV-infected persons. Firstly, ART has been 
shown to reduce influenza-related hospitalisations in the US (Neuzil et al., 2003), as well as 
influenza-related deaths in South Africa (Cohen et al., 2012b). Although we have not demonstrated 
an impact in our study, continued expansion of HIV testing and ART scale-up means an increasing 
number of HIV-infected individuals will have access to ART (Malawi Ministry of Health, 2014). 
Whether ART will have an impact on influenza hospitalisation in the long term needs assessment. 
Secondly, inactivated influenza vaccines (IIV) has been shown to be safe and effective in HIV-infected 
persons without severe immunosuppression, though no significant effects on other clinical 
outcomes, such as all-cause pneumonia, hospitalisation and mortality, have been observed 
(Remschmidt et al., 2014). The only randomized controlled trial that have evaluated efficacy of IIV in 
HIV-infected persons in SSA demonstrated a 76% reduction in laboratory-confirmed influenza, but 
the study excluded patients with co-morbidities and ART-naïve patients with a CD4 cell count <100 
cells/l (Madhi et al., 2011). However, IIV is not currently available in the public sector in Malawi, 
and most SSA countries (Palache et al., 2014; Duque et al., 2014).  
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The identification of poor sanitation and food insecurity as risk factors of severe influenza in adults 
highlight the importance of ongoing public health interventions to combat these poverty-related 
issues; both are targets of Millennium Development Goals (MDGs): Goal 1C – to halve the 
proportion of people who suffer from hunger, and Goal 7C – to halve the proportion of people 
without sustainable access to safe drinking water and basic sanitation, by 2015 (United Nations, 
2015a). Whilst community hand-hygiene interventions have been shown to reduce respiratory 
illness in developed settings (Aiello et al., 2008), this is irrelevant while 60% of our study population 
have to travel over 200m from their dwelling to a water source, and almost half have unimproved 
sanitation facility.  
Although we have identified HIV-infected adults as an important risk group, and effective vaccines 
exists, a number of unanswered questions remain. Firstly, the impact of the degree of 
immunosuppression and duration of antiretroviral treatment on influenza severity among HIV-
infected individuals needs further evaluation as more effective ART regimens are available, and a 
growing number of HIV-infected individuals gain access to ART (World Health Organization, 2013a). 
Secondly, HIV-infected individuals with advanced immunosuppression were found to have the 
greatest risk of influenza severity. However, data on the safety, immunogenicity and efficacy of IIV in 
this group is lacking. Additional factors that require elucidation include the feasibility of 
administering influenza vaccine at ART clinics, acceptability of an annual vaccine to patients in SSA, 
genomic data to inform policymakers as to whether which vaccine recommendation (northern or 
southern hemisphere) to follow, and optimal timing of vaccine administration given the absence of 
clear seasonality.  
In conclusion, we have demonstrated that influenza has an important aetiological role in severe 
respiratory presentations in Malawian adults. Additionally, in a high HIV prevalence setting, HIV 
infection is a major risk factor for severe influenza disease in Malawian adults, especially in those 
with a CD4+ cell count of <200 cells/l. Further evaluation of the effect of degree of 
immunosuppression and ART treatment status on influenza severity are needed. Additionally, 
feasibility and effectiveness studies of IIV in HIV-infected adults with advanced immunosuppression 
or co-morbidities may better guide targeted immunisation polices in similar low resource and high 
HIV prevalence settings.  
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CHAPTER 6.  Association Between Respiratory Viral Infection and 
the Nasopharyngeal Carriage of Streptococcus pneumoniae: a 
Cross-sectional and Nested Case Control Analysis 
             
6.1  Introduction 
There is convincing epidemiological evidence, particularly from previous influenza pandemics, that a 
substantial proportion of influenza-related morbidity and mortality is due to secondary bacterial 
pneumonia, particularly with Streptococcus pneumoniae (Morens et al., 2008). Emerging data 
suggest that respiratory viruses other than influenza, such as rhinovirus, RSV, adenovirus and 
parainfluenza viruses, also predispose to pneumococcal pneumonia (Angeles Marcos et al., 2006; 
Jennings et al., 2008; Johnstone et al., 2008; Templeton et al., 2005; Luchsinger et al., 2013; Damasio 
et al., 2015). As detailed in Chapter 1.6, the pathogenic synergism between respiratory viruses and S. 
pneumoniae are supported by several lines of evidence, including epidemiological data from 
previous influenza pandemics (Morens et al., 2008; Brundage and Shanks, 2008; Fleming-Dutra et al., 
2013); in vitro and animal models that have demonstrated a variety of pathogenic mechanisms 
through which viral infections may predispose to pneumococcal pneumonia (Peltola et al., 2005; 
Pittet et al., 2010; Nakamura et al., 2011); a high proportion of confirmed pneumococcal pneumonia 
with viral co-infection found in pneumonia aetiology studies (Lieberman et al., 1996; Ruiz et al., 
1999; de Roux et al., 2006; Camps Serra et al., 2008; Jennings et al., 2008); in addition to vaccine 
probes studies that have shown reduced incidence of influenza A, PIV and hMPV in children who 
received PCV (Madhi and Klugman, 2004; Madhi et al., 2006). Pneumonia, therefore, commonly 
manifests as a polymicrobial disease. 
Acquisition of nasopharyngeal carriage of a new pneumococcal serotype is the first step in the 
process that leads to invasive disease (Bogaert et al., 2004). Animal models and human studies 
suggest that respiratory viral infection may predispose to incident carriage of new pneumococcal 
serotypes, and enhance carriage density, with subsequent increased susceptibility to invasive 
infection (Albrich et al., 2012; Wolter et al., 2014b).  
Several murine models have demonstrated that influenza A infection significantly increased the 
density of colonising pneumococci (Nakamura et al., 2011; Mina et al., 2013), as well as duration of 
carriage in the nasopharynx (Mina et al., 2013). A recent cohort study in Andean children 
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demonstrated increased acquisition new pneumococcal serotypes in ARI related to influenza and 
parainfluenza (Grijalva et al., 2014). Studies from Vietnam (Vu et al., 2011) and South Africa (Wolter 
et al., 2014b) have also found higher pneumococcal colonization density in individuals with 
respiratory viral co-infection. However, the latter studies were cross-sectional in design, thus were 
unable to assess the dynamic relationship between the onset of viral infection and nasopharyngeal 
pneumococcal carriage.  
We therefore conducted two studies nested within the BASH-FLU prospective cohort (Chapter 4): i) 
a cross-sectional study to examine the relationship between influenza or other respiratory viral 
infections and nasopharyngeal carriage of S. pneumoniae at ILI presentation, and ii) a case control 
study to determine whether respiratory viral infections are associated with an increase in 
pneumococcal carriage density as well an increased risk of pneumococcal acquisition in Malawian 
adults.  
6.2  Methods 
6.2.1  Study design and population 
The first part consists of a cross-sectional analysis of the association between laboratory-confirmed 
influenza infection and pneumococcal carriage among all influenza-like illness (ILI) episodes (n=348) 
of the BASH-FLU cohort participants that took place between April 2013 and March 2015 (Chapter 
4.3.4). The second is a nested case control study within the prospective cohort. Figure 6.1 illustrates 
the method by which cases and controls were identified. Cases were cohort participants with an ILI 
episode that was PCR-positive for one or more respiratory viruses, and had an asymptomatic swab 
taken less than six weeks before the ILI episode. Controls were a random sample of participants with 
virus-negative ILI episodes, who also had an asymptomatic swab taken within six weeks of the ILI 
episode. Controls were frequency-matched by calendar month of ILI episode to cases. A cohort 
participant who serves as a control at one point may subsequently become a case; and a cohort 
member may be a case or control more than once. This study design was chosen as a time- and cost-
efficient method of addressing the research question: viral aetiology of the ILI episodes had already 
been determined; performance of quantitative lytA PCR was confined to cohort participants with a 
confirmed virus-positive ILI event, and a sample of those with virus-negative ILI; and data on 
exposures and risk factors were collected prior to the ILI episodes, therefore eliminating recall bias. 
Moreover, regular nasopharyngeal sampling throughout the study enabled a longitudinal 
assessment of the impact of viral infection on pneumococcal density. However, the compromise is  
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the reduced precision in effect estimates that results from the clustering by individuals (see also 
Chapter 6.4). 
6.2.1.1 Definition of cases and controls 
Cases 
Cohort study participant with a positive PCR for influenza A & B, adenovirus, bocavirus, 
coronaviruses HKU1, 229E, OC43 & NL63, enterovirus, human metapneumovirus (hMPV), 
parainfluenza virus 1-4, rhinovirus or respiratory syncytial virus (RSV) from an ILI episode AND  
asymptomatic when a swab taken <6 weeks prior to ILI episode. 
Controls  
Cohort study participants with a virus-negative ILI episode, frequency-matched to calendar month of 
cases AND asymptomatic when a swab taken <6 weeks prior to ILI episode. 
 
  
 
 
 
Figure 6.1  Identification of cases and controls 
NP, nasopharyngeal; ILI, influenza-like illness 
*Frequency-matched for calendar month of cases 
Cases 
BASH-FLU 
Cohort Study 
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6.2.2  Study procedures 
At every routine visit and ILI presentation, combined nasopharyngeal and oropharyngeal swabs 
(FLOQswabs, Copan Diagnostics, Brescia, Italy) were obtained and placed in Universal Transport 
Medium (UTM, Copan Diagnostics, Brescia, Italy).     
6.2.2.1  Detection of respiratory viruses 
For all ILI episodes, the CDC Human Influenza RT-PCR diagnostic panel (CDC Influenza Division), and 
the Fast-track Diagnostics (FTD) Respiratory 33  kit (Fast-track Diagnostics Ltd., Luxembourg) were 
performed on combined nasopharyngeal and oropharyngeal specimens (Chapter 2.2.7). Respiratory 
viruses tested included influenza A & B, adenovirus, bocavirus, coronaviruses HKU1, 229E, OC43 & 
NL63, enterovirus, hMPV, parainfluenza virus 1-4, rhinovirus and RSV.  
6.2.2.2  Detection and quantification of S. pneumoniae 
For all ILI episodes, nasopharyngeal pneumococcal colonisation was identified using the FTD 
Respiratory 33  kit. In the case control study, a lytA quantitative PCR assay (Chapter 2.2.8) was also 
performed on the ILI episodes and preceding asymptomatic samples of cases and controls. Bacterial 
load (genomic copies/mL) was calculated from a standard curve using serially diluted DNA extracts 
with a known quantity of S. pneumoniae. lytA PCR results was considered positive only if the lytA 
gene was amplified (cycle threshold [CT] <40).  
 
 
Figure 6.2  Timing of asymptomatic and ILI NP samples in case control study 
ILI, influenza-like illness; NP, nasopharyngeal 
Case 
Control 
2- 6 weeks 
Virus-positive 
ILI episode 
Virus-negative 
ILI episode 
Asymptomatic 
NP sampling 
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6.2.3  Sample size  
The cross-sectional study included all 348 ILI presentations in 208 cohort participants (130 HIV-
infected). The case control study was exploratory, hence the number of cases comprised all virus-
positive ILI episodes with a corresponding pre-ILI asymptomatic swab. Controls were frequency-
matched to cases by calendar month of ILI episode, in a 1:1 ratio. 
6.2.4  Statistical analysis 
In the cross-sectional study, pneumococcal carriage was assessed as a binary outcome (S. 
pneumoniae PCR positive or negative from combined naso/oropharyngeal swabs). To account for 
the cohort participants’ multiple ILI attendances in the longitudinal follow-up, we used a Generalised 
Estimating Equations (GEE) (Hanley et al., 2003) model with an exchangeable correlation structure to 
examine the association between influenza and pneumococcal carriage.  GEE uses robust estimation 
of standard errors to account for the correlated observations.  
In the case control study, a base 10 logarithmic transformation of pneumococcal bacterial load of S. 
pneumoniae was used to standardise and normalise the distribution. Change in bacterial density was 
defined as nasopharyngeal pneumococcal load at ILI episode minus pneumococcal load at the 
preceding asymptomatic visit. For the purposes of calculating changes in pneumococcal load, a 
sample with a negative lytA qPCR was assigned a value of 1 copy/ml. A new colonisation episode was 
defined as a positive S. pneumoniae lytA PCR at ILI episode after having none detected in the 
previous sample. 
Virus-positive ILI was the main study exposure. Chi-square or Fisher’s exact test was used to 
compare categorical variables, and median log-transformed bacterial loads were compared using 
Wilcoxon rank sum test. Multivariable GEE logistic regression models were implemented to identify 
factors associated with two primary end points: i) a 1-log10 (i.e. 10-fold) increase in nasopharyngeal 
pneumococcal density; and ii) a new nasopharyngeal pneumococcal colonization episode among 
virus-positive and virus-negative ILI cases. There was insufficient power to assess the effect of 
individual respiratory viruses on pneumococcal acquisition or increase in pneumococcal density. 
Since no published study has evaluated the temporal change in pneumococcal carriage density in ILI, 
the decision to utilise a 1-1og10 increase in pneumococcal density as the model outcome was based 
on the effect estimates from the above-mentioned cross-sectional studies (Vu et al., 2011; Wolter et 
al., 2014b). As a sensitivity analysis, a lower magnitude of density increase (log2, i.e. doubling) was 
also investigated.  
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6.3  Results 
6.3.1  The association between influenza and pneumococcal carriage at ILI visit 
Of the 348 ILI episodes, 154 (44.5%) were FTD PCR positive for S.pneumoniae (see also Table 4.6). 
The univariable and multivariable analyses of factors associated with pneumococcal carriage during 
ILI are shown in Table 6.1. In the univariable analysis, influenza-positive ILI episodes were associated 
with twice the odds of concurrent pneumococcal carriage, compared to influenza-negative episodes 
(62.1 vs 42.9%, OR 2.06 [95%CI 0.95-4.47], p=0.07). Participants that have two or more young 
children (< 5 years) in the household (67.7 vs. 39.7%, OR 3.21 [95%CI 1.25-8.21]), compared to no 
children], unimproved water supply (OR 2.51 [95%CI 1.20-5.26]), and those with fewer assets (OR 
2.72, 95%CI 1.24-5.95, 0-2 vs. 4-5 household assets owned) also had higher pneumococcal carriage.   
In contrast, age, sex, HIV status, past history of tuberculosis and pneumonia, recent antibiotic use, 
season of ILI attendance, household crowding, sanitation facility, principal cooking fuel, education, 
employment status, and presence of respiratory viruses other than influenza were not associated 
with pneumococcal colonisation.  
In the multivariable analysis, the association between influenza infection and pneumococcal carriage 
remained borderline significant after adjusting for number of young children in household and water 
supply (aOR 2.03, 95%CI 0.93-4.46, p=0.08). 
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Table 6.1  Factors associated with nasopharyngeal carriage of S. pneumoniae during ILI episodes 
(N=346) 
Characteristic N (%) 
S.pneumoniae 
PCR positive 
 Univariablea  Multivariablea,b 
OR (95% CI) p-value  OR (95%CI) p-value 
Demographics 
Sex 
   Female 
   Male 
 
 
96/213 (45.1) 
58/133 (43.6) 
  
 
1 
 1.02 (0.63-1.67) 
 
 
 
0.92 
   
Age group (years) 
   18-29 
   30-39 
   > 40 
 
40/95 (42.1) 
57/128 (44.5) 
57/123 (46.3) 
  
1 
1.10 (0.63-1.92) 
1.18 (0.67-2.08) 
 
 
 
0.85 
   
Medical history 
HIV status 
   Negative 
   Positive 
 
 
50/118 (42.4) 
104/228 (45.6) 
  
 
1 
1.21 (0.74-1.96) 
 
 
 
0.45 
   
Previous pulmonary TB 
   No 
   Yes 
 
129/298 (43.3) 
25/48 (52.1) 
  
1 
1.32 (0.69-2.55) 
 
 
0.40 
   
Pneumonia within 5 years 
   No 
   Yes 
 
123/290 (42.4) 
31/56 (56.4) 
  
1 
1.66 (0.93-2.94) 
 
 
0.08 
   
Recent antibiotics (<2 weeks) 
   No 
   Yes 
 
141/315 (44.8) 
13/31 (41.9) 
  
1 
0.94 (0.45-1.94) 
 
 
0.86 
   
Season 
  Hot & rainy (Dec-Apr) 
  Hot & dry (Sept-Nov) 
  Cool & dry (May-Aug) 
 
58/126 (46.0) 
62/140 (44.3) 
34/80 (42.5) 
  
1.14 (0.62-2.08) 
1.08 (0.62-1.88) 
1 
 
0.91 
 
   
Household characteristics        
Children <5 yrs in household 
  0 
  1 
  >2 
 
83/209 (39.7) 
50/106 (47.2) 
21/31 (67.7) 
  
1 
1.43 (0.86-2.36) 
3.21 (1.25-8.20) 
 
 
 
0.03 
  
1 
1.33 (0.80-2.22) 
3.28 (1.27-8.47) 
 
 
 
0.04 
Crowding indexc 
   <1.5 
   1.5-2.4 
   2.5 
 
33/84 (39.3) 
61/130 (46.9) 
60/132 (45.5) 
  
1 
1.42 (0.80-2.52) 
1.37 (0.73-2.54) 
 
 
 
0.47 
   
Water supply 
  River/stream/borehole 
  Public tap/standpipe 
  Piped to dwelling 
 
41/70 (58.6) 
90/211 (42.7) 
21/60 (35.0) 
  
2.51 (1.20-5.26) 
1.31 (0.70-2.46) 
1 
 
0.03 
  
2.27 (1.06-4.87) 
1.16 (0.61-2.22) 
1 
 
0.04 
Distance from water supply 
  <200 metres 
  >200 metres 
 
124/281 (44.1) 
27/61 (44.3) 
  
1 
0.99 (0.57-1.72) 
 
 
0.96 
   
Sanitation facility 
  None/non-VIP toilet 
  VIP/flush toilet 
 
143/317 (45.1) 
11/29 (37.9) 
  
1 
0.75 (0.32-1.80) 
 
 
0.53 
   
Principal cooking fuel 
  Electricity 
  Charcoal 
  Firewood 
 
22/43 (34.4) 
99/227 (43.6) 
42/82 (51.2) 
  
1 
1.51 (0.63-4.14) 
2.18 (0.78-6.08) 
 
 
 
0.29 
   
Socioeconomic status        
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Highest level of education 
  Never attended/primary 
  Secondary/tertiary 
 
61/132 (46.2) 
93/214 (43.5) 
  
1 
0.92 (0.58-1.46) 
 
 
 
   
Employment  
  No 
  Yes 
 
24/47 (51.1) 
130/299 (43.5) 
  
1 
0.72 (0.40-1.28) 
    
Assets ownedd 
  0-2 
  3 
  4-5 
 
76/158 (48.1) 
65/140 (46.4) 
13/48 (27.1) 
  
2.72 (1.24-5.95) 
2.43 (1.10-5.36) 
1 
 
0.04 
 
   
Difficulty obtaining foode 
  Never 
  Sometimes 
  Often/always 
 
61/135 (45.2) 
57/129 (44.2) 
36/82 (43.9) 
  
1 
0.97 (0.58-1.63) 
1.00 (0.54-1.85) 
 
 
 
0.99 
   
Viral PCR results        
Influenza infection 
  No 
  Yes 
 
136/317 (42.9) 
18/29 (62.1) 
  
1 
2.06 (0.95-4.47) 
 
 
0.07 
  
1 
2.03 (0.93-4.46) 
 
 
0.08 
Other respiratory viral 
infectionf 
  No 
  Yes 
 
 
102/232 (44.0) 
52/114 (45.6) 
  
 
1 
1.08 (0.68-1.70) 
 
 
 
0.74 
   
PCR, polymerase chain reaction; OR, odds ratio; CI, confidence interval; TB, tuberculosis; VIP, ventilated improved pit latrine. 
aOdds ratios estimated by population average model using generalised estimating equation (GEE). 
bAdjusted for influenza PCR status, number of children < 5 years in household, and water supply. 
cTotal number of household members divided by the number of living rooms in household (kitchen or bathroom not included). 
dNumber of the following assets owned in household: working refrigerator, radio, mobile phone, bed and car/motorbike. 
eSometimes (1-2 times/month), often (up to once a week), always (every day) 
fIncludes adenovirus, bocavirus, coronavirus OC43/NL63/229E/HKU1, enterovirus, human metapneumovirus, parainfluenza 
viruses 1-4, rhinovirus and respiratory syncytial virus.  
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6.3.2  The impact of respiratory viral infections on pneumococcal carriage density and 
acquisition 
6.3.2.1  Demographic and clinical characteristics of cases and controls 
143 of 348 (41.1%) ILI attendances by cohort participants had one or more respiratory viruses 
detected (Figure 6.3). Of those, 80 (55.9%) episodes had a corresponding pre-ILI NP specimen (taken 
<6 weeks before ILI episode). 80 controls were selected by stratified random sampling from the 210 
virus-negative ILI episodes, frequency-matched for calendar month to the cases. Overall, this nested 
case control study included data from 131 participants, or 21.5% of the BASH-FLU prospective 
cohort (Chapter 4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The demographic characteristics of the cases and controls are compared in Table 6.2. The 80 cases 
and 80 controls comprised 131 cohort participants. Twenty-two participants contributed more than 
1 ILI episode as either a case or control; sixteen contributed two episodes (1 x case and 1 x control 
(n=10); 2 x case (n=3); 2 x control (n=3)), and six contributed three episodes (2 x case & 1 x control 
(n=5); 1 x case & 2 x control (n=1)). The minimum time interval between two included ILI episodes 
within the same participant was 1 month. Additionally, no ILI episode was included more than once. 
Cases and controls were evenly matched in terms of age, gender, HIV status, past medical history, 
household characteristics and antibiotic exposure prior to ILI event. The only significant difference 
 
 
 
Figure 6.3  Flow diagram of cases ad controls 
ILI, influenza-like illness; NP, nasopharyngeal 
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identified was in food security – cases were more likely to report difficulty in accessing food 
compared to controls. 
 
To assess for possible bias, the demographic characteristics and viral aetiology of the 80 cases were 
compared to the 63 virus-positive ILI attendances that were excluded as cases due to the absence of 
a preceding asymptomatic specimen. Age, gender and the prevalence of HIV infection were similar 
between the two groups (Table 6.3). However, as a result of low number of routine reviews (and 
therefore fewer asymptomatic samples collected) between September and November 2013 
(Chapter 4.3.2), proportionally fewer virus-positive ILI episodes were included as cases during that 
period (figure 6.4A). Consequently, viruses that were prevalent around that period were under-
represented, including influenza A(H3N2) and RSV (figure 6.4B). Conversely, influenza B, coronavirus 
229E, parainfluenza virus 3, and rhinovirus were over-represented. 
Table 6.2  Demographic and clinical characteristics of cases and controls 
Characteristica Case (n=80) Control (n=80) p-valueb 
N (%) N (%) 
Number of cohort participantsc 71 76 - 
Gender - male 28 (35.0) 35 (43.8) 0.26 
Age (years) – median (IQR) 37.4 (31.3-48.0) 36.7 (29.7-45.9) 0.69 
HIV status 
   CD4 count (cells/l) – median (IQR) 
   On ART 
56 (70.0) 
411 (293-630) 
38 (79.2) 
49 (62.0) 
380 (255-564) 
30 (65.0) 
0.29 
0.49 
0.13 
Children <5 years in household (n) 
   0 
   1 
   >2 
 
53 (66.3) 
20 (25.0) 
7 (8.8) 
 
48 (60.0) 
20 (25.0) 
12 (15.0) 
 
 
 
0.46 
Crowding index 
   <1.5 
   1.5-2.4 
   >2.5  
 
21 (26.2) 
31 (38.8) 
28 (35.0) 
 
16 (20.0) 
31 (38.8) 
33 (41.2) 
 
 
 
0.58 
Difficulty accessing food 
   Never 
   Sometimes 
   Often/always 
 
22 (27.5) 
28 (35.0) 
30 (37.5) 
 
30 (37.5) 
35 (43.8) 
15 (18.7) 
 
 
 
0.03 
Antibiotics within 2 weeks of ILI episode 9 (11.2) 11 (13.8) 0.63 
Interval between asymptomatic & ILI 
samples (days) – median (IQR) 
20 (12-28) 22.5 (12-28) 0.43 
IQR, interquartile range; ART, antiretroviral treatment; ILI, influenza-like illness 
aNo difference was observed between cases and controls in past medical conditions, including asthma, chronic 
lung disease, heart failure, chronic kidney disease, chronic liver disease, diabetes, pregnancy, previous history 
of tuberculosis or pneumonia, smoking, alcohol use, level of education, employment status, sanitation or water 
access and principal fuel use. 
bChi-square or Wilcoxon rank sum test 
c16 participants contributed to both case and control ILI episodes. 
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Table 6.3  A comparison of the demographic characteristics of virus-positive ILI that were 
included and excluded as cases in the analysis (N=143) 
 Case (n=80) Excluded  (n=63)  
Characteristic N (%) N (%) p-valuea 
Gender - male 28 (35.0) 22 (34.5) 0.95 
Age (years) – median (IQR) 37.4 (31.3-48.0) 38.9 (28.3-47.9) 0.43 
HIV-positive 
   CD4 count (cells/l) – median (IQR)  
56 (70.0) 
411 (293-630) 
44 (69.8) 
416 (291-552) 
0.93 
0.72 
IQR, interquartile range; ILI, influenza-like illness aChi-square or Wilcoxon rank sum test 
 
 
 
 
 
Figure 6.4  Virus-positive ILIs that were included (n=80) and excluded (n=63) as cases by A) 
calendar month; and B) individual respiratory viruses. 
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6.3.2.2  Comparison of nasopharyngeal density of Streptococcus pneumoniae between ILI episode 
and preceding asymptomatic visit 
The viral aetiology identified in the ILI episodes among cases is illustrated in Figure 6.5. Rhinovirus 
(n=33), influenza B (n=14) and coronavirus NL63 (n=10) were the most frequently detected viruses. 
13/80 (16.2%) cases had viral co-infection.  
 
 
 
Pneumococcal carriage at ILI time-point was determined by both the Fast-track Diagnostics (FTD) 
multiplex kit and quantitative lytA PCR; lytA qPCR detected a much higher prevalence of 
nasopharyngeal carriage than the FTD PCR (74.4 vs. 46.3%, p <0.001), though FTD PCR was positive 
in 7 cases that were lytA PCR negative (Inter-observer agreement between the two PCR tests, = 
0.2885). Only lytA PCR was performed on the pre-ILI samples. Therefore, for the purposes of the 
analysis of pneumococcal density change and acquisition, only lytA PCR results were used. 
Pneumococcal carriage prevalence by quantitative lytA PCR did not differ between cases and 
controls, at both pre-ILI (60 vs. 60%, p=1.00) and ILI (73 v. 76%, p=0.59) time-points (Table 6.4). The 
median bacterial load among those that were lytA PCR positive were also similar between cases and 
RSV, respiratory syncytial virus; PCR, polymerase chain reaction; ILI, influenza-like illness 
 
 
 
Figure 6.5  Viral aetiology from ILI episodes of cases (N=80) 
hMPV, human metapneumovirus; PIV, parainfluenza virus; RSV, respiratory syncytial virus. 
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controls at asymptomatic visit (4.10 vs. 4.21 log10 copies/ml, respectively) and ILI visit (4.07 vs. 4.11 
log10 copies/ml).  
 
 
The magnitude of change in NP pneumococcal density between the NP specimens taken at ILI 
episode and the preceding asymptomatic visit varied widely in both cases (-6.3 to +5.2 log10 
copies/ml) and controls (-7.4 to +5.3 log10 copies/ml). However, the median difference in NP 
pneumococcal load was similar between cases and controls (0 vs. +0.05 log10 copies/ml (p=0.25) 
respectively; Table 6.4 & figure 6.6A). There was also no difference when cases were stratified into 
influenza (median change 0 log10 copies/ml, p=0.89) and other respiratory viruses (median change 
+0.12 log10 copies/ml, p=0.17).  
Additionally, we investigated whether the time interval between asymptomatic and illness sampling 
impacted on the magnitude of change in NP colonisation density (Figure 6.7). No correlation was 
demonstrated. 
 
  
Table 6.4  Nasopharyngeal carriage of S. pneumoniae during ILI episodes and asymptomatic 
visits in cases and controls 
 Case (n=80) Control (n=80)  
Characteristic N (%) N (%) p-value1 
ILI episode     
 FTD PCR positive  
 LytA qPCR positive 
39 (49) 
59 (73) 
35 (44) 
61 (76) 
0.53 
0.59 
  Median (IQR), log10 copies/ml 4.10 (3.66-5.05) 4.21 (3.72-6.55) 0.51 
Asymptomatic visit  
 LytA qPCR positive 
 
48 (60) 
 
48 (60) 
 
1.00 
     Median (IQR), log10 copies/ml 4.07 (1-4.86)  4.11 (1-4.78) 0.84 
Difference between ILI episode  & asymptomatic visit   
 Median  in lytA qPCR (IQR), log10 copies/ml  0  (-0.72-1.81)  0.05 (-0.20-2.40) 0.12 
 1-log10 increase in lytA qPCR between ILI & 
asymptomatic episode 
23 (29) 
 
29 (36) 
 
0.31 
 
 1-log2 increase in lytA qPCR between ILI & 
asymptomatic episode 
31 (39) 36 (45) 0.42 
New colonisation episode2 12 (15.0) 15 (18.8) 0.53 
qPCR, quantitative polymerase chain reaction; IQR, interquartile range; ILI, influenza-like illness 
1 Chi-square or Wilcoxon rank sum test 
2 Spn negative at asymptomatic visit, but positive at ILI episode 
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Figure 6.6  Changes in quantitative pneumococcal colonisation densities between asymptomatic visit 
and ILI episode among A) controls (n=80) and cases (n=80); and B) controls and cases stratified by 
episodes in which influenza A & B (n=16) and other respiratory viruses (n=64) were identified. 
NP colonisation densities were obtained by lytA real-time PCR from nasopharyngeal swab samples. 
Data are presented as medians, interquartile ranges (box) and minimum and maximum values 
(whiskers). P-values are calculated by Wilcoxon rank sum test.   
 qPCR, quantitative polymerase chain reaction. 
 
 
 
 
Figure 6.7  Correlation between NP sampling interval and change in quantitative lytA qPCR between 
asymptomatic visit and ILI episode among cases and controls 
ILI, influenza-like illness; NP, nasopharyngeal; qPCR, quantitative polymerase chain reaction 
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6.3.2.3  Factors associated with an increase in pneumococcal colonisation density during influenza-
like illness    
Factors associated with a 1-log10 increase in pneumococcal colonisation density between at ILI visit 
were explored using a GEE logistic regression model (Table 6.5). A 10-fold rise in NP pneumococcal 
load between asymptomatic visit and ILI episode was observed in 23 (29%) of cases vs. 29 (36%) 
controls.  In the univariable analysis, cases (virus-positive ILI) were not associated with an increase in 
pneumococcal load compared to controls (virus-negative ILI) (28.8 vs. 36.3%, OR 0.72, 95% CI 0.38-
1.34, p=0.30). Individuals that did not take antibiotics in the 2 weeks preceding an ILI episode were 
more likely to have an increase in pneumoocccal load than those that did not (35 vs. 15%, OR 3.21, 
95%CI 0.87-11.87). Furthermore, an increase in pneumococcal load was found in those who used 
firewood as their principal cooking fuel versus those that did not (OR 2.66, 95%CI 1.15-6.16). Other 
factors, such as age, gender, HIV infection, viral co-infection, living with children  <5 years, 
household crowding, sampling interval, and season in which ILI occurred were not associated with 
increased colonisation density.  
Case control status was entered Into the multivariable model as the main exposure of interest. 
However, only firewood use was independently associated with an increase in NP pneumococcal 
load at ILI visit (aOR 2.62, 95%C 1.14-5.98).  
Association between respiratory viral infections and pneumococcal carriage density 
 
 
 
 
193 
OR, odds ratio; CI, confidence interval; AV, asymptomatic visit; ILI, influenza-like illness  
aLogistic regression with generalised estimating equation 
a,bAdjusted for case control status (main exposure of interest) and principal cooking fuel 
 
Table 6.5  Factors associated with a log10 increase in pneumococcal colonisation density at ILI 
episode 
Characteristic 1-log10 increase 
in Spn density  
 n=52  
Univariablea   Multivariable a,b  
OR (95% CI) p-value  OR (95% CI) p-value 
Case control status 
   Control 
   Case 
Gender  
   Male 
   Female 
 
29/80 (36.3) 
23/80 (28.8) 
 
22/63 (34.9) 
30/97 (30.9) 
 
1 
0.72 (0.38-1.34) 
 
1 
0.80 (0.41-1.58) 
 
 
0.30 
 
 
0.53 
  
1 
0.74 (0.39-1.41) 
 
 
0.35 
Age group (years) 
  18-29 
  30-39 
  >40 
 
11/37 (29.7) 
24/64 (37.5) 
17/59 (28.8) 
 
1 
1.45 (0.63-3.32) 
0.94 (0.32-2.05) 
 
 
 
0.50 
   
HIV status 
  Negative 
  Positive 
 
16/54 (29.6) 
35/105 (33.3) 
 
1 
1.17 (0.60-2.30) 
 
 
0.64 
    
Antibiotics in past 2 
weeks 
  No 
  Yes 
 
 
49/140 (35.0) 
3/20 (15.0) 
 
 
3.21(0.87-11.87) 
1 
 
 
0.08 
    
Season 
  Hot and rainy 
  Cold and dry 
  Hot and dry 
 
19/71 (26.7) 
28/76 (36.8) 
5/13 (38.5) 
 
1 
1.58 (0.77-3.26) 
1.68 (0.47-5.98) 
 
 
 
0.43 
    
Interval between AV & 
ILI (days) 
  7-14  
  15-28 
  29-42 
 
 
17 (32.1) 
27 (37.0) 
8 (23.5) 
 
 
1 
1.23 (0.55-2.74) 
0.66 (0.27-1.62) 
 
 
 
 
0.42 
    
Viral co-infection 
  No 
  Yes 
 
46/147 (31.3) 
6/13 (46.1) 
 
1 
1.84 (0.58-5.85) 
 
 
0.30 
    
Children <5 years in 
household (n) 
   0 
   1 
   >2 
 
 
37/101 (36.6) 
7/40 (17.5) 
8/19 (42.1) 
 
 
1 
0.39 (0.17-0.89) 
1.47 (0.43-5.06) 
 
 
 
 
0.055 
    
Crowding index 
   <1.5 
   1.5-2.4 
   >2.5  
 
11/37 (29.7) 
17/62 (27.4) 
24/61 (39.3) 
 
1 
0.87 (0.40-1.90) 
1.63 (0.74-3.62) 
 
 
 
0.25 
    
Principal cooking fuel 
   Electricity 
   Charcoal 
   Firewood 
 
5/7 (41.7) 
29/107 (27.1) 
18/38 (47.4)  
 
2.12 (0.65-6.94) 
1 
2.66 (1.15-6.16) 
 
 
 
0.047 
  
2.06 (0.60-7.13) 
1 
 2.62 (1.14-5.98) 
 
 
 
0.05 
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As a sensitivity analysis, we also examined factors associated with a 1-log base 2 increase (i.e. 
doubling) in colonisation density. However, no significant associations, including case control status, 
were found (data not shown).  
6.3.2.4  Factors associated with a new episode of pneumococcal colonisation during influenza-like 
illness 
Among the 32 cases and 32 controls that were not colonised with S. pneumoniae at the pre-ILI visit, 
a new pneumococcal colonisation episode was found at 27 ILI visits (Table 6.6). Virus-positive ILI (i.e. 
being a case) was not associated with pneumococcal acquisition (12 (37.5%) vs. 15 (46.9%), in cases 
and controls respectively). HIV-infected adults had a significantly higher risk of pneumococcal 
acquisition, compared to HIV-uninfected adults (56.5 vs. 20.0%, p=0.004). In contrast, age, sex, 
preceding antibiotic use, season of ILI episode, sampling interval, in addition to household and 
socioeconomic variables were not associated with pneumococcal acquisition. There were insufficient 
numbers to construct a multivariable model using logistic regression with GEE.  
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Table 6.6  Factors associated with pneumococcal acquisition at ILI episode 
among cases (n=32) and controls (n=32) that had no pneumococcal 
colonisation at pre-ILI visit 
Characteristic Pneumococcal 
acquisition 
 (n=27) 
P-valuea 
Case control status 
   Control 
   Case 
Gender  
   Male 
   Female 
 
15/32 (46.9) 
12/32 (37.5) 
 
9/27 (33.3) 
18/37 (48.7) 
 
 
0.45 
 
 
0.22 
Age group (years) 
  18-29 
  30-39 
  >40 
 
7/17 (41.2) 
10/25 (40.0) 
10/22 (45.5) 
 
 
 
0.93 
HIV status 
  Negative 
  Positive 
 
5/25 (20.0) 
22/39 (56.4) 
 
 
0.004 
Season 
  Hot and rainy 
  Cold and dry 
  Hot and dry 
 
12/223 (52.2) 
12/37 (33.3) 
3/5 (60.0) 
 
 
 
0.25 
Interval between AV & ILI (days) 
  7-14  
  15-28 
  29-42 
 
6/21 (28.6) 
17/33 (51.5) 
4/10 (40.0) 
 
 
 
0.25 
Children <5 years in household (n) 
   0 
   1 
   >2 
 
21/57 (45.7) 
4/14 (28.6) 
2/4 (50.0) 
 
 
 
0.50 
Crowding index 
   <1.5 
   1.5-2.4 
   >2.5  
 
8/15 (53.3) 
7/22 (31.8) 
12/27 (44.4) 
 
 
 
0.41 
Principal cooking fuel 
   Electricity 
   Charcoal 
   Firewood  
 
3/5 (60.0) 
16/40 (40.0) 
8/17 (47.1)  
 
 
 
0.66 
OR, odds ratio; CI, confidence interval; AV, asymptomatic visit; ILI, influenza-like illness  
aChi-square or Fisher’s exact test 
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6.3.2.5 Exploring fluctuations in nasopharyngeal pneumococcal density in cohort participants that 
have contributed multiple ILI episodes 
The inclusion of multiple ILI episodes in a number of participants provided an opportunity to study 
the fluctuations in NP pneumococcal carriage density within an individual over time. In participants 
that had contributed more than two ILI episodes, quantitative lytA qPCR results from asymptomatic 
and ILI episodes were plotted on a timeline (Figure 6.8). Marked variations in pneumococcal 
colonisation densities were observed in all six participants. Significant increases in pneumococcal 
load between pre-ILI and ILI specimens were observed in several virus-positive ILI episodes 
(participant 73 (rhinovirus & coronavirus 229E), 138 (bocavirus & coronavirus 229E), 144 
(rhinovirus), 228 (coronavirus NL63) and 514 (coronavirus NL63)), but not in others (participant 073 
(coronavirus NL63), 079 (influenza B & coronavirus HKU1; rhinovirus), participant 138 (rhinovirus). 
Conversely, large rises in pneumococcal densities were also detected in a number of virus-negative 
ILI episodes (participants 073 & 514).  Overall, no individual- or virus-specific patterns in relation to 
changes in colonisation density were identified. However, substantial rises in pneumococcal load 
were noted in a number of instances where an asymptomatic sample was taken one month after an 
ILI episode. In participant 079, a 5-log increase in lytA qPCR was detected 30 days after an influenza 
B & coronavirus HKU1 ILI episode. Similarly, a 6-log increase in pneumococcal density was seen 29 
days after a rhinovirus ILI episode in participant 228. 
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Figure 6.8  Sequential nasopharyngeal pneumococcal load in asymptomatic  and ILI visits in participants that contributed 3 episodes to the case control 
study (N=6) 
 virus-positive ILI episode (case)   virus-negative ILI episode (control)    pre-ILI asymptomatic sample 
2
4
 M
a
y
 1
3
2
9
 J
u
n
 1
3
2
4
 J
u
l 
1
3
1
3
 A
u
g
 1
4
1
0
 S
e
p
 1
4
0
2
4
6
8
lo
g
1
0
 l
y
tA
 q
P
C
R
 
(c
o
p
ie
s
/m
l)
Participant 228
Rhinovirus
Corona 63
3
1
 M
a
y
 1
3
2
9
 N
o
v
 1
3
0
8
 D
e
c
 1
3
1
0
 J
a
n
 1
4
1
2
 F
e
b
 1
4
2
3
 A
p
r 
1
4
3
0
 A
p
r 
1
4
0
2
4
6
8
lo
g
1
0
 ly
tA
 q
P
C
R
 
(c
o
p
ie
s
/m
l)
Participant 514
Rhinovirus
Severe and Mild Influenza-related Respiratory Presentations in Malawian Adults: a Case Control Study 
 
 
199 
6.4  Discussion 
As highlighted in Chapter 1.6, the synergistic interaction between influenza and S. pneumoniae has 
been well described in the context of influenza pandemics and animal models. However, few 
epidemiological studies have evaluated the relationship between influenza and other respiratory 
viruses and pneumococcal carriage, the necessary precursor to invasive disease. We explored this 
relationship through two studies nested within the BASH-FLU prospective cohort: a cross-sectional 
and a case control study. We identified a high prevalence of pneumococcal carriage in Malawian 
adults (lytA-positive in 60% asymptomatic, and 74% ILI samples). At ILI presentation, infection with 
influenza, but not other respiratory viruses, was associated with a higher prevalence of 
pneumococcal carriage (62 vs. 43%, aOR 2.03), compared to those that were influenza-negative. 
Having two or more children <5 years in the household and inadequate water supply also 
predisposed to pneumococcal carriage during ILI. We also examined the dynamic impact of 
respiratory viral infections on nasopharyngeal pneumococcal density, before and during ILI, and the 
risk of pneumococcal acquisition using a quantitative lytA PCR. Contrary to our hypothesis, 
respiratory viral infection did not predispose to a greater increase in pneumococcal colonisation 
density, or a higher risk of pneumococcal acquisition. Firewood use was associated with an increase 
in pneumococcal bacterial load, while HIV infection predisposed to pneumococcal acquisition during 
ILI. Additionally, dynamic variations in nasopharyngeal pneumococcal load (up to 6 log10 copies/ml) 
were observed among participants that had quantitative lytA PCRs performed at multiple time-
points. 
Only one other study has evaluated the association between influenza and pneumococcal carriage in 
a high HIV prevalence setting; Wolter et al. (Wolter et al., 2014a) found that NP pneumococcal 
carriage was significantly associated with influenza virus (aOR 2.2), as well as adenovirus (aOR 1.7) 
and rhinovirus (aOR 1.6). Due to limited numbers, we were unable to examine the effect of 
individual respiratory viruses except for influenza. Collectively, viruses other than influenza had no 
impact on colonisation.  
Exposure to young children in the household is a known determinant of adult pneumococcal 
carriage (Hussain et al., 2005; Regev-Yochay et al., 2004), since children <5 years have the highest 
carriage incidence (Leiberman et al., 1999; Ghaffar et al., 1999), and are thought to be the main 
source of transmission to adults in the household (Hussain et al., 2005; Hendley et al., 1975; Mosser 
et al., 2014). Pneumococcal colonisation has not been directly linked to poor sanitation. However, 
inadequate water supply has been identified as a risk factor for IPD in Alaskan children (Wenger et 
al., 2010). Poor access to water likely compromises hand hygiene, leading to increased transmission 
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of respiratory pathogens. Handwashing has been shown to reduce pneumococcal carriage among 
children attending day care centres (Gudnason et al., 2014), as well as the risk of respiratory illness 
in a military population (Ryan et al., 2001). 
With regards to the case control study, our findings contrast with existing studies that have 
evaluated the impact of viral infection on NP pneumococcal colonisation density (Vu et al., 2011; 
Wolter et al., 2014b) and acquisition (Grijalva et al., 2014). Among Vietnamese children with 
radiologically confirmed pneumonia, those with viral co-infection had a 15-fold higher NP 
pneumococcal load, compared to children without viral co-infection (Vu et al., 2011). Wolter et al. 
(Wolter et al., 2014b) also demonstrated higher NP pneumococcal colonisation density in 
hospitalised LRTI adults and children with respiratory viral co-infection in South Africa (adjusted OR 
1.7 [95%CI 1.1-2.6], per log10 increase in colonization density). A case control study nested within a 
cohort of Peruvian children with acute respiratory illness (ARI) found that influenza and 
parainfluenza-related ARI facilitated the acquisition of new pneumococcal serotypes (Grijalva et al., 
2014). This, however, only applied to children who were already colonised with pneumococcus. 
Infections with other respiratory viruses (adenovirus, hMPV, rhinovirus and RSV) were not 
associated with pneumococcal acquisition.  
Our case control study differs from those described above in many respects. They were focused on 
young children (48% were <5 years of age in Wolter et al. (Wolter et al., 2014b)), while our study 
was undertaken exclusively in adults. The South African study demonstrated significantly lower 
carriage density in adults compared to young children (>15 years vs. <2 years, aOR 0.4) (Wolter et 
al., 2014b). Two-thirds of our study population were HIV-infected, whereas only the South African 
study included HIV-infected individuals. Furthermore, the studies that examined pneumococcal 
colonisation density were cross-sectional. In contrast, our case control study is the first to evaluate 
temporal changes in nasopharyngeal pneumococcal density in relation to respiratory viral infections 
in adults. Cases and controls were derived from the same study population, thus reducing selection 
bias. Recall bias is also minimised since exposures and potential risk factors were ascertained before 
ILI episodes. The fact that an individual can be enrolled as a case or a control on more than one 
occasion is both a strength and a limitation. Inclusion of several ILI episodes in the same individual 
permitted the longitudinal assessment of pneumococcal density in relation to illness episodes. 
However, the need to account for within-individual correlation of observations in statistical analysis 
inevitably resulted in a decrease in precision in effect estimates. 
Longitudinal assessment of pneumococcal colonisation density has only occurred in the context of 
the Experimental Human Pneumococcal Challenge (EHPC) model (Ferreira et al., 2011; Gritzfeld et 
al., 2014), where healthy adults are inoculated intranasally with a controlled dose of a 
Severe and Mild Influenza-related Respiratory Presentations in Malawian Adults: a Case Control Study 
 
 
201 
pneumococcal isolate; carriage status and bacterial density are then evaluated at regular time-
points. A 4-5 log10 increases in carriage densities have been observed among carriage-positive 
volunteers following pneumococcal challenge, with an average carriage duration of 28-35 days 
(Gritzfeld et al., 2014). Nonetheless, this model has not assessed pneumococcal carriage density in 
relation to viral infections. 
Several factors may explain why we did not observe a greater increase in pneumococcal density 
among the cases, compared to controls. Firstly, our sample size was small. The total number of cases 
was restricted to ILI attendances that were PCR positive for at least one virus, and had an NP 
specimen taken within 6 weeks of ILI visit. Our sample of 80 cases and 80 controls provided 80% 
power to detect factors associated with an increase in pneumococcal density with an odds ratio of 
2.5 or greater, therefore compromising our ability to detect smaller effect sizes. Similarly, we were 
unable to assess the impact of influenza virus on pneumococcal density due to the limited number 
of influenza infections among cases (n=16). The inclusion of respiratory viruses that are often 
detected in asymptomatic individuals, such as rhinovirus and adenovirus, and more recently 
discovered viruses that have uncertain clinical significance, e.g. bocavirus (Jartti et al., 2008), could 
have diluted any real effect of influenza infection on pneumococcal colonisation density if one had 
been present.   
Secondly, both studies that observed higher NP pneumococcal density with viral co-infection 
comprised individuals with severe LRTI (Vu et al., 2011; Wolter et al., 2014b). In particular, Vu et al. 
(Vu et al., 2011) observed significantly higher pneumococcal load only in virally co-infected children 
with radiologically confirmed pneumonia, but not other types of LRTI. It is therefore possible that 
substantial increases in carriage density only occur in patients with severe respiratory presentations, 
while mild viral illness may be associated with subtler density changes. The majority of ILI 
presentations among the cohort participants were mild (Chapter 4.3.4.3).  
Thirdly, pneumococcal carriage status and densities were compared at ILI presentation and the 
preceding well visit, with a sampling interval ranging between 7 to 42 days. The magnitude of 
density change was not related to the varying time interval between samples. However, acquisition 
episodes could have been missed, as limited evidence suggest that adults have a shorter duration of 
carriage compared to children (14-17 [23-31 in mothers] vs. 13-71 days respectively) (Ekdahl et al., 
1997; Melegaro et al., 2004; Darboe et al., 2010; Turner et al., 2012). This potential misclassification 
error is likely to be non-differential to case control status, therefore biasing towards the null. 
Furthermore, the absence of serotype information is an important limitation, as we could only 
ascertain new colonisation in individuals that were not previously colonised, but not the acquisition 
of a new pneumococcal serotype, in those that were already colonised. 
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Lastly, pneumococcal density increases may have been missed if they occurred after, rather than at 
the time of respiratory viral infection. In several participants, we noted a 5-6 log10 increase in 
pneumococcal load around 4 weeks after a virus-positive ILI episode (Chapter 6.3.5), though it is 
unclear whether this rise is related to the preceding viral infection. In murine models, rapid 
increases in pneumococcal carriage density occurred within 7 days of inoculation of influenza virus 
(Nakamura et al., 2011; Mina et al., 2013). However, observations in mice are not necessarily 
translatable to humans, given the differences in their NP microbial ecology and immunological 
responses (Ferreira et al., 2011). Carriage duration also appear to be shorter in mice than human 
subjects (McCool et al., 2002; McCool et al., 2003; McCool and Weiser, 2004). Thus the timing and 
magnitude of density increase in relation to viral infections in humans remain unclear. We are 
investigate this further by performing lytA PCR on asymptomatic NP samples that were taken 4-8 
weeks after an ILI episode. 
This study highlights the challenges of studying the temporal effects of respiratory viral infection on 
pneumococcal colonisation density in human subjects. Although an inadequate sample size and the 
above-mentioned methodological issues may have hampered our ability to detect an association if 
one was present, our observations that respiratory viral infections have no effect on pneumococcal 
colonisation density or acquisition risk could be real. Instead of enhancing bacterial load in the 
nasopharynx, respiratory viruses may facilitate the direct extension of S. pneumoniae into the lower 
respiratory tract through other mechanisms as shown in animal models (Chapter 1.6.4), including 
virus-mediated damage to the respiratory epithelium (Harford and Hara, 1950; Loosli et al., 1975; Pittet 
et al., 2010), increased receptor availability to aid pneumococcal binding (Peltola and McCullers, 2004; 
McCullers and Bartmess, 2003), promotion of bacterial emergence from biofilms (Marks et al., 2013), 
as well as down-regulation of host innate immune responses (Sun and Metzger, 2008; Didierlaurent 
et al., 2008; Shahangian et al., 2009; Nakamura et al., 2011). Alternatively, the association observed 
between influenza and pneumococcal carriage in cross-sectional studies to date may be due to the 
converse of our hypothesis, i.e. NP carriage of S. pneumoniae increases the probability of clinically 
manifesting influenza infection. This is unlikely, but worth further exploration.   
Other potential factors associated with an increase in NP pneumococcal load at ILI were also 
explored. The use of firewood as the principal cooking fuel was associated with a 2.5 times greater 
risk of an increase in pneumococcal density during ILI, compared to charcoal use. Exposure to indoor 
air pollution (IAP) is a well-known risk factor of severe pneumonia, particularly in young children 
(Dherani et al., 2008). However, the impact of IAP, or more specifically, firewood on pneumococcal 
carriage has not been studied. Pneumococcal carriage surveys are currently being conducted within 
clinical trials on the use of biomass briquettes in the Gambia (Medical Research Council Unit The 
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Gambia, 2002-), and advanced cookstoves in Malawi (Jary et al., 2014), to assess whether reduced 
exposure to IAP will affect pneumococcal carriage in babies and mothers.  
Among the cases and controls that did not have pneumococcal colonisation at the pre-ILI visit, HIV-
infection was associated with a significantly increased risk of pneumococcal acquisition (56 vs. 20%, 
p=0.004, in HIV-infected and HIV-uninfected participants respectively). This is unsurprising, since the 
host immune response has an important regulatory role in the acquisition and clearance of 
pathogens in the upper respiratory tract (Garcia-Rodriguez and Fresnadillo Martinez, 2002). Poor 
mucosal immunity associated with HIV infection may result in increased risk of acquisition and 
persistence of colonisation. Our finding is consistent with the other studies have longitudinally 
assessed pneumococcal carriage in adults. Rodriguez-Barradas et al. (Rodriguez-Barradas et al., 
1997) observed higher rate of pneumococcal acquisition and persistent carriage in HIV-infected 
individuals. In a cohort study of Zambia, HIV-infected mothers were more likely to have repeated 
colonisation, earlier new colonisation, as well as more prolonged duration of colonisation, than HIV-
negative mothers (Gill et al., 2008). These observations likely explain why HIV-infected individuals 
have higher rates of pneumococcal carriage than HIV-uninfected individuals (Gill et al., 2008; Paul, 
1997; Sepako et al., 2014), which in turn, may partly contribute to the increased frequency of 
pneumococcal pneumonia and bacteraemia and also severity of influenza disease seen in HIV-
infected individuals (as illustrated in Chapter 5). Nevertheless, this result should be cautiously 
interpreted as we were unable to control for confounders, such as smoking, exposure to young 
children and crowding in household, or socioeconomic status due to small numbers. 
The rate of NP pneumococcal colonisation in our study (60% in asymptomatic, and 74% in ILI 
samples) is substantially higher than that reported in other African settings. A recent review of 
pneumococcal carriage studies in SSA reported a pooled prevalence of 28% (95%CI 19-37%) in adults 
>15 years (Usuf et al., 2014). The disparity in carriage rates may in part be due to the different 
detection methods. All studies included in the review used culture to determine pneumococcal 
carriage.  Although culture and lytA qPCR have shown good correlation in terms of bacterial 
quantitation (Albrich et al., 2012; Gritzfeld et al., 2014), lytA qPCRs are unaffected by the effects of 
previous antibiotics (Albrich et al., 2012) and have superior sensitivity at low pneumococcal densities 
(Gritzfeld et al., 2014). On the other hand, qPCR can detect both viable and non-viable bacterial 
cells, thus can overestimate pneumococcal colonisation prevalence (Chien et al., 2013). 
Interestingly, the lytA qPCR detected a significantly higher pneumococcal carriage prevalence than 
the FTD multiplex PCR, even though both PCRs target the lytA gene. Since there is currently there is 
no gold standard for NP colonisation (Satzke et al., 2013), it is unclear whether this represents 
under-detection by FTD PCR, or over-detection by lytA qPCR. There are no published data comparing 
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the performance of the two PCR tests, but we are investigating this further in other carriage studies 
in Blantyre. 
A number of other limitations in this study should be considered. Since the selection of cases and 
controls was contingent on the presence of an asymptomatic sample within 6 weeks before an ILI 
attendance, ILI episodes were more likely to be included if they occurred at certain times of year. In 
the first year of follow-up, routine visits only occurred between May and August. Thus certain 
viruses that were prevalent outside that period, such as influenza A(H3N2) and RSV, were under-
represented (Figure 6.4B). The demographic characteristics did not differ between virus-positive ILIs 
that were or were not included as cases, but the distribution of respiratory viruses among the 80 
cases was not representative of all virus-positive ILI events. This is likely affected cases and controls 
equally, since they were frequency-matched for the calendar month of ILI episode. 
Lastly, given the dynamic variations in pneumococcal colonisation densities observed, it is likely that 
there are a number of confounding factors at play that have not been accounted for in our analysis. 
These may include climatic factors, detailed biomass exposure, and antibiotic usage in the 
community. An important unmeasured confounder is the PCV vaccination status of the children in 
the participant’s household. PCVs have been found to reduce vaccine-type pneumococcal carriage in 
adults through herd protection (Davis et al., 2013). In this study, 34% case and 40% control 
households had children under the age of five; many of whom would have received >1 dose of the 
13-valent pneumococcal conjugate vaccine (PCV13), which has been part of the national 
immunisation programme in Malawi since November 2011.  
PCV has been shown to reduce the overall incidence of IPD (Conklin et al., 2014), as well as 
influenza-related pneumococcal pneumonia (Madhi and Klugman, 2004). A recent murine study has 
shown that a live-attenuated influenza vaccine (LAIV) significantly reduced influenza-mediated 
excess pneumococcal carriage density and duration of carriage, while no benefit was observed with 
PCV (Mina et al., 2013). The latter observation reinforces existing knowledge that PCV reduces 
pneumococcal serotype-specific carriage by reducing acquisition rather than density or duration of 
existing carriage (Klugman, 2001). These findings imply that influenza vaccination may have an 
important role in reducing excess pneumococcal co-infections during influenza epidemics, by 
interrupting influenza-associated pneumococcal transmission. A study utilising the Experimental 
Human Pneumococcal Carriage model is under way, to compare the impact of LAIV and inactivated 
influenza vaccine (IIV) on pneumococcal carriage in human volunteers.  
In summary, we found that infection with influenza, but not other respiratory viruses, was 
associated with pneumococcal colonisation during ILI, but respiratory viral infection did not impact 
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impact on pneumococcal carriage density or the risk of pneumococcal acquisition. The role of 
respiratory viruses in the transition from asymptomatic pneumococcal carriage to invasive disease 
remains unclear. Further assessment of the dynamic interaction between respiratory viruses and 
pneumococcal colonisation in human subjects is warranted to better understand the pathogenic 
mechanisms underlying the strong link between respiratory viral infections and secondary 
pneumococcal pneumonia.  
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CHAPTER 7.   OVERALL DISCUSSION  
            
   
7.1  Overview 
The epidemiology of influenza infection in adults has been rigorously studied in developed settings 
with temperate climates. In contrast, as highlighted in Chapter 1, relatively little is known about the 
clinical manifestation, epidemiology and risk factors of influenza in sub-Saharan Africa. In a region 
with high prevalence of HIV infection and co-morbid conditions, scarce health resources, as well as 
poverty-related factors, influenza is likely to have considerable impact on morbidity and mortality. 
Annual vaccination of vulnerable high-risk groups is the cornerstone of influenza prevention in many 
developed settings, but influenza vaccine is not available for anyone in the public sector in most SSA 
countries (Palache et al., 2014). Therefore, gathering robust evidence on influenza disease burden 
and groups that are most at-risk of severe influenza complications in SSA are critical for the 
development of influenza prevention and control strategies.  
Key areas of research focus required for decision making include influenza disease burden, its impact 
on health systems, risk factors for severe influenza presentations, in addition to its interaction with 
other prevalent co-morbidities such as tuberculosis, malaria and malnutrition (Gessner et al., 2011; 
World Health Organization, 2012a). Furthermore, understanding the impact of immunosuppression 
on influenza presentation is particularly pertinent in a continent that accounts for 70% of all people 
living with HIV globally (UNAIDS, 2014a). HIV-infected individuals are considered to be at greater risk 
of influenza-related complications, and thus designated a priority group in many national 
immunisation guidelines (Geretti et al., 2008; Grohskopf et al., 2014; National Advisory Committee 
on Immunization (NACI), 2014). However, available data suggest that the impact of HIV may differ in 
low and high prevalence settings (Chapter 1.4). 
This thesis sets out to address some of these important unanswered questions in a high HIV 
prevalence urban setting in Malawi. First of all, the epidemiology, seasonality and risk factors for 
influenza infection were characterised in Malawian adults enrolled in a sentinel surveillance study, in 
the three years following the influenza A(H1N1)pdm09 pandemic. Secondly, the impact of HIV 
infection on the frequency and severity of influenza illness, and potential risk factors for severe 
influenza presentation (i.e. hospitalised LRTI) were assessed through two prospective observational 
studies. Lastly, as a potential mechanism through which influenza and other respiratory viral 
infections predispose to secondary bacterial pneumonia, the association between respiratory viral 
infections and nasopharyngeal Streptococcus pneumoniae density was investigated in a case control 
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study nested within the existing cohort. This final chapter will review and summarise the key findings 
of this thesis, discuss the clinical, research and policy implications of the findings, and suggest future 
studies.  
7.2  Principal findings of the research  
7.2.1  The epidemiology of HIV and influenza in sub-Saharan Africa 
As the first description of adult influenza epidemiology in Southern Africa outside of South Africa, 
the comprehensive hospital-based sentinel surveillance study identified influenza as a common 
cause of mild (16%) and severe (15%) acute respiratory infections in Malawian adults. Although 
cyclical, no consistent, distinct seasonality to influenza activity was observed. A minimum incidence 
of influenza-positive hospital-attended SARI of 9.6 to 16.8 per 100,000 adult population was 
estimated; a finding that is likely generalisable to other urban settings in SSA. Importantly, 
pregnancy was identified as a risk factor for influenza; pregnant women had nearly double the risk of 
hospitalised influenza infection compared to non-gravid women of childbearing age (aRR 1.84 
(95%CI 0.99-3.43), which has not been described in SSA outside a pandemic. Furthermore, HIV 
infection, which was detected in >50% adults presenting with SARI, predicted clinical severity (as 
defined by Modified Early Warning Score >4 (Subbe et al., 2001)) in both influenza-positive and 
influenza-negative adults with SARI.  
Through the 2-year follow-up of a prospective cohort, a high burden of influenza illness was found in 
both HIV-infected and HIV-uninfected adults (46 vs. 14.5 per 1000 person-years). After accounting 
for potential confounders, HIV-infected adults had an approximately three times greater 
susceptibility to influenza infection compared to HIV-uninfected adults. To the best of our 
knowledge, this is the first longitudinal study to investigate the incidence rates of influenza and its 
associations in a well-described cohort of HIV-infected and HIV-uninfected persons. In the case 
control study of patients with influenza-confirmed hospitalised LRTI and ILI, HIV was the single most 
important risk factor for severe influenza-related presentation; HIV-infected adults experienced a 
five-fold greater risk of severe influenza disease compared to HIV-uninfected adults, and over 50% of 
influenza-related hospitalised LRTI were attributable to HIV.  Neither study was designed to 
specifically investigate the effect of HIV at different levels of immunosuppression. However, the 
trend towards a higher incidence of influenza, as well as greater disease severity in those with an 
CD4+ cell count of <200 cells/µl would support the hypothesis of greater susceptibility and risk of 
severe complications among those with advanced immunosuppression.  
Data from the surveillance, cohort and case control studies, taken together, present a convincing 
argument for a causal relationship between HIV and influenza susceptibility and severity. 
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Surveillance data highlighted the high prevalence of HIV infection and its role in severe respiratory 
hospital presentations in Malawian adults. The cohort and case control studies confirmed strong 
associations between HIV and influenza susceptibility as well as severity, even after controlling for 
potential confounders. The trend towards greater risk in those with more profound 
immunosuppression suggests a dose-response relationship. Moreover, the finding that almost 60% 
of severe/hospitalised influenza presentations in Malawian adults were attributable to HIV infection 
further emphasises the critical role of HIV infection in severe influenza in this population. These 
findings are consistent with that of the few studies that have examined this association in SSA (Feikin 
et al., 2012b; Cohen et al., 2013; Ope et al., 2011). What sets this study apart from the surveillance 
studies in South Africa and Kenya are the comprehensive ascertainment of HIV status, CD4+ cell 
count and information on antiretroviral treatment, and the prospective collection of exposures and 
risk factors, including household or socio-economic characteristics that may confound the 
association between HIV and influenza. Furthermore, HIV infection is known to increase risk of 
infection and disease severity in other respiratory pathogens, such as S. pneumoniae, thus the 
relationship is biologically plausible.  
Our results, together with other data from SSA, contrast with those from developed setting. As 
expected, the effect of HIV infection on Influenza differs in settings where the majority of HIV-
infected patients are receiving ART and have good virological control, in stark contrast to high HIV 
prevalence populations in SSA accompanied by a high proportion of advanced disease and co-
existent morbidities, such as tuberculosis, malnutrition, as well as external poverty-related factors. 
Some of the risk factors for influenza identified from this study potentially explain why disease is 
may be more severe in HIV-infected adults in SSA, compared to other settings (Section 7.2.2). The 
marked difference in impact also highlights the danger of extrapolating findings from developed 
setting, to inform policy regarding targeted influenza control strategies in SSA.  
The incidence estimates of influenza-associated SARI and ILI presentations from the sentinel 
surveillance and cohort studies respectively, were substantially different. This underscores the fact 
that health facility-based surveillance greatly underestimates the number of mild community cases. 
Studies on healthcare utilisation in Malawi and other African settings have shown that most 
individuals do not seek medical care for mild illness, particularly adults and those from poor 
socioeconomic backgrounds (Desmond et al., 2013; Burton et al., 2011). As the cohort participants 
were actively encouraged to attend for mild ILI and reimbursed their transport costs, the incidence 
rates derived from the cohort study are more likely to reflect community burden of disease.  
Furthermore, most influenza surveillance studies from SSA have included individuals of all ages; few 
have examined influenza epidemiology exclusively in adults. Adults and children have different co-
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morbidity profiles, social contact patterns (Johnstone-Robertson et al., 2011; Ferraro et al., 2014), 
viral aetiology of acute respiratory illnesses (Feikin et al., 2012b; Zhang et al., 2014; Self et al., 2015), 
as well as varying influenza attack rates (World Health Organization, 2014c) and transmission 
dynamics (White et al., 2014). The epidemiology and risk factors for influenza in the two groups are 
therefore likely to be distinct, and should be evaluated separately.  
7.2.2  Other risk factors for increased burden and severity of influenza in SSA 
Aside from HIV, a number of risk factors for influenza infection and severity previously unrecognised 
in adults were identified; some may be unique to SSA settings. Household crowding was an 
independent risk factor for acquiring influenza infection, whereas a past history of pneumonia and 
poor sanitation facility were associated with severe influenza presentation. Those that reported 
difficulties accessing food at least once a week had a significantly higher rate of influenza infection, 
as well as increased risk of severe disease, compared to those that reported no food insecurity. 
Furthermore, severe food insecurity potentiated the effect of HIV on influenza risk. A correlation 
between food insecurity and low BMI (<18.5 kg/m2) was found in both studies, but low BMI was not 
associated with increased influenza incidence or severity.  
7.2.3  Other viral and bacterial aetiology of acute respiratory presentation in adults in SSA 
Respiratory viruses were prevalent in Malawian adults presenting with ILI (40%), SARI (47%) and 
hospitalised LRTI (34%). Viral co-infections were detected in 14-27% of those with a viral aetiology. 
In the case control study, we identified one or more aetiological agents in two-thirds of patients with 
hospitalised LRTI – bacteria in 39%, virus 34%, and M. tuberculosis in 18% [24% among those that 
submitted sputum]). 22% had mixed pathogen infections. These findings concur with contemporary 
pneumonia studies (de Roux et al., 2006; Jennings et al., 2008; Johansson et al., 2010; Luchsinger et 
al., 2013) that are increasingly recognising pneumonia as a polymicrobial disease. However, the 
epidemiology of pneumonia in our study differs in many respects to that of developed settings. Key 
distinctions include a younger age group, lower prevalence of chronic medical conditions (except 
HIV), a greater incidence of pulmonary tuberculosis, and higher mortality. Most of these factors are 
likely driven by HIV infection.  
7.2.4  The association between respiratory viruses and pneumococcal nasopharyngeal 
density 
In the cross-sectional analysis of ILI presentations by the cohort participants, infection with 
influenza, but not other respiratory viruses, were associated with pneumococcal colonisation. 
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However, proven respiratory viral infection was not associated with an increase in nasopharyngeal 
pneumococcal density or increased risk of pneumococcal acquisition. HIV-infected participants were 
more likely to acquire pneumococcal carriage during an ILI.  
7.3  Limitations 
Before considering the wider implications of the results, a number of aspects of the design and 
conduct of the study, that have not been previously discussed, should be considered in interpreting 
the findings.  
Firstly, this study was conducted in a single centre in an urban setting, which may limit the 
generalisability of the findings. However, patients were recruited from three different sites, ranging 
from well individuals from the outpatient department to patients with severe LRTI requiring 
hospitalisation. It is likely that the findings are applicable to other urban SSA populations with a high 
prevalence of HIV infection. 
Secondly, the sample sizes of the cohort and case control studies were calculated according to the 
estimated impact of HIV infection on influenza incidence and severity, but were not powered to 
evaluate different CD4+ stratifications or ART status. Achieving adequate statistical power for the 
stratified analyses would have required a substantially larger sample size, which was unlikely to be 
achievable within the time frame and budget of this project.  
Thirdly, several household and socioeconomic indicators emerged as risk factors for influenza. As 
they were not the main exposures of interest, some were crudely measured. Furthermore, a number 
of household and socioeconomic variables with multiple categories were collapsed, and several 
continuous variables, namely crowding index and asset ownership, were also converted to 
categorical form, due to small numbers. This loss of information and precision could have resulted in 
residual confounding or missed associations if a small linear effect was present. We recommend 
further detailed evaluation of sanitation, household crowding and, particularly food insecurity, as 
risk factors for influenza and other respiratory pathogens.   
   Lastly, ascertainment of cases in all three studies relied on passive surveillance, i.e. patients 
presenting to healthcare facility when they developed symptoms. This could have led to a partial or 
biased picture. Potential under-ascertainment of ILI cases in the cohort study was discussed in 
Chapter 4.4. In a recent household cohort study in England, around 20% of the study population 
showed serological evidence of influenza infection, but most (75%) were asymptomatic (Hayward et 
al., 2014). It is possible that HIV-infected individuals are more likely to develop symptoms given 
infection compared to HIV-infected individuals, instead of an absolute higher risk of influenza 
Overall discussion 
 211 
acquisition. We aim to examine this further by analysing a proportion of the control samples, in 
order to establish the background prevalence of asymptomatic influenza carriage over the study 
period (Section 7.5). 
7.4  Implications  
7.4.1  Clinical implications of the work in this thesis 
7.4.1.1  Recognition of influenza 
The results of this thesis show that influenza is commonly associated with both upper and lower 
respiratory tract illness in Malawian adults. However, the majority of healthcare workers as well as 
the general public do not perceive influenza as a important problem. Consequently, it is rarely 
considered in the differential diagnosis of patients presenting with an acute febrile illness. In the 
absence of laboratory confirmation, non-specific febrile illnesses are often empirically treated with 
antimalarials and/or antimicrobials. Therefore, improving clinicians’ awareness of influenza and 
other respiratory viruses could facilitate a reduction of polypharmacy, as well as the propagation of 
antimalarial and antimicrobial resistance. Differentiation of influenza from other acute respiratory 
infections and other febrile disease, such as malaria, can be challenging. In the case control study, 
influenza-related LRTI was clinically indistinguishable from other causes of LRTI, thus making the 
rationalisation of antibiotic use at clinical presentation difficult.  
7.4.1.2  Infection control and antivirals  
In developed settings, the management of individuals with severe hospitalised influenza comprise 
isolation, infection control, antiviral ± antimicrobial treatment to prevent/treat secondary bacterial 
infection. The identification of influenza in one in nine patients admitted with severe respiratory 
presentations indicates a substantial risk of nosocomial transmission in the overcrowded wards at 
QECH. Few studies have examined health care-associated infections in SSA, and none have studied 
nosocomial spread of respiratory viruses (Bagheri Nejad et al., 2011). It also emphasises the need for 
infection control measures in hospitals, particularly during the months of peak influenza 
transmission. While patient isolation is impractical in most resource-poor health facilities, physical 
interventions such as handwashing, and the use of face masks, gloves and aprons could be feasibly 
implemented in some settings to curtail nosocomial spread (Jefferson et al., 2011; Murni et al., 
2013). Furthermore, any new health facilities in SSA should be designed to minimise crowding and 
maximise airflow. 
Antiviral treatment, namely neuraminidase inhibitors (NI), is prohibitively expensive and is largely 
unavailable in SSA (Duque et al., 2014). They are most effective if administered within 48 hours of 
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symptom onset (Aoki et al., 2003), but very few present to health care within this timeframe (3.1% 
hospitalised LRTI and 7.2% ILI patients in the case control study). The lack of ‘real-time’ viral testing, 
in addition to the broad differential diagnosis of acute respiratory presentations, high cost and lack 
of availability, suggest there is currently no place for antiviral treatment in patients suspected to 
have severe influenza-related presentation in most SSA healthcare settings.  
7.4.1.3  The impact of ART  
Trends toward lower risk of influenza infection and severe disease were observed among HIV-
infected individuals with higher CD4+ cell counts (>200 cells/l). This implies that ART-associated 
immune reconstitution may protect against influenza illness, as is the case for other mucosal 
infections, notably pneumococcal disease (Feikin et al., 2004). No association was found between 
ART treatment status and influenza burden or severity, but the study was not designed to 
specifically assess the effect of HIV by CD4+ cell count or antiretroviral treatment status. Evaluating 
the impact of ART duration on influenza risk is likely to be more informative than whether a patient 
is receiving ART. As highlighted in Chapter 5.4, there are conflicting data regarding the effect of ART 
on influenza. In developed settings, the introduction of ART was associated with a reduction in 
influenza-attributable hospitalisations (Neuzil et al., 2003), and improved survival during the recent 
influenza A(H1N1) pandemic (Ormsby et al., 2011). Conversely, antiretroviral treatment status had 
no effect on CFR among HIV-infected individuals with influenza-positive SARI (Cohen et al., 2015c). A 
study in Malawi also found poor reconstitution of influenza-specific CD4+ T-cell response in HIV-
infected adults with WHO clinical stage III/IV disease despite completing 12 months of ART (see 
Section 7.6.2) (Jambo et al., 2012). A possible explanation is that pathogen-specific immune 
reconstitution may vary according to nadir CD4+ count or the duration of ART treatment. In view of 
ongoing efforts to scale up antiretroviral treatment in Malawi and other high HIV prevalence settings 
(Joint United Nations Programme on HIV/AIDS (UNAIDS), 2012), as well as the recent revision of 
CD4+ threshold for initiating ART from 350 to 500 cells/l (World Health Organization, 2013a), 
further studies are needed to fully characterise the interplaying effects of CD4+ count and ART 
duration on the relationship between HIV and influenza burden and severity. In particular, to clarify 
whether long-term effective ART may attenuate the elevated burden and severity of influenza seen 
in HIV-infected adults.  
7.4.2  Epidemiological/research implications of the work in this thesis 
7.4.2.1  Increased susceptibility = increased transmission?  
In the cohort study, HIV-infected individuals were approximately three times more likely to develop 
laboratory-confirmed influenza illness compared to HIV-uninfected individuals. Although the 
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majority of ILI presentations were mild, this could have important public health implications for two 
reasons. First, in the case control study, a five-fold greater risk of severe influenza presentation was 
demonstrated in HIV-infected individuals given infection. Secondly, increased susceptibility to 
influenza infection may also represent a greater risk of transmission. HIV-infected individuals with 
mild infection are less likely to be confined (at home or in hospital), therefore more likely to mix 
widely in the community. This risk may be further amplified if HIV-infected persons have more 
prolonged viral replication and shedding than HIV-uninfected individuals. Prolonged viral shedding 
has been demonstrated in non-HIV-related immunosuppression (Klimov et al., 1995; Boivin et al., 
2002; Weinstock et al., 2003; Gooskens et al., 2009), but few studies have evaluated the effect of 
HIV infection on influenza virus shedding and transmission (Chapter 1.4.4). If the above hypotheses 
are true, HIV-infected individuals may play an important role in the community transmission of 
influenza, thus strengthening the argument to implement influenza preventative measures in this 
group. They may also play a key role in nosocomial transmission, particularly to other susceptible 
HIV-infected individuals in overcrowded ART clinics and hospital wards, where up to 75% adult 
patients have HIV infection (SanJoaquin et al., 2013). 
7.4.2.2  The immunology of HIV and influenza in SSA 
There is a paucity of information regarding the effect of HIV, and the likely impact of long-term ART, 
on innate and acquired immune responses to influenza infection. Several studies undertaken in 
Malawi have demonstrated lower proportions of total CD4+ T cells and impaired influenza-specific 
CD4+ T cell responses within the lungs of asymptomatic HIV-infected individuals, compared to HIV-
uninfected adults (Jambo et al., 2011). These defects in pulmonary immunity were found in 
individuals with relatively high CD4+ cell counts (>350 cells/l), and did not recover after 12 months 
on ART, despite immune recovery as indicated by an increase in CD4+ cell count and marked 
reduction in viral load (Jambo et al., 2012). This impairment in influenza-specific CD4+ T cell 
immunity may be partly responsible for the increased risk of influenza infection and associated 
complications in HIV-infected persons. HIV-infected patients on ART may be at risk to influenza-
related complications. The evidence of poor influenza-specific immune reconstitution suggests that 
ART alone may not circumvent the elevated risk in HIV-infected persons. Although not the main 
focus of this thesis, further studies on the effect of HIV and ART on intra-pulmonary immune 
response to influenza infection, particularly CD8+ T cell and anti-influenza haemagglutinin (HA) 
antibodies, are warranted.  
7.4.2.3  Synergism between influenza and pneumococcus   
Given the synergistic interaction between influenza and Streptococcus pneumoniae (McCullers, 
2006), increased risk of influenza acquisition may act as a potential mechanism for the higher rates 
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of bacterial pneumonia (Sogaard et al., 2008) and IPD (Nuorti et al., 2000; Harboe et al., 2014) 
observed among HIV-infected individuals, compared to HIV-uninfected persons, i.e. influenza may 
partly mediate the effect of HIV on pneumococcal infection (Figure 7.1). As highlighted in Chapter 
1.6, few epidemiological studies have examined the relationship between influenza and S. 
pneumoniae outside of pandemics. Even fewer have done so in high HIV prevalence settings (Cohen 
et al., 2013; Wolter et al., 2014a; Wolter et al., 2014b). Further epidemiological studies of the inter-
relationships among HIV, influenza and S. pneumoniae are warranted. Effective prevention of 
influenza-related complications in HIV-infected persons may necessitate targeting of both influenza 
and pneumococcus. 
 
 
Figure 7.1 Relationship between HIV, influenza and S. pneumoniae  
 
7.4.2.3  Modification of ongoing virological surveillance   
In response to the findings from this study, adult sentinel surveillance at QECH has adapted to focus 
on HIV-infected individuals and pregnant women. Furthermore, enhanced efforts have been made 
to capture pneumococcal diagnosis and outcome data, including hospitalisation, duration of hospital 
stay, and mortality. 
7.4.3  Policy implications of the work in this thesis 
Most countries in SSA do not have established seasonal influenza vaccination policies (World Health 
Organization, 2010c). The World Health Organization designated pregnant women as the highest 
priority target group in 2012, but individual nations were advised to tailor their influenza vaccination 
policies according to country-specific disease burden, risk groups, and cost effectiveness, that is 
achievable within their local capacity and resources (World Health Organization, 2012b). Up till now, 
due to a lack of awareness of influenza across healthcare workers and policy makers, poor 
understanding of the disease burden and groups at risk of severe influenza, as well as scarce 
resources in a region beset with a great number of other health priorities, the demand for influenza 
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HIV 
Streptococcus 
pneumoniae 
Overall discussion 
 215 
vaccine in SSA has been low. Of 489 million influenza vaccine doses distributed in 2011, the WHO 
African (AFRO) region accounted for only 0.7% distributed doses (Palache et al., 2014).   
The results of this study, together with published studies from South Africa and Kenya, provide 
substantive evidence of the high burden of influenza disease in adults in SSA, and identify HIV-
infected persons at particular risk of infection and severe disease. Nevertheless, identification of 
priority groups is only the first step in the process towards developing influenza control policies that 
are specific to the continent’s needs. Decision makers will also require evidence of vaccine efficacy 
and effectiveness, as well as cost benefits, in the target groups. Additionally, numerous regulatory, 
logistical, and financial obstacles will need to be overcome if targeted influenza vaccination policies 
were to be successfully and sustainably implemented in SSA.  
7.4.3.1  Clinical efficacy of IIV in HIV-infected population 
The findings from this thesis suggest that among HIV-infected adults, those with advanced 
immunosuppression (CD4+ count <200 cells/l) are more vulnerable to influenza infection and 
severe complications than those with higher CD4+ counts. However, they have poorer immune 
response to IIV (Kroon et al., 1994; Fuller et al., 1999; Yamanaka et al., 2005; Yanagisawa et al., 
2011), and evidence of clinical efficacy in this group is lacking. The only study that has evaluated IIV 
in an African adult HIV population demonstrated a 75.5% reduction in laboratory-confirmed 
influenza illness in IIV3-vaccinated adults (Madhi et al., 2011). However, the study excluded 
individuals with CD4+ cell count <100 cells/l that were naïve to ART, and those with co-morbidities. 
Aside from an ongoing study that is exploring the effect of HIV and/or active tuberculosis on IIV3 
immunogenicity in South African adults (Groome, 2013), IIV has not been evaluated in HIV-infected 
individuals with co-morbidities. Additionally, the study was not powered to observe differences in 
the rates of hospitalisation or deaths between IIV and placebo recipients.  Thus the effectiveness of 
IIV in adults with advanced immunosuppression and/or co-morbid conditions, and the impact of IIV 
on severe respiratory outcomes and death need to be assessed. 
Quadrivalent inactivated vaccines (IIV4) have not been evaluated in SSA. Encompassing both 
circulating influenza B strains, IIV4 may yield better clinical efficacy in HIV-infected individuals than 
IIV3, as influenza B viruses were more frequently detected in HIV-infected adults with hospitalised 
SARI in South Africa (Cohen et al., 2014), as well as in our cohort participants that presented with ILI 
(Chapter 4.3). However, the potential benefits of enhanced efficacy will need to be weighed against 
the additional costs. 
7.4.3.2  Cost effectiveness of IIV in HIV-infected population 
Seasonal influenza vaccination has been shown to provide substantial public health benefits as well 
Overall discussion 
 216 
as cost savings in industrialised settings (Clements et al., 2011; Preaud et al., 2014), but there are no 
data from low income countries (Peasah et al., 2013). Economic evaluation of targeted vaccine 
introduction in SSA will need to be undertaken. The high burden of influenza and the high PAF of HIV 
in severe influenza presentations suggest that vaccine interventions targeted at HIV-infected 
individuals are likely to be cost-effective. 
7.4.3.3  IIV source and delivery to HIV-infected populations in SSA 
With the exception of tetanus toxoid immunization in pregnant women, there are currently no adult 
vaccination programmes in Malawi. The optimal vaccine delivery mechanism will need to be 
evaluated. IIV may be deliverable through antiretroviral treatments clinics, since the majority of HIV-
infected adults receiving both pre-ART and ART care attend for regular clinical assessments (Malawi 
Ministry of Health, 2014).  
The absence of clear seasonal patterns of influenza activity from the sentinel surveillance data 
(Figure 3.1) also presents a challenge in determining the ideal timing for vaccination. From the 
available data, the predicted best time would be between October and December (before the onset 
of influenza activity). This will favour the use of the vaccine composition recommended for the 
Northern Hemisphere, rather than the Southern Hemisphere. Additional surveillance data from 2014 
and 2015 should be included. 
In terms of vaccine supply, sustainable local manufacturing capacity will be required for feasible 
deployment of influenza vaccination policies. Although there is currently no indigenous influenza 
vaccine production in SSA, South Africa is one of 14 developing countries that have been awarded a 
grant to develop in-country manufacturing capacity for influenza vaccine, as part of the Global 
Action Plan for Influenza Vaccines (GAP) (World Health Organization, 2015c). The Biovac Institute 
(www.biovac.co.za) in Cape Town, South Africa, has developed the capacity for multi-product 
formulation and filling, including that for imported influenza vaccine. A licence to manufacture IIV is 
anticipated this year (Schoub et al., 2013). Additional challenges in vaccine cold chain storage, 
distribution and handling delays in importation will need to be considered. Lastly, the requirement 
for annual vaccination renders it financially and logistically unfeasible in most African settings. 
Given the challenges highlighted above, what are the realistic prospects of influenza vaccine 
becoming available in SSA? In developing countries, access to new and underused vaccines has been 
hugely improved over the past 15 years by the launch of the Global Alliance for Vaccines and 
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Immunisation (GAVI), a unique public-private global health partnershipix whose mission is to save 
children’s lives and protect people’s health by increasing access to immunisation in poor countries. 
At present, GAVI supports 11 vaccines (including PCV, rotavirus, and polio) in 72 countries. Although 
its main focus has been on childhood vaccination, GAVI explored the possibility of funding influenza 
vaccination in pregnant women as part of their Vaccine Investment Strategy in 2013 (GAVI the 
Vaccine Alliance, 2013), but are awaiting further data on the impact of maternal immunisation in 
developing settings (Section 7.6). 
7.4.3.4  Alternative strategies to prevent influenza in HIV-infected populations  
Strategies to boost sub-optimal immune responses in HIV-infected individuals have been explored, 
particularly during the 2009 influenza A(H1N1) pandemic. Administration of higher or more frequent 
doses of standard non-adjuvanted vaccine preparations in HIV-positive adults was not consistently 
associated with improved immunogenicity (Bickel et al., 2011; Cooper et al., 2011; El Sahly et al., 
2012; Hatakeyama et al., 2011; McKittrick et al., 2013; Nielsen et al., 2012), though enhanced 
responses (Ho et al., 2011; Launay et al., 2011; Iorio et al., 2003) have been observed with novel 
adjuvanted preparations.  
As stated early, the requirement for annual vaccination represent a major hurdle for the 
introduction of current influenza vaccines in SSA. Therefore new vaccines with better efficacy, and 
more prolonged and heterosubtypic protection may be valuable in African settings. Researchers 
have recently engineered several novel vaccine candidates targeting the stem of the HA molecule, 
which is similar across different strains and mutates much less readily than the head. These vaccine 
candidates have demonstrated broad protection against multiple influenza strains in mice and non-
human primates (Impagliazzo et al., 2015; Yassine et al., 2015). This exciting development suggests 
we may be one step closer to a universal influenza vaccine that protects against all seasonal and 
pandemic strains, and eliminate the need for annual vaccination. 
PCV vaccination in HIV-infected adults could be an alternative approach to prevent influenza-related 
complications, since secondary pneumococcal pneumonia is a common severe complication. PCV 
was efficacious against recurrent pneumococcal infection in HIV-infected Malawian adults (French et 
al., 2010). As discussed earlier, a probe study of PCV9 in South Africa children demonstrated a 45% 
efficacy against influenza-associated pneumonia hospitalization. A similar study could be undertaken 
in HIV-infected adults. However, the herd protection arising from the widespread introduction of 
PCV13 in SSA (Hammitt et al., 2014) is likely to limit the impact of PCV13 in lessening pneumococcal 
                                                        
ix Includes developing country and donor governments, the WHO, UNICEF, the World Bank, research and 
technical agents, the vaccine industry, the Bill & Melinda Gates Foundation and other philanthropic 
organisations. 
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burden in adults. 
7.4.3.5  Strategies against poverty 
The identification of household crowding, poor sanitation and food insecurity as risk factors for 
influenza highlight the importance of ongoing public health interventions to alleviate hunger and 
poverty, and to improve access to clean water and sanitation (United Nations, 2015b). Many of 
these factors are likely to coexist in persons living in SSA. Nearly half of the case control study 
participants had unimprovedx sanitation, which is comparable to the country estimates by the l 
WHO/UNICEF Joint Monitoring Programme for Water Supply and Sanitation. Water supply and 
sanitation facilities have seen substantial improvements in rural parts of Malawi over the past 25 
years, but they have remained unchanged in the urban areas (WHO/UNICEF, 2015).   
Food insecurity emerged as a previously unrecognised risk factor for influenza. Since this exposure 
was derived from a single question – “How often have you had difficulty accessing food?”, more in-
depth evaluation of food insecurity (Jones et al., 2013) and its association with influenza and other 
respiratory infections are warranted.  
Great strides have been made to alleviate hunger on the continent, through national and regional 
initiatives to improve food availability, access, as well as food stability and utilisation. The proportion 
of undernourished persons in Malawi has fallen from 44.7 to 20.7% in the past 25 years, making it 
one of 18 SSA countries to have successfully achieved the MDG target of halving the number of 
persons suffering from hunger. Nevertheless, one in five in the Malawian population are still 
undernourished. This finding, if confirmed, could have important policy implications. Current WHO 
guidelines for seasonal influenza vaccination do not include undernourished persons in the list of 
high-risk groups, but the new findings would perhaps support its inclusion. 
7.5  Outstanding investigations  
Several planned aspects of work are not covered in this thesis. Firstly, paired acute and convalescent 
sera were collected from cohort participants during, and 4 to 6 weeks after ILI presentation for 
haemagglutination inhibition (HAI) antibody titres. We aim to correlate PCR with serology results, in 
particular, to establish influenza diagnosis in patients presenting with ILI who may have stopped 
shedding virus at the time of nasopharyngeal sampling, thus could have been missed by PCR testing. 
The HAI assays are due to be processed at the National Center for Immunization and Respiratory 
Diseases Laboratory, CDC, Atlanta, US, at the end of 2015. 
                                                        
xSanitation facilities that do not ensure a hygienic separation of human excreta from human contact, including 
pit latrines without slabs or open pit, hanging or bucket latrines, and open defecation. 
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Secondly, we aim to ascertain the background prevalence of respiratory viruses in asymptomatic 
Malawian adults during the study period. From the 3094 combined NP/OP specimens taken at 
routine visits of cohort participants (when they were asymptomatic), 15 samples from HIV-infected 
participants, and 15 from HIV-uninfected participants per calendar month will be randomly selected, 
and tested for adenovirus, bocavirus, coronaviruses OC43/NL63/229E/HKU1, enterovirus, hMPV, 
influenza A & B, parainfluenza viruses 1-4, rhinovirus, and RSV, using the CDC Human Influenza qRT-
PCR diagnostic panel (CDC Influenza division) and Fast-track Diagnostics (FTD) Respiratory 33  kit 
(Fast-track Diagnostics Ltd., Luxembourg) (Chapter 2.2.7). These ‘controls’ will be compared to the 
prevalence of viruses identified from i) the ILI presentations by cohort participants, and ii) the 
patients hospitalised with LRTI in the case control study. The comparison will allow a better 
understanding of the causative role of these respiratory viruses in mild and severe acute respiratory 
presentations. 
7.6  Future directions  
From the findings presented in this thesis, important research questions that have arisen include:  
1. Where do HIV-infected individuals contract influenza from?  
2. What is the most effective strategy to reduce the burden of influenza in resource-limited 
settings in SSA? 
This thesis has established a high burden of infection and severe disease in HIV-infected Malawian 
adults. However, young children (<5 years) and pregnant women are the other key target groups in 
SSA. In light of limited resources and competing health needs, decisions are required as to which at-
risk groups should be prioritised. Factors that require consideration include the contribution of the 
risk group to the overall influenza disease burden in the population, disease severity within 
individual risk groups, vaccine effectiveness, feasibility of delivery, likely acceptability of vaccine, 
indirect effects of vaccination, as well as cost-effectiveness (Table 7.1). The goal is to develop 
influenza vaccine policies that maximise health benefit through efficient use of limited resources. 
Children under 5 years of age experience the highest burden of influenza infection and illness, 
compared to other age groups (Nair et al., 2011; Cohen et al., 2013). They also believed to be the 
principal transmitters of influenza in the community (Viboud et al., 2004; Cauchemez et al., 2008). 
Furthermore, there is evidence of more intense and prolonged viral shedding in children (Hall et al., 
1979; Frank et al., 1981), and for frequent contacts among children as well as between children and 
adults (Mossong et al., 2008). Therefore vaccinating children may efficiently disrupt the transmission 
and spread of influenza, conferring indirect protection of close household contacts as well as the 
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wider community (Vynnycky et al., 2008). Indeed, dynamic transmission models have suggested that 
the extension of influenza vaccination to include children of all ages, instead of restricting to those 
with clinical risk, is cost-effective due to the anticipated herd protection (Pitman et al., 2012; 
Baguelin et al., 2012). As a result, several countries, including the US (Fiore et al., 2010) and UK (Joint 
Committee on Vaccination and Immunisation, 2012), have since adopted universal childhood 
influenza vaccination. 
With regards to SSA, a cluster-randomised trial (CRT) of IIV3 vs. control vaccine in children aged 6 
months to 10 years was undertaken in Senegal between 2009 and 2011 (Diallo, 2014a). Preliminary 
results suggest moderate overall vaccine effectiveness (44%, 95%CI 16-63%); VE was higher among 
older (6-10 years) compared to younger (<5 years) children (VE 60-64% vs. 25%). Although 
vaccination programmes are in place, immunising children against influenza will present logistical 
challenges. Firstly, they are the largest of the three risk groups. Secondly, LAIV is the preferred 
vaccine for children in developed settings due to superior efficacy compared to IIV3 (Ambrose et al., 
2012), as well as observed indirect protection to older children when delivered through schools 
(Glezen et al., 2010). However, only one study in Senegal has evaluated LAIV in children (aged 2-6 
years). Initial report suggested that LAIV was well-tolerated, but efficacy data are awaited (Diallo, 
2014b). In the UK, LAIV is not recommended in HIV-infected children and adolescents who are not 
established on ART or those with advanced immunosuppression (England, 2013). In terms of IIV, 
children <9 years are recommended two doses due to inadequate immune response (Grohskopf et 
al., 2015). Furthermore, an RCT of IIV3 in HIV-infected children aged 6 months to 5 years in South 
Africa demonstrated poor immunogenicity and efficacy (Madhi et al., 2013). Thus further studies on 
the role of LAIV and adjuvanted preparations of IIV in protecting children in SSA against influenza are 
needed. 
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Table 7.1  Identification of current knowledge and data gaps among the key clinical risk groups in SSA 
 Target population 
 Children 
(<5 years) 
Pregnant women HIV-infected adults 
Estimated population size in 
Malawi 
~2,860,000 (UNICEF, 2012) ~113,120a 930,000 (UNICEF, 2012) 
Disease burden High High High 
Vaccine efficacy/ 
effectiveness 
44% (16-63%) (Diallo, 2014a) HIV- 50.4% [14.5-71.1%] (Madhi 
et al., 2014) 
HIV+ 57.7% [0.2-82.1%]  
Await Mali trial results 
75.5% [9.2-95.6%]b  
(Madhi et al., 2011) 
Public health impact NA To be addressed by RCTs in Mali 
and South Africa 
NA 
Cost-effectiveness NA NA NA 
Pros 
 
- Existing vaccination programme 
- Evidence of indirect protection 
 
- Existing vaccination programme 
- Increase birth weight 
- Protect infants < 6 months 
- May reduce community and  
nosocomial transmission (i.e. indirect 
protection) 
Cons - Poor immunogenicity in younger 
children (require a 2nd dose) 
- Require year-round IIV supply - No existing vaccination programme 
- Poor immunogenicity in those with 
advanced immunosuppression 
NA, not assessed 
aEstimated from number of women of childbearing age (15-49 years) that are HIV-infected (n=560,000) (UNAIDS, 2014b) multiplied by general fertility rate, i.e. the 
number of total live births per 1000 women of reproductive age, in Malawi (202 per 1,000 women(National Statistics Office (NSO) and ICF Macro, 2011)). This is 
likely to represent an underestimate as the survey may not have captured all pregnancies (e.g. some women may not have known they were pregnant at the time 
of survey), and a proportion of pregnancies do not result in live births. 
bExcluded individuals with co-morbidities or CD4+ cell count < 100 cells/l naïve to ART. 
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With regards to pregnant women, there is compelling evidence of substantially greater risk of severe 
disease and mortality in this group, both in developed settings (Neuzil et al., 1998; Callaghan et al., 
2010; Louie et al., 2010; Jamieson et al., 2009) and in SSA (Archer et al., 2009; Tempia et al., 2015a), 
hence they are deemed the highest priority for vaccination (World Health Organization, 2012b). 
Vaccination of pregnant women have the additional benefits of protecting against adverse birth 
outcomes such as prematurity and small for gestational age (SGA) (Steinhoff et al., 2012), as well as 
protecting infants less than 6 months, who have high disease burden but are ineligible for influenza 
vaccine (Englund et al., 1993; Zaman et al., 2008). On one hand, antenatal clinics in Malawi and 
other SSA settings have substantial experience in administering tetanus toxoid vaccine in pregnancy. 
On the other hand, careful consideration of supply chain logistics will be needed as maternal 
immunisation will require a year-round supply of IIV, which the vaccine industry is not currently set 
up to provide. It may also necessitate a mid-year switch in formulation. Furthermore, the 
acceptability of the vaccine among pregnant women in SSA should be explored.  
Three RCTs evaluated the safety and efficacy of maternal IIV3 immunisation in preventing maternal 
and infant (<6 months) influenza disease in Nepal, Mali and South Africa between 2011 and 2013 
(Omer et al., 2015). The South African study was recently published, while results from the other 
two trials are anticipated at the end of 2015. Madhi et al. (Madhi et al., 2014) demonstrated partial 
protection of IIV3 against confirmed influenza in HIV-uninfected pregnant women (VE 50.4%, 95%CI 
14.5-71.1%), as well as HIV-infected women (VE 57.7%, 95%CI 0.2-82.1%). Pooled analyses of data 
from the three trials are planned to assess outcomes for which the individual trials may not have 
been powered, including the impact of maternal IIV3 vaccination on neonatal outcomes, such as pre-
term and SGA births, infant growth, infant pneumonia, maternal and infant mortality, as well as 
indirect effects on household contacts (Omer et al., 2015). These results will inform GAVI’s decision 
regarding the adoption of maternal influenza immunization in developing countries. Pregnant 
women could potentially be the first clinical risk group to receive targeted influenza immunisation in 
SSA. 
From the above, it appears that the evidence base for immunising young children and HIV-infected 
adults against influenza require strengthening before comparison of potential vaccine impact can be 
made between the risk groups. Since this thesis has confirmed elevated disease burden and severity 
in HIV-infected adults, key data gaps include the potential public health impact of targeted influenza 
vaccination in HIV-infected adults, as well as the feasibility of vaccine delivery at ART clinic, clinical 
effectiveness of IIV among individuals with advanced immunosuppression + co-morbidities, and 
cost-effectiveness. A community cluster-randomised vaccine probe study of IIV in HIV-infected 
adults could efficiently address most of these gaps. Vaccine probe studies utilise a randomised 
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clinical trial design to evaluate the impact of a vaccine against a wide range of clinical syndromes 
associated with a particular infection for which aetiological confirmation may be difficult (Feikin et 
al., 2014) (Figure 7.2). This is particularly applicable to influenza, as it can cause asymptomatic 
infection, respiratory presentations of varying severity, in addition to increased susceptibility to 
secondary bacterial pneumonia. The impact of IIV on severe disease (e.g. hospitalisation) and 
mortality end-points could be studied, provided there is an adequate sample size. Probe studies 
therefore allows estimation of the absolute burden of disease that is preventable by vaccine (Feikin 
et al., 2014), i.e. the vaccine preventable disease incidence (VPDI), by deriving the difference in 
disease incidence between vaccinated and unvaccinated persons. 
Furthermore, a household transmission study could also be nested within the vaccine trial, in order 
to gain a better understanding of the effect of HIV on the viral shedding and transmission dynamics 
of influenza, as well as estimating the potential indirect benefit from reduced community 
transmission of influenza by HIV-infected adults. Other factors that may affect influenza 
transmission, such as the effects of season, household size, age of household members, as well as 
magnitude and duration of viral shedding, can be evaluated concurrently. These data will inform 
transmission models in SSA settings of high HIV prevalence.   
Madhi et al. (Madhi and Klugman, 2004) have probed the role of pneumococcal super-infections in 
virus-associated pneumonia. South African children vaccinated with a 9-valent PCV were associated 
with a 45% reduction in influenza-associated pneumonia hospitalization, thus confirming that a 
significant fraction of severe influenza presentation is attributable to pneumococcal co-infection. 
This interaction can alternatively be explored by using IIV to probe the contribution of influenza in 
the pathogenesis of culture-confirmed pneumococcal pneumonia.  
 Vaccine probe studies have been instrumental in driving public health decisions regarding 
Haemophilus influenzae type b (Hib), pneumococcal (Cutts et al., 2005), as well as rotavirus (Feikin et 
al., 2012a) vaccines. Our proposed cluster-randomised vaccine probe study of IIV in HIV-infected 
adults could provide a clear picture of the overall preventable disease burden and hence the public 
health value of the vaccine. In a setting with a high background incidence of influenza and severe 
respiratory disease, such as Malawi, even a vaccine with a relatively low VE can lead to a large 
vaccine-preventable disease burden and thus targeted vaccine introduction could be justified (Feikin 
et al., 2014).  
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7.7  Conclusion   
 
This study has demonstrated that the high prevalence of HIV infection and poverty-related factors, 
characteristics specific to sub-Saharan Africa, render the epidemiology of influenza in the region 
distinct from other parts of the world. In an urban setting with high HIV prevalence, we have clearly 
shown that HIV infection increases the susceptibility to influenza infection, as well as the risk of 
severe influenza disease. Individuals with advanced immunosuppression may be particularly 
vulnerable. Reasons for the elevated risk in HIV-infected individuals are likely to be multifactorial, 
and may include impaired immune response to influenza, higher prevalence of co-morbid 
conditions, greater susceptibility to co-existent or secondary bacterial infection, in addition to higher 
prevalence of other identified risk factors, such as household crowding, sanitation and food 
insecurity. All these factors are likely to be exacerbated by the continuing population expansion on 
the continent (Population Reference Bureau, 2014).  
The findings from this thesis suggest that influenza preventative strategies should be an important 
aspect of the management of HIV-infected adults in SSA. Inactivated vaccine would be the obvious 
 
 
Figure 7.2  Proportions of different clinical syndromes attributable to influenza (left) and the 
effect of inactivated influenza vaccine (right). Adapted from Feikin et al. (Feikin et al., 2014) 
LRTI, lower respiratory tract infection 
Pneumococcal LRTI  
 
All hospitalised LRTI   
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choice to prevent influenza infection and its complications in this risk group, but the high cost, 
logistical, programmatic and production difficulties, and inadequate data on clinical efficacy in 
persons with advanced immunosuppression, as well as public health impact of targeted influenza 
vaccination in HIV-infected adults represent important barriers to its introduction. Further studies to 
improve this knowledge are needed in Malawi and other high HIV prevalence settings.
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CHAPTER 8.   APPENDICES 
             
 
8.1  Publications arising from PhD 
Viral pneumonia in adults in sub-Saharan Africa – epidemiology, aetiology, diagnosis and 
management 
Ho A. Pneumonia 2014; 5:18-29 
 
British HIV Association Guidelines on the use of vaccines in HIV-positive adults 2015 
Geretti  AM, Brook G, Cameron C, Chadwick D, French N, Heyderman R, Ho A, Hunter M, Ladhani S, 
Lawton M, MacMahon E, McSorley J, Pozniak A, Rodger A. www.bhiva.org/Guidelines. HIV Medicine 
(in press) 
 
8.2  Manuscripts submitted and in preparation 
The Epidemiology and Risk Factors of Influenza in Malawian Adults with High HIV Prevalence 
following the 2009 AH1N1 Pandemic, 2011-2013 
Ho A, Mallewa J, Peterson I, SanJoaquin M, Garg S, Bar-Zeev N, Menyere M, Alaerts M, Mapurisa G, 
Chilombe M, Nyirenda M, Lalloo DG, Rothe C, Widdowson MA, McMorrow M, French N, Everett D, 
Heyderman RS. 
 
Predictors of mortality among Malawian infants hospitalized with pneumonia 
Newberry N, Pollock L, Ho A, Heyderman R, Peterson I, Everett D, McMorrow M, Bar-Zeev N. 
 
Coronavirus Surveillance in Malawi: No MERS-CoV but temperature and age associated hCoV 
infections in SARI patients 
Alaerts M, Nagelkerke N, Peterson I, Bar-Zeev N, Ho A, Aston S, Peno C, Sisya T, Chammudzi P, 
Brown C, Chinyama E, Mkandawire C, French N, McMorrow M, Heyderman RS, Everett DB 
 
 
8.3  Patient consent and case report forms (see attached CD) 
8.3.1  Influenza surveillance study 
i. Consent form (English & Chichewa)  
ii. Case report forms 
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8.3.2  Cohort study 
i. Consent form (English & Chichewa)  
ii. Case report forms  
8.3.3 Case control study 
i. Consent form – Hospitalised LRTI patients (English & Chichewa)  
ii. Consent form – ILI patients (English & Chichewa)  
iii. Case report forms – Hospitalised LRTI & ILI patientsxi  
 
 
8.4  Missing values  
 
8.4.1  Influenza surveillance study 
Variable N missing % missing 
Table 3.3    
HIV status (SARI patients only) 17 1.5 
Pregnancy 54 3.2 
Current smoker 49 2.9 
Antibiotics in past 2 weeks 53 3.1 
Reported influenza vaccination in past 
year 
47 2.8 
 
 
8.4.2  Cohort study 
Variable N missing % missing 
Table 4.2    
Drinks alcohol  2 0.3 
Highest level of education 1 0.2 
Children <5 years in household 3 0.5 
Individuals > years in household 1 0.2 
Crowding index 2 0.3 
Toilet 1 0.2 
Water supply 8 1.3 
Principal cooking fuel 6 1.0 
Highest level of education 1 0.2 
Employment 4 0.7 
Food security 5 0.8 
Table 4.3   
CD4 at enrolment (HIV+ only) 3 0.8 
                                                        
xi Same CRFs were used for hospitalised LRTI and ILI patients, except for eligibility criteria form.  
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On co-trimoxazole prophylaxis at 
enrolment  
2 0.6 
Table 4.4   
Cough  3 0.9 
Sore throat 3 0.9 
Rhinorrhoea 3 0.9 
Myalgia 3 0.9 
Nausea/vomiting 3 0.9 
Shortness of breath 3 0.9 
Diarrhoea 3 0.9 
Headache 3 0.9 
Temperature (°c) 4 1.2 
Heart rate 4 1.2 
Respiratory rate  4 1.2 
Oxygen saturation 3 0.9 
Upper respiratory tract signs 3 0.9 
Lower respiratory tract signs 3 0.9 
Table 4.6   
Other respiratory virusesxii 3 0.9 
Malaria RDT 1 0.3 
 
8.4.3  Case control study 
Variable N missing % missing 
Table 5.2    
Attended another health facility  11 1.0 
Antibiotics within 2 weeks 21 1.8 
Antimalarials within 2 weeks 19 1.6 
Traditional medicine within 2 weeks 20 1.7 
Known HIV+ at enrolment (in HIV+) 4 0.7 
On ART at enrolment (in HIV+) 18 3.1 
CD4 count (in HIV+) 58 9.9 
Medical historyxii 22 1.9 
Past history of tuberculosis 8 0.7 
Pneumonia within last 5 years 10 0.9 
Pregnant 10 0.9 
Smoking - current 9 0.8 
Alcohol 10 0.9 
Children <5 years 9 0.8 
Crowding index 51 4.4 
Highest level of education 1 0.2 
Water supply 8 0.7 
Distance to water supply 8 0.7 
Toilet 9 0.8 
Principal cooking fuel 8 0.7 
Highest level of education 14 1.2 
Employment status 21 1.8 
                                                        
xii Including chronic lung/cardiac/kidney/liver disease, hypertension, cancer, and stroke. 
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Asset ownership 7 0.6 
Food security 8 0.7 
Table 5.3   
Cough 9 0.8 
Sputum 9 0.8 
Shortness of breath 9 0.8 
Chest pain 10 0.9 
Myalgia 9 0.8 
Headache 9 0.8 
Rhinorrhoea 9 0.8 
Sore throat 9 0.8 
Nausea/vomiting 11 1.0 
Diarrhoea 12 1.0 
Weight loss 9 0.8 
Night sweats 11 1.0 
Skin rash 9 0.8 
Disorientation 19 1.6 
Temperature 8 0.7 
Systolic/diastolic blood pressure 8 0.7 
Heart rate  9 0.8 
Respiratory rate  26 2.2 
Oxygen saturation 18 1.6 
Unable to stand 13 1.1 
BMI 27 2.3 
MUAC 19 1.6 
Red throat 12 1.0 
Pus in throat  12 1.0 
Cervical lymphadenopathy 17 1.5 
Sinus tenderness 19 1.6 
Crepitations 12 1.0 
Bronchial breathing 11 1.0 
Effusion 10 0.9 
Pleural rub 12 1.0 
Wheeze 11 1.0 
Finger clubbing 14 1.2 
Pale conjunctivae 13 1.1 
Oral candidiasis 15 1.3 
Kaposi’s sarcoma lesions 14 1.2 
Jaundice 16 1.4 
Hepatomegaly 16 1.4 
Splenomegaly 16 1.4 
Pedal oedema 18  1.6 
Table 5.10   
CD4 count (in HIV+) 4 6.2 
On ART at enrolment (in HIV+) 2 3.1 
Pregnant 2 1.4 
BMI  3 2.1 
Crowding index 10 6.9 
Highest level of education 1  0.7 
Employment status 3 2.1 
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8.4.4  Association between respiratory viral infection and pneumococcal carriage 
  
Table 6.2    
CD4 count (in HIV+)  1 1.0 
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